{"nct_id": "NCT00001302", "eligibility_text": "Biopsy proven metastatic cancer, for whom no better therapy exists. All patients are eligible. Enrollment of patients with kidney, breast, ovarian cancers, and lymphomas is encouraged.. A life expectancy of at least 16 weeks, and a performance status (Karnofsky scale) of 70% or greater. Patients without rapidly growing disease.. Any prior therapy except for previous bone marrow transplantation.. WBC greater than 3,000/mm3 and ACG greater than 1,000/mm3; platelets greater than 100,000/mm3.. Creatinine Clearance greater than 50 ml/min; bilirubin less than 1.5 mg/dl; SGOT less than 70u/L; SGPT less than 80u/L.. A signed informed consent and geographic accessibility for the patient to return for follow up and treatment.. No history of brain metastases.. Not currently receiving treatment with the following agents or any other agent known to significantly interact with cyclosporine, and treatment cannot be discontinued, or changed to another therapeutically equivalent allowable drug: acetazolamide, barbiturates, corticosteroids, diltiazem, erythromycin, fluconazole, ketoconazole, nicardipine, phenothiazines, phenytoin, rifampin, sulfonamides, trimethoprim, verapamil, tamoxifen, progesterone, quinine, quinidine, or amiodarone.. No symptomatic peripheral neuropathy (grade 2 or greater arising from prior vinca alkaloid therapy).. No positive serology for HIV.. No ongoing pregnancy or unwillingness to practice adequate contraception.", "labeled_rules": [{"type": "EXCLUSION", "field": "condition", "operator": "IN", "value": "brain metastases", "unit": null, "evidence_text": "Biopsy proven metastatic cancer, for whom no better therapy exists. All patients are eligible. Enrollment of patients with kidney, breast, ovarian cancers, and lymphomas is encouraged.. A life expectancy of at least 16 weeks, and a performance status (Karnofsky scale) of 70% or greater. Patients without rapidly growing disease.. Any prior therapy except for previous bone marrow transplantation.. WBC greater than 3,000/mm3 and ACG greater than 1,000/mm3; platelets greater than 100,000/mm3.. Creatinine Clearance greater than 50 ml/min; bilirubin less than 1.5 mg/dl; SGOT less than 70u/L; SGPT less than 80u/L.. A signed informed consent and geographic accessibility for the patient to return for follow up and treatment.. No history of brain metastases.. Not currently receiving treatment with the following agents or any other agent known to significantly interact with cyclosporine, and treatment cannot be discontinued, or changed to another therapeutically equivalent allowable drug: acetazolamide, barbiturates, corticosteroids, diltiazem, erythromycin, fluconazole, ketoconazole, nicardipine, phenothiazines, phenytoin, rifampin, sulfonamides, trimethoprim, verapamil, tamoxifen, progesterone, quinine, quinidine, or amiodarone.. No symptomatic peripheral neuropathy (grade 2 or greater arising from prior vinca alkaloid therapy).. No positive serology for HIV.. No ongoing pregnancy or unwillingness to practice adequate contraception"}, {"type": "EXCLUSION", "field": "condition", "operator": "IN", "value": "cyclosporine", "unit": null, "evidence_text": "Biopsy proven metastatic cancer, for whom no better therapy exists. All patients are eligible. Enrollment of patients with kidney, breast, ovarian cancers, and lymphomas is encouraged.. A life expectancy of at least 16 weeks, and a performance status (Karnofsky scale) of 70% or greater. Patients without rapidly growing disease.. Any prior therapy except for previous bone marrow transplantation.. WBC greater than 3,000/mm3 and ACG greater than 1,000/mm3; platelets greater than 100,000/mm3.. Creatinine Clearance greater than 50 ml/min; bilirubin less than 1.5 mg/dl; SGOT less than 70u/L; SGPT less than 80u/L.. A signed informed consent and geographic accessibility for the patient to return for follow up and treatment.. No history of brain metastases.. Not currently receiving treatment with the following agents or any other agent known to significantly interact with cyclosporine, and treatment cannot be discontinued, or changed to another therapeutically equivalent allowable drug: acetazolamide, barbiturates, corticosteroids, diltiazem, erythromycin, fluconazole, ketoconazole, nicardipine, phenothiazines, phenytoin, rifampin, sulfonamides, trimethoprim, verapamil, tamoxifen, progesterone, quinine, quinidine, or amiodarone.. No symptomatic peripheral neuropathy (grade 2 or greater arising from prior vinca alkaloid therapy).. No positive serology for HIV.. No ongoing pregnancy or unwillingness to practice adequate contraception"}, {"type": "EXCLUSION", "field": "condition", "operator": "IN", "value": "kidney", "unit": null, "evidence_text": "Biopsy proven metastatic cancer, for whom no better therapy exists. All patients are eligible. Enrollment of patients with kidney, breast, ovarian cancers, and lymphomas is encouraged.. A life expectancy of at least 16 weeks, and a performance status (Karnofsky scale) of 70% or greater. Patients without rapidly growing disease.. Any prior therapy except for previous bone marrow transplantation.. WBC greater than 3,000/mm3 and ACG greater than 1,000/mm3; platelets greater than 100,000/mm3.. Creatinine Clearance greater than 50 ml/min; bilirubin less than 1.5 mg/dl; SGOT less than 70u/L; SGPT less than 80u/L.. A signed informed consent and geographic accessibility for the patient to return for follow up and treatment.. No history of brain metastases.. Not currently receiving treatment with the following agents or any other agent known to significantly interact with cyclosporine, and treatment cannot be discontinued, or changed to another therapeutically equivalent allowable drug: acetazolamide, barbiturates, corticosteroids, diltiazem, erythromycin, fluconazole, ketoconazole, nicardipine, phenothiazines, phenytoin, rifampin, sulfonamides, trimethoprim, verapamil, tamoxifen, progesterone, quinine, quinidine, or amiodarone.. No symptomatic peripheral neuropathy (grade 2 or greater arising from prior vinca alkaloid therapy).. No positive serology for HIV.. No ongoing pregnancy or unwillingness to practice adequate contraception"}, {"type": "EXCLUSION", "field": "condition", "operator": "IN", "value": "kidney, breast, ovarian cancers, and lymphomas", "unit": null, "evidence_text": "Biopsy proven metastatic cancer, for whom no better therapy exists. All patients are eligible. Enrollment of patients with kidney, breast, ovarian cancers, and lymphomas is encouraged.. A life expectancy of at least 16 weeks, and a performance status (Karnofsky scale) of 70% or greater. Patients without rapidly growing disease.. Any prior therapy except for previous bone marrow transplantation.. WBC greater than 3,000/mm3 and ACG greater than 1,000/mm3; platelets greater than 100,000/mm3.. Creatinine Clearance greater than 50 ml/min; bilirubin less than 1.5 mg/dl; SGOT less than 70u/L; SGPT less than 80u/L.. A signed informed consent and geographic accessibility for the patient to return for follow up and treatment.. No history of brain metastases.. Not currently receiving treatment with the following agents or any other agent known to significantly interact with cyclosporine, and treatment cannot be discontinued, or changed to another therapeutically equivalent allowable drug: acetazolamide, barbiturates, corticosteroids, diltiazem, erythromycin, fluconazole, ketoconazole, nicardipine, phenothiazines, phenytoin, rifampin, sulfonamides, trimethoprim, verapamil, tamoxifen, progesterone, quinine, quinidine, or amiodarone.. No symptomatic peripheral neuropathy (grade 2 or greater arising from prior vinca alkaloid therapy).. No positive serology for HIV.. No ongoing pregnancy or unwillingness to practice adequate contraception"}, {"type": "EXCLUSION", "field": "history", "operator": "IN", "value": "Biopsy proven metastatic cancer, for whom no better therapy exists. All patients are eligible. Enrollment of patients with kidney, breast, o", "unit": null, "evidence_text": "Biopsy proven metastatic cancer, for whom no better therapy exists. All patients are eligible. Enrollment of patients with kidney, breast, ovarian cancers, and lymphomas is encouraged.. A life expectancy of at least 16 weeks, and a performance status (Karnofsky scale) of 70% or greater. Patients without rapidly growing disease.. Any prior therapy except for previous bone marrow transplantation.. WBC greater than 3,000/mm3 and ACG greater than 1,000/mm3; platelets greater than 100,000/mm3.. Creatinine Clearance greater than 50 ml/min; bilirubin less than 1.5 mg/dl; SGOT less than 70u/L; SGPT less than 80u/L.. A signed informed consent and geographic accessibility for the patient to return for follow up and treatment.. No history of brain metastases.. Not currently receiving treatment with the following agents or any other agent known to significantly interact with cyclosporine, and treatment cannot be discontinued, or changed to another therapeutically equivalent allowable drug: acetazolamide, barbiturates, corticosteroids, diltiazem, erythromycin, fluconazole, ketoconazole, nicardipine, phenothiazines, phenytoin, rifampin, sulfonamides, trimethoprim, verapamil, tamoxifen, progesterone, quinine, quinidine, or amiodarone.. No symptomatic peripheral neuropathy (grade 2 or greater arising from prior vinca alkaloid therapy).. No positive serology for HIV.. No ongoing pregnancy or unwillingness to practice adequate contraception"}, {"type": "EXCLUSION", "field": "history", "operator": "IN", "value": "SGPT less than 80u/L.. A signed informed consent and geographic accessibility for the patient to return for follow up and treatment.. No his", "unit": null, "evidence_text": "Biopsy proven metastatic cancer, for whom no better therapy exists. All patients are eligible. Enrollment of patients with kidney, breast, ovarian cancers, and lymphomas is encouraged.. A life expectancy of at least 16 weeks, and a performance status (Karnofsky scale) of 70% or greater. Patients without rapidly growing disease.. Any prior therapy except for previous bone marrow transplantation.. WBC greater than 3,000/mm3 and ACG greater than 1,000/mm3; platelets greater than 100,000/mm3.. Creatinine Clearance greater than 50 ml/min; bilirubin less than 1.5 mg/dl; SGOT less than 70u/L; SGPT less than 80u/L.. A signed informed consent and geographic accessibility for the patient to return for follow up and treatment.. No history of brain metastases.. Not currently receiving treatment with the following agents or any other agent known to significantly interact with cyclosporine, and treatment cannot be discontinued, or changed to another therapeutically equivalent allowable drug: acetazolamide, barbiturates, corticosteroids, diltiazem, erythromycin, fluconazole, ketoconazole, nicardipine, phenothiazines, phenytoin, rifampin, sulfonamides, trimethoprim, verapamil, tamoxifen, progesterone, quinine, quinidine, or amiodarone.. No symptomatic peripheral neuropathy (grade 2 or greater arising from prior vinca alkaloid therapy).. No positive serology for HIV.. No ongoing pregnancy or unwillingness to practice adequate contraception"}, {"type": "EXCLUSION", "field": "lab", "operator": "<=", "value": 1.5, "unit": "mg/dl", "evidence_text": "Biopsy proven metastatic cancer, for whom no better therapy exists. All patients are eligible. Enrollment of patients with kidney, breast, ovarian cancers, and lymphomas is encouraged.. A life expectancy of at least 16 weeks, and a performance status (Karnofsky scale) of 70% or greater. Patients without rapidly growing disease.. Any prior therapy except for previous bone marrow transplantation.. WBC greater than 3,000/mm3 and ACG greater than 1,000/mm3; platelets greater than 100,000/mm3.. Creatinine Clearance greater than 50 ml/min; bilirubin less than 1.5 mg/dl; SGOT less than 70u/L; SGPT less than 80u/L.. A signed informed consent and geographic accessibility for the patient to return for follow up and treatment.. No history of brain metastases.. Not currently receiving treatment with the following agents or any other agent known to significantly interact with cyclosporine, and treatment cannot be discontinued, or changed to another therapeutically equivalent allowable drug: acetazolamide, barbiturates, corticosteroids, diltiazem, erythromycin, fluconazole, ketoconazole, nicardipine, phenothiazines, phenytoin, rifampin, sulfonamides, trimethoprim, verapamil, tamoxifen, progesterone, quinine, quinidine, or amiodarone.. No symptomatic peripheral neuropathy (grade 2 or greater arising from prior vinca alkaloid therapy).. No positive serology for HIV.. No ongoing pregnancy or unwillingness to practice adequate contraception"}, {"type": "EXCLUSION", "field": "lab", "operator": "<=", "value": 80, "unit": "u/l", "evidence_text": "Biopsy proven metastatic cancer, for whom no better therapy exists. All patients are eligible. Enrollment of patients with kidney, breast, ovarian cancers, and lymphomas is encouraged.. A life expectancy of at least 16 weeks, and a performance status (Karnofsky scale) of 70% or greater. Patients without rapidly growing disease.. Any prior therapy except for previous bone marrow transplantation.. WBC greater than 3,000/mm3 and ACG greater than 1,000/mm3; platelets greater than 100,000/mm3.. Creatinine Clearance greater than 50 ml/min; bilirubin less than 1.5 mg/dl; SGOT less than 70u/L; SGPT less than 80u/L.. A signed informed consent and geographic accessibility for the patient to return for follow up and treatment.. No history of brain metastases.. Not currently receiving treatment with the following agents or any other agent known to significantly interact with cyclosporine, and treatment cannot be discontinued, or changed to another therapeutically equivalent allowable drug: acetazolamide, barbiturates, corticosteroids, diltiazem, erythromycin, fluconazole, ketoconazole, nicardipine, phenothiazines, phenytoin, rifampin, sulfonamides, trimethoprim, verapamil, tamoxifen, progesterone, quinine, quinidine, or amiodarone.. No symptomatic peripheral neuropathy (grade 2 or greater arising from prior vinca alkaloid therapy).. No positive serology for HIV.. No ongoing pregnancy or unwillingness to practice adequate contraception"}, {"type": "EXCLUSION", "field": "lab", "operator": ">=", "value": 100, "unit": null, "evidence_text": "Biopsy proven metastatic cancer, for whom no better therapy exists. All patients are eligible. Enrollment of patients with kidney, breast, ovarian cancers, and lymphomas is encouraged.. A life expectancy of at least 16 weeks, and a performance status (Karnofsky scale) of 70% or greater. Patients without rapidly growing disease.. Any prior therapy except for previous bone marrow transplantation.. WBC greater than 3,000/mm3 and ACG greater than 1,000/mm3; platelets greater than 100,000/mm3.. Creatinine Clearance greater than 50 ml/min; bilirubin less than 1.5 mg/dl; SGOT less than 70u/L; SGPT less than 80u/L.. A signed informed consent and geographic accessibility for the patient to return for follow up and treatment.. No history of brain metastases.. Not currently receiving treatment with the following agents or any other agent known to significantly interact with cyclosporine, and treatment cannot be discontinued, or changed to another therapeutically equivalent allowable drug: acetazolamide, barbiturates, corticosteroids, diltiazem, erythromycin, fluconazole, ketoconazole, nicardipine, phenothiazines, phenytoin, rifampin, sulfonamides, trimethoprim, verapamil, tamoxifen, progesterone, quinine, quinidine, or amiodarone.. No symptomatic peripheral neuropathy (grade 2 or greater arising from prior vinca alkaloid therapy).. No positive serology for HIV.. No ongoing pregnancy or unwillingness to practice adequate contraception"}, {"type": "EXCLUSION", "field": "lab", "operator": ">=", "value": 3, "unit": null, "evidence_text": "Biopsy proven metastatic cancer, for whom no better therapy exists. All patients are eligible. Enrollment of patients with kidney, breast, ovarian cancers, and lymphomas is encouraged.. A life expectancy of at least 16 weeks, and a performance status (Karnofsky scale) of 70% or greater. Patients without rapidly growing disease.. Any prior therapy except for previous bone marrow transplantation.. WBC greater than 3,000/mm3 and ACG greater than 1,000/mm3; platelets greater than 100,000/mm3.. Creatinine Clearance greater than 50 ml/min; bilirubin less than 1.5 mg/dl; SGOT less than 70u/L; SGPT less than 80u/L.. A signed informed consent and geographic accessibility for the patient to return for follow up and treatment.. No history of brain metastases.. Not currently receiving treatment with the following agents or any other agent known to significantly interact with cyclosporine, and treatment cannot be discontinued, or changed to another therapeutically equivalent allowable drug: acetazolamide, barbiturates, corticosteroids, diltiazem, erythromycin, fluconazole, ketoconazole, nicardipine, phenothiazines, phenytoin, rifampin, sulfonamides, trimethoprim, verapamil, tamoxifen, progesterone, quinine, quinidine, or amiodarone.. No symptomatic peripheral neuropathy (grade 2 or greater arising from prior vinca alkaloid therapy).. No positive serology for HIV.. No ongoing pregnancy or unwillingness to practice adequate contraception"}, {"type": "EXCLUSION", "field": "medication", "operator": "IN", "value": "Biopsy proven metastatic cancer, for whom no better therapy exists. All patients are eligible. Enrollment of patients with kidney, breast, o", "unit": null, "evidence_text": "Biopsy proven metastatic cancer, for whom no better therapy exists. All patients are eligible. Enrollment of patients with kidney, breast, ovarian cancers, and lymphomas is encouraged.. A life expectancy of at least 16 weeks, and a performance status (Karnofsky scale) of 70% or greater. Patients without rapidly growing disease.. Any prior therapy except for previous bone marrow transplantation.. WBC greater than 3,000/mm3 and ACG greater than 1,000/mm3; platelets greater than 100,000/mm3.. Creatinine Clearance greater than 50 ml/min; bilirubin less than 1.5 mg/dl; SGOT less than 70u/L; SGPT less than 80u/L.. A signed informed consent and geographic accessibility for the patient to return for follow up and treatment.. No history of brain metastases.. Not currently receiving treatment with the following agents or any other agent known to significantly interact with cyclosporine, and treatment cannot be discontinued, or changed to another therapeutically equivalent allowable drug: acetazolamide, barbiturates, corticosteroids, diltiazem, erythromycin, fluconazole, ketoconazole, nicardipine, phenothiazines, phenytoin, rifampin, sulfonamides, trimethoprim, verapamil, tamoxifen, progesterone, quinine, quinidine, or amiodarone.. No symptomatic peripheral neuropathy (grade 2 or greater arising from prior vinca alkaloid therapy).. No positive serology for HIV.. No ongoing pregnancy or unwillingness to practice adequate contraception"}, {"type": "EXCLUSION", "field": "medication", "operator": "IN", "value": "SGPT less than 80u/L.. A signed informed consent and geographic accessibility for the patient to return for follow up and treatment.. No his", "unit": null, "evidence_text": "Biopsy proven metastatic cancer, for whom no better therapy exists. All patients are eligible. Enrollment of patients with kidney, breast, ovarian cancers, and lymphomas is encouraged.. A life expectancy of at least 16 weeks, and a performance status (Karnofsky scale) of 70% or greater. Patients without rapidly growing disease.. Any prior therapy except for previous bone marrow transplantation.. WBC greater than 3,000/mm3 and ACG greater than 1,000/mm3; platelets greater than 100,000/mm3.. Creatinine Clearance greater than 50 ml/min; bilirubin less than 1.5 mg/dl; SGOT less than 70u/L; SGPT less than 80u/L.. A signed informed consent and geographic accessibility for the patient to return for follow up and treatment.. No history of brain metastases.. Not currently receiving treatment with the following agents or any other agent known to significantly interact with cyclosporine, and treatment cannot be discontinued, or changed to another therapeutically equivalent allowable drug: acetazolamide, barbiturates, corticosteroids, diltiazem, erythromycin, fluconazole, ketoconazole, nicardipine, phenothiazines, phenytoin, rifampin, sulfonamides, trimethoprim, verapamil, tamoxifen, progesterone, quinine, quinidine, or amiodarone.. No symptomatic peripheral neuropathy (grade 2 or greater arising from prior vinca alkaloid therapy).. No positive serology for HIV.. No ongoing pregnancy or unwillingness to practice adequate contraception"}, {"type": "EXCLUSION", "field": "other", "operator": "IN", "value": "SGPT less than 80u/L.. A signed informed consent and geographic accessibility for the patient to return for follow up and treatment.. No his", "unit": null, "evidence_text": "Biopsy proven metastatic cancer, for whom no better therapy exists. All patients are eligible. Enrollment of patients with kidney, breast, ovarian cancers, and lymphomas is encouraged.. A life expectancy of at least 16 weeks, and a performance status (Karnofsky scale) of 70% or greater. Patients without rapidly growing disease.. Any prior therapy except for previous bone marrow transplantation.. WBC greater than 3,000/mm3 and ACG greater than 1,000/mm3; platelets greater than 100,000/mm3.. Creatinine Clearance greater than 50 ml/min; bilirubin less than 1.5 mg/dl; SGOT less than 70u/L; SGPT less than 80u/L.. A signed informed consent and geographic accessibility for the patient to return for follow up and treatment.. No history of brain metastases.. Not currently receiving treatment with the following agents or any other agent known to significantly interact with cyclosporine, and treatment cannot be discontinued, or changed to another therapeutically equivalent allowable drug: acetazolamide, barbiturates, corticosteroids, diltiazem, erythromycin, fluconazole, ketoconazole, nicardipine, phenothiazines, phenytoin, rifampin, sulfonamides, trimethoprim, verapamil, tamoxifen, progesterone, quinine, quinidine, or amiodarone.. No symptomatic peripheral neuropathy (grade 2 or greater arising from prior vinca alkaloid therapy).. No positive serology for HIV.. No ongoing pregnancy or unwillingness to practice adequate contraception"}, {"type": "EXCLUSION", "field": "procedure", "operator": "IN", "value": "Biopsy proven metastatic cancer, for whom no better therapy exists. All patients are eligible. Enrollment of patients with kidney, breast, o", "unit": null, "evidence_text": "Biopsy proven metastatic cancer, for whom no better therapy exists. All patients are eligible. Enrollment of patients with kidney, breast, ovarian cancers, and lymphomas is encouraged.. A life expectancy of at least 16 weeks, and a performance status (Karnofsky scale) of 70% or greater. Patients without rapidly growing disease.. Any prior therapy except for previous bone marrow transplantation.. WBC greater than 3,000/mm3 and ACG greater than 1,000/mm3; platelets greater than 100,000/mm3.. Creatinine Clearance greater than 50 ml/min; bilirubin less than 1.5 mg/dl; SGOT less than 70u/L; SGPT less than 80u/L.. A signed informed consent and geographic accessibility for the patient to return for follow up and treatment.. No history of brain metastases.. Not currently receiving treatment with the following agents or any other agent known to significantly interact with cyclosporine, and treatment cannot be discontinued, or changed to another therapeutically equivalent allowable drug: acetazolamide, barbiturates, corticosteroids, diltiazem, erythromycin, fluconazole, ketoconazole, nicardipine, phenothiazines, phenytoin, rifampin, sulfonamides, trimethoprim, verapamil, tamoxifen, progesterone, quinine, quinidine, or amiodarone.. No symptomatic peripheral neuropathy (grade 2 or greater arising from prior vinca alkaloid therapy).. No positive serology for HIV.. No ongoing pregnancy or unwillingness to practice adequate contraception"}, {"type": "EXCLUSION", "field": "procedure", "operator": "IN", "value": "SGPT less than 80u/L.. A signed informed consent and geographic accessibility for the patient to return for follow up and treatment.. No his", "unit": null, "evidence_text": "Biopsy proven metastatic cancer, for whom no better therapy exists. All patients are eligible. Enrollment of patients with kidney, breast, ovarian cancers, and lymphomas is encouraged.. A life expectancy of at least 16 weeks, and a performance status (Karnofsky scale) of 70% or greater. Patients without rapidly growing disease.. Any prior therapy except for previous bone marrow transplantation.. WBC greater than 3,000/mm3 and ACG greater than 1,000/mm3; platelets greater than 100,000/mm3.. Creatinine Clearance greater than 50 ml/min; bilirubin less than 1.5 mg/dl; SGOT less than 70u/L; SGPT less than 80u/L.. A signed informed consent and geographic accessibility for the patient to return for follow up and treatment.. No history of brain metastases.. Not currently receiving treatment with the following agents or any other agent known to significantly interact with cyclosporine, and treatment cannot be discontinued, or changed to another therapeutically equivalent allowable drug: acetazolamide, barbiturates, corticosteroids, diltiazem, erythromycin, fluconazole, ketoconazole, nicardipine, phenothiazines, phenytoin, rifampin, sulfonamides, trimethoprim, verapamil, tamoxifen, progesterone, quinine, quinidine, or amiodarone.. No symptomatic peripheral neuropathy (grade 2 or greater arising from prior vinca alkaloid therapy).. No positive serology for HIV.. No ongoing pregnancy or unwillingness to practice adequate contraception"}], "annotator_id": "annotator_c", "guideline_version": "m5-v1", "adjudicated": true, "adjudication_source": "parsing_relabel_round1"}
{"nct_id": "NCT00001677", "eligibility_text": "Ability to provide informed consent to all aspects of the study after full information is provided.. Age equal to or older than 18.. A diagnosis of Rheumatoid Arthritis (RA) of more than 6 months as defined by the revised American College of Rheumatology criteria.. Active RA defined as: 6 or more swollen joints;. 6 or more tender joints;. ESR greater than 28 mm/hr (or CRP greater than 0.8) or morning stiffness greater than 45 minutes.. Incomplete response (defined as persistently active disease as described above) to treatment with at least one of the following regimens for over 3 months:. MTX alone (greater than or equal to 17.5 mg/week);. MTX (greater than or equal to 17.5 mg/week) plus HCQ (greater than or equal to 200 mg/day);. MTX (greater than or equal to 17.5 mg/week) plus SSZ (greater than or equal to 1 gm/d);. MTX (greater than or equal to 17.5 mg/week) plus CsA (1-3 mg/kg/day);. MTX (greater than or equal to 17.5 mg/week) plus SSZ (greater than 1 gm/day) plus HCQ (greater than or equal to 200 mg/day);. No requirement of corticosteroids in doses equivalent to over 10 mg/d prednisone nor other immunosuppressive agents required for the control of extraarticular manifestations at the time of study entry.. No active acute or chronic infections requiring antibiotic therapy, serious viral infections (such as hepatitis, herpes zoster, or HIV), or serious fungal infections. Patients with a positive PPD who have not received INH or other antituberculous therapy will be excluded.. No pregnant women, nursing mothers, or patients of childbearing age not practicing birth control.. No preexisting malignancy other than basal cell carcinoma.. No history of stroke, seizure disorder, or chronic neurologic disease.. No unstable coronary artery disease, cardiomyopathy, conduction heart block greater than first degree, or a dysrhythmia requiring therapy.. No confounding medical illness that in the judgment of the investigators would pose added risk for study participants (e.g., chronic hepatic, renal, or pulmonary disease or bone marrow hypoplasia).. No presence of seronegative spondyloarthropathy, systemic lupus erythematosus, systemic sclerosis, inflammatory myopathy, systemic vasculitis, psoriasis, or inflammatory bowel disease.. No serum creatinine greater than 2.0 mg/dL on at least 2 different occasions which is sustained for at least 1 month.. No hematocrit less than 28% (or hemoglobin less than 9.0 mg/dL), or platelet count less than 100,000, or white blood count less than 3,500/dL.. No patients with active lung disease, patients with a chronic and progressive lung disease, or patients with a chronic but stable lung disease with pulmonary function tests of less than 70% of predicted (DLCO less than 60%).. No patients with hypogammaglobulinemia (IgG count less than 300).. No patients treated with alkylating agents for over 1 year at any time or treated with a purine nucleoside analog at any time.", "labeled_rules": [{"type": "EXCLUSION", "field": "age", "operator": ">=", "value": 18, "unit": "years", "evidence_text": "Ability to provide informed consent to all aspects of the study after full information is provided.. Age equal to or older than 18.. A diagnosis of Rheumatoid Arthritis (RA) of more than 6 months as defined by the revised American College of Rheumatology criteria.. Active RA defined as: 6 or more swollen joints;. 6 or more tender joints;. ESR greater than 28 mm/hr (or CRP greater than 0.8) or morning stiffness greater than 45 minutes.. Incomplete response (defined as persistently active disease as described above) to treatment with at least one of the following regimens for over 3 months:. MTX alone (greater than or equal to 17.5 mg/week);. MTX (greater than or equal to 17.5 mg/week) plus HCQ (greater than or equal to 200 mg/day);. MTX (greater than or equal to 17.5 mg/week) plus SSZ (greater than or equal to 1 gm/d);. MTX (greater than or equal to 17.5 mg/week) plus CsA (1-3 mg/kg/day);. MTX (greater than or equal to 17.5 mg/week) plus SSZ (greater than 1 gm/day) plus HCQ (greater than or equal to 200 mg/day);. No requirement of corticosteroids in doses equivalent to over 10 mg/d prednisone nor other immunosuppressive agents required for the control of extraarticular manifestations at the time of study entry.. No active acute or chronic infections requiring antibiotic therapy, serious viral infections (such as hepatitis, herpes zoster, or HIV), or serious fungal infections. Patients with a positive PPD who have not received INH or other antituberculous therapy will be excluded.. No pregnant women, nursing mothers, or patients of childbearing age not practicing birth control.. No preexisting malignancy other than basal cell carcinoma.. No history of stroke, seizure disorder, or chronic neurologic disease.. No unstable coronary artery disease, cardiomyopathy, conduction heart block greater than first degree, or a dysrhythmia requiring therapy.. No confounding medical illness that in the judgment of the investigators would pose added risk for study participants (e.g., chronic hepatic, renal, or pulmonary disease or bone marrow hypoplasia).. No presence of seronegative spondyloarthropathy, systemic lupus erythematosus, systemic sclerosis, inflammatory myopathy, systemic vasculitis, psoriasis, or inflammatory bowel disease.. No serum creatinine greater than 2.0 mg/dL on at least 2 different occasions which is sustained for at least 1 month.. No hematocrit less than 28% (or hemoglobin less than 9.0 mg/dL), or platelet count less than 100,000, or white blood count less than 3,500/dL.. No patients with active lung disease, patients with a chronic and progressive lung disease, or patients with a chronic but stable lung disease with pulmonary function tests of less than 70% of predicted (DLCO less than 60%).. No patients with hypogammaglobulinemia (IgG count less than 300).. No patients treated with alkylating agents for over 1 year at any time or treated with a purine nucleoside analog at any time"}, {"type": "EXCLUSION", "field": "age", "operator": ">=", "value": 2, "unit": "years", "evidence_text": "Ability to provide informed consent to all aspects of the study after full information is provided.. Age equal to or older than 18.. A diagnosis of Rheumatoid Arthritis (RA) of more than 6 months as defined by the revised American College of Rheumatology criteria.. Active RA defined as: 6 or more swollen joints;. 6 or more tender joints;. ESR greater than 28 mm/hr (or CRP greater than 0.8) or morning stiffness greater than 45 minutes.. Incomplete response (defined as persistently active disease as described above) to treatment with at least one of the following regimens for over 3 months:. MTX alone (greater than or equal to 17.5 mg/week);. MTX (greater than or equal to 17.5 mg/week) plus HCQ (greater than or equal to 200 mg/day);. MTX (greater than or equal to 17.5 mg/week) plus SSZ (greater than or equal to 1 gm/d);. MTX (greater than or equal to 17.5 mg/week) plus CsA (1-3 mg/kg/day);. MTX (greater than or equal to 17.5 mg/week) plus SSZ (greater than 1 gm/day) plus HCQ (greater than or equal to 200 mg/day);. No requirement of corticosteroids in doses equivalent to over 10 mg/d prednisone nor other immunosuppressive agents required for the control of extraarticular manifestations at the time of study entry.. No active acute or chronic infections requiring antibiotic therapy, serious viral infections (such as hepatitis, herpes zoster, or HIV), or serious fungal infections. Patients with a positive PPD who have not received INH or other antituberculous therapy will be excluded.. No pregnant women, nursing mothers, or patients of childbearing age not practicing birth control.. No preexisting malignancy other than basal cell carcinoma.. No history of stroke, seizure disorder, or chronic neurologic disease.. No unstable coronary artery disease, cardiomyopathy, conduction heart block greater than first degree, or a dysrhythmia requiring therapy.. No confounding medical illness that in the judgment of the investigators would pose added risk for study participants (e.g., chronic hepatic, renal, or pulmonary disease or bone marrow hypoplasia).. No presence of seronegative spondyloarthropathy, systemic lupus erythematosus, systemic sclerosis, inflammatory myopathy, systemic vasculitis, psoriasis, or inflammatory bowel disease.. No serum creatinine greater than 2.0 mg/dL on at least 2 different occasions which is sustained for at least 1 month.. No hematocrit less than 28% (or hemoglobin less than 9.0 mg/dL), or platelet count less than 100,000, or white blood count less than 3,500/dL.. No patients with active lung disease, patients with a chronic and progressive lung disease, or patients with a chronic but stable lung disease with pulmonary function tests of less than 70% of predicted (DLCO less than 60%).. No patients with hypogammaglobulinemia (IgG count less than 300).. No patients treated with alkylating agents for over 1 year at any time or treated with a purine nucleoside analog at any time"}, {"type": "EXCLUSION", "field": "condition", "operator": "IN", "value": "a chronic and progressive lung disease", "unit": null, "evidence_text": "Ability to provide informed consent to all aspects of the study after full information is provided.. Age equal to or older than 18.. A diagnosis of Rheumatoid Arthritis (RA) of more than 6 months as defined by the revised American College of Rheumatology criteria.. Active RA defined as: 6 or more swollen joints;. 6 or more tender joints;. ESR greater than 28 mm/hr (or CRP greater than 0.8) or morning stiffness greater than 45 minutes.. Incomplete response (defined as persistently active disease as described above) to treatment with at least one of the following regimens for over 3 months:. MTX alone (greater than or equal to 17.5 mg/week);. MTX (greater than or equal to 17.5 mg/week) plus HCQ (greater than or equal to 200 mg/day);. MTX (greater than or equal to 17.5 mg/week) plus SSZ (greater than or equal to 1 gm/d);. MTX (greater than or equal to 17.5 mg/week) plus CsA (1-3 mg/kg/day);. MTX (greater than or equal to 17.5 mg/week) plus SSZ (greater than 1 gm/day) plus HCQ (greater than or equal to 200 mg/day);. No requirement of corticosteroids in doses equivalent to over 10 mg/d prednisone nor other immunosuppressive agents required for the control of extraarticular manifestations at the time of study entry.. No active acute or chronic infections requiring antibiotic therapy, serious viral infections (such as hepatitis, herpes zoster, or HIV), or serious fungal infections. Patients with a positive PPD who have not received INH or other antituberculous therapy will be excluded.. No pregnant women, nursing mothers, or patients of childbearing age not practicing birth control.. No preexisting malignancy other than basal cell carcinoma.. No history of stroke, seizure disorder, or chronic neurologic disease.. No unstable coronary artery disease, cardiomyopathy, conduction heart block greater than first degree, or a dysrhythmia requiring therapy.. No confounding medical illness that in the judgment of the investigators would pose added risk for study participants (e.g., chronic hepatic, renal, or pulmonary disease or bone marrow hypoplasia).. No presence of seronegative spondyloarthropathy, systemic lupus erythematosus, systemic sclerosis, inflammatory myopathy, systemic vasculitis, psoriasis, or inflammatory bowel disease.. No serum creatinine greater than 2.0 mg/dL on at least 2 different occasions which is sustained for at least 1 month.. No hematocrit less than 28% (or hemoglobin less than 9.0 mg/dL), or platelet count less than 100,000, or white blood count less than 3,500/dL.. No patients with active lung disease, patients with a chronic and progressive lung disease, or patients with a chronic but stable lung disease with pulmonary function tests of less than 70% of predicted (DLCO less than 60%).. No patients with hypogammaglobulinemia (IgG count less than 300).. No patients treated with alkylating agents for over 1 year at any time or treated with a purine nucleoside analog at any time"}, {"type": "EXCLUSION", "field": "condition", "operator": "IN", "value": "a purine nucleoside analog at any", "unit": null, "evidence_text": "Ability to provide informed consent to all aspects of the study after full information is provided.. Age equal to or older than 18.. A diagnosis of Rheumatoid Arthritis (RA) of more than 6 months as defined by the revised American College of Rheumatology criteria.. Active RA defined as: 6 or more swollen joints;. 6 or more tender joints;. ESR greater than 28 mm/hr (or CRP greater than 0.8) or morning stiffness greater than 45 minutes.. Incomplete response (defined as persistently active disease as described above) to treatment with at least one of the following regimens for over 3 months:. MTX alone (greater than or equal to 17.5 mg/week);. MTX (greater than or equal to 17.5 mg/week) plus HCQ (greater than or equal to 200 mg/day);. MTX (greater than or equal to 17.5 mg/week) plus SSZ (greater than or equal to 1 gm/d);. MTX (greater than or equal to 17.5 mg/week) plus CsA (1-3 mg/kg/day);. MTX (greater than or equal to 17.5 mg/week) plus SSZ (greater than 1 gm/day) plus HCQ (greater than or equal to 200 mg/day);. No requirement of corticosteroids in doses equivalent to over 10 mg/d prednisone nor other immunosuppressive agents required for the control of extraarticular manifestations at the time of study entry.. No active acute or chronic infections requiring antibiotic therapy, serious viral infections (such as hepatitis, herpes zoster, or HIV), or serious fungal infections. Patients with a positive PPD who have not received INH or other antituberculous therapy will be excluded.. No pregnant women, nursing mothers, or patients of childbearing age not practicing birth control.. No preexisting malignancy other than basal cell carcinoma.. No history of stroke, seizure disorder, or chronic neurologic disease.. No unstable coronary artery disease, cardiomyopathy, conduction heart block greater than first degree, or a dysrhythmia requiring therapy.. No confounding medical illness that in the judgment of the investigators would pose added risk for study participants (e.g., chronic hepatic, renal, or pulmonary disease or bone marrow hypoplasia).. No presence of seronegative spondyloarthropathy, systemic lupus erythematosus, systemic sclerosis, inflammatory myopathy, systemic vasculitis, psoriasis, or inflammatory bowel disease.. No serum creatinine greater than 2.0 mg/dL on at least 2 different occasions which is sustained for at least 1 month.. No hematocrit less than 28% (or hemoglobin less than 9.0 mg/dL), or platelet count less than 100,000, or white blood count less than 3,500/dL.. No patients with active lung disease, patients with a chronic and progressive lung disease, or patients with a chronic but stable lung disease with pulmonary function tests of less than 70% of predicted (DLCO less than 60%).. No patients with hypogammaglobulinemia (IgG count less than 300).. No patients treated with alkylating agents for over 1 year at any time or treated with a purine nucleoside analog at any time"}, {"type": "EXCLUSION", "field": "condition", "operator": "IN", "value": "a purine nucleoside analog at any time", "unit": null, "evidence_text": "Ability to provide informed consent to all aspects of the study after full information is provided.. Age equal to or older than 18.. A diagnosis of Rheumatoid Arthritis (RA) of more than 6 months as defined by the revised American College of Rheumatology criteria.. Active RA defined as: 6 or more swollen joints;. 6 or more tender joints;. ESR greater than 28 mm/hr (or CRP greater than 0.8) or morning stiffness greater than 45 minutes.. Incomplete response (defined as persistently active disease as described above) to treatment with at least one of the following regimens for over 3 months:. MTX alone (greater than or equal to 17.5 mg/week);. MTX (greater than or equal to 17.5 mg/week) plus HCQ (greater than or equal to 200 mg/day);. MTX (greater than or equal to 17.5 mg/week) plus SSZ (greater than or equal to 1 gm/d);. MTX (greater than or equal to 17.5 mg/week) plus CsA (1-3 mg/kg/day);. MTX (greater than or equal to 17.5 mg/week) plus SSZ (greater than 1 gm/day) plus HCQ (greater than or equal to 200 mg/day);. No requirement of corticosteroids in doses equivalent to over 10 mg/d prednisone nor other immunosuppressive agents required for the control of extraarticular manifestations at the time of study entry.. No active acute or chronic infections requiring antibiotic therapy, serious viral infections (such as hepatitis, herpes zoster, or HIV), or serious fungal infections. Patients with a positive PPD who have not received INH or other antituberculous therapy will be excluded.. No pregnant women, nursing mothers, or patients of childbearing age not practicing birth control.. No preexisting malignancy other than basal cell carcinoma.. No history of stroke, seizure disorder, or chronic neurologic disease.. No unstable coronary artery disease, cardiomyopathy, conduction heart block greater than first degree, or a dysrhythmia requiring therapy.. No confounding medical illness that in the judgment of the investigators would pose added risk for study participants (e.g., chronic hepatic, renal, or pulmonary disease or bone marrow hypoplasia).. No presence of seronegative spondyloarthropathy, systemic lupus erythematosus, systemic sclerosis, inflammatory myopathy, systemic vasculitis, psoriasis, or inflammatory bowel disease.. No serum creatinine greater than 2.0 mg/dL on at least 2 different occasions which is sustained for at least 1 month.. No hematocrit less than 28% (or hemoglobin less than 9.0 mg/dL), or platelet count less than 100,000, or white blood count less than 3,500/dL.. No patients with active lung disease, patients with a chronic and progressive lung disease, or patients with a chronic but stable lung disease with pulmonary function tests of less than 70% of predicted (DLCO less than 60%).. No patients with hypogammaglobulinemia (IgG count less than 300).. No patients treated with alkylating agents for over 1 year at any time or treated with a purine nucleoside analog at any time"}, {"type": "EXCLUSION", "field": "condition", "operator": "IN", "value": "active lung disease", "unit": null, "evidence_text": "Ability to provide informed consent to all aspects of the study after full information is provided.. Age equal to or older than 18.. A diagnosis of Rheumatoid Arthritis (RA) of more than 6 months as defined by the revised American College of Rheumatology criteria.. Active RA defined as: 6 or more swollen joints;. 6 or more tender joints;. ESR greater than 28 mm/hr (or CRP greater than 0.8) or morning stiffness greater than 45 minutes.. Incomplete response (defined as persistently active disease as described above) to treatment with at least one of the following regimens for over 3 months:. MTX alone (greater than or equal to 17.5 mg/week);. MTX (greater than or equal to 17.5 mg/week) plus HCQ (greater than or equal to 200 mg/day);. MTX (greater than or equal to 17.5 mg/week) plus SSZ (greater than or equal to 1 gm/d);. MTX (greater than or equal to 17.5 mg/week) plus CsA (1-3 mg/kg/day);. MTX (greater than or equal to 17.5 mg/week) plus SSZ (greater than 1 gm/day) plus HCQ (greater than or equal to 200 mg/day);. No requirement of corticosteroids in doses equivalent to over 10 mg/d prednisone nor other immunosuppressive agents required for the control of extraarticular manifestations at the time of study entry.. No active acute or chronic infections requiring antibiotic therapy, serious viral infections (such as hepatitis, herpes zoster, or HIV), or serious fungal infections. Patients with a positive PPD who have not received INH or other antituberculous therapy will be excluded.. No pregnant women, nursing mothers, or patients of childbearing age not practicing birth control.. No preexisting malignancy other than basal cell carcinoma.. No history of stroke, seizure disorder, or chronic neurologic disease.. No unstable coronary artery disease, cardiomyopathy, conduction heart block greater than first degree, or a dysrhythmia requiring therapy.. No confounding medical illness that in the judgment of the investigators would pose added risk for study participants (e.g., chronic hepatic, renal, or pulmonary disease or bone marrow hypoplasia).. No presence of seronegative spondyloarthropathy, systemic lupus erythematosus, systemic sclerosis, inflammatory myopathy, systemic vasculitis, psoriasis, or inflammatory bowel disease.. No serum creatinine greater than 2.0 mg/dL on at least 2 different occasions which is sustained for at least 1 month.. No hematocrit less than 28% (or hemoglobin less than 9.0 mg/dL), or platelet count less than 100,000, or white blood count less than 3,500/dL.. No patients with active lung disease, patients with a chronic and progressive lung disease, or patients with a chronic but stable lung disease with pulmonary function tests of less than 70% of predicted (DLCO less than 60%).. No patients with hypogammaglobulinemia (IgG count less than 300).. No patients treated with alkylating agents for over 1 year at any time or treated with a purine nucleoside analog at any time"}, {"type": "EXCLUSION", "field": "condition", "operator": "IN", "value": "stroke, seizure disorder, or chronic neurologic", "unit": null, "evidence_text": "Ability to provide informed consent to all aspects of the study after full information is provided.. Age equal to or older than 18.. A diagnosis of Rheumatoid Arthritis (RA) of more than 6 months as defined by the revised American College of Rheumatology criteria.. Active RA defined as: 6 or more swollen joints;. 6 or more tender joints;. ESR greater than 28 mm/hr (or CRP greater than 0.8) or morning stiffness greater than 45 minutes.. Incomplete response (defined as persistently active disease as described above) to treatment with at least one of the following regimens for over 3 months:. MTX alone (greater than or equal to 17.5 mg/week);. MTX (greater than or equal to 17.5 mg/week) plus HCQ (greater than or equal to 200 mg/day);. MTX (greater than or equal to 17.5 mg/week) plus SSZ (greater than or equal to 1 gm/d);. MTX (greater than or equal to 17.5 mg/week) plus CsA (1-3 mg/kg/day);. MTX (greater than or equal to 17.5 mg/week) plus SSZ (greater than 1 gm/day) plus HCQ (greater than or equal to 200 mg/day);. No requirement of corticosteroids in doses equivalent to over 10 mg/d prednisone nor other immunosuppressive agents required for the control of extraarticular manifestations at the time of study entry.. No active acute or chronic infections requiring antibiotic therapy, serious viral infections (such as hepatitis, herpes zoster, or HIV), or serious fungal infections. Patients with a positive PPD who have not received INH or other antituberculous therapy will be excluded.. No pregnant women, nursing mothers, or patients of childbearing age not practicing birth control.. No preexisting malignancy other than basal cell carcinoma.. No history of stroke, seizure disorder, or chronic neurologic disease.. No unstable coronary artery disease, cardiomyopathy, conduction heart block greater than first degree, or a dysrhythmia requiring therapy.. No confounding medical illness that in the judgment of the investigators would pose added risk for study participants (e.g., chronic hepatic, renal, or pulmonary disease or bone marrow hypoplasia).. No presence of seronegative spondyloarthropathy, systemic lupus erythematosus, systemic sclerosis, inflammatory myopathy, systemic vasculitis, psoriasis, or inflammatory bowel disease.. No serum creatinine greater than 2.0 mg/dL on at least 2 different occasions which is sustained for at least 1 month.. No hematocrit less than 28% (or hemoglobin less than 9.0 mg/dL), or platelet count less than 100,000, or white blood count less than 3,500/dL.. No patients with active lung disease, patients with a chronic and progressive lung disease, or patients with a chronic but stable lung disease with pulmonary function tests of less than 70% of predicted (DLCO less than 60%).. No patients with hypogammaglobulinemia (IgG count less than 300).. No patients treated with alkylating agents for over 1 year at any time or treated with a purine nucleoside analog at any time"}, {"type": "EXCLUSION", "field": "history", "operator": "IN", "value": "No requirement of corticosteroids in doses equivalent to over 10 mg/d prednisone nor other immunosuppressive agents required for the contr", "unit": null, "evidence_text": "Ability to provide informed consent to all aspects of the study after full information is provided.. Age equal to or older than 18.. A diagnosis of Rheumatoid Arthritis (RA) of more than 6 months as defined by the revised American College of Rheumatology criteria.. Active RA defined as: 6 or more swollen joints;. 6 or more tender joints;. ESR greater than 28 mm/hr (or CRP greater than 0.8) or morning stiffness greater than 45 minutes.. Incomplete response (defined as persistently active disease as described above) to treatment with at least one of the following regimens for over 3 months:. MTX alone (greater than or equal to 17.5 mg/week);. MTX (greater than or equal to 17.5 mg/week) plus HCQ (greater than or equal to 200 mg/day);. MTX (greater than or equal to 17.5 mg/week) plus SSZ (greater than or equal to 1 gm/d);. MTX (greater than or equal to 17.5 mg/week) plus CsA (1-3 mg/kg/day);. MTX (greater than or equal to 17.5 mg/week) plus SSZ (greater than 1 gm/day) plus HCQ (greater than or equal to 200 mg/day);. No requirement of corticosteroids in doses equivalent to over 10 mg/d prednisone nor other immunosuppressive agents required for the control of extraarticular manifestations at the time of study entry.. No active acute or chronic infections requiring antibiotic therapy, serious viral infections (such as hepatitis, herpes zoster, or HIV), or serious fungal infections. Patients with a positive PPD who have not received INH or other antituberculous therapy will be excluded.. No pregnant women, nursing mothers, or patients of childbearing age not practicing birth control.. No preexisting malignancy other than basal cell carcinoma.. No history of stroke, seizure disorder, or chronic neurologic disease.. No unstable coronary artery disease, cardiomyopathy, conduction heart block greater than first degree, or a dysrhythmia requiring therapy.. No confounding medical illness that in the judgment of the investigators would pose added risk for study participants (e.g., chronic hepatic, renal, or pulmonary disease or bone marrow hypoplasia).. No presence of seronegative spondyloarthropathy, systemic lupus erythematosus, systemic sclerosis, inflammatory myopathy, systemic vasculitis, psoriasis, or inflammatory bowel disease.. No serum creatinine greater than 2.0 mg/dL on at least 2 different occasions which is sustained for at least 1 month.. No hematocrit less than 28% (or hemoglobin less than 9.0 mg/dL), or platelet count less than 100,000, or white blood count less than 3,500/dL.. No patients with active lung disease, patients with a chronic and progressive lung disease, or patients with a chronic but stable lung disease with pulmonary function tests of less than 70% of predicted (DLCO less than 60%).. No patients with hypogammaglobulinemia (IgG count less than 300).. No patients treated with alkylating agents for over 1 year at any time or treated with a purine nucleoside analog at any time"}, {"type": "EXCLUSION", "field": "lab", "operator": ">=", "value": 2, "unit": "mg/dl", "evidence_text": "Ability to provide informed consent to all aspects of the study after full information is provided.. Age equal to or older than 18.. A diagnosis of Rheumatoid Arthritis (RA) of more than 6 months as defined by the revised American College of Rheumatology criteria.. Active RA defined as: 6 or more swollen joints;. 6 or more tender joints;. ESR greater than 28 mm/hr (or CRP greater than 0.8) or morning stiffness greater than 45 minutes.. Incomplete response (defined as persistently active disease as described above) to treatment with at least one of the following regimens for over 3 months:. MTX alone (greater than or equal to 17.5 mg/week);. MTX (greater than or equal to 17.5 mg/week) plus HCQ (greater than or equal to 200 mg/day);. MTX (greater than or equal to 17.5 mg/week) plus SSZ (greater than or equal to 1 gm/d);. MTX (greater than or equal to 17.5 mg/week) plus CsA (1-3 mg/kg/day);. MTX (greater than or equal to 17.5 mg/week) plus SSZ (greater than 1 gm/day) plus HCQ (greater than or equal to 200 mg/day);. No requirement of corticosteroids in doses equivalent to over 10 mg/d prednisone nor other immunosuppressive agents required for the control of extraarticular manifestations at the time of study entry.. No active acute or chronic infections requiring antibiotic therapy, serious viral infections (such as hepatitis, herpes zoster, or HIV), or serious fungal infections. Patients with a positive PPD who have not received INH or other antituberculous therapy will be excluded.. No pregnant women, nursing mothers, or patients of childbearing age not practicing birth control.. No preexisting malignancy other than basal cell carcinoma.. No history of stroke, seizure disorder, or chronic neurologic disease.. No unstable coronary artery disease, cardiomyopathy, conduction heart block greater than first degree, or a dysrhythmia requiring therapy.. No confounding medical illness that in the judgment of the investigators would pose added risk for study participants (e.g., chronic hepatic, renal, or pulmonary disease or bone marrow hypoplasia).. No presence of seronegative spondyloarthropathy, systemic lupus erythematosus, systemic sclerosis, inflammatory myopathy, systemic vasculitis, psoriasis, or inflammatory bowel disease.. No serum creatinine greater than 2.0 mg/dL on at least 2 different occasions which is sustained for at least 1 month.. No hematocrit less than 28% (or hemoglobin less than 9.0 mg/dL), or platelet count less than 100,000, or white blood count less than 3,500/dL.. No patients with active lung disease, patients with a chronic and progressive lung disease, or patients with a chronic but stable lung disease with pulmonary function tests of less than 70% of predicted (DLCO less than 60%).. No patients with hypogammaglobulinemia (IgG count less than 300).. No patients treated with alkylating agents for over 1 year at any time or treated with a purine nucleoside analog at any time"}, {"type": "EXCLUSION", "field": "lab", "operator": ">=", "value": 28, "unit": "mm/hr", "evidence_text": "Ability to provide informed consent to all aspects of the study after full information is provided.. Age equal to or older than 18.. A diagnosis of Rheumatoid Arthritis (RA) of more than 6 months as defined by the revised American College of Rheumatology criteria.. Active RA defined as: 6 or more swollen joints;. 6 or more tender joints;. ESR greater than 28 mm/hr (or CRP greater than 0.8) or morning stiffness greater than 45 minutes.. Incomplete response (defined as persistently active disease as described above) to treatment with at least one of the following regimens for over 3 months:. MTX alone (greater than or equal to 17.5 mg/week);. MTX (greater than or equal to 17.5 mg/week) plus HCQ (greater than or equal to 200 mg/day);. MTX (greater than or equal to 17.5 mg/week) plus SSZ (greater than or equal to 1 gm/d);. MTX (greater than or equal to 17.5 mg/week) plus CsA (1-3 mg/kg/day);. MTX (greater than or equal to 17.5 mg/week) plus SSZ (greater than 1 gm/day) plus HCQ (greater than or equal to 200 mg/day);. No requirement of corticosteroids in doses equivalent to over 10 mg/d prednisone nor other immunosuppressive agents required for the control of extraarticular manifestations at the time of study entry.. No active acute or chronic infections requiring antibiotic therapy, serious viral infections (such as hepatitis, herpes zoster, or HIV), or serious fungal infections. Patients with a positive PPD who have not received INH or other antituberculous therapy will be excluded.. No pregnant women, nursing mothers, or patients of childbearing age not practicing birth control.. No preexisting malignancy other than basal cell carcinoma.. No history of stroke, seizure disorder, or chronic neurologic disease.. No unstable coronary artery disease, cardiomyopathy, conduction heart block greater than first degree, or a dysrhythmia requiring therapy.. No confounding medical illness that in the judgment of the investigators would pose added risk for study participants (e.g., chronic hepatic, renal, or pulmonary disease or bone marrow hypoplasia).. No presence of seronegative spondyloarthropathy, systemic lupus erythematosus, systemic sclerosis, inflammatory myopathy, systemic vasculitis, psoriasis, or inflammatory bowel disease.. No serum creatinine greater than 2.0 mg/dL on at least 2 different occasions which is sustained for at least 1 month.. No hematocrit less than 28% (or hemoglobin less than 9.0 mg/dL), or platelet count less than 100,000, or white blood count less than 3,500/dL.. No patients with active lung disease, patients with a chronic and progressive lung disease, or patients with a chronic but stable lung disease with pulmonary function tests of less than 70% of predicted (DLCO less than 60%).. No patients with hypogammaglobulinemia (IgG count less than 300).. No patients treated with alkylating agents for over 1 year at any time or treated with a purine nucleoside analog at any time"}, {"type": "EXCLUSION", "field": "medication", "operator": "IN", "value": "ESR greater than 28 mm/hr (or CRP greater than 0.8) or morning stiffness greater than 45 minutes.. Incomplete response (defined as persist", "unit": null, "evidence_text": "Ability to provide informed consent to all aspects of the study after full information is provided.. Age equal to or older than 18.. A diagnosis of Rheumatoid Arthritis (RA) of more than 6 months as defined by the revised American College of Rheumatology criteria.. Active RA defined as: 6 or more swollen joints;. 6 or more tender joints;. ESR greater than 28 mm/hr (or CRP greater than 0.8) or morning stiffness greater than 45 minutes.. Incomplete response (defined as persistently active disease as described above) to treatment with at least one of the following regimens for over 3 months:. MTX alone (greater than or equal to 17.5 mg/week);. MTX (greater than or equal to 17.5 mg/week) plus HCQ (greater than or equal to 200 mg/day);. MTX (greater than or equal to 17.5 mg/week) plus SSZ (greater than or equal to 1 gm/d);. MTX (greater than or equal to 17.5 mg/week) plus CsA (1-3 mg/kg/day);. MTX (greater than or equal to 17.5 mg/week) plus SSZ (greater than 1 gm/day) plus HCQ (greater than or equal to 200 mg/day);. No requirement of corticosteroids in doses equivalent to over 10 mg/d prednisone nor other immunosuppressive agents required for the control of extraarticular manifestations at the time of study entry.. No active acute or chronic infections requiring antibiotic therapy, serious viral infections (such as hepatitis, herpes zoster, or HIV), or serious fungal infections. Patients with a positive PPD who have not received INH or other antituberculous therapy will be excluded.. No pregnant women, nursing mothers, or patients of childbearing age not practicing birth control.. No preexisting malignancy other than basal cell carcinoma.. No history of stroke, seizure disorder, or chronic neurologic disease.. No unstable coronary artery disease, cardiomyopathy, conduction heart block greater than first degree, or a dysrhythmia requiring therapy.. No confounding medical illness that in the judgment of the investigators would pose added risk for study participants (e.g., chronic hepatic, renal, or pulmonary disease or bone marrow hypoplasia).. No presence of seronegative spondyloarthropathy, systemic lupus erythematosus, systemic sclerosis, inflammatory myopathy, systemic vasculitis, psoriasis, or inflammatory bowel disease.. No serum creatinine greater than 2.0 mg/dL on at least 2 different occasions which is sustained for at least 1 month.. No hematocrit less than 28% (or hemoglobin less than 9.0 mg/dL), or platelet count less than 100,000, or white blood count less than 3,500/dL.. No patients with active lung disease, patients with a chronic and progressive lung disease, or patients with a chronic but stable lung disease with pulmonary function tests of less than 70% of predicted (DLCO less than 60%).. No patients with hypogammaglobulinemia (IgG count less than 300).. No patients treated with alkylating agents for over 1 year at any time or treated with a purine nucleoside analog at any time"}, {"type": "EXCLUSION", "field": "medication", "operator": "IN", "value": "No requirement of corticosteroids in doses equivalent to over 10 mg/d prednisone nor other immunosuppressive agents required for the contr", "unit": null, "evidence_text": "Ability to provide informed consent to all aspects of the study after full information is provided.. Age equal to or older than 18.. A diagnosis of Rheumatoid Arthritis (RA) of more than 6 months as defined by the revised American College of Rheumatology criteria.. Active RA defined as: 6 or more swollen joints;. 6 or more tender joints;. ESR greater than 28 mm/hr (or CRP greater than 0.8) or morning stiffness greater than 45 minutes.. Incomplete response (defined as persistently active disease as described above) to treatment with at least one of the following regimens for over 3 months:. MTX alone (greater than or equal to 17.5 mg/week);. MTX (greater than or equal to 17.5 mg/week) plus HCQ (greater than or equal to 200 mg/day);. MTX (greater than or equal to 17.5 mg/week) plus SSZ (greater than or equal to 1 gm/d);. MTX (greater than or equal to 17.5 mg/week) plus CsA (1-3 mg/kg/day);. MTX (greater than or equal to 17.5 mg/week) plus SSZ (greater than 1 gm/day) plus HCQ (greater than or equal to 200 mg/day);. No requirement of corticosteroids in doses equivalent to over 10 mg/d prednisone nor other immunosuppressive agents required for the control of extraarticular manifestations at the time of study entry.. No active acute or chronic infections requiring antibiotic therapy, serious viral infections (such as hepatitis, herpes zoster, or HIV), or serious fungal infections. Patients with a positive PPD who have not received INH or other antituberculous therapy will be excluded.. No pregnant women, nursing mothers, or patients of childbearing age not practicing birth control.. No preexisting malignancy other than basal cell carcinoma.. No history of stroke, seizure disorder, or chronic neurologic disease.. No unstable coronary artery disease, cardiomyopathy, conduction heart block greater than first degree, or a dysrhythmia requiring therapy.. No confounding medical illness that in the judgment of the investigators would pose added risk for study participants (e.g., chronic hepatic, renal, or pulmonary disease or bone marrow hypoplasia).. No presence of seronegative spondyloarthropathy, systemic lupus erythematosus, systemic sclerosis, inflammatory myopathy, systemic vasculitis, psoriasis, or inflammatory bowel disease.. No serum creatinine greater than 2.0 mg/dL on at least 2 different occasions which is sustained for at least 1 month.. No hematocrit less than 28% (or hemoglobin less than 9.0 mg/dL), or platelet count less than 100,000, or white blood count less than 3,500/dL.. No patients with active lung disease, patients with a chronic and progressive lung disease, or patients with a chronic but stable lung disease with pulmonary function tests of less than 70% of predicted (DLCO less than 60%).. No patients with hypogammaglobulinemia (IgG count less than 300).. No patients treated with alkylating agents for over 1 year at any time or treated with a purine nucleoside analog at any time"}, {"type": "EXCLUSION", "field": "other", "operator": "IN", "value": "Ability to provide informed consent to all aspects of the study after full information is provided.. Age equal to or older than 18.. A diagn", "unit": null, "evidence_text": "Ability to provide informed consent to all aspects of the study after full information is provided.. Age equal to or older than 18.. A diagnosis of Rheumatoid Arthritis (RA) of more than 6 months as defined by the revised American College of Rheumatology criteria.. Active RA defined as: 6 or more swollen joints;. 6 or more tender joints;. ESR greater than 28 mm/hr (or CRP greater than 0.8) or morning stiffness greater than 45 minutes.. Incomplete response (defined as persistently active disease as described above) to treatment with at least one of the following regimens for over 3 months:. MTX alone (greater than or equal to 17.5 mg/week);. MTX (greater than or equal to 17.5 mg/week) plus HCQ (greater than or equal to 200 mg/day);. MTX (greater than or equal to 17.5 mg/week) plus SSZ (greater than or equal to 1 gm/d);. MTX (greater than or equal to 17.5 mg/week) plus CsA (1-3 mg/kg/day);. MTX (greater than or equal to 17.5 mg/week) plus SSZ (greater than 1 gm/day) plus HCQ (greater than or equal to 200 mg/day);. No requirement of corticosteroids in doses equivalent to over 10 mg/d prednisone nor other immunosuppressive agents required for the control of extraarticular manifestations at the time of study entry.. No active acute or chronic infections requiring antibiotic therapy, serious viral infections (such as hepatitis, herpes zoster, or HIV), or serious fungal infections. Patients with a positive PPD who have not received INH or other antituberculous therapy will be excluded.. No pregnant women, nursing mothers, or patients of childbearing age not practicing birth control.. No preexisting malignancy other than basal cell carcinoma.. No history of stroke, seizure disorder, or chronic neurologic disease.. No unstable coronary artery disease, cardiomyopathy, conduction heart block greater than first degree, or a dysrhythmia requiring therapy.. No confounding medical illness that in the judgment of the investigators would pose added risk for study participants (e.g., chronic hepatic, renal, or pulmonary disease or bone marrow hypoplasia).. No presence of seronegative spondyloarthropathy, systemic lupus erythematosus, systemic sclerosis, inflammatory myopathy, systemic vasculitis, psoriasis, or inflammatory bowel disease.. No serum creatinine greater than 2.0 mg/dL on at least 2 different occasions which is sustained for at least 1 month.. No hematocrit less than 28% (or hemoglobin less than 9.0 mg/dL), or platelet count less than 100,000, or white blood count less than 3,500/dL.. No patients with active lung disease, patients with a chronic and progressive lung disease, or patients with a chronic but stable lung disease with pulmonary function tests of less than 70% of predicted (DLCO less than 60%).. No patients with hypogammaglobulinemia (IgG count less than 300).. No patients treated with alkylating agents for over 1 year at any time or treated with a purine nucleoside analog at any time"}, {"type": "EXCLUSION", "field": "procedure", "operator": "IN", "value": "Ability to provide informed consent to all aspects of the study after full information is provided.. Age equal to or older than 18.. A diagn", "unit": null, "evidence_text": "Ability to provide informed consent to all aspects of the study after full information is provided.. Age equal to or older than 18.. A diagnosis of Rheumatoid Arthritis (RA) of more than 6 months as defined by the revised American College of Rheumatology criteria.. Active RA defined as: 6 or more swollen joints;. 6 or more tender joints;. ESR greater than 28 mm/hr (or CRP greater than 0.8) or morning stiffness greater than 45 minutes.. Incomplete response (defined as persistently active disease as described above) to treatment with at least one of the following regimens for over 3 months:. MTX alone (greater than or equal to 17.5 mg/week);. MTX (greater than or equal to 17.5 mg/week) plus HCQ (greater than or equal to 200 mg/day);. MTX (greater than or equal to 17.5 mg/week) plus SSZ (greater than or equal to 1 gm/d);. MTX (greater than or equal to 17.5 mg/week) plus CsA (1-3 mg/kg/day);. MTX (greater than or equal to 17.5 mg/week) plus SSZ (greater than 1 gm/day) plus HCQ (greater than or equal to 200 mg/day);. No requirement of corticosteroids in doses equivalent to over 10 mg/d prednisone nor other immunosuppressive agents required for the control of extraarticular manifestations at the time of study entry.. No active acute or chronic infections requiring antibiotic therapy, serious viral infections (such as hepatitis, herpes zoster, or HIV), or serious fungal infections. Patients with a positive PPD who have not received INH or other antituberculous therapy will be excluded.. No pregnant women, nursing mothers, or patients of childbearing age not practicing birth control.. No preexisting malignancy other than basal cell carcinoma.. No history of stroke, seizure disorder, or chronic neurologic disease.. No unstable coronary artery disease, cardiomyopathy, conduction heart block greater than first degree, or a dysrhythmia requiring therapy.. No confounding medical illness that in the judgment of the investigators would pose added risk for study participants (e.g., chronic hepatic, renal, or pulmonary disease or bone marrow hypoplasia).. No presence of seronegative spondyloarthropathy, systemic lupus erythematosus, systemic sclerosis, inflammatory myopathy, systemic vasculitis, psoriasis, or inflammatory bowel disease.. No serum creatinine greater than 2.0 mg/dL on at least 2 different occasions which is sustained for at least 1 month.. No hematocrit less than 28% (or hemoglobin less than 9.0 mg/dL), or platelet count less than 100,000, or white blood count less than 3,500/dL.. No patients with active lung disease, patients with a chronic and progressive lung disease, or patients with a chronic but stable lung disease with pulmonary function tests of less than 70% of predicted (DLCO less than 60%).. No patients with hypogammaglobulinemia (IgG count less than 300).. No patients treated with alkylating agents for over 1 year at any time or treated with a purine nucleoside analog at any time"}, {"type": "EXCLUSION", "field": "procedure", "operator": "IN", "value": "ESR greater than 28 mm/hr (or CRP greater than 0.8) or morning stiffness greater than 45 minutes.. Incomplete response (defined as persist", "unit": null, "evidence_text": "Ability to provide informed consent to all aspects of the study after full information is provided.. Age equal to or older than 18.. A diagnosis of Rheumatoid Arthritis (RA) of more than 6 months as defined by the revised American College of Rheumatology criteria.. Active RA defined as: 6 or more swollen joints;. 6 or more tender joints;. ESR greater than 28 mm/hr (or CRP greater than 0.8) or morning stiffness greater than 45 minutes.. Incomplete response (defined as persistently active disease as described above) to treatment with at least one of the following regimens for over 3 months:. MTX alone (greater than or equal to 17.5 mg/week);. MTX (greater than or equal to 17.5 mg/week) plus HCQ (greater than or equal to 200 mg/day);. MTX (greater than or equal to 17.5 mg/week) plus SSZ (greater than or equal to 1 gm/d);. MTX (greater than or equal to 17.5 mg/week) plus CsA (1-3 mg/kg/day);. MTX (greater than or equal to 17.5 mg/week) plus SSZ (greater than 1 gm/day) plus HCQ (greater than or equal to 200 mg/day);. No requirement of corticosteroids in doses equivalent to over 10 mg/d prednisone nor other immunosuppressive agents required for the control of extraarticular manifestations at the time of study entry.. No active acute or chronic infections requiring antibiotic therapy, serious viral infections (such as hepatitis, herpes zoster, or HIV), or serious fungal infections. Patients with a positive PPD who have not received INH or other antituberculous therapy will be excluded.. No pregnant women, nursing mothers, or patients of childbearing age not practicing birth control.. No preexisting malignancy other than basal cell carcinoma.. No history of stroke, seizure disorder, or chronic neurologic disease.. No unstable coronary artery disease, cardiomyopathy, conduction heart block greater than first degree, or a dysrhythmia requiring therapy.. No confounding medical illness that in the judgment of the investigators would pose added risk for study participants (e.g., chronic hepatic, renal, or pulmonary disease or bone marrow hypoplasia).. No presence of seronegative spondyloarthropathy, systemic lupus erythematosus, systemic sclerosis, inflammatory myopathy, systemic vasculitis, psoriasis, or inflammatory bowel disease.. No serum creatinine greater than 2.0 mg/dL on at least 2 different occasions which is sustained for at least 1 month.. No hematocrit less than 28% (or hemoglobin less than 9.0 mg/dL), or platelet count less than 100,000, or white blood count less than 3,500/dL.. No patients with active lung disease, patients with a chronic and progressive lung disease, or patients with a chronic but stable lung disease with pulmonary function tests of less than 70% of predicted (DLCO less than 60%).. No patients with hypogammaglobulinemia (IgG count less than 300).. No patients treated with alkylating agents for over 1 year at any time or treated with a purine nucleoside analog at any time"}, {"type": "EXCLUSION", "field": "procedure", "operator": "IN", "value": "No requirement of corticosteroids in doses equivalent to over 10 mg/d prednisone nor other immunosuppressive agents required for the contr", "unit": null, "evidence_text": "Ability to provide informed consent to all aspects of the study after full information is provided.. Age equal to or older than 18.. A diagnosis of Rheumatoid Arthritis (RA) of more than 6 months as defined by the revised American College of Rheumatology criteria.. Active RA defined as: 6 or more swollen joints;. 6 or more tender joints;. ESR greater than 28 mm/hr (or CRP greater than 0.8) or morning stiffness greater than 45 minutes.. Incomplete response (defined as persistently active disease as described above) to treatment with at least one of the following regimens for over 3 months:. MTX alone (greater than or equal to 17.5 mg/week);. MTX (greater than or equal to 17.5 mg/week) plus HCQ (greater than or equal to 200 mg/day);. MTX (greater than or equal to 17.5 mg/week) plus SSZ (greater than or equal to 1 gm/d);. MTX (greater than or equal to 17.5 mg/week) plus CsA (1-3 mg/kg/day);. MTX (greater than or equal to 17.5 mg/week) plus SSZ (greater than 1 gm/day) plus HCQ (greater than or equal to 200 mg/day);. No requirement of corticosteroids in doses equivalent to over 10 mg/d prednisone nor other immunosuppressive agents required for the control of extraarticular manifestations at the time of study entry.. No active acute or chronic infections requiring antibiotic therapy, serious viral infections (such as hepatitis, herpes zoster, or HIV), or serious fungal infections. Patients with a positive PPD who have not received INH or other antituberculous therapy will be excluded.. No pregnant women, nursing mothers, or patients of childbearing age not practicing birth control.. No preexisting malignancy other than basal cell carcinoma.. No history of stroke, seizure disorder, or chronic neurologic disease.. No unstable coronary artery disease, cardiomyopathy, conduction heart block greater than first degree, or a dysrhythmia requiring therapy.. No confounding medical illness that in the judgment of the investigators would pose added risk for study participants (e.g., chronic hepatic, renal, or pulmonary disease or bone marrow hypoplasia).. No presence of seronegative spondyloarthropathy, systemic lupus erythematosus, systemic sclerosis, inflammatory myopathy, systemic vasculitis, psoriasis, or inflammatory bowel disease.. No serum creatinine greater than 2.0 mg/dL on at least 2 different occasions which is sustained for at least 1 month.. No hematocrit less than 28% (or hemoglobin less than 9.0 mg/dL), or platelet count less than 100,000, or white blood count less than 3,500/dL.. No patients with active lung disease, patients with a chronic and progressive lung disease, or patients with a chronic but stable lung disease with pulmonary function tests of less than 70% of predicted (DLCO less than 60%).. No patients with hypogammaglobulinemia (IgG count less than 300).. No patients treated with alkylating agents for over 1 year at any time or treated with a purine nucleoside analog at any time"}, {"type": "EXCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "Ability to provide informed consent to all aspects of the study after full information is provided.. Age equal to or older than 18.. A diagnosis of Rheumatoid Arthritis (RA) of more than 6 months as defined by the revised American College of Rheumatology criteria.. Active RA defined as: 6 or more swollen joints;. 6 or more tender joints;. ESR greater than 28 mm/hr (or CRP greater than 0.8) or morning stiffness greater than 45 minutes.. Incomplete response (defined as persistently active disease as described above) to treatment with at least one of the following regimens for over 3 months:. MTX alone (greater than or equal to 17.5 mg/week);. MTX (greater than or equal to 17.5 mg/week) plus HCQ (greater than or equal to 200 mg/day);. MTX (greater than or equal to 17.5 mg/week) plus SSZ (greater than or equal to 1 gm/d);. MTX (greater than or equal to 17.5 mg/week) plus CsA (1-3 mg/kg/day);. MTX (greater than or equal to 17.5 mg/week) plus SSZ (greater than 1 gm/day) plus HCQ (greater than or equal to 200 mg/day);. No requirement of corticosteroids in doses equivalent to over 10 mg/d prednisone nor other immunosuppressive agents required for the control of extraarticular manifestations at the time of study entry.. No active acute or chronic infections requiring antibiotic therapy, serious viral infections (such as hepatitis, herpes zoster, or HIV), or serious fungal infections. Patients with a positive PPD who have not received INH or other antituberculous therapy will be excluded.. No pregnant women, nursing mothers, or patients of childbearing age not practicing birth control.. No preexisting malignancy other than basal cell carcinoma.. No history of stroke, seizure disorder, or chronic neurologic disease.. No unstable coronary artery disease, cardiomyopathy, conduction heart block greater than first degree, or a dysrhythmia requiring therapy.. No confounding medical illness that in the judgment of the investigators would pose added risk for study participants (e.g., chronic hepatic, renal, or pulmonary disease or bone marrow hypoplasia).. No presence of seronegative spondyloarthropathy, systemic lupus erythematosus, systemic sclerosis, inflammatory myopathy, systemic vasculitis, psoriasis, or inflammatory bowel disease.. No serum creatinine greater than 2.0 mg/dL on at least 2 different occasions which is sustained for at least 1 month.. No hematocrit less than 28% (or hemoglobin less than 9.0 mg/dL), or platelet count less than 100,000, or white blood count less than 3,500/dL.. No patients with active lung disease, patients with a chronic and progressive lung disease, or patients with a chronic but stable lung disease with pulmonary function tests of less than 70% of predicted (DLCO less than 60%).. No patients with hypogammaglobulinemia (IgG count less than 300).. No patients treated with alkylating agents for over 1 year at any time or treated with a purine nucleoside analog at any time"}], "annotator_id": "annotator_c", "guideline_version": "m5-v1", "adjudicated": true, "adjudication_source": "parsing_relabel_round1"}
{"nct_id": "NCT00001885", "eligibility_text": "* INCLUSION CRITERIA:. Individuals 21 years of age or older with any of the following:. RA (based on 1987 American College of Rheumatology Revised Criteria for the Classification of RA) with PF (biopsy-proven), or. RA-only, or. Biopsy-proven idiopathic PF-only, or. Healthy research volunteers.. EXCLUSION CRITERIA:. Individuals with any of the following:. Inhalational exposure to fibrogenic fibers or dusts (e.g., asbestos, silica, coal, beryllium).. Chronic pulmonary disorders other than pulmonary fibrosis.. Other collagen vascular disorders (e.g., systemic lupus erythematosus, scleroderma, polymyositis, mixed connective tissue disease).. Non-rheumatoid arthritis.. Viral infections associated with PF (e.g., hepatitis B, hepatitis C, human immunodeficiency virus).. Pregnancy.", "labeled_rules": [{"type": "EXCLUSION", "field": "age", "operator": ">=", "value": 21, "unit": "years", "evidence_text": "* INCLUSION CRITERIA:. Individuals 21 years of age or older with any of the following:. RA (based on 1987 American College of Rheumatology Revised Criteria for the Classification of RA) with PF (biopsy-proven), or. RA-only, or. Biopsy-proven idiopathic PF-only, or. Healthy research volunteers.. EXCLUSION CRITERIA:. Individuals with any of the following:. Inhalational exposure to fibrogenic fibers or dusts (e.g., asbestos, silica, coal, beryllium).. Chronic pulmonary disorders other than pulmonary fibrosis.. Other collagen vascular disorders (e.g., systemic lupus erythematosus, scleroderma, polymyositis, mixed connective tissue disease).. Non-rheumatoid arthritis.. Viral infections associated with PF (e.g., hepatitis B, hepatitis C, human immunodeficiency virus).. Pregnancy"}, {"type": "EXCLUSION", "field": "procedure", "operator": "IN", "value": "Individuals 21 years of age or older with any of the following:. RA (based on 1987 American College of Rheumatology Rev", "unit": null, "evidence_text": "* INCLUSION CRITERIA:. Individuals 21 years of age or older with any of the following:. RA (based on 1987 American College of Rheumatology Revised Criteria for the Classification of RA) with PF (biopsy-proven), or. RA-only, or. Biopsy-proven idiopathic PF-only, or. Healthy research volunteers.. EXCLUSION CRITERIA:. Individuals with any of the following:. Inhalational exposure to fibrogenic fibers or dusts (e.g., asbestos, silica, coal, beryllium).. Chronic pulmonary disorders other than pulmonary fibrosis.. Other collagen vascular disorders (e.g., systemic lupus erythematosus, scleroderma, polymyositis, mixed connective tissue disease).. Non-rheumatoid arthritis.. Viral infections associated with PF (e.g., hepatitis B, hepatitis C, human immunodeficiency virus).. Pregnancy"}], "annotator_id": "annotator_c", "guideline_version": "m5-v1", "adjudicated": true, "adjudication_source": "parsing_relabel_round1"}
{"nct_id": "NCT00002781", "eligibility_text": "DISEASE CHARACTERISTICS: Biopsy-proven melanoma that is clinical stage III Estimated clinical tumor depth 1.0-6.0 cm from the epidermis Tumor surface diameter no greater than 10 cm Grossly evident cutaneous or subcutaneous tumor nodules are eligible for irradiation. PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Karnofsky 70%-100% Life expectancy: More than 3 months Hematopoietic: Not specified Hepatic: Not specified Renal: Not specified Other: No history of phenylketonuria Negative serum pregnancy test required of fertile women Adequate contraception required of fertile women during and for 6 months after the study. PRIOR CONCURRENT THERAPY: No prior radiotherapy to the target area", "labeled_rules": [{"type": "EXCLUSION", "field": "condition", "operator": "IN", "value": "fertile", "unit": null, "evidence_text": "DISEASE CHARACTERISTICS: Biopsy-proven melanoma that is clinical stage III Estimated clinical tumor depth 1.0-6.0 cm from the epidermis Tumor surface diameter no greater than 10 cm Grossly evident cutaneous or subcutaneous tumor nodules are eligible for irradiation. PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Karnofsky 70%-100% Life expectancy: More than 3 months Hematopoietic: Not specified Hepatic: Not specified Renal: Not specified Other: No history of phenylketonuria Negative serum pregnancy test required of fertile women Adequate contraception required of fertile women during and for 6 months after the study. PRIOR CONCURRENT THERAPY: No prior radiotherapy to the target area"}, {"type": "EXCLUSION", "field": "history", "operator": "IN", "value": "DISEASE CHARACTERISTICS: Biopsy-proven melanoma that is clinical stage III Estimated clinical tumor depth 1.0-6.0 cm from the epidermis Tumo", "unit": null, "evidence_text": "DISEASE CHARACTERISTICS: Biopsy-proven melanoma that is clinical stage III Estimated clinical tumor depth 1.0-6.0 cm from the epidermis Tumor surface diameter no greater than 10 cm Grossly evident cutaneous or subcutaneous tumor nodules are eligible for irradiation. PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Karnofsky 70%-100% Life expectancy: More than 3 months Hematopoietic: Not specified Hepatic: Not specified Renal: Not specified Other: No history of phenylketonuria Negative serum pregnancy test required of fertile women Adequate contraception required of fertile women during and for 6 months after the study. PRIOR CONCURRENT THERAPY: No prior radiotherapy to the target area"}, {"type": "EXCLUSION", "field": "lab", "operator": ">=", "value": 10, "unit": "cm", "evidence_text": "DISEASE CHARACTERISTICS: Biopsy-proven melanoma that is clinical stage III Estimated clinical tumor depth 1.0-6.0 cm from the epidermis Tumor surface diameter no greater than 10 cm Grossly evident cutaneous or subcutaneous tumor nodules are eligible for irradiation. PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Karnofsky 70%-100% Life expectancy: More than 3 months Hematopoietic: Not specified Hepatic: Not specified Renal: Not specified Other: No history of phenylketonuria Negative serum pregnancy test required of fertile women Adequate contraception required of fertile women during and for 6 months after the study. PRIOR CONCURRENT THERAPY: No prior radiotherapy to the target area"}, {"type": "EXCLUSION", "field": "lab", "operator": "IN", "value": "negative pregnancy test", "unit": null, "evidence_text": "DISEASE CHARACTERISTICS: Biopsy-proven melanoma that is clinical stage III Estimated clinical tumor depth 1.0-6.0 cm from the epidermis Tumor surface diameter no greater than 10 cm Grossly evident cutaneous or subcutaneous tumor nodules are eligible for irradiation. PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Karnofsky 70%-100% Life expectancy: More than 3 months Hematopoietic: Not specified Hepatic: Not specified Renal: Not specified Other: No history of phenylketonuria Negative serum pregnancy test required of fertile women Adequate contraception required of fertile women during and for 6 months after the study. PRIOR CONCURRENT THERAPY: No prior radiotherapy to the target area"}, {"type": "EXCLUSION", "field": "medication", "operator": "IN", "value": "DISEASE CHARACTERISTICS: Biopsy-proven melanoma that is clinical stage III Estimated clinical tumor depth 1.0-6.0 cm from the epidermis Tumo", "unit": null, "evidence_text": "DISEASE CHARACTERISTICS: Biopsy-proven melanoma that is clinical stage III Estimated clinical tumor depth 1.0-6.0 cm from the epidermis Tumor surface diameter no greater than 10 cm Grossly evident cutaneous or subcutaneous tumor nodules are eligible for irradiation. PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Karnofsky 70%-100% Life expectancy: More than 3 months Hematopoietic: Not specified Hepatic: Not specified Renal: Not specified Other: No history of phenylketonuria Negative serum pregnancy test required of fertile women Adequate contraception required of fertile women during and for 6 months after the study. PRIOR CONCURRENT THERAPY: No prior radiotherapy to the target area"}, {"type": "EXCLUSION", "field": "procedure", "operator": "IN", "value": "DISEASE CHARACTERISTICS: Biopsy-proven melanoma that is clinical stage III Estimated clinical tumor depth 1.0-6.0 cm from the epidermis Tumo", "unit": null, "evidence_text": "DISEASE CHARACTERISTICS: Biopsy-proven melanoma that is clinical stage III Estimated clinical tumor depth 1.0-6.0 cm from the epidermis Tumor surface diameter no greater than 10 cm Grossly evident cutaneous or subcutaneous tumor nodules are eligible for irradiation. PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Karnofsky 70%-100% Life expectancy: More than 3 months Hematopoietic: Not specified Hepatic: Not specified Renal: Not specified Other: No history of phenylketonuria Negative serum pregnancy test required of fertile women Adequate contraception required of fertile women during and for 6 months after the study. PRIOR CONCURRENT THERAPY: No prior radiotherapy to the target area"}, {"type": "EXCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "DISEASE CHARACTERISTICS: Biopsy-proven melanoma that is clinical stage III Estimated clinical tumor depth 1.0-6.0 cm from the epidermis Tumor surface diameter no greater than 10 cm Grossly evident cutaneous or subcutaneous tumor nodules are eligible for irradiation. PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Karnofsky 70%-100% Life expectancy: More than 3 months Hematopoietic: Not specified Hepatic: Not specified Renal: Not specified Other: No history of phenylketonuria Negative serum pregnancy test required of fertile women Adequate contraception required of fertile women during and for 6 months after the study. PRIOR CONCURRENT THERAPY: No prior radiotherapy to the target area"}], "annotator_id": "annotator_c", "guideline_version": "m5-v1", "adjudicated": true, "adjudication_source": "parsing_relabel_round1"}
{"nct_id": "NCT00003750", "eligibility_text": "DISEASE CHARACTERISTICS:. * Histologically confirmed neuroblastoma or melanoma at original diagnosis. * Refractory to chemotherapy or recurrence after prior multiagent chemotherapy. * Measurable or evaluable (detectable by bone scan) metastatic disease OR. * No evidence of disease if complete response to prior surgical resection, radiotherapy, and/or chemotherapy OR. * Histologically confirmed tumor expressing GD2 antigen at original diagnosis or relapse. * Refractory to standard treatment. * Measurable or evaluable disease by clinical assessments or laboratory markers OR. * No evidence of disease after prior surgical resection of metastatic, recurrent disease. * Histologically confirmed recurrent osteogenic sarcoma after prior chemotherapy allowed. * Soft tissue sarcoma allowed. * No primary CNS tumors. * Prior CNS metastases allowed, provided:. * Disease previously treated. * Disease clinically stable for 4 weeks before study. * At least 4 weeks since prior steroids for CNS metastases. * No clinically detectable pleural effusions or ascites. PATIENT CHARACTERISTICS:. Age:. * 21 and under. Performance status:. * Karnofsky 60-100% for children over age 10. * Lansky 60-100% for children age 10 and under. Life expectancy:. * At least 12 weeks. Hematopoietic:. * Absolute neutrophil count greater than 1,000/mm\\^3. * Platelet count at least 75,000/mm\\^3 (transfusion allowed). * Hemoglobin at least 9.0 g/dL (transfusion allowed). Hepatic:. * Bilirubin less than 1.5 mg/dL. * ALT or AST no greater than 2.5 times normal. * Hepatitis B surface antigen negative. Renal:. * Creatinine no greater than 1.5 mg/dL OR. * Creatinine clearance or radioisotope glomerular filtration rate at least 60 mL/min. Cardiovascular:. * Shortening fraction at least 27% by echocardiogram OR. * Ejection fraction more than 50% by MUGA scan. * No congestive heart failure. * No uncontrolled cardiac rhythm disturbance. Pulmonary:. * FEV\\_1 and FVC more than 60% of predicted OR. * No dyspnea at rest. * No exercise intolerance. * Oxygen saturation more than 94% by pulse oximetry on room air. Neurologic:. * No seizure disorders requiring antiseizure medications. * No significant neurologic deficit or grade 2 or greater objective peripheral neuropathy. Other:. * Not pregnant or nursing. * Negative pregnancy test. * Fertile patients must use effective contraception. * HIV negative. * No significant concurrent illnesses unrelated to cancer or its treatment. * No significant psychiatric disabilities. * No uncontrolled active infections. * No uncontrolled active peptic ulcer. PRIOR CONCURRENT THERAPY:. Biologic therapy:. * At least 1 week since prior growth factors. * At least 1 week since prior immunomodulatory therapy. * Prior monoclonal antibodies allowed if no detectable antibody to hu14.18. * Prior autologous bone marrow transplantation (BMT) or stem cell transplantation (SCT) allowed. * Prior autologous BMT or SCT with monoclonal antibody-purged specimens allowed. * No concurrent growth factors. * No concurrent interferon. Chemotherapy:. * See Disease Characteristics. * At least 3 weeks since prior chemotherapy (6 weeks for nitrosoureas, mitomycin, or melphalan). * No concurrent palliative chemotherapy. Endocrine therapy:. * See Disease Characteristics. * At least 2 weeks since prior glucocorticoids, except for life-threatening symptoms. * No concurrent corticosteroids. * No concurrent glucocorticoids, except for life-threatening symptoms. Radiotherapy:. * See Disease Characteristics. * At least 3 weeks since prior radiotherapy. * No concurrent palliative radiotherapy. Surgery:. * See Disease Characteristics. * At least 2 weeks since prior major surgery (e.g., laparotomy or thoracotomy). * No prior organ allografts. * No concurrent palliative surgery. Other:. * Recovered from prior therapy. * At least 1 week since prior tretinoin. * At least 3 weeks since prior immunosuppressive therapy. * No other concurrent immunosuppressive drugs", "labeled_rules": [{"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "fertile", "unit": null, "evidence_text": "* Fertile patients must use effective contraception"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "monoclonal antibody-purged specimens allowed", "unit": null, "evidence_text": "* Prior autologous BMT or SCT with monoclonal antibody-purged specimens allowed"}]}
{"nct_id": "NCT00004810", "eligibility_text": "PROTOCOL ENTRY CRITERIA:. * Mildly to moderately severe ulcerative colitis. * Patient age: 18 to 80", "labeled_rules": [{"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "study-specific condition", "unit": null, "evidence_text": "PROTOCOL ENTRY CRITERIA:"}]}
{"nct_id": "NCT00004925", "eligibility_text": "DISEASE CHARACTERISTICS:. * Histologically or cytologically confirmed locally advanced, inflammatory, or metastatic adenocarcinoma of the breast that has been treated with no more than 1 prior systemic cytotoxic regimen. * Overexpression of HER2 protein (2+ or 3+). * Evaluable disease. * History of brain metastases allowed if off steroids and asymptomatic, with a 3 month or greater interval since last dose of brain irradiation, and no evidence of progression. * Hormone receptor status:. * Not specified. PATIENT CHARACTERISTICS:. Age:. * 18 and over. Sex:. * Female. Menopausal status:. * Not specified. Performance status:. * ECOG 0-1. Life expectancy:. * Not specified. Hematopoietic:. * Absolute neutrophil count at least 1,500/mm\\^3. * Platelet count at least 100,000/mm\\^3. * Hemoglobin at least 10 g/dL. Hepatic:. * Bilirubin no greater than 1.5 times upper limit of normal (ULN). Renal:. * AST or ALT no greater than 4 times ULN. Cardiovascular:. * Adequate cardiac function. * LVEF at least 50% predicted or lower limit of normal. Other:. * Not pregnant or nursing. * Negative pregnancy test. * Fertile patients must use effective contraception. * No other concurrent medical or psychological condition that would preclude study compliance. * No history of hypersensitivity to anthracyclines, eggs, or egg products. PRIOR CONCURRENT THERAPY:. Biologic therapy:. * Prior trastuzumab (Herceptin) allowed. Chemotherapy:. * See Disease Characteristics. * At least 3 weeks since prior antineoplastic therapy. * No more than 1 prior systemic cytotoxic regimen for locally advanced, metastatic, or inflammatory breast cancer. * No prior anthracyclines greater than 240 mg/m2. * No other concurrent antineoplastic agents. * No concurrent treatment with other liposomal products other than doxorubicin HCl liposome. Endocrine therapy:. * See Disease Characteristics. * At least 3 weeks since prior hormonal agents. * No concurrent hormonal therapy. Radiotherapy:. * See Disease Characteristics. Surgery:. * Not specified. Other:. * At least 3 weeks since other prior investigational drugs", "labeled_rules": [{"type": "INCLUSION", "field": "history", "operator": "IN", "value": "DISEASE CHARACTERISTICS:. * Histologically or cytologically confirmed locally advanced, inflammatory, or metastatic adenocarcinoma of the br", "unit": null, "evidence_text": "Histologically or cytologically confirmed locally advanced, inflammatory, or metastatic adenocarcinoma of the breast that has been treated with no more than 1 prior systemic cytotoxic regimen"}, {"type": "INCLUSION", "field": "medication", "operator": "IN", "value": "DISEASE CHARACTERISTICS:. * Histologically or cytologically confirmed locally advanced, inflammatory, or metastatic adenocarcinoma of the br", "unit": null, "evidence_text": "Histologically or cytologically confirmed locally advanced, inflammatory, or metastatic adenocarcinoma of the breast that has been treated with no more than 1 prior systemic cytotoxic regimen"}, {"type": "INCLUSION", "field": "procedure", "operator": "IN", "value": "DISEASE CHARACTERISTICS:. * Histologically or cytologically confirmed locally advanced, inflammatory, or metastatic adenocarcinoma of the br", "unit": null, "evidence_text": "Histologically or cytologically confirmed locally advanced, inflammatory, or metastatic adenocarcinoma of the breast that has been treated with no more than 1 prior systemic cytotoxic regimen"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "a 3 month or greater interval since", "unit": null, "evidence_text": "History of brain metastases allowed if off steroids and asymptomatic, with a 3 month or greater interval since last dose of brain irradiation, and no evidence of progression"}, {"type": "INCLUSION", "field": "age", "operator": ">=", "value": 1, "unit": "years", "evidence_text": "18 and over. Sex:"}, {"type": "INCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "Female. Menopausal status:"}, {"type": "INCLUSION", "field": "lab", "operator": ">=", "value": 1.5, "unit": "times", "evidence_text": "Bilirubin no greater than 1.5 times upper limit of normal (ULN). Renal:"}, {"type": "INCLUSION", "field": "lab", "operator": "IN", "value": "negative pregnancy test", "unit": null, "evidence_text": "Negative pregnancy test"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "fertile", "unit": null, "evidence_text": "Fertile patients must use effective contraception"}, {"type": "EXCLUSION", "field": "condition", "operator": "IN", "value": "hypersensitivity to anthracyclines, eggs, or egg", "unit": null, "evidence_text": "No history of hypersensitivity to anthracyclines, eggs, or egg products. PRIOR CONCURRENT THERAPY:. Biologic therapy:"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "other liposomal products other than doxorubicin", "unit": null, "evidence_text": "No concurrent treatment with other liposomal products other than doxorubicin HCl liposome. Endocrine therapy:"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "other liposomal products other than doxorubicin hcl", "unit": null, "evidence_text": "No concurrent treatment with other liposomal products other than doxorubicin HCl liposome. Endocrine therapy:"}], "annotator_id": "annotator_c", "guideline_version": "m5-v1", "adjudicated": true, "adjudication_source": "parsing_relabel_round1"}
{"nct_id": "NCT00018122", "eligibility_text": "Type 1 diabetics that have received a kidney transplant as well as (under Project 1) Islet Cell Transplant. A control group of 8 kidney transplant recipients who do not have diabetes will also be sought. Age range for both groups is expected to fall in the 25-50 year/old range based upon statistical data, although those between the ages of 18 and 65 may also qualify.", "labeled_rules": [{"type": "INCLUSION", "field": "age", "operator": ">=", "value": 25, "unit": "years", "evidence_text": "Age range for both groups is expected to fall in the 25-50 year/old range based upon statistical data, although those between the ages of 18 and 65 may also qualify"}, {"type": "INCLUSION", "field": "age", "operator": "<=", "value": 50, "unit": "years", "evidence_text": "Age range for both groups is expected to fall in the 25-50 year/old range based upon statistical data, although those between the ages of 18 and 65 may also qualify"}]}
{"nct_id": "NCT00048542", "eligibility_text": "Inclusion Criteria:. * Subjects must have a diagnosis of polyarticular juvenile idiopathic arthritis (JIA) age 4 to 17 by the American College of Rheumatology (ACR) criteria. Disease onset may have been systemic, polyarticular, or pauciarticular. If the disease was systemic onset, then the subjects must be free of any systemic JIA manifestations for at least 3 months before the time of qualification.. * At the time of study screening, the subject must have continuing active disease defined as \\>= 5 swollen joints and \\>= 3 joints with limitation of motion (LOM). These joints are not mutually exclusive.. * Subjects may be either nave to MTX, inadequate responders to MTX, or intolerant to MTX. Intolerance to MTX will be defined by the subject's physician. The MTX must be maintained at a dose of at least 10 mg/m2 body surface area/week for a minimum of 3 months, prior to screening.. * Duration of disease is not limited, but must have been long enough for a subject to have been given an adequate trial of nonsteroidal anti-inflammatory drugs (NSAIDs).. * Have not received other disease-modifying anti-rheumatic drugs (DMARDs) including penicillamine, hydroxychloroquine, sulfasalazine, oral or injectable gold, cyclosporin; or intravenous immunoglobulin (IV Ig); or cytotoxic agents, for at least 4 weeks prior to receiving 1st dose of study drug. Subjects currently on one or more of these DMARDs must demonstrate active disease (defined above) prior to a minimum 4 weeks (28 days) washout of all DMARDs.. * Subjects who are refractory to MTX after 3 months of treatment must demonstrate active disease (defined above) prior to enrollment in the open-label part of the trial.. * Have not received an intra-articular glucocorticoid injection within 4 weeks (28 days) prior to enrollment into the study.. * Have good venous access and stable hematocrit \\>= 24%.. * All sexually active male and female study participants must be practicing adequate contraception. Post-pubertal females must have a negative serum pregnancy test no greater than 10 days prior to the first dose of study drug.. * Parent or guardian has voluntarily signed and dated an informed consent form, approved by an Institutional Review Board (IRB)/Independent Ethics Committee (IEC), after the nature of the study has been explained and the subject's parent or legal guardian has had the opportunity to ask questions.. Exclusion Criteria:. * Pregnant or nursing female.. * Functional class IV by ACR criteria.. * Laboratory parameters outside limits established in the protocol.. * Medical history, medical condition, or previous treatment not allowed by the protocol.", "labeled_rules": [{"type": "INCLUSION", "field": "age", "operator": ">=", "value": 3, "unit": "years", "evidence_text": "Subjects must have a diagnosis of polyarticular juvenile idiopathic arthritis (JIA) age 4 to 17 by the American College of Rheumatology (ACR) criteria. Disease onset may have been systemic, polyarticular, or pauciarticular. If the disease was systemic onset, then the subjects must be free of any systemic JIA manifestations for at least 3 months before the time of qualification"}, {"type": "INCLUSION", "field": "medication", "operator": "IN", "value": "* Subjects must have a diagnosis of polyarticular juvenile idiopathic arthritis (JIA) age 4 to 17 by the American Colle", "unit": null, "evidence_text": "Subjects must have a diagnosis of polyarticular juvenile idiopathic arthritis (JIA) age 4 to 17 by the American College of Rheumatology (ACR) criteria. Disease onset may have been systemic, polyarticular, or pauciarticular. If the disease was systemic onset, then the subjects must be free of any systemic JIA manifestations for at least 3 months before the time of qualification"}, {"type": "INCLUSION", "field": "procedure", "operator": "IN", "value": "* Subjects must have a diagnosis of polyarticular juvenile idiopathic arthritis (JIA) age 4 to 17 by the American Colle", "unit": null, "evidence_text": "Subjects must have a diagnosis of polyarticular juvenile idiopathic arthritis (JIA) age 4 to 17 by the American College of Rheumatology (ACR) criteria. Disease onset may have been systemic, polyarticular, or pauciarticular. If the disease was systemic onset, then the subjects must be free of any systemic JIA manifestations for at least 3 months before the time of qualification"}, {"type": "INCLUSION", "field": "lab", "operator": ">=", "value": 5, "unit": "swollen", "evidence_text": "At the time of study screening, the subject must have continuing active disease defined as \\>= 5 swollen joints and \\>= 3 joints with limitation of motion (LOM). These joints are not mutually exclusive"}, {"type": "INCLUSION", "field": "history", "operator": "IN", "value": "or cytotoxic agents, for at least 4 weeks prior to receiving 1st dose of study drug. Subjects currently on one or more of these DMARDs must", "unit": null, "evidence_text": "Have not received other disease-modifying anti-rheumatic drugs (DMARDs) including penicillamine, hydroxychloroquine, sulfasalazine, oral or injectable gold, cyclosporin; or intravenous immunoglobulin (IV Ig); or cytotoxic agents, for at least 4 weeks prior to receiving 1st dose of study drug. Subjects currently on one or more of these DMARDs must demonstrate active disease (defined above) prior to a minimum 4 weeks (28 days) washout of all DMARDs"}, {"type": "INCLUSION", "field": "other", "operator": "IN", "value": "or cytotoxic agents, for at least 4 weeks prior to receiving 1st dose of study drug. Subjects currently on one or more of these DMARDs must", "unit": null, "evidence_text": "Have not received other disease-modifying anti-rheumatic drugs (DMARDs) including penicillamine, hydroxychloroquine, sulfasalazine, oral or injectable gold, cyclosporin; or intravenous immunoglobulin (IV Ig); or cytotoxic agents, for at least 4 weeks prior to receiving 1st dose of study drug. Subjects currently on one or more of these DMARDs must demonstrate active disease (defined above) prior to a minimum 4 weeks (28 days) washout of all DMARDs"}, {"type": "INCLUSION", "field": "lab", "operator": ">=", "value": 3, "unit": "joints", "evidence_text": "Subjects who are refractory to MTX after 3 months of treatment must demonstrate active disease (defined above) prior to enrollment in the open-label part of the trial"}, {"type": "INCLUSION", "field": "medication", "operator": "WITHIN_LAST", "value": 4, "unit": "weeks", "evidence_text": "Have not received an intra-articular glucocorticoid injection within 4 weeks (28 days) prior to enrollment into the study"}, {"type": "INCLUSION", "field": "procedure", "operator": "WITHIN_LAST", "value": 4, "unit": "weeks", "evidence_text": "Have not received an intra-articular glucocorticoid injection within 4 weeks (28 days) prior to enrollment into the study"}, {"type": "INCLUSION", "field": "lab", "operator": ">=", "value": 24, "unit": "%", "evidence_text": "Have good venous access and stable hematocrit \\>= 24%"}, {"type": "INCLUSION", "field": "lab", "operator": "IN", "value": "negative pregnancy test", "unit": null, "evidence_text": "All sexually active male and female study participants must be practicing adequate contraception. Post-pubertal females must have a negative serum pregnancy test no greater than 10 days prior to the first dose of study drug"}, {"type": "INCLUSION", "field": "sex", "operator": "=", "value": "all", "unit": null, "evidence_text": "All sexually active male and female study participants must be practicing adequate contraception. Post-pubertal females must have a negative serum pregnancy test no greater than 10 days prior to the first dose of study drug"}, {"type": "EXCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "Pregnant or nursing female"}], "annotator_id": "annotator_c", "guideline_version": "m5-v1", "adjudicated": true, "adjudication_source": "parsing_relabel_round1"}
{"nct_id": "NCT00054145", "eligibility_text": "DISEASE CHARACTERISTICS:. * Histologically or cytologically confirmed breast cancer. * Recurrent or refractory, locally advanced or metastatic disease. * At least 1 unidimensionally measurable lesion. * At least 20 mm by conventional techniques OR 10 mm by spiral CT scan. * Previously irradiated lesions are not considered measurable unless they have demonstrated progression before study entry. * No measurable disease limited to bone lesions. * No known brain metastases. * Hormone receptor status:. * Not specified. PATIENT CHARACTERISTICS:. Age. * 18 and over. Sex. * Male or female. Menopausal status. * Not specified. Performance status. * ECOG 0-2 OR. * Karnofsky 60-100%. Life expectancy. * More than 3 months. Hematopoietic. * WBC at least 3,000/mm\\^3. * Absolute neutrophil count at least 1,500/mm\\^3. * Platelet count at least 100,000/mm\\^3. * No history of hemolytic disorder. Hepatic. * Bilirubin no greater than 1.25 times upper limit of normal (ULN). * AST/ALT no greater than 2.5 times ULN (5 times ULN if liver metastases present). Renal. * Creatinine normal OR. * Creatinine clearance at least 60 mL/min. Cardiovascular. * No symptomatic congestive heart failure. * No unstable angina pectoris. * No cardiac arrhythmia. * No evidence of cardiac dysfunction. Gastrointestinal. * No history of biliary flow obstruction. * No abnormalities of the gastrointestinal tract that would preclude study drug absorption. * No active peptic ulcer disease. Other. * Not pregnant or nursing. * Negative pregnancy test. * Fertile patients must use effective contraception. * No ongoing or active infection. * No poorly controlled diabetes mellitus. * No other uncontrolled illness. * No prior allergic reactions to compounds of similar chemical or biological composition to perifosine. * No psychiatric illness or social situation that would preclude study compliance. PRIOR CONCURRENT THERAPY:. Biologic therapy. * Not specified. Chemotherapy. * No more than 2 prior lines of chemotherapy for advanced disease, excluding adjuvant chemotherapy. * Prior adjuvant chemotherapy allowed. * At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and recovered. Endocrine therapy. * At least 4 weeks since prior endocrine therapy. * Multiple lines of endocrine therapy for advanced disease allowed. Radiotherapy. * At least 4 weeks since prior radiotherapy and recovered. * Prior radiotherapy for metastatic disease allowed. Surgery. * No prior major gastric surgery. * Prior surgery, including for metastatic disease, allowed. Other. * No other concurrent anticancer or investigational agents. * No concurrent antiretroviral therapy in HIV-positive patients. * Concurrent bisphosphonates allowed", "labeled_rules": [{"type": "INCLUSION", "field": "history", "operator": "IN", "value": "DISEASE CHARACTERISTICS:. * Histologically or cytologically confirmed breast cancer. * Recurrent or refractory, locally advanced or metastat", "unit": null, "evidence_text": "Histologically or cytologically confirmed breast cancer"}, {"type": "INCLUSION", "field": "medication", "operator": "IN", "value": "DISEASE CHARACTERISTICS:. * Histologically or cytologically confirmed breast cancer. * Recurrent or refractory, locally advanced or metastat", "unit": null, "evidence_text": "Histologically or cytologically confirmed breast cancer"}, {"type": "INCLUSION", "field": "procedure", "operator": "IN", "value": "DISEASE CHARACTERISTICS:. * Histologically or cytologically confirmed breast cancer. * Recurrent or refractory, locally advanced or metastat", "unit": null, "evidence_text": "Histologically or cytologically confirmed breast cancer"}, {"type": "INCLUSION", "field": "age", "operator": ">=", "value": 1, "unit": "years", "evidence_text": "18 and over. Sex"}, {"type": "EXCLUSION", "field": "condition", "operator": "IN", "value": "hemolytic disorder", "unit": null, "evidence_text": "No history of hemolytic disorder. Hepatic"}, {"type": "INCLUSION", "field": "lab", "operator": ">=", "value": 1.25, "unit": "times", "evidence_text": "Bilirubin no greater than 1.25 times upper limit of normal (ULN)"}, {"type": "EXCLUSION", "field": "condition", "operator": "IN", "value": "biliary flow obstruction", "unit": null, "evidence_text": "No history of biliary flow obstruction"}, {"type": "INCLUSION", "field": "lab", "operator": "IN", "value": "negative pregnancy test", "unit": null, "evidence_text": "Negative pregnancy test"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "fertile", "unit": null, "evidence_text": "Fertile patients must use effective contraception"}, {"type": "INCLUSION", "field": "sex", "operator": "=", "value": "all", "unit": null, "evidence_text": "Concurrent bisphosphonates allowed"}], "annotator_id": "annotator_c", "guideline_version": "m5-v1", "adjudicated": true, "adjudication_source": "parsing_relabel_round1"}
{"nct_id": "NCT00055926", "eligibility_text": "Inclusion Criteria:. * Histologically or cytologically confirmed HER2-overexpressing breast cancer. * Prior or newly documented HER2 amplification by fluorescence in situ hybridization (FISH). * Progressive metastatic disease. * Must have received at least one prior chemotherapy regimen for metastatic breast cancer. * At least 1 measurable or evaluable lesion. * At least 1 lesion accessible for 2 separate core biopsies for pharmacodynamic evaluation. * 18 and over. * Male or female. * ECOG 0-1. * Life expectancy, More than 3 months. * Hematopoietic. * Absolute neutrophil count at least 1,500/mm\\^3\\*. * Platelet count at least 100,000/mm\\^3\\* NOTE: \\*Without hematopoietic growth factors or transfusions. * Hepatic. * Bilirubin no greater than 1.5 mg/dL. * AST/ALT no greater than 2.5 times upper limit of normal (ULN) (5 times ULN if liver metastases are present). * Renal. * Creatinine no greater than 1.5 times ULN OR. * Creatinine clearance at least 60 mL/min. * Cardiovascular. * 12-lead ECG with normal tracing. * history of cardiovascular disease (i.e., ischemic heart disease, arrhythmia, or congestive heart failure) unless asymptomatic for the past year with no requirement for antiarrhythmics or a clinically significant medical management change. * Gastrointestinal. * Able to take oral medication\\* Negative pregnancy test. * Fertile patients must use effective contraception. * At least 4 weeks since prior trastuzumab (Herceptin). * At least 4 weeks since other prior biologic therapy or immunotherapy. * At least 4 weeks since prior chemotherapy (6 weeks for mitomycin or nitrosoureas). * At least 6 months since prior doxorubicin or doxorubicin equivalents without any prior or developing signs or symptoms of cardiomyopathy. * No cumulative doses of more than 300 mg/m\\^2. * At least 2 weeks since prior hormonal therapy for the primary disease. * Concurrent hormone replacement therapy or luteinizing hormone-releasing hormone agonists allowed. * At least 4 weeks since prior radiotherapy. * At least 3 weeks since prior major surgery (2 weeks for minor surgery). * Recovered from prior therapy. * At least 4 weeks since prior investigational treatment. * Coumarin or heparin derivatives allowed for the prevention of deep vein thrombosis or port patency. Exclusion Criteria:. * known or clinically suspected brain metastases or leptomeningeal disease. * symptomatic edema or third-space fluid (e.g., ascites or pleural effusions). * known hepatitis B or C infection. * significant ECG changes that require medical intervention. * QTc interval less than 460 msec. * No history of torsade or other symptomatic QTc abnormality. * LVEF greater than 50% by MUGA. * gastrointestinal abnormality that would require medications (including all antacids). * persistent symptoms of an esophageal or digestive disorder. * pregnant or nursing. * known HIV infection. * active infection. * concurrent uncontrolled systemic disorders or laboratory abnormalities that would preclude study drug safety evaluation. * mental disorder that would preclude study compliance or ability to give informed consent. * No more than 2 prior trastuzumab-based regimens for advanced disease. * concurrent immunotherapy. * more than 1 prior anthracycline- or anthracenedione-containing regimen (except with approval of the sponsor). * prior high-dose chemotherapy with hematopoietic stem cell transplantation. * concurrent anticancer chemotherapy. * No concurrent anticancer hormonal therapy, including tamoxifen. * prior radiotherapy to the only disease site that would be assessed for response. * concurrent radiotherapy. * prior partial or complete gastrectomy. * concurrent antiarrhythmics. * concurrent antacids. * concurrent anticoagulant at therapeutic doses. * other concurrent experimental anticancer medications for breast cancer", "labeled_rules": [{"type": "INCLUSION", "field": "history", "operator": "IN", "value": "* Histologically or cytologically confirmed HER2-overexpressing breast cancer. * Prior or newly documented HER2 amplifi", "unit": null, "evidence_text": "Histologically or cytologically confirmed HER2-overexpressing breast cancer"}, {"type": "INCLUSION", "field": "medication", "operator": "IN", "value": "* Histologically or cytologically confirmed HER2-overexpressing breast cancer. * Prior or newly documented HER2 amplifi", "unit": null, "evidence_text": "Histologically or cytologically confirmed HER2-overexpressing breast cancer"}, {"type": "INCLUSION", "field": "other", "operator": "IN", "value": "* Histologically or cytologically confirmed HER2-overexpressing breast cancer. * Prior or newly documented HER2 amplifi", "unit": null, "evidence_text": "Histologically or cytologically confirmed HER2-overexpressing breast cancer"}, {"type": "INCLUSION", "field": "procedure", "operator": "IN", "value": "* Histologically or cytologically confirmed HER2-overexpressing breast cancer. * Prior or newly documented HER2 amplifi", "unit": null, "evidence_text": "Histologically or cytologically confirmed HER2-overexpressing breast cancer"}, {"type": "INCLUSION", "field": "lab", "operator": ">=", "value": 1.5, "unit": "mg/dl", "evidence_text": "Bilirubin no greater than 1.5 mg/dL"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "normal tracing", "unit": null, "evidence_text": "12-lead ECG with normal tracing"}, {"type": "INCLUSION", "field": "lab", "operator": "IN", "value": "negative pregnancy test", "unit": null, "evidence_text": "Able to take oral medication\\* Negative pregnancy test"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "fertile", "unit": null, "evidence_text": "Fertile patients must use effective contraception"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "doxorubicin or doxorubicin equivalents without any prior", "unit": null, "evidence_text": "At least 6 months since prior doxorubicin or doxorubicin equivalents without any prior or developing signs or symptoms of cardiomyopathy"}, {"type": "EXCLUSION", "field": "sex", "operator": "=", "value": "all", "unit": null, "evidence_text": "known or clinically suspected brain metastases or leptomeningeal disease"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "torsade or other symptomatic qtc abnormality", "unit": null, "evidence_text": "No history of torsade or other symptomatic QTc abnormality"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "persistent", "unit": null, "evidence_text": "persistent symptoms of an esophageal or digestive disorder"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "hiv positive", "unit": null, "evidence_text": "known HIV infection"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "active infection", "unit": null, "evidence_text": "active infection"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "hematopoietic stem cell transplantation", "unit": null, "evidence_text": "prior high-dose chemotherapy with hematopoietic stem cell transplantation"}], "annotator_id": "annotator_c", "guideline_version": "m5-v1", "adjudicated": true, "adjudication_source": "parsing_relabel_round1"}
{"nct_id": "NCT00060125", "eligibility_text": "Inclusion Criteria:. * Histological or cytological diagnosis of cutaneous melanoma and clinical evidence of distant metastatic, non-resectable regional lymphatic, or extensive in transit recurrent disease. * Patients must have at least 2 cutaneous lesions amenable to excisional biopsy for correlative studies; in addition, patients must have measurable disease; the disease remaining after the first excisional biopsy must be measurable; lesions that are considered intrinsically non-measurable include the following:. * Bone lesions. * Leptomeningeal disease. * Ascites. * Pleural/pericardial effusion. * Lymphangitis cutis/pulmonis. * Abdominal masses that are not confirmed and followed by imaging techniques. * Cystic lesions. * Lesions that are situated in a previously irradiated area. * No history of brain metastases. * No allergies to azoles (e.g. ketoconazole) or allergies to compounds structurally similar to R115777. * No more than 1 prior immunotherapy regimen for treatment of advanced melanoma; an additional immunologic therapy in the adjuvant setting (e.g. IFN-a) is acceptable; prior chemotherapy for any stage of melanoma is not allowed. * No radiotherapy or immunotherapy within four weeks prior to the initiation of therapy on this study. * CTC (ECOG) performance status 0-1. * Non-pregnant, non-nursing; treatment under this protocol would expose an unborn child to significant risks; women and men of reproductive potential should agree to use an effective means of birth control; women of child-bearing age will undergo pregnancy testing. * ANC \\>= 1500/uL. * Platelets \\>= 100,000/uL. * Bilirubin =\\< 1.5 mg/dL. * Creatinine =\\< 2.0 mg/dL", "labeled_rules": [{"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "histological or cytological", "unit": null, "evidence_text": "Histological or cytological diagnosis of cutaneous melanoma and clinical evidence of distant metastatic, non-resectable regional lymphatic, or extensive in transit recurrent disease"}, {"type": "INCLUSION", "field": "procedure", "operator": "IN", "value": "* Histological or cytological diagnosis of cutaneous melanoma and clinical evidence of distant metastatic, non-resectab", "unit": null, "evidence_text": "Histological or cytological diagnosis of cutaneous melanoma and clinical evidence of distant metastatic, non-resectable regional lymphatic, or extensive in transit recurrent disease"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "in addition", "unit": null, "evidence_text": "Patients must have at least 2 cutaneous lesions amenable to excisional biopsy for correlative studies; in addition, patients must have measurable disease; the disease remaining after the first excisional biopsy must be measurable; lesions that are considered intrinsically non-measurable include the following:"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "in addition, patients must have measurable disease", "unit": null, "evidence_text": "Patients must have at least 2 cutaneous lesions amenable to excisional biopsy for correlative studies; in addition, patients must have measurable disease; the disease remaining after the first excisional biopsy must be measurable; lesions that are considered intrinsically non-measurable include the following:"}, {"type": "INCLUSION", "field": "history", "operator": "IN", "value": "lesions that are considered intrinsically non-measurable include the following:. * Bone lesions. * Leptomeningeal disease. * Ascites. * Pleu", "unit": null, "evidence_text": "Patients must have at least 2 cutaneous lesions amenable to excisional biopsy for correlative studies; in addition, patients must have measurable disease; the disease remaining after the first excisional biopsy must be measurable; lesions that are considered intrinsically non-measurable include the following:"}, {"type": "INCLUSION", "field": "medication", "operator": "IN", "value": "lesions that are considered intrinsically non-measurable include the following:. * Bone lesions. * Leptomeningeal disease. * Ascites. * Pleu", "unit": null, "evidence_text": "Patients must have at least 2 cutaneous lesions amenable to excisional biopsy for correlative studies; in addition, patients must have measurable disease; the disease remaining after the first excisional biopsy must be measurable; lesions that are considered intrinsically non-measurable include the following:"}, {"type": "INCLUSION", "field": "procedure", "operator": "IN", "value": "lesions that are considered intrinsically non-measurable include the following:. * Bone lesions. * Leptomeningeal disease. * Ascites. * Pleu", "unit": null, "evidence_text": "Patients must have at least 2 cutaneous lesions amenable to excisional biopsy for correlative studies; in addition, patients must have measurable disease; the disease remaining after the first excisional biopsy must be measurable; lesions that are considered intrinsically non-measurable include the following:"}, {"type": "INCLUSION", "field": "procedure", "operator": "IN", "value": "the disease remaining after the first excisional biopsy must be measurable", "unit": null, "evidence_text": "Patients must have at least 2 cutaneous lesions amenable to excisional biopsy for correlative studies; in addition, patients must have measurable disease; the disease remaining after the first excisional biopsy must be measurable; lesions that are considered intrinsically non-measurable include the following:"}, {"type": "INCLUSION", "field": "lab", "operator": ">=", "value": 100000, "unit": "/ul", "evidence_text": "Ascites"}, {"type": "EXCLUSION", "field": "condition", "operator": "IN", "value": "brain metastases", "unit": null, "evidence_text": "No history of brain metastases"}, {"type": "INCLUSION", "field": "sex", "operator": "=", "value": "all", "unit": null, "evidence_text": "No allergies to azoles (e.g. ketoconazole) or allergies to compounds structurally similar to R115777"}, {"type": "INCLUSION", "field": "medication", "operator": "IN", "value": "an additional immunologic therapy in the adjuvant setting (e.g. IFN-a) is acceptable", "unit": null, "evidence_text": "No more than 1 prior immunotherapy regimen for treatment of advanced melanoma; an additional immunologic therapy in the adjuvant setting (e.g. IFN-a) is acceptable; prior chemotherapy for any stage of melanoma is not allowed"}, {"type": "INCLUSION", "field": "medication", "operator": "IN", "value": "prior chemotherapy for any stage of melanoma is not allowed. * No radiotherapy or immunotherapy within four weeks prior to the initiation of", "unit": null, "evidence_text": "No more than 1 prior immunotherapy regimen for treatment of advanced melanoma; an additional immunologic therapy in the adjuvant setting (e.g. IFN-a) is acceptable; prior chemotherapy for any stage of melanoma is not allowed"}, {"type": "INCLUSION", "field": "procedure", "operator": "IN", "value": "prior chemotherapy for any stage of melanoma is not allowed. * No radiotherapy or immunotherapy within four weeks prior to the initiation of", "unit": null, "evidence_text": "No more than 1 prior immunotherapy regimen for treatment of advanced melanoma; an additional immunologic therapy in the adjuvant setting (e.g. IFN-a) is acceptable; prior chemotherapy for any stage of melanoma is not allowed"}, {"type": "EXCLUSION", "field": "medication", "operator": "IN", "value": "treatment under this protocol would expose an unborn child to significant risks", "unit": null, "evidence_text": "Non-pregnant, non-nursing; treatment under this protocol would expose an unborn child to significant risks; women and men of reproductive potential should agree to use an effective means of birth control; women of child-bearing age will undergo pregnancy testing"}, {"type": "EXCLUSION", "field": "procedure", "operator": "IN", "value": "women and men of reproductive potential should agree to use an effective means of birth control", "unit": null, "evidence_text": "Non-pregnant, non-nursing; treatment under this protocol would expose an unborn child to significant risks; women and men of reproductive potential should agree to use an effective means of birth control; women of child-bearing age will undergo pregnancy testing"}, {"type": "EXCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "Non-pregnant, non-nursing; treatment under this protocol would expose an unborn child to significant risks; women and men of reproductive potential should agree to use an effective means of birth control; women of child-bearing age will undergo pregnancy testing"}, {"type": "INCLUSION", "field": "lab", "operator": ">=", "value": 1500, "unit": "/ul", "evidence_text": "ANC \\>= 1500/uL"}, {"type": "INCLUSION", "field": "lab", "operator": "<=", "value": 1.5, "unit": "mg/dl", "evidence_text": "Bilirubin =\\< 1.5 mg/dL"}, {"type": "INCLUSION", "field": "lab", "operator": "<=", "value": 2, "unit": "mg/dl", "evidence_text": "Creatinine =\\< 2.0 mg/dL"}], "annotator_id": "annotator_c", "guideline_version": "m5-v1", "adjudicated": true, "adjudication_source": "parsing_relabel_round1"}
{"nct_id": "NCT00062491", "eligibility_text": "* Confirmed diagnosis of malignant melanoma. * Measurable disease. * Granulocytes 1,500/l, Platelets 100,000/l, Creatinine ULN, Bilirubin 1.5 mg/dl, AST 2.5 x ULN. * No prior treatment with other camptothecin drug.. *  21 days since completion of prior chemotherapy, 6 weeks since prior Mitomycin-C. * ECOG Performance Status 0-1. * Negative pregnancy test for female patients", "labeled_rules": [{"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "confirmed", "unit": null, "evidence_text": "* Confirmed diagnosis of malignant melanoma"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "malignant melanoma", "unit": null, "evidence_text": "* Confirmed diagnosis of malignant melanoma"}, {"type": "INCLUSION", "field": "medication", "operator": "IN", "value": "Confirmed diagnosis of malignant melanoma. * Measurable disease. * Granulocytes 1,500/l, Platelets 100,000/l, Creatinine ULN, Bilirubin", "unit": null, "evidence_text": "* Confirmed diagnosis of malignant melanoma"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "other camptothecin drug", "unit": null, "evidence_text": "No prior treatment with other camptothecin drug"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "negative pregnancy test for female", "unit": null, "evidence_text": "Negative pregnancy test for female patients"}, {"type": "INCLUSION", "field": "lab", "operator": "IN", "value": "negative pregnancy test", "unit": null, "evidence_text": "Negative pregnancy test for female patients"}, {"type": "INCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "Negative pregnancy test for female patients"}], "annotator_id": "annotator_c", "guideline_version": "m5-v1", "adjudicated": true, "adjudication_source": "parsing_relabel_round1"}
{"nct_id": "NCT00068003", "eligibility_text": "* ELIGIBILITY CRITERIA FOR PATIENTS WITH A CURRENT DIAGNOSIS OF CANCER:. INCLUSION CRITERIA:. * Patients must have a form of cancer currently being studied in the NCI-SB.. * Patient is able to understand and willing to sign a written informed consent document.. * Age greater than or equal to 18 years.. * Clinical performance status of ECOG 0 or 1.. * Serology. * Seronegative for HIV antibody. (The experimental treatments being evaluated depend upon an intact immune system. Patients who are HIV seropositive can have decreased immune-competence and thus may be less responsive to the experimental treatment and more susceptible to its toxicities).. * Seronegative for hepatitis B surface antigen and seronegative for hepatitis C antibody. If hepatitis C antibody test is positive, then the patient must be tested for the presence of antigen by RT-PCR and be HCV RNA negative.. * Lesions which will be harvested for the generation of TIL should be accessible via standard surgical or radiological techniques and be associated with acceptable morbidity.. EXCLUSION CRITERIA:. * Active systemic infections, coagulation disorders, or other major medical illnesses of the cardiovascular, respiratory, or immune system.. * Patients who cannot give proper informed consent to the experimental therapy due to an active psychiatric disorder or inability to understand the nature of the proposed therapy and attendant risk.. * Women of child-bearing potential who are pregnant because of the potentially dangerous effects of some of the procedures (e.g., tumor biopsy or surgery for tumor resection) on the fetus.. ELIGIBILITY CRITERIA FOR HEALTHY VOLUNTEERS:. INCLUSION CRITERIA for PBMC Donors:. * Age greater than or equal to 18 years.. * Non-reactive for HBsAg, anti-HBc, anti-HCV, anti-HIV-1/2, HBV/HCV/HIV-1 NAT, anti-HTLV-I/II, anti-T. cruzi, West Nile Virus NAT,syphilis, and babesia.. * PBMC donors must meet the strict behavioral and medical history requirements as per applicable NCI-SB Apheresis Donor SOP(s).. INCLUSION CRITERIA FOR WHOLE BLOOD DONORS:. * Age greater than or equal to 18 years.. * Whole blood donors must meet the DTM inclusion criteria for allogeneic whole blood donation.. EXCLUSION CRITERIA for PBMC Donors:. * Has had babesiosis.. * Is at risk or has Creutzfeldt-Jakob Disease.. * Is on steroid therapy or any other medication or has received vaccination that might interfere with cell preparation per Principal Investigator s (PI) discretion.. * Has ongoing illness that would cause harm to the volunteer during the apheresis procedure as determined by the PI.. * Has had yellow jaundice, liver disease, or hepatitis since the age of 11.. * Has uncontrolled diabetes.. * Has a hematologic malignancy or any bleeding abnormalities.. * Has received any type of organ transplant in the past 12 months.. * Has undergone xenotransplantation at any time.. * Has received a dura mater graft.. * If female, is pregnant or has given birth within the last six weeks.. * Has had an ear or body piercing or tattoos within the past 12 months.. * Has had a blood transfusion within the past 12 months.. * Has spent time outside the United States to a restricted country.. * Has participated in any high-risk activities.. EXCLUSION CRITERIA for Whole Blood Donors:. \\- Whole blood donors who do not meet the DTM criteria for allogeneic whole blood donation.", "labeled_rules": [{"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "for patients with a current", "unit": null, "evidence_text": "* ELIGIBILITY CRITERIA FOR PATIENTS WITH A CURRENT DIAGNOSIS OF CANCER:. INCLUSION CRITERIA:"}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "pregnancy", "unit": null, "evidence_text": "* ELIGIBILITY CRITERIA FOR PATIENTS WITH A CURRENT DIAGNOSIS OF CANCER:. INCLUSION CRITERIA:"}, {"type": "INCLUSION", "field": "history", "operator": "IN", "value": "Patients must have a form of cancer currently being studied in the NCI-SB", "unit": null, "evidence_text": "Patients must have a form of cancer currently being studied in the NCI-SB"}, {"type": "INCLUSION", "field": "other", "operator": "IN", "value": "Patients must have a form of cancer currently being studied in the NCI-SB", "unit": null, "evidence_text": "Patients must have a form of cancer currently being studied in the NCI-SB"}, {"type": "INCLUSION", "field": "lab", "operator": ">=", "value": 18, "unit": "years", "evidence_text": "Age greater than or equal to 18 years"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "eligibility for", "unit": null, "evidence_text": "Clinical performance status of ECOG 0 or 1"}, {"type": "INCLUSION", "field": "condition", "operator": "NOT_IN", "value": "hiv positive", "unit": null, "evidence_text": "Seronegative for HIV antibody. (The experimental treatments being evaluated depend upon an intact immune system. Patients who are HIV seropositive can have decreased immune-competence and thus may be less responsive to the experimental treatment and more susceptible to its toxicities)"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "acceptable morbidity", "unit": null, "evidence_text": "Lesions which will be harvested for the generation of TIL should be accessible via standard surgical or radiological techniques and be associated with acceptable morbidity.. EXCLUSION CRITERIA:"}, {"type": "EXCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "If female, is pregnant or has given birth within the last six weeks"}, {"type": "EXCLUSION", "field": "medication", "operator": "WITHIN_LAST", "value": 12, "unit": "months", "evidence_text": "Has had a blood transfusion within the past 12 months"}, {"type": "EXCLUSION", "field": "procedure", "operator": "WITHIN_LAST", "value": 12, "unit": "months", "evidence_text": "Has had a blood transfusion within the past 12 months"}], "annotator_id": "annotator_c", "guideline_version": "m5-v1", "adjudicated": true, "adjudication_source": "parsing_relabel_round1"}
{"nct_id": "NCT00072085", "eligibility_text": "DISEASE CHARACTERISTICS:. * Diagnosis of metastatic melanoma. * Measurable disease. * Progressive disease during or after prior standard treatment with or without interleukin-2. PATIENT CHARACTERISTICS:. Age. * 16 and over. Performance status. * ECOG 0-2. Life expectancy. * More than 6 months. Hematopoietic. * WBC at least 3,000/mm\\^3. * Platelet count at least 90,000/mm\\^3. * Lymphocyte count greater than 500/mm\\^3. Hepatic. * Bilirubin no greater than 2.0 mg/dL (less than 3.0 mg/dL for patients with Gilbert's syndrome). * ALT and AST less than 3 times normal. * Hepatitis B surface antigen negative. Renal. * Creatinine no greater than 2.0 mg/dL. Cardiovascular. * No symptomatic cardiac disease. Immunologic. * No active systemic infection. * No autoimmune disease. * No known immunodeficiency disease. * No known hypersensitivity to study agents. * No form of primary or secondary immunodeficiency. * No opportunistic infection. * HIV negative. Other. * Not pregnant or nursing. * Negative pregnancy test. * Fertile patients must use effective contraception. PRIOR CONCURRENT THERAPY:. Biologic therapy. * See Disease Characteristics. * No prior gp100 peptide vaccine. Chemotherapy. * More than 6 weeks since prior nitrosoureas. Endocrine therapy. * No concurrent systemic steroid therapy. Radiotherapy. * Not specified. Surgery. * Prior recent (within the past 3 weeks) minor surgical procedures allowed. Other. * Recovered from prior therapy (toxicity no greater than grade 1). * More than 3 weeks since prior systemic anticancer therapy. * No other concurrent systemic anticancer therapy", "labeled_rules": [{"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "metastatic melanoma", "unit": null, "evidence_text": "Diagnosis of metastatic melanoma"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "or without interleukin-2", "unit": null, "evidence_text": "Progressive disease during or after prior standard treatment with or without interleukin-2. PATIENT CHARACTERISTICS:. Age"}, {"type": "INCLUSION", "field": "lab", "operator": ">=", "value": 500, "unit": "/mm", "evidence_text": "Lymphocyte count greater than 500/mm\\^3. Hepatic"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "dl for", "unit": null, "evidence_text": "Bilirubin no greater than 2.0 mg/dL (less than 3.0 mg/dL for patients with Gilbert's syndrome)"}, {"type": "INCLUSION", "field": "lab", "operator": "IN", "value": "negative pregnancy test", "unit": null, "evidence_text": "Negative pregnancy test"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "fertile", "unit": null, "evidence_text": "Fertile patients must use effective contraception. PRIOR CONCURRENT THERAPY:. Biologic therapy"}, {"type": "INCLUSION", "field": "medication", "operator": "WITHIN_LAST", "value": 3, "unit": "weeks", "evidence_text": "More than 3 weeks since prior systemic anticancer therapy"}, {"type": "INCLUSION", "field": "procedure", "operator": "WITHIN_LAST", "value": 3, "unit": "weeks", "evidence_text": "More than 3 weeks since prior systemic anticancer therapy"}], "annotator_id": "annotator_c", "guideline_version": "m5-v1", "adjudicated": true, "adjudication_source": "parsing_relabel_round1"}
{"nct_id": "NCT00106535", "eligibility_text": "Inclusion Criteria:. * adult patients at least 18 years of age with moderate to severe active RA for at least 6 months;. * inadequate response to a stable dose of MTX;. * patients of reproductive potential must be using reliable methods of contraception.. Exclusion Criteria:. * major surgery (including joint surgery) within 8 weeks before entering study, or planned surgery within 6 months after entering study;. * prior treatment failure with an anti-tumor necrosis factor agent;. * women who are pregnant or breast-feeding.", "labeled_rules": [{"type": "INCLUSION", "field": "age", "operator": ">=", "value": 18, "unit": "years", "evidence_text": "adult patients at least 18 years of age with moderate to severe active RA for at least 6 months"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "moderate to severe active ra for", "unit": null, "evidence_text": "adult patients at least 18 years of age with moderate to severe active RA for at least 6 months"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "moderate to severe active ra for at", "unit": null, "evidence_text": "adult patients at least 18 years of age with moderate to severe active RA for at least 6 months"}, {"type": "INCLUSION", "field": "procedure", "operator": "IN", "value": "* adult patients at least 18 years of age with moderate to severe active RA for at least 6 months", "unit": null, "evidence_text": "adult patients at least 18 years of age with moderate to severe active RA for at least 6 months"}, {"type": "INCLUSION", "field": "procedure", "operator": "WITHIN_LAST", "value": 8, "unit": "weeks", "evidence_text": "major surgery (including joint surgery) within 8 weeks before entering study, or planned surgery within 6 months after entering study"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "an anti-tumor necrosis factor agent", "unit": null, "evidence_text": "prior treatment failure with an anti-tumor necrosis factor agent"}, {"type": "INCLUSION", "field": "medication", "operator": "IN", "value": "* prior treatment failure with an anti-tumor necrosis factor agent", "unit": null, "evidence_text": "prior treatment failure with an anti-tumor necrosis factor agent"}, {"type": "INCLUSION", "field": "procedure", "operator": "IN", "value": "* prior treatment failure with an anti-tumor necrosis factor agent", "unit": null, "evidence_text": "prior treatment failure with an anti-tumor necrosis factor agent"}, {"type": "EXCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "women who are pregnant or breast-feeding"}, {"type": "INCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "women who are pregnant or breast-feeding"}], "annotator_id": "annotator_c", "guideline_version": "m5-v1", "adjudicated": true, "adjudication_source": "parsing_relabel_round1"}
{"nct_id": "NCT00111722", "eligibility_text": "Inclusion Criteria:. * Female patient at least 18 years old. * Patient has menses approximately monthly. * Patient has at least a 6 month history of migraine and at least a 6 month history of menstrual migraine. Exclusion Criteria:. * Pregnant and/or nursing mother. * Cardiovascular disease. * Uncontrolled hypertension", "labeled_rules": [{"type": "INCLUSION", "field": "age", "operator": ">=", "value": 18, "unit": "years", "evidence_text": "* Female patient at least 18 years old"}, {"type": "INCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "* Female patient at least 18 years old"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "migraine and at least a 6", "unit": null, "evidence_text": "* Patient has at least a 6 month history of migraine and at least a 6 month history of menstrual migraine"}]}
{"nct_id": "NCT00112229", "eligibility_text": "Inclusion Criteria:. * Histologically confirmed stage III or stage IV melanoma. * Tumor expression of Melan-A +/- Tyrosinase. * Human leukocyte antigen-A2 (HLA-A2) positive. Exclusion Criteria:. * Clinically significant heart disease. * Serious illnesses, eg, serious infections requiring antibiotics, bleeding disorders or uncontrolled peptic ulcer, or seizure or central nervous system disorders. * History of immunodeficiency disease or autoimmune disease. * Coagulation or bleeding disorders", "labeled_rules": [{"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "immunodeficiency disease or autoimmune disease", "unit": null, "evidence_text": "* History of immunodeficiency disease or autoimmune disease"}]}
{"nct_id": "NCT00116701", "eligibility_text": "Inclusion Criteria: -at least 18 years old - Diagnosis of chronic kidney disease (CKD) and receiving dialysis for at least 3 months prior to screening - Baseline Hb level greater than or equal to 10.0 g/dL and less than or equal to 13.0 g/dL - Adequate iron stores (defined as serum ferritin greater than or equal to 100 g/L or transferrin saturation \\[TSAT\\] greater than or equal to 20%) - Stable IV (epoetin alfa or beta) or SC rHuEPO (epoetin beta) therapy 2 or 3 times per week for at least 8 weeks before screening (stable is defined as less than 25% change in weekly dose and no change in frequency or route) - All subjects must practice adequate contraception (in the judgment of the investigator) throughout this trial. Exclusion Criteria: - Received SC epoetin alfa in the 12 months before screening - Uncontrolled hypertension (diastolic blood pressure greater than 100 mmHg or systolic blood pressure greater than 180 mmHg on 2 separate occasions during screening) - Prior history (within 12 weeks before enrolment) of cardiovascular events including:. * acute myocardial ischemia;. * hospitalization for congestive heart failure;. * myocardial infarction. - Pregnant or breast-feeding women - Treatment with an investigational agent or device within 30 days before screening or scheduled to receive an investigational agent other than those specified by this protocol during the course of this study - Known sensitivity to any of the products to be administered during dosing - Disorder that compromises the ability of the subject to give written informed consent and/or to comply with study procedures", "labeled_rules": [{"type": "EXCLUSION", "field": "age", "operator": "<=", "value": 13, "unit": "years", "evidence_text": "Inclusion Criteria: -at least 18 years old - Diagnosis of chronic kidney disease (CKD) and receiving dialysis for at least 3 months prior to screening - Baseline Hb level greater than or equal to 10.0 g/dL and less than or equal to 13.0 g/dL - Adequate iron stores (defined as serum ferritin greater than or equal to 100 g/L or transferrin saturation \\[TSAT\\] greater than or equal to 20%) - Stable IV (epoetin alfa or beta) or SC rHuEPO (epoetin beta) therapy 2 or 3 times per week for at least 8 weeks before screening (stable is defined as less than 25% change in weekly dose and no change in frequency or route) - All subjects must practice adequate contraception (in the judgment of the investigator) throughout this trial. Exclusion Criteria: - Received SC epoetin alfa in the 12 months before screening - Uncontrolled hypertension (diastolic blood pressure greater than 100 mmHg or systolic blood pressure greater than 180 mmHg on 2 separate occasions during screening) - Prior history (within 12 weeks before enrolment) of cardiovascular events including:"}, {"type": "EXCLUSION", "field": "age", "operator": ">=", "value": 18, "unit": "years", "evidence_text": "Inclusion Criteria: -at least 18 years old - Diagnosis of chronic kidney disease (CKD) and receiving dialysis for at least 3 months prior to screening - Baseline Hb level greater than or equal to 10.0 g/dL and less than or equal to 13.0 g/dL - Adequate iron stores (defined as serum ferritin greater than or equal to 100 g/L or transferrin saturation \\[TSAT\\] greater than or equal to 20%) - Stable IV (epoetin alfa or beta) or SC rHuEPO (epoetin beta) therapy 2 or 3 times per week for at least 8 weeks before screening (stable is defined as less than 25% change in weekly dose and no change in frequency or route) - All subjects must practice adequate contraception (in the judgment of the investigator) throughout this trial. Exclusion Criteria: - Received SC epoetin alfa in the 12 months before screening - Uncontrolled hypertension (diastolic blood pressure greater than 100 mmHg or systolic blood pressure greater than 180 mmHg on 2 separate occasions during screening) - Prior history (within 12 weeks before enrolment) of cardiovascular events including:"}, {"type": "EXCLUSION", "field": "condition", "operator": "IN", "value": "at least 18 years old", "unit": null, "evidence_text": "Inclusion Criteria: -at least 18 years old - Diagnosis of chronic kidney disease (CKD) and receiving dialysis for at least 3 months prior to screening - Baseline Hb level greater than or equal to 10.0 g/dL and less than or equal to 13.0 g/dL - Adequate iron stores (defined as serum ferritin greater than or equal to 100 g/L or transferrin saturation \\[TSAT\\] greater than or equal to 20%) - Stable IV (epoetin alfa or beta) or SC rHuEPO (epoetin beta) therapy 2 or 3 times per week for at least 8 weeks before screening (stable is defined as less than 25% change in weekly dose and no change in frequency or route) - All subjects must practice adequate contraception (in the judgment of the investigator) throughout this trial. Exclusion Criteria: - Received SC epoetin alfa in the 12 months before screening - Uncontrolled hypertension (diastolic blood pressure greater than 100 mmHg or systolic blood pressure greater than 180 mmHg on 2 separate occasions during screening) - Prior history (within 12 weeks before enrolment) of cardiovascular events including:"}, {"type": "EXCLUSION", "field": "history", "operator": "IN", "value": "at least 18 years old - Diagnosis of chronic kidney disease (CKD) and receiving dialysis for at least 3 months prior to", "unit": null, "evidence_text": "Inclusion Criteria: -at least 18 years old - Diagnosis of chronic kidney disease (CKD) and receiving dialysis for at least 3 months prior to screening - Baseline Hb level greater than or equal to 10.0 g/dL and less than or equal to 13.0 g/dL - Adequate iron stores (defined as serum ferritin greater than or equal to 100 g/L or transferrin saturation \\[TSAT\\] greater than or equal to 20%) - Stable IV (epoetin alfa or beta) or SC rHuEPO (epoetin beta) therapy 2 or 3 times per week for at least 8 weeks before screening (stable is defined as less than 25% change in weekly dose and no change in frequency or route) - All subjects must practice adequate contraception (in the judgment of the investigator) throughout this trial. Exclusion Criteria: - Received SC epoetin alfa in the 12 months before screening - Uncontrolled hypertension (diastolic blood pressure greater than 100 mmHg or systolic blood pressure greater than 180 mmHg on 2 separate occasions during screening) - Prior history (within 12 weeks before enrolment) of cardiovascular events including:"}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "pregnancy", "unit": null, "evidence_text": "Inclusion Criteria: -at least 18 years old - Diagnosis of chronic kidney disease (CKD) and receiving dialysis for at least 3 months prior to screening - Baseline Hb level greater than or equal to 10.0 g/dL and less than or equal to 13.0 g/dL - Adequate iron stores (defined as serum ferritin greater than or equal to 100 g/L or transferrin saturation \\[TSAT\\] greater than or equal to 20%) - Stable IV (epoetin alfa or beta) or SC rHuEPO (epoetin beta) therapy 2 or 3 times per week for at least 8 weeks before screening (stable is defined as less than 25% change in weekly dose and no change in frequency or route) - All subjects must practice adequate contraception (in the judgment of the investigator) throughout this trial. Exclusion Criteria: - Received SC epoetin alfa in the 12 months before screening - Uncontrolled hypertension (diastolic blood pressure greater than 100 mmHg or systolic blood pressure greater than 180 mmHg on 2 separate occasions during screening) - Prior history (within 12 weeks before enrolment) of cardiovascular events including:"}, {"type": "EXCLUSION", "field": "lab", "operator": ">=", "value": 10, "unit": "g/dl", "evidence_text": "Inclusion Criteria: -at least 18 years old - Diagnosis of chronic kidney disease (CKD) and receiving dialysis for at least 3 months prior to screening - Baseline Hb level greater than or equal to 10.0 g/dL and less than or equal to 13.0 g/dL - Adequate iron stores (defined as serum ferritin greater than or equal to 100 g/L or transferrin saturation \\[TSAT\\] greater than or equal to 20%) - Stable IV (epoetin alfa or beta) or SC rHuEPO (epoetin beta) therapy 2 or 3 times per week for at least 8 weeks before screening (stable is defined as less than 25% change in weekly dose and no change in frequency or route) - All subjects must practice adequate contraception (in the judgment of the investigator) throughout this trial. Exclusion Criteria: - Received SC epoetin alfa in the 12 months before screening - Uncontrolled hypertension (diastolic blood pressure greater than 100 mmHg or systolic blood pressure greater than 180 mmHg on 2 separate occasions during screening) - Prior history (within 12 weeks before enrolment) of cardiovascular events including:"}, {"type": "EXCLUSION", "field": "medication", "operator": "WITHIN_LAST", "value": 12, "unit": "weeks", "evidence_text": "Inclusion Criteria: -at least 18 years old - Diagnosis of chronic kidney disease (CKD) and receiving dialysis for at least 3 months prior to screening - Baseline Hb level greater than or equal to 10.0 g/dL and less than or equal to 13.0 g/dL - Adequate iron stores (defined as serum ferritin greater than or equal to 100 g/L or transferrin saturation \\[TSAT\\] greater than or equal to 20%) - Stable IV (epoetin alfa or beta) or SC rHuEPO (epoetin beta) therapy 2 or 3 times per week for at least 8 weeks before screening (stable is defined as less than 25% change in weekly dose and no change in frequency or route) - All subjects must practice adequate contraception (in the judgment of the investigator) throughout this trial. Exclusion Criteria: - Received SC epoetin alfa in the 12 months before screening - Uncontrolled hypertension (diastolic blood pressure greater than 100 mmHg or systolic blood pressure greater than 180 mmHg on 2 separate occasions during screening) - Prior history (within 12 weeks before enrolment) of cardiovascular events including:"}, {"type": "EXCLUSION", "field": "procedure", "operator": "WITHIN_LAST", "value": 12, "unit": "weeks", "evidence_text": "Inclusion Criteria: -at least 18 years old - Diagnosis of chronic kidney disease (CKD) and receiving dialysis for at least 3 months prior to screening - Baseline Hb level greater than or equal to 10.0 g/dL and less than or equal to 13.0 g/dL - Adequate iron stores (defined as serum ferritin greater than or equal to 100 g/L or transferrin saturation \\[TSAT\\] greater than or equal to 20%) - Stable IV (epoetin alfa or beta) or SC rHuEPO (epoetin beta) therapy 2 or 3 times per week for at least 8 weeks before screening (stable is defined as less than 25% change in weekly dose and no change in frequency or route) - All subjects must practice adequate contraception (in the judgment of the investigator) throughout this trial. Exclusion Criteria: - Received SC epoetin alfa in the 12 months before screening - Uncontrolled hypertension (diastolic blood pressure greater than 100 mmHg or systolic blood pressure greater than 180 mmHg on 2 separate occasions during screening) - Prior history (within 12 weeks before enrolment) of cardiovascular events including:"}, {"type": "EXCLUSION", "field": "condition", "operator": "IN", "value": "* hospitalization for congestive heart failure", "unit": null, "evidence_text": "hospitalization for congestive heart failure"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "study procedures", "unit": null, "evidence_text": "myocardial infarction. - Pregnant or breast-feeding women - Treatment with an investigational agent or device within 30 days before screening or scheduled to receive an investigational agent other than those specified by this protocol during the course of this study - Known sensitivity to any of the products to be administered during dosing - Disorder that compromises the ability of the subject to give written informed consent and/or to comply with study procedures"}, {"type": "EXCLUSION", "field": "medication", "operator": "WITHIN_LAST", "value": 30, "unit": "days", "evidence_text": "myocardial infarction. - Pregnant or breast-feeding women - Treatment with an investigational agent or device within 30 days before screening or scheduled to receive an investigational agent other than those specified by this protocol during the course of this study - Known sensitivity to any of the products to be administered during dosing - Disorder that compromises the ability of the subject to give written informed consent and/or to comply with study procedures"}, {"type": "EXCLUSION", "field": "other", "operator": "IN", "value": "* myocardial infarction. - Pregnant or breast-feeding women - Treatment with an investigational agent or device within 30 days before scre", "unit": null, "evidence_text": "myocardial infarction. - Pregnant or breast-feeding women - Treatment with an investigational agent or device within 30 days before screening or scheduled to receive an investigational agent other than those specified by this protocol during the course of this study - Known sensitivity to any of the products to be administered during dosing - Disorder that compromises the ability of the subject to give written informed consent and/or to comply with study procedures"}, {"type": "EXCLUSION", "field": "procedure", "operator": "WITHIN_LAST", "value": 30, "unit": "days", "evidence_text": "myocardial infarction. - Pregnant or breast-feeding women - Treatment with an investigational agent or device within 30 days before screening or scheduled to receive an investigational agent other than those specified by this protocol during the course of this study - Known sensitivity to any of the products to be administered during dosing - Disorder that compromises the ability of the subject to give written informed consent and/or to comply with study procedures"}, {"type": "EXCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "myocardial infarction. - Pregnant or breast-feeding women - Treatment with an investigational agent or device within 30 days before screening or scheduled to receive an investigational agent other than those specified by this protocol during the course of this study - Known sensitivity to any of the products to be administered during dosing - Disorder that compromises the ability of the subject to give written informed consent and/or to comply with study procedures"}], "annotator_id": "annotator_c", "guideline_version": "m5-v1", "adjudicated": true, "adjudication_source": "parsing_relabel_round1"}
{"nct_id": "NCT00123799", "eligibility_text": "Inclusion Criteria:. * Male or female. If female of child bearing potential and outside of the window of 10 days since the last menstrual period, a negative pregnancy test.. * Biopsy proven breast carcinoma (core biopsy or fine needle aspiration, although core biopsies are preferred.). * Tumour size T1-3, N0 clinically. * All patients will have pre-operative mammography +/- ultrasound of the breast. * Age equal to or greater than 18 years. * Able and willing to follow instructions and comply with the protocol. * Provide written informed consent prior to participation in this study. Exclusion Criteria:. * Nursing or pregnant females. * Previous malignancy or diagnosis less than 10 (ten) years ago. Skin cancers (excluding malignant melanoma) and carcinoma in situ of the cervix are exceptions.. * Excisional biopsy of the tumour has been performed. * Age less than 18 years. * Patient has diabetes", "labeled_rules": [{"type": "INCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "* Male or female"}, {"type": "INCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "If female of child bearing potential and outside of the window of 10 days since the last menstrual period, a negative pregnancy test"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "the protocol", "unit": null, "evidence_text": "* Able and willing to follow instructions and comply with the protocol"}]}
{"nct_id": "NCT00128297", "eligibility_text": "Inclusion Criteria:. * Written informed consent.. * Up to two previous or current hormone therapy treatments for metastatic breast cancer are allowed.. * Normal or borderline renal function (serum creatinine \\< 1.5 x upper normal limit \\[UNL\\]).. * Normal calcium levels in serum, or slightly non-symptomatic high levels (\\< 1.25 x UNL).. * Performance status 0, I or II in World Health Organization (WHO) scale.. Exclusion Criteria:. * Treatment with bisphosphonates in the 30 previous days, or any time if the indication was treatment of metastatic bone lesions.. * Treatment with bisphosphonates is only allowed if the indication is hypercalcaemia.. * Metastases in central nervous system (CNS).. * Hypersensitivity to bisphosphonates or other components of the formula.. * Pregnant or lactating women.. * Previous or current treatment with a second chemotherapy line or a third hormone therapy line for metastatic disease.", "labeled_rules": [{"type": "INCLUSION", "field": "history", "operator": "IN", "value": "* Written informed consent.. * Up to two previous or current hormone therapy treatments for metastatic breast cancer ar", "unit": null, "evidence_text": "Written informed consent"}, {"type": "INCLUSION", "field": "medication", "operator": "IN", "value": "* Written informed consent.. * Up to two previous or current hormone therapy treatments for metastatic breast cancer ar", "unit": null, "evidence_text": "Written informed consent"}, {"type": "INCLUSION", "field": "other", "operator": "IN", "value": "* Written informed consent.. * Up to two previous or current hormone therapy treatments for metastatic breast cancer ar", "unit": null, "evidence_text": "Written informed consent"}, {"type": "INCLUSION", "field": "procedure", "operator": "IN", "value": "* Written informed consent.. * Up to two previous or current hormone therapy treatments for metastatic breast cancer ar", "unit": null, "evidence_text": "Written informed consent"}, {"type": "INCLUSION", "field": "lab", "operator": "<=", "value": 1.5, "unit": "x", "evidence_text": "Normal or borderline renal function (serum creatinine \\< 1.5 x upper normal limit \\[UNL\\])"}, {"type": "INCLUSION", "field": "lab", "operator": "<=", "value": 1.25, "unit": "x", "evidence_text": "Normal calcium levels in serum, or slightly non-symptomatic high levels (\\< 1.25 x UNL)"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "bisphosphonates in the 30 previous days", "unit": null, "evidence_text": "Treatment with bisphosphonates in the 30 previous days, or any time if the indication was treatment of metastatic bone lesions"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "bisphosphonates is only allowed", "unit": null, "evidence_text": "Treatment with bisphosphonates is only allowed if the indication is hypercalcaemia"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "bisphosphonates is only allowed if the", "unit": null, "evidence_text": "Treatment with bisphosphonates is only allowed if the indication is hypercalcaemia"}, {"type": "EXCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "Pregnant or lactating women"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "a second chemotherapy line or a", "unit": null, "evidence_text": "Previous or current treatment with a second chemotherapy line or a third hormone therapy line for metastatic disease"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "a second chemotherapy line or a third", "unit": null, "evidence_text": "Previous or current treatment with a second chemotherapy line or a third hormone therapy line for metastatic disease"}], "annotator_id": "annotator_c", "guideline_version": "m5-v1", "adjudicated": true, "adjudication_source": "parsing_relabel_round1"}
{"nct_id": "NCT00129701", "eligibility_text": "Inclusion Criteria:. Patients who had already attended a respiratory clinic on at least two occasions and in whom it was perceived that there was a need for continued follow up in a hospital clinic with review needed more often than once per year Patients with no need for physical examinations or investigations such as chest X-rays, blood tests or lung function tests at every attendance Patients who had access to a confidential telephone line Patients who had no mental, hearing or linguistic problems. Exclusion criteria. New patients or those who need frequent follow up Patients with mental or cognitive issues Patients requiring physical examination and testing.", "labeled_rules": [{"type": "EXCLUSION", "field": "condition", "operator": "IN", "value": "follow up in a hospital clinic", "unit": null, "evidence_text": "Inclusion Criteria:. Patients who had already attended a respiratory clinic on at least two occasions and in whom it was perceived that there was a need for continued follow up in a hospital clinic with review needed more often than once per year Patients with no need for physical examinations or investigations such as chest X-rays, blood tests or lung function tests at every attendance Patients who had access to a confidential telephone line Patients who had no mental, hearing or linguistic problems. Exclusion criteria. New patients or those who need frequent follow up Patients with mental or cognitive issues Patients requiring physical examination and testing"}, {"type": "EXCLUSION", "field": "condition", "operator": "IN", "value": "mental or cognitive issues patients", "unit": null, "evidence_text": "Inclusion Criteria:. Patients who had already attended a respiratory clinic on at least two occasions and in whom it was perceived that there was a need for continued follow up in a hospital clinic with review needed more often than once per year Patients with no need for physical examinations or investigations such as chest X-rays, blood tests or lung function tests at every attendance Patients who had access to a confidential telephone line Patients who had no mental, hearing or linguistic problems. Exclusion criteria. New patients or those who need frequent follow up Patients with mental or cognitive issues Patients requiring physical examination and testing"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "mental or cognitive issues requiring physical", "unit": null, "evidence_text": "Inclusion Criteria:. Patients who had already attended a respiratory clinic on at least two occasions and in whom it was perceived that there was a need for continued follow up in a hospital clinic with review needed more often than once per year Patients with no need for physical examinations or investigations such as chest X-rays, blood tests or lung function tests at every attendance Patients who had access to a confidential telephone line Patients who had no mental, hearing or linguistic problems. Exclusion criteria. New patients or those who need frequent follow up Patients with mental or cognitive issues Patients requiring physical examination and testing"}, {"type": "EXCLUSION", "field": "other", "operator": "IN", "value": "Patients who had already attended a respiratory clinic on at least two occasions and in whom it was perceived that ther", "unit": null, "evidence_text": "Inclusion Criteria:. Patients who had already attended a respiratory clinic on at least two occasions and in whom it was perceived that there was a need for continued follow up in a hospital clinic with review needed more often than once per year Patients with no need for physical examinations or investigations such as chest X-rays, blood tests or lung function tests at every attendance Patients who had access to a confidential telephone line Patients who had no mental, hearing or linguistic problems. Exclusion criteria. New patients or those who need frequent follow up Patients with mental or cognitive issues Patients requiring physical examination and testing"}, {"type": "EXCLUSION", "field": "procedure", "operator": "IN", "value": "Patients who had already attended a respiratory clinic on at least two occasions and in whom it was perceived that ther", "unit": null, "evidence_text": "Inclusion Criteria:. Patients who had already attended a respiratory clinic on at least two occasions and in whom it was perceived that there was a need for continued follow up in a hospital clinic with review needed more often than once per year Patients with no need for physical examinations or investigations such as chest X-rays, blood tests or lung function tests at every attendance Patients who had access to a confidential telephone line Patients who had no mental, hearing or linguistic problems. Exclusion criteria. New patients or those who need frequent follow up Patients with mental or cognitive issues Patients requiring physical examination and testing"}], "annotator_id": "annotator_c", "guideline_version": "m5-v1", "adjudicated": true, "adjudication_source": "parsing_relabel_round1"}
{"nct_id": "NCT00134797", "eligibility_text": "Inclusion Criteria:. * All patients in the Internal Medicine Clinic at Naval Medical Center, San Diego (NMCSD) who were sent to the lab to obtain follow up by their primary care providers.. Exclusion Criteria:. * All patients referred to or being followed by nephrologists.", "labeled_rules": [{"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "study-specific condition", "unit": null, "evidence_text": "Inclusion Criteria:"}]}
{"nct_id": "NCT00145158", "eligibility_text": "Inclusion Criteria. 1. Histologically proven cutaneous melanoma, or clear cell sarcoma, which is considered as a subtype of melanoma.. 2. Melanoma must be at one of the following AJCC 2002 stages:. * Regional metastatic disease (any T; N2b, N2c or N3; M0).. * Distant metastatic disease (any T; any N; M1a, M1b or M1c), except brain or leptomeningeal localizations, and except elevated LDH.. 3. Patients must be HLA-A2.. 4. A pre-immune tumor biopsy must be kept frozen for post-study PCR analysis.. 5. Presence of at least one measurable or non-measurable tumor lesion.. 6. Expected survival of at least 3 months.. 7. Karnofsky performance scale 70 or WHO performance status of 0 or 1.. 8. Within the last 4 weeks prior to study day 1, vital laboratory parameters should be within normal range, except for the following laboratory parameters, which must be within the ranges specified:. Lab Parameter Range. * Hemoglobin  10 g/dl or  6,25 mmol/l. * Granulocytes  1,500/l. * Lymphocytes  700/l. * Platelets  100,000/l. * Serum creatinine  2.0 mg/dl or  177 mol/l. * Serum bilirubin  2.0 mg/dl or  34.2 mol/l. * ASAT and ALAT  2 x the normal upper limits. * LDH  the normal upper limit.. 9. Viral tests:. * HIV (human immunodeficiency virus): negative antibodies.. * HBV (hepatitis B virus): negative antigens; antibodies may be positive.. * HCV (hepatitis C virus): negative antibodies.. 10. Age  18 years.. 11. Able and willing to give valid written informed consent.. Exclusion Criteria. 1. Previous treatment with more than one regimen of systemic chemotherapy, combined or not with non-specific immunotherapy such as interferon alpha or interleukins. Chemoimmunotherapy or radiotherapy must be stopped within the preceding 4 weeks (6 weeks for nitrosoureas and mitomycin C).. 2. Clinically significant heart disease (NYHA Class III or IV) i.e. NYHA class 3 congestive heart failure; myocardial infarction within the past six months; unstable angina; coronary angioplasty within the past 6 months; uncontrolled atrial or ventricular cardiac arrhythmias.. 3. Active immunodeficiency or autoimmune disease. Vitiligo was not an exclusion criterion.. 4. Other serious acute or chronic illnesses, e.g. active infections requiring antibiotics, bleeding disorders, or other conditions requiring concurrent medications not allowed during this study.. 5. Other malignancy within 3 years prior to entry into the study, except for treated non-melanoma skin cancer and cervical carcinoma in situ.. 6. Lack of availability for immunological and clinical follow-up assessments.. 7. Participation in any other clinical trial involving another investigational agent within 4 weeks prior to enrollment.. 8. Pregnancy or breastfeeding.. 9. Women of childbearing potential: Refusal or inability to use effective means of contraception.", "labeled_rules": [{"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "1. Histologically proven cutaneous melanoma, or clear cell sarcoma, which is considered as a subtype of melanoma.. 2. Me", "unit": null, "evidence_text": "Inclusion Criteria. 1. Histologically proven cutaneous melanoma, or clear cell sarcoma, which is considered as a subtype of melanoma.. 2. Melanoma must be at one of the following AJCC 2002 stages:"}, {"type": "INCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "Inclusion Criteria. 1. Histologically proven cutaneous melanoma, or clear cell sarcoma, which is considered as a subtype of melanoma.. 2. Melanoma must be at one of the following AJCC 2002 stages:"}, {"type": "EXCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "Inclusion Criteria. 1. Histologically proven cutaneous melanoma, or clear cell sarcoma, which is considered as a subtype of melanoma.. 2. Melanoma must be at one of the following AJCC 2002 stages:"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "M0).. * Distant metastatic disease (any T", "unit": null, "evidence_text": "Regional metastatic disease (any T; N2b, N2c or N3; M0)"}, {"type": "INCLUSION", "field": "history", "operator": "WITHIN_LAST", "value": 4, "unit": "weeks", "evidence_text": "Distant metastatic disease (any T; any N; M1a, M1b or M1c), except brain or leptomeningeal localizations, and except elevated LDH.. 3. Patients must be HLA-A2.. 4. A pre-immune tumor biopsy must be kept frozen for post-study PCR analysis.. 5. Presence of at least one measurable or non-measurable tumor lesion.. 6. Expected survival of at least 3 months.. 7. Karnofsky performance scale 70 or WHO performance status of 0 or 1.. 8. Within the last 4 weeks prior to study day 1, vital laboratory parameters should be within normal range, except for the following laboratory parameters, which must be within the ranges specified:. Lab Parameter Range"}, {"type": "INCLUSION", "field": "medication", "operator": "WITHIN_LAST", "value": 3, "unit": "years", "evidence_text": "Distant metastatic disease (any T; any N; M1a, M1b or M1c), except brain or leptomeningeal localizations, and except elevated LDH.. 3. Patients must be HLA-A2.. 4. A pre-immune tumor biopsy must be kept frozen for post-study PCR analysis.. 5. Presence of at least one measurable or non-measurable tumor lesion.. 6. Expected survival of at least 3 months.. 7. Karnofsky performance scale 70 or WHO performance status of 0 or 1.. 8. Within the last 4 weeks prior to study day 1, vital laboratory parameters should be within normal range, except for the following laboratory parameters, which must be within the ranges specified:. Lab Parameter Range"}, {"type": "INCLUSION", "field": "medication", "operator": "WITHIN_LAST", "value": 4, "unit": "weeks", "evidence_text": "Distant metastatic disease (any T; any N; M1a, M1b or M1c), except brain or leptomeningeal localizations, and except elevated LDH.. 3. Patients must be HLA-A2.. 4. A pre-immune tumor biopsy must be kept frozen for post-study PCR analysis.. 5. Presence of at least one measurable or non-measurable tumor lesion.. 6. Expected survival of at least 3 months.. 7. Karnofsky performance scale 70 or WHO performance status of 0 or 1.. 8. Within the last 4 weeks prior to study day 1, vital laboratory parameters should be within normal range, except for the following laboratory parameters, which must be within the ranges specified:. Lab Parameter Range"}, {"type": "INCLUSION", "field": "procedure", "operator": "WITHIN_LAST", "value": 3, "unit": "years", "evidence_text": "Distant metastatic disease (any T; any N; M1a, M1b or M1c), except brain or leptomeningeal localizations, and except elevated LDH.. 3. Patients must be HLA-A2.. 4. A pre-immune tumor biopsy must be kept frozen for post-study PCR analysis.. 5. Presence of at least one measurable or non-measurable tumor lesion.. 6. Expected survival of at least 3 months.. 7. Karnofsky performance scale 70 or WHO performance status of 0 or 1.. 8. Within the last 4 weeks prior to study day 1, vital laboratory parameters should be within normal range, except for the following laboratory parameters, which must be within the ranges specified:. Lab Parameter Range"}, {"type": "INCLUSION", "field": "procedure", "operator": "WITHIN_LAST", "value": 4, "unit": "weeks", "evidence_text": "Distant metastatic disease (any T; any N; M1a, M1b or M1c), except brain or leptomeningeal localizations, and except elevated LDH.. 3. Patients must be HLA-A2.. 4. A pre-immune tumor biopsy must be kept frozen for post-study PCR analysis.. 5. Presence of at least one measurable or non-measurable tumor lesion.. 6. Expected survival of at least 3 months.. 7. Karnofsky performance scale 70 or WHO performance status of 0 or 1.. 8. Within the last 4 weeks prior to study day 1, vital laboratory parameters should be within normal range, except for the following laboratory parameters, which must be within the ranges specified:. Lab Parameter Range"}, {"type": "INCLUSION", "field": "history", "operator": "IN", "value": "antibodies may be positive.. * HCV (hepatitis C virus): negative antibodies.. 10. Age  18 years.. 11. Able and willing to give valid writte", "unit": null, "evidence_text": "HBV (hepatitis B virus): negative antigens; antibodies may be positive"}, {"type": "INCLUSION", "field": "medication", "operator": "IN", "value": "antibodies may be positive.. * HCV (hepatitis C virus): negative antibodies.. 10. Age  18 years.. 11. Able and willing to give valid writte", "unit": null, "evidence_text": "HBV (hepatitis B virus): negative antigens; antibodies may be positive"}, {"type": "INCLUSION", "field": "other", "operator": "IN", "value": "antibodies may be positive.. * HCV (hepatitis C virus): negative antibodies.. 10. Age  18 years.. 11. Able and willing to give valid writte", "unit": null, "evidence_text": "HBV (hepatitis B virus): negative antigens; antibodies may be positive"}, {"type": "INCLUSION", "field": "procedure", "operator": "IN", "value": "antibodies may be positive.. * HCV (hepatitis C virus): negative antibodies.. 10. Age  18 years.. 11. Able and willing to give valid writte", "unit": null, "evidence_text": "HBV (hepatitis B virus): negative antigens; antibodies may be positive"}, {"type": "EXCLUSION", "field": "condition", "operator": "IN", "value": "more than one regimen of systemic chemotherapy", "unit": null, "evidence_text": "HCV (hepatitis C virus): negative antibodies.. 10. Age  18 years.. 11. Able and willing to give valid written informed consent.. Exclusion Criteria. 1. Previous treatment with more than one regimen of systemic chemotherapy, combined or not with non-specific immunotherapy such as interferon alpha or interleukins. Chemoimmunotherapy or radiotherapy must be stopped within the preceding 4 weeks (6 weeks for nitrosoureas and mitomycin C).. 2. Clinically significant heart disease (NYHA Class III or IV) i.e. NYHA class 3 congestive heart failure; myocardial infarction within the past six months; unstable angina; coronary angioplasty within the past 6 months; uncontrolled atrial or ventricular cardiac arrhythmias.. 3. Active immunodeficiency or autoimmune disease. Vitiligo was not an exclusion criterion.. 4. Other serious acute or chronic illnesses, e.g. active infections requiring antibiotics, bleeding disorders, or other conditions requiring concurrent medications not allowed during this study.. 5. Other malignancy within 3 years prior to entry into the study, except for treated non-melanoma skin cancer and cervical carcinoma in situ.. 6. Lack of availability for immunological and clinical follow-up assessments.. 7. Participation in any other clinical trial involving another investigational agent within 4 weeks prior to enrollment.. 8. Pregnancy or breastfeeding.. 9. Women of childbearing potential: Refusal or inability to use effective means of contraception"}, {"type": "EXCLUSION", "field": "condition", "operator": "IN", "value": "non specific immunotherapy such as interferon alpha", "unit": null, "evidence_text": "HCV (hepatitis C virus): negative antibodies.. 10. Age  18 years.. 11. Able and willing to give valid written informed consent.. Exclusion Criteria. 1. Previous treatment with more than one regimen of systemic chemotherapy, combined or not with non-specific immunotherapy such as interferon alpha or interleukins. Chemoimmunotherapy or radiotherapy must be stopped within the preceding 4 weeks (6 weeks for nitrosoureas and mitomycin C).. 2. Clinically significant heart disease (NYHA Class III or IV) i.e. NYHA class 3 congestive heart failure; myocardial infarction within the past six months; unstable angina; coronary angioplasty within the past 6 months; uncontrolled atrial or ventricular cardiac arrhythmias.. 3. Active immunodeficiency or autoimmune disease. Vitiligo was not an exclusion criterion.. 4. Other serious acute or chronic illnesses, e.g. active infections requiring antibiotics, bleeding disorders, or other conditions requiring concurrent medications not allowed during this study.. 5. Other malignancy within 3 years prior to entry into the study, except for treated non-melanoma skin cancer and cervical carcinoma in situ.. 6. Lack of availability for immunological and clinical follow-up assessments.. 7. Participation in any other clinical trial involving another investigational agent within 4 weeks prior to enrollment.. 8. Pregnancy or breastfeeding.. 9. Women of childbearing potential: Refusal or inability to use effective means of contraception"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "active infection", "unit": null, "evidence_text": "HCV (hepatitis C virus): negative antibodies.. 10. Age  18 years.. 11. Able and willing to give valid written informed consent.. Exclusion Criteria. 1. Previous treatment with more than one regimen of systemic chemotherapy, combined or not with non-specific immunotherapy such as interferon alpha or interleukins. Chemoimmunotherapy or radiotherapy must be stopped within the preceding 4 weeks (6 weeks for nitrosoureas and mitomycin C).. 2. Clinically significant heart disease (NYHA Class III or IV) i.e. NYHA class 3 congestive heart failure; myocardial infarction within the past six months; unstable angina; coronary angioplasty within the past 6 months; uncontrolled atrial or ventricular cardiac arrhythmias.. 3. Active immunodeficiency or autoimmune disease. Vitiligo was not an exclusion criterion.. 4. Other serious acute or chronic illnesses, e.g. active infections requiring antibiotics, bleeding disorders, or other conditions requiring concurrent medications not allowed during this study.. 5. Other malignancy within 3 years prior to entry into the study, except for treated non-melanoma skin cancer and cervical carcinoma in situ.. 6. Lack of availability for immunological and clinical follow-up assessments.. 7. Participation in any other clinical trial involving another investigational agent within 4 weeks prior to enrollment.. 8. Pregnancy or breastfeeding.. 9. Women of childbearing potential: Refusal or inability to use effective means of contraception"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "non-specific immunotherapy such as interferon alpha", "unit": null, "evidence_text": "HCV (hepatitis C virus): negative antibodies.. 10. Age  18 years.. 11. Able and willing to give valid written informed consent.. Exclusion Criteria. 1. Previous treatment with more than one regimen of systemic chemotherapy, combined or not with non-specific immunotherapy such as interferon alpha or interleukins. Chemoimmunotherapy or radiotherapy must be stopped within the preceding 4 weeks (6 weeks for nitrosoureas and mitomycin C).. 2. Clinically significant heart disease (NYHA Class III or IV) i.e. NYHA class 3 congestive heart failure; myocardial infarction within the past six months; unstable angina; coronary angioplasty within the past 6 months; uncontrolled atrial or ventricular cardiac arrhythmias.. 3. Active immunodeficiency or autoimmune disease. Vitiligo was not an exclusion criterion.. 4. Other serious acute or chronic illnesses, e.g. active infections requiring antibiotics, bleeding disorders, or other conditions requiring concurrent medications not allowed during this study.. 5. Other malignancy within 3 years prior to entry into the study, except for treated non-melanoma skin cancer and cervical carcinoma in situ.. 6. Lack of availability for immunological and clinical follow-up assessments.. 7. Participation in any other clinical trial involving another investigational agent within 4 weeks prior to enrollment.. 8. Pregnancy or breastfeeding.. 9. Women of childbearing potential: Refusal or inability to use effective means of contraception"}, {"type": "EXCLUSION", "field": "other", "operator": "IN", "value": "uncontrolled atrial or ventricular cardiac arrhythmias.. 3. Active immunodeficiency or autoimmune disease. Vitiligo was not an exclusion cri", "unit": null, "evidence_text": "HCV (hepatitis C virus): negative antibodies.. 10. Age  18 years.. 11. Able and willing to give valid written informed consent.. Exclusion Criteria. 1. Previous treatment with more than one regimen of systemic chemotherapy, combined or not with non-specific immunotherapy such as interferon alpha or interleukins. Chemoimmunotherapy or radiotherapy must be stopped within the preceding 4 weeks (6 weeks for nitrosoureas and mitomycin C).. 2. Clinically significant heart disease (NYHA Class III or IV) i.e. NYHA class 3 congestive heart failure; myocardial infarction within the past six months; unstable angina; coronary angioplasty within the past 6 months; uncontrolled atrial or ventricular cardiac arrhythmias.. 3. Active immunodeficiency or autoimmune disease. Vitiligo was not an exclusion criterion.. 4. Other serious acute or chronic illnesses, e.g. active infections requiring antibiotics, bleeding disorders, or other conditions requiring concurrent medications not allowed during this study.. 5. Other malignancy within 3 years prior to entry into the study, except for treated non-melanoma skin cancer and cervical carcinoma in situ.. 6. Lack of availability for immunological and clinical follow-up assessments.. 7. Participation in any other clinical trial involving another investigational agent within 4 weeks prior to enrollment.. 8. Pregnancy or breastfeeding.. 9. Women of childbearing potential: Refusal or inability to use effective means of contraception"}, {"type": "EXCLUSION", "field": "procedure", "operator": "IN", "value": "myocardial infarction within the past six months", "unit": null, "evidence_text": "HCV (hepatitis C virus): negative antibodies.. 10. Age  18 years.. 11. Able and willing to give valid written informed consent.. Exclusion Criteria. 1. Previous treatment with more than one regimen of systemic chemotherapy, combined or not with non-specific immunotherapy such as interferon alpha or interleukins. Chemoimmunotherapy or radiotherapy must be stopped within the preceding 4 weeks (6 weeks for nitrosoureas and mitomycin C).. 2. Clinically significant heart disease (NYHA Class III or IV) i.e. NYHA class 3 congestive heart failure; myocardial infarction within the past six months; unstable angina; coronary angioplasty within the past 6 months; uncontrolled atrial or ventricular cardiac arrhythmias.. 3. Active immunodeficiency or autoimmune disease. Vitiligo was not an exclusion criterion.. 4. Other serious acute or chronic illnesses, e.g. active infections requiring antibiotics, bleeding disorders, or other conditions requiring concurrent medications not allowed during this study.. 5. Other malignancy within 3 years prior to entry into the study, except for treated non-melanoma skin cancer and cervical carcinoma in situ.. 6. Lack of availability for immunological and clinical follow-up assessments.. 7. Participation in any other clinical trial involving another investigational agent within 4 weeks prior to enrollment.. 8. Pregnancy or breastfeeding.. 9. Women of childbearing potential: Refusal or inability to use effective means of contraception"}], "annotator_id": "annotator_c", "guideline_version": "m5-v1", "adjudicated": true, "adjudication_source": "parsing_relabel_round1"}
{"nct_id": "NCT00151892", "eligibility_text": "Inclusion Criteria:. * previous diagnosis of ulcerative colitis confirmed by histology that has been considered to be in remission for =\\> 30 days. * female subjects must be post-menopausal, surgically or biologically sterile, or with a negative urine pregnancy test at screening and on adequate contraception. Exclusion Criteria:. * proctitis. * previous resective colonic surgery. * Crohn's disease. * hypersensitivity to salicylates. * moderate/severe renal impairment", "labeled_rules": [{"type": "INCLUSION", "field": "history", "operator": "IN", "value": "* previous diagnosis of ulcerative colitis confirmed by histology that has been considered to be in remission for =\\> 3", "unit": null, "evidence_text": "previous diagnosis of ulcerative colitis confirmed by histology that has been considered to be in remission for =\\> 30 days"}, {"type": "INCLUSION", "field": "lab", "operator": ">=", "value": 30, "unit": "days", "evidence_text": "previous diagnosis of ulcerative colitis confirmed by histology that has been considered to be in remission for =\\> 30 days"}, {"type": "INCLUSION", "field": "medication", "operator": "IN", "value": "* previous diagnosis of ulcerative colitis confirmed by histology that has been considered to be in remission for =\\> 3", "unit": null, "evidence_text": "previous diagnosis of ulcerative colitis confirmed by histology that has been considered to be in remission for =\\> 30 days"}, {"type": "INCLUSION", "field": "procedure", "operator": "IN", "value": "* previous diagnosis of ulcerative colitis confirmed by histology that has been considered to be in remission for =\\> 3", "unit": null, "evidence_text": "previous diagnosis of ulcerative colitis confirmed by histology that has been considered to be in remission for =\\> 30 days"}, {"type": "EXCLUSION", "field": "condition", "operator": "IN", "value": "a negative urine pregnancy test at", "unit": null, "evidence_text": "female subjects must be post-menopausal, surgically or biologically sterile, or with a negative urine pregnancy test at screening and on adequate contraception. Exclusion Criteria:"}, {"type": "EXCLUSION", "field": "condition", "operator": "IN", "value": "a negative urine pregnancy test at screening", "unit": null, "evidence_text": "female subjects must be post-menopausal, surgically or biologically sterile, or with a negative urine pregnancy test at screening and on adequate contraception. Exclusion Criteria:"}, {"type": "EXCLUSION", "field": "lab", "operator": "IN", "value": "negative pregnancy test", "unit": null, "evidence_text": "female subjects must be post-menopausal, surgically or biologically sterile, or with a negative urine pregnancy test at screening and on adequate contraception. Exclusion Criteria:"}, {"type": "EXCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "female subjects must be post-menopausal, surgically or biologically sterile, or with a negative urine pregnancy test at screening and on adequate contraception. Exclusion Criteria:"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "previous", "unit": null, "evidence_text": "previous resective colonic surgery"}], "annotator_id": "annotator_c", "guideline_version": "m5-v1", "adjudicated": true, "adjudication_source": "parsing_relabel_round1"}
{"nct_id": "NCT00153569", "eligibility_text": "Inclusion Criteria:. * Metastatic melanoma. * HLA-A1, -A2, -A24, -B44. Exclusion Criteria:", "labeled_rules": [{"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "study-specific condition", "unit": null, "evidence_text": "Inclusion Criteria:"}]}
{"nct_id": "NCT00156507", "eligibility_text": "Inclusion Criteria:. * Premature babies weighing less than 1500 grams at birth receiving care at Strong Memorial Hospital Neonatal Intensive Care Unit. Exclusion Criteria:. * Non-English speaking parents", "labeled_rules": [{"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "study-specific condition", "unit": null, "evidence_text": "Inclusion Criteria:"}]}
{"nct_id": "NCT00158002", "eligibility_text": "Inclusion Criteria:. * Must have either completed the Double-Blind Phase of CAPSS-271 or discontinued the Double-Blind Phase of CAPSS-271 due to lack of efficacy after a minimum of 2 weeks of maintenance treatment.. * Must continue to meet the specific inclusion criteria outlined in CAPSS-271.. * Female subjects must be premenarchal, surgically sterile (hysterectomy, tubal ligation or otherwise incapable of pregnancy); or practicing an effective method of birth control (e.g., intrauterine device, double-barrier method, male partner sterilization) at study entry and throughout the study; or hormonal contraceptives for at least a 3-month period prior to the start of the study and throughout the study, or be practicing abstinence and agree to continue abstinence or to use an acceptable method of contraception (as listed above) should sexual activity commence. In addition, female subjects of childbearing potential must have a negative urine pregnancy test at Open-Label Visit 1 (Day 1).. * Must be able to read and comprehend written instructions and be willing to complete all headache records and questionnaires as required by the protocol.. * After full explanation of the study, subjects, or their parent/legally authorized representative(s), must demonstrate their willingness to participate by signing an informed consent form. If applicable, pediatric subjects capable of giving assent must sign the assent form.. Exclusion Criteria:. * Subjects who have developed a more painful condition than their headache pain.. * Subjects taking any of the prohibited concomitant medications (See Concomitant Medications section).. * Subjects who are pregnant.. * Subjects with liver function tests  2 times the upper limit of the normal range.. * In the investigator's opinion, subjects with poor compliance during the CAPSS-271 study", "labeled_rules": [{"type": "INCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "* Female subjects must be premenarchal, surgically sterile (hysterectomy, tubal ligation or otherwise incapable of pregnancy)"}, {"type": "INCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "In addition, female subjects of childbearing potential must have a negative urine pregnancy test at Open-Label Visit 1 (Day 1)"}, {"type": "INCLUSION", "field": "sex", "operator": "=", "value": "male", "unit": null, "evidence_text": "or practicing an effective method of birth control (e.g., intrauterine device, double-barrier method, male partner sterilization) at study entry and throughout the study"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "poor compliance during the capss-271 study", "unit": null, "evidence_text": "* In the investigator's opinion, subjects with poor compliance during the CAPSS-271 study"}]}
{"nct_id": "NCT00159380", "eligibility_text": "Inclusion Criteria:. Healthy non-smokers (n=10):. * Nonatopic subjects (exhaled NO greater than or equal to 10 ppb; flow 50 ml/s). * Normal spirometry. * Able to comprehend and grant a written informed consent. Asthmatic subjects (n=15):. * Forced expiratory volume in one second (FEV1) of no less than 70% of predicted (exhaled NO greater than or equal to 15 ppb; flow 50 ml/s). * Clinically stable (steroid-nave or taking no \\> 600 mcg/day of inhaled steroids). * Able to comprehend and grant a written informed consent. Exclusion Criteria:. * Currently smoking. * Any lung disease other than asthma which may interfere with the study. * Treatment within the last 4 weeks with oral steroids. * Respiratory infection within 4 weeks prior to entry into the trial. * Females who are pregnant or lactating. * History of current or past drug or alcohol abuse", "labeled_rules": [{"type": "INCLUSION", "field": "lab", "operator": ">=", "value": 10, "unit": "ppb", "evidence_text": "Nonatopic subjects (exhaled NO greater than or equal to 10 ppb; flow 50 ml/s)"}, {"type": "INCLUSION", "field": "procedure", "operator": "IN", "value": "Healthy non-smokers (n=10):. * Nonatopic subjects (exhaled NO greater than or equal to 10 ppb", "unit": null, "evidence_text": "Nonatopic subjects (exhaled NO greater than or equal to 10 ppb; flow 50 ml/s)"}, {"type": "INCLUSION", "field": "other", "operator": "IN", "value": "flow 50 ml/s). * Normal spirometry. * Able to comprehend and grant a written informed consent. Asthmatic subjects (n=15):. * Forced expirato", "unit": null, "evidence_text": "Able to comprehend and grant a written informed consent. Asthmatic subjects (n=15):"}, {"type": "INCLUSION", "field": "procedure", "operator": "IN", "value": "flow 50 ml/s). * Normal spirometry. * Able to comprehend and grant a written informed consent. Asthmatic subjects (n=15):. * Forced expirato", "unit": null, "evidence_text": "Able to comprehend and grant a written informed consent. Asthmatic subjects (n=15):"}, {"type": "INCLUSION", "field": "lab", "operator": "<=", "value": 70, "unit": "%", "evidence_text": "Forced expiratory volume in one second (FEV1) of no less than 70% of predicted (exhaled NO greater than or equal to 15 ppb; flow 50 ml/s)"}, {"type": "INCLUSION", "field": "history", "operator": "IN", "value": "flow 50 ml/s). * Clinically stable (steroid-nave or taking no \\> 600 mcg/day of inhaled steroids). * Able to comprehend and grant a written", "unit": null, "evidence_text": "Clinically stable (steroid-nave or taking no \\> 600 mcg/day of inhaled steroids)"}, {"type": "INCLUSION", "field": "lab", "operator": ">=", "value": 600, "unit": "mcg/day", "evidence_text": "Clinically stable (steroid-nave or taking no \\> 600 mcg/day of inhaled steroids)"}, {"type": "INCLUSION", "field": "other", "operator": "IN", "value": "flow 50 ml/s). * Clinically stable (steroid-nave or taking no \\> 600 mcg/day of inhaled steroids). * Able to comprehend and grant a written", "unit": null, "evidence_text": "Clinically stable (steroid-nave or taking no \\> 600 mcg/day of inhaled steroids)"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "the study", "unit": null, "evidence_text": "Any lung disease other than asthma which may interfere with the study"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "oral steroids", "unit": null, "evidence_text": "Treatment within the last 4 weeks with oral steroids"}, {"type": "EXCLUSION", "field": "medication", "operator": "WITHIN_LAST", "value": 4, "unit": "weeks", "evidence_text": "Treatment within the last 4 weeks with oral steroids"}, {"type": "EXCLUSION", "field": "procedure", "operator": "WITHIN_LAST", "value": 4, "unit": "weeks", "evidence_text": "Treatment within the last 4 weeks with oral steroids"}, {"type": "EXCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "Females who are pregnant or lactating"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "current or past drug or alcohol", "unit": null, "evidence_text": "History of current or past drug or alcohol abuse"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "current or past drug or alcohol abuse", "unit": null, "evidence_text": "History of current or past drug or alcohol abuse"}], "annotator_id": "annotator_c", "guideline_version": "m5-v1", "adjudicated": true, "adjudication_source": "parsing_relabel_round1"}
{"nct_id": "NCT00159458", "eligibility_text": "Inclusion Criteria:. * Histologically proven dx of recurrent or metastatic breast cancer. * Must have received at least 1 but not more than 3 prior chemotherapy regimens for recurrent or metastatic breast cancer. Patients who relapse within 12 months of completing adjuvant chemotherapy can only have had up to 2 prior regimens for metastatic disease. Patients who relapse within 12 months of completing adjuvant chemotherapy containing an anthracycline and a taxane, do not require prior chemotherapy for metastatic disease.. * Unidimensionally measurable dz (by RECIST). * At least 18 yrs of age. * SWOG PS 0-2. * AGC greater than or equal to 1.5; platelets greater than or equal to 100,000; Hgb greater than or equal to 8.0. * Total bilirubin less than or equal to 2 x uln; SGOT and/or SGPT and alk phos up to 2.5 x uln. * Creatinine less than or equal to 2.0. * Fully recovered from acute toxicities secondary to prior tx. * Signed informed consent (including HIPAA authorization). * Peripheral neuropathy grade 0-1. Exclusion Criteria. * Prior tx with gemcitabine or oxaliplatin. Prior tx with cisplatin or carboplatin allowed if completed \\>12 mos prior to enrollment.. * Underlying medical, psychiatric, or social conditions that would preclude patient from receiving tx. * Peripheral neuropathy greater than or equal to Gr 2. Exclusion Criteria:. \\-", "labeled_rules": [{"type": "INCLUSION", "field": "age", "operator": ">=", "value": 18, "unit": "years", "evidence_text": "At least 18 yrs of age"}, {"type": "INCLUSION", "field": "age", "operator": ">=", "value": 1, "unit": "years", "evidence_text": "At least 18 yrs of age"}, {"type": "INCLUSION", "field": "lab", "operator": ">=", "value": 8, "unit": null, "evidence_text": "At least 18 yrs of age"}, {"type": "INCLUSION", "field": "lab", "operator": ">=", "value": 1.5, "unit": null, "evidence_text": "AGC greater than or equal to 1.5; platelets greater than or equal to 100,000; Hgb greater than or equal to 8.0"}, {"type": "INCLUSION", "field": "lab", "operator": ">=", "value": 100, "unit": null, "evidence_text": "AGC greater than or equal to 1.5; platelets greater than or equal to 100,000; Hgb greater than or equal to 8.0"}, {"type": "INCLUSION", "field": "other", "operator": "IN", "value": "SGOT and/or SGPT and alk phos up to 2.5 x uln. * Creatinine less than or equal to 2.0. * Fully recovered from acute toxicities secondary to", "unit": null, "evidence_text": "Total bilirubin less than or equal to 2 x uln; SGOT and/or SGPT and alk phos up to 2.5 x uln"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "gemcitabine or oxaliplatin", "unit": null, "evidence_text": "Prior tx with gemcitabine or oxaliplatin. Prior tx with cisplatin or carboplatin allowed if completed \\>12 mos prior to enrollment"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "gemcitabine or oxaliplatin", "unit": null, "evidence_text": "Prior tx with gemcitabine or oxaliplatin. Prior tx with cisplatin or carboplatin allowed if completed \\>12 mos prior to enrollment"}, {"type": "INCLUSION", "field": "lab", "operator": ">=", "value": 12, "unit": "mos", "evidence_text": "Prior tx with gemcitabine or oxaliplatin. Prior tx with cisplatin or carboplatin allowed if completed \\>12 mos prior to enrollment"}, {"type": "INCLUSION", "field": "medication", "operator": "WITHIN_LAST", "value": 12, "unit": "months", "evidence_text": "Prior tx with gemcitabine or oxaliplatin. Prior tx with cisplatin or carboplatin allowed if completed \\>12 mos prior to enrollment"}], "annotator_id": "annotator_c", "guideline_version": "m5-v1", "adjudicated": true, "adjudication_source": "parsing_relabel_round1"}
{"nct_id": "NCT00162305", "eligibility_text": "Inclusion Criteria:. * Established diagnosis of Type 2 diabetes mellitus, who are treated with metformin or diet alone (drug naive).. * Fasting glucose (FG) \\< - 240 mg/dL, while on metformin or antidiabetic diet alone.. * HbA1c (Hemoglobin A1c) in the range of 6.0-10.0%. Exclusion Criteria:. * Women of childbearing potential", "labeled_rules": [{"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "established", "unit": null, "evidence_text": "Established diagnosis of Type 2 diabetes mellitus, who are treated with metformin or diet alone (drug naive)"}, {"type": "INCLUSION", "field": "medication", "operator": "IN", "value": "* Established diagnosis of Type 2 diabetes mellitus, who are treated with metformin or diet alone (drug naive).. * Fast", "unit": null, "evidence_text": "Established diagnosis of Type 2 diabetes mellitus, who are treated with metformin or diet alone (drug naive)"}, {"type": "EXCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "Women of childbearing potential"}, {"type": "INCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "Women of childbearing potential"}], "annotator_id": "annotator_c", "guideline_version": "m5-v1", "adjudicated": true, "adjudication_source": "parsing_relabel_round1"}
{"nct_id": "NCT00181272", "eligibility_text": "Inclusion Criteria:. * Physician-diagnosis of asthma, COPD exacerbation, or undifferentiated asthma/COPD exacerbation. * Admitted to the inpatient medical service at Johns Hopkins Hospital or Johns Hopkins Bayview Medical Center. * Evidence of airflow obstruction on spirometry (FEV1/FVC\\<70%). * Age 18 years or older. Exclusion Criteria:. * History of allergy or other contraindication to macrolides (azithromycin, erythromycin, clarithromycin). * Treatment with any macrolide in the 4 weeks prior to study entry. * Elevated AST or ALT (2 or more times the upper limit of normal) on current admission. * Elevated alkaline phosphatase (\\>1.25 times the upper limit of normal) on current admission. * Elevated total serum bilirubin (more than upper limit of normal) on current admission. * Previous participation in this study. * Patients prescribed digoxin (azithromycin may increase digoxin levels). * Patients prescribed warfarin (azithromycin may increase INR in patients on warfarin). * Patients prescribed pimozide (azithromycin may increase risk of arrhythmias). * Patient unable to provide consent (e.g., language difficulty or history of dementia). * Patient to be discharged to a location other than home (e.g., other hospital, long-term care facility)", "labeled_rules": [{"type": "INCLUSION", "field": "history", "operator": "IN", "value": "* Physician-diagnosis of asthma, COPD exacerbation, or undifferentiated asthma/COPD exacerbation. * Admitted to the inp", "unit": null, "evidence_text": "Physician-diagnosis of asthma, COPD exacerbation, or undifferentiated asthma/COPD exacerbation"}, {"type": "INCLUSION", "field": "medication", "operator": "IN", "value": "* Physician-diagnosis of asthma, COPD exacerbation, or undifferentiated asthma/COPD exacerbation. * Admitted to the inp", "unit": null, "evidence_text": "Physician-diagnosis of asthma, COPD exacerbation, or undifferentiated asthma/COPD exacerbation"}, {"type": "INCLUSION", "field": "other", "operator": "IN", "value": "* Physician-diagnosis of asthma, COPD exacerbation, or undifferentiated asthma/COPD exacerbation. * Admitted to the inp", "unit": null, "evidence_text": "Physician-diagnosis of asthma, COPD exacerbation, or undifferentiated asthma/COPD exacerbation"}, {"type": "INCLUSION", "field": "procedure", "operator": "IN", "value": "* Physician-diagnosis of asthma, COPD exacerbation, or undifferentiated asthma/COPD exacerbation. * Admitted to the inp", "unit": null, "evidence_text": "Physician-diagnosis of asthma, COPD exacerbation, or undifferentiated asthma/COPD exacerbation"}, {"type": "INCLUSION", "field": "lab", "operator": "<=", "value": 70, "unit": "%", "evidence_text": "Evidence of airflow obstruction on spirometry (FEV1/FVC\\<70%)"}, {"type": "EXCLUSION", "field": "age", "operator": ">=", "value": 18, "unit": "years", "evidence_text": "Age 18 years or older. Exclusion Criteria:"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "allergy or other contraindication to macrolides (azithromycin, erythromycin, clarithromycin)", "unit": null, "evidence_text": "History of allergy or other contraindication to macrolides (azithromycin, erythromycin, clarithromycin)"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "any macrolide in the 4 weeks", "unit": null, "evidence_text": "Treatment with any macrolide in the 4 weeks prior to study entry"}, {"type": "INCLUSION", "field": "lab", "operator": ">=", "value": 1.25, "unit": "times", "evidence_text": "Elevated alkaline phosphatase (\\>1.25 times the upper limit of normal) on current admission"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "azithromycin may increase inr in", "unit": null, "evidence_text": "Patients prescribed warfarin (azithromycin may increase INR in patients on warfarin)"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "dementia)", "unit": null, "evidence_text": "Patient unable to provide consent (e.g., language difficulty or history of dementia)"}], "annotator_id": "annotator_c", "guideline_version": "m5-v1", "adjudicated": true, "adjudication_source": "parsing_relabel_round1"}
{"nct_id": "NCT00184288", "eligibility_text": "Inclusion Criteria:. * Clinical diagnosis of brain metastases. Exclusion Criteria:. * children. * pregnancy", "labeled_rules": [{"type": "EXCLUSION", "field": "condition", "operator": "IN", "value": "brain metastases", "unit": null, "evidence_text": "Clinical diagnosis of brain metastases. Exclusion Criteria:"}, {"type": "EXCLUSION", "field": "condition", "operator": "IN", "value": "clinical", "unit": null, "evidence_text": "Clinical diagnosis of brain metastases. Exclusion Criteria:"}, {"type": "EXCLUSION", "field": "condition", "operator": "IN", "value": "Clinical diagnosis of brain metastases. Exclusion Criteria", "unit": null, "evidence_text": "Clinical diagnosis of brain metastases. Exclusion Criteria:"}], "annotator_id": "annotator_c", "guideline_version": "m5-v1", "adjudicated": true, "adjudication_source": "parsing_relabel_round1"}
{"nct_id": "NCT00189332", "eligibility_text": "Inclusion Criteria:. * Advanced melanoma not responding to 1st line chemotherapy. * Histological evidence of melanoma. * Measurable disease according to RECIST criteria. * ECOG performance status less than or equal to 2. * Life expectancy 6 months or more. * Normal organ and bone marrow function as defined by hematological and serum chemistry limits. * Adequate contraception for females of childbearing potential. Exclusion Criteria:. * Stage IV disease which has previously progressed during interferon treatment.. * Restriction of some therapies/medications for a certain timeframe prior to enrollment and during the study including: investigational drugs, high dose corticosteroids, immunotherapy, immunosuppressive medications, radiotherapy and drugs known to prolong QT interval and/or induce Torsades De Pointes. * History of uncontrolled seizure disorders. * Uncontrolled coagulation disorders.. * History or evidence of myocardial ischemia, congestive heart failure or arrythmias requiring treatment in the past 6 months. * History of uncontrolled intercurrent or chronic illness. * Concurrent malignancies.. * Brain metastases.. * HIV positive.. * Prolonged QTc interval. * Uncontrolled intercurrent or chronic illnesses.. * Pregnant or lactating women", "labeled_rules": [{"type": "EXCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "* Pregnant or lactating women"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "hiv positive", "unit": null, "evidence_text": "* HIV positive"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "uncontrolled seizure disorders", "unit": null, "evidence_text": "* History of uncontrolled seizure disorders"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "uncontrolled intercurrent or chronic illness", "unit": null, "evidence_text": "* History of uncontrolled intercurrent or chronic illness"}]}
{"nct_id": "NCT00207038", "eligibility_text": "Inclusion Criteria:. * Swimmer. Exclusion Criteria:. * Current smoker or more than 3 pack-years", "labeled_rules": [{"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "study-specific condition", "unit": null, "evidence_text": "Inclusion Criteria:"}]}
{"nct_id": "NCT00232726", "eligibility_text": "Inclusion Criteria:. * Patients with histologically or cytologically confirmed stage IV or unresectable stage III non-ocular malignant melanoma who have not undergone prior chemotherapy for the treatment of melanoma (chemotherapy-nave). * Measurable disease according to Response Criteria in Solid Tumours (RECIST). * Performance Status 0 - 2 according to ECOG (Eastern Cooperative Oncology Group) Performance Status. * Age 18 years or more. * Life expectancy \\> 3 months. * Signed informed consent. * Adequate haematological and biological functions:. * Bone marrow function:. 1. Neutrophils  1.5 x 10\\^9/L. 2. Platelets  100 x 10\\^9/L. 3. Hemoglobin (Hb)  10 g/dL. * Hepatic function:. 1. AST/ALT  2.5 times institutional upper limit of normal (ULN). If liver metastases,  5 times institutional ULN.. 2. Serum bilirubin and alkaline phosphatase  1.5 times institutional ULN. * Renal function:. * Creatinine  1.5 times institutional ULN. Exclusion Criteria:. * Known brain metastases. * Diagnosis of ocular malignant melanoma. * Radiotherapy to more than 30% of bone marrow. * Participation in another therapeutic clinical study within 30 days of enrolment or during this clinical study. * Prior immunotherapy and/or chemotherapy for the treatment of melanoma. * Requirement of concomitant treatment with a non-permitted medication:. * Alternative drugs. * High doses of vitamins. * History of allergic reactions to Ara-C or egg. * Presence of any serious concomitant systemic disorders incompatible with the clinical study (e.g. uncontrolled intercurrent illness including ongoing or active infection). * Presence of any significant central nervous system or psychiatric disorder(s) that would hamper the patient's compliance. * Pregnancy, breastfeeding, or absence of adequate contraception for both male and female fertile patients. * Known positive status for HIV and/or hepatitis B or C. * Drug and/or alcohol abuse. * Any reason why, in the Investigator's opinion, the patient should not participate", "labeled_rules": [{"type": "INCLUSION", "field": "history", "operator": "IN", "value": "* Patients with histologically or cytologically confirmed stage IV or unresectable stage III non-ocular malignant melan", "unit": null, "evidence_text": "Patients with histologically or cytologically confirmed stage IV or unresectable stage III non-ocular malignant melanoma who have not undergone prior chemotherapy for the treatment of melanoma (chemotherapy-nave)"}, {"type": "INCLUSION", "field": "other", "operator": "IN", "value": "* Patients with histologically or cytologically confirmed stage IV or unresectable stage III non-ocular malignant melan", "unit": null, "evidence_text": "Patients with histologically or cytologically confirmed stage IV or unresectable stage III non-ocular malignant melanoma who have not undergone prior chemotherapy for the treatment of melanoma (chemotherapy-nave)"}, {"type": "INCLUSION", "field": "lab", "operator": ">=", "value": 3, "unit": "months", "evidence_text": "Life expectancy \\> 3 months"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "ocular malignant melanoma", "unit": null, "evidence_text": "Diagnosis of ocular malignant melanoma"}, {"type": "EXCLUSION", "field": "medication", "operator": "WITHIN_LAST", "value": 30, "unit": "days", "evidence_text": "Participation in another therapeutic clinical study within 30 days of enrolment or during this clinical study"}, {"type": "EXCLUSION", "field": "procedure", "operator": "WITHIN_LAST", "value": 30, "unit": "days", "evidence_text": "Participation in another therapeutic clinical study within 30 days of enrolment or during this clinical study"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "allergic reactions to ara-c or egg", "unit": null, "evidence_text": "History of allergic reactions to Ara-C or egg"}, {"type": "EXCLUSION", "field": "sex", "operator": "=", "value": "all", "unit": null, "evidence_text": "History of allergic reactions to Ara-C or egg"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "active infection", "unit": null, "evidence_text": "Presence of any serious concomitant systemic disorders incompatible with the clinical study (e.g. uncontrolled intercurrent illness including ongoing or active infection)"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "fertile", "unit": null, "evidence_text": "Pregnancy, breastfeeding, or absence of adequate contraception for both male and female fertile patients"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "or absence of adequate contraception for", "unit": null, "evidence_text": "Pregnancy, breastfeeding, or absence of adequate contraception for both male and female fertile patients"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "hiv positive", "unit": null, "evidence_text": "Known positive status for HIV and/or hepatitis B or C"}], "annotator_id": "annotator_c", "guideline_version": "m5-v1", "adjudicated": true, "adjudication_source": "parsing_relabel_round1"}
{"nct_id": "NCT00235859", "eligibility_text": "Inclusion Criteria:. * Meet ACR criteria for diagnosis of active RA and have at \\>6 swollen joints and \\>9 tender joints. * Subjects must have received at least one prior DMARD besides MTX, but may have had efficacy failures on no more than four standard DMARDs other than MTX. * Therapy with MTX for at least 6 months prior to screening and on a stable dose of MTX for at least 4 weeks prior to screening visit. * Age 18 years and older. Exclusion Criteria:. * Prior treatment with any TNF antagonist, including adalimumab. * History of clinically significant drug or alcohol abuse in the previous year, iv drug abuse, active infection with listeria or tuberculosis (TB), lymphoma or leukemia,and any malignancy with the exception of successfully treated non-metastatic basal-cell carcinoma of the skin.. * Subjects may not have been administered a live vaccine within three months prior to study drug administration or during the study, treatment with any other investigational agent within 30 days or 5 half-lives of the agent, whichever is longer, prior to the screening evaluation, treatment with any investigational biologic agent, including anti-CD4 antibody, within 6 months prior to the screening evaluation, prior treatment with any TNF antagonist, including Adalimumab, prior exposure to alkylating agents such as chlorambucil or cyclophosphamide.. * Chest X-ray with calcified granuloma and/or pleural scarring. * Positive TB skin test, RT23 dose skin test, \\>5 mm at 48 to 72 hours. * Unstable ischemic heart disease, active inflammatory bowel disease, active peptic ulcer disease, recent stroke (within 3 months of the screening evaluation) or any poorly controlled medical condition. * Intra-articular, intramuscular or iv administration of corticosteroids within 4 weeks prior to screening evaluation. * Female who is pregnant or breast-feeding.", "labeled_rules": [{"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "meet acr criteria for", "unit": null, "evidence_text": "Meet ACR criteria for diagnosis of active RA and have at \\>6 swollen joints and \\>9 tender joints"}, {"type": "INCLUSION", "field": "history", "operator": "IN", "value": "* Meet ACR criteria for diagnosis of active RA and have at \\>6 swollen joints and \\>9 tender joints. * Subjects must ha", "unit": null, "evidence_text": "Meet ACR criteria for diagnosis of active RA and have at \\>6 swollen joints and \\>9 tender joints"}, {"type": "INCLUSION", "field": "lab", "operator": ">=", "value": 6, "unit": "swollen", "evidence_text": "Meet ACR criteria for diagnosis of active RA and have at \\>6 swollen joints and \\>9 tender joints"}, {"type": "INCLUSION", "field": "lab", "operator": ">=", "value": 9, "unit": "tender", "evidence_text": "Meet ACR criteria for diagnosis of active RA and have at \\>6 swollen joints and \\>9 tender joints"}, {"type": "INCLUSION", "field": "age", "operator": ">=", "value": 18, "unit": "years", "evidence_text": "Age 18 years and older. Exclusion Criteria:"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "any tnf antagonist", "unit": null, "evidence_text": "Prior treatment with any TNF antagonist, including adalimumab"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "any tnf antagonist, including adalimumab", "unit": null, "evidence_text": "Prior treatment with any TNF antagonist, including adalimumab"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "active infection", "unit": null, "evidence_text": "History of clinically significant drug or alcohol abuse in the previous year, iv drug abuse, active infection with listeria or tuberculosis (TB), lymphoma or leukemia,and any malignancy with the exception of successfully treated non-metastatic basal-cell carcinoma of the skin"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "clinically significant drug or alcohol abuse in the previous year, iv drug abuse, active infection with listeria or tuberculosis (tb), lymphoma or leukemia,and any malignancy with the exception of successfully treated non metastatic basal cell carcinoma of the skin", "unit": null, "evidence_text": "History of clinically significant drug or alcohol abuse in the previous year, iv drug abuse, active infection with listeria or tuberculosis (TB), lymphoma or leukemia,and any malignancy with the exception of successfully treated non-metastatic basal-cell carcinoma of the skin"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "any investigational biologic agent", "unit": null, "evidence_text": "Subjects may not have been administered a live vaccine within three months prior to study drug administration or during the study, treatment with any other investigational agent within 30 days or 5 half-lives of the agent, whichever is longer, prior to the screening evaluation, treatment with any investigational biologic agent, including anti-CD4 antibody, within 6 months prior to the screening evaluation, prior treatment with any TNF antagonist, including Adalimumab, prior exposure to alkylating agents such as chlorambucil or cyclophosphamide"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "any other investigational agent within 30 days", "unit": null, "evidence_text": "Subjects may not have been administered a live vaccine within three months prior to study drug administration or during the study, treatment with any other investigational agent within 30 days or 5 half-lives of the agent, whichever is longer, prior to the screening evaluation, treatment with any investigational biologic agent, including anti-CD4 antibody, within 6 months prior to the screening evaluation, prior treatment with any TNF antagonist, including Adalimumab, prior exposure to alkylating agents such as chlorambucil or cyclophosphamide"}, {"type": "EXCLUSION", "field": "medication", "operator": "WITHIN_LAST", "value": 30, "unit": "days", "evidence_text": "Subjects may not have been administered a live vaccine within three months prior to study drug administration or during the study, treatment with any other investigational agent within 30 days or 5 half-lives of the agent, whichever is longer, prior to the screening evaluation, treatment with any investigational biologic agent, including anti-CD4 antibody, within 6 months prior to the screening evaluation, prior treatment with any TNF antagonist, including Adalimumab, prior exposure to alkylating agents such as chlorambucil or cyclophosphamide"}, {"type": "EXCLUSION", "field": "procedure", "operator": "WITHIN_LAST", "value": 30, "unit": "days", "evidence_text": "Subjects may not have been administered a live vaccine within three months prior to study drug administration or during the study, treatment with any other investigational agent within 30 days or 5 half-lives of the agent, whichever is longer, prior to the screening evaluation, treatment with any investigational biologic agent, including anti-CD4 antibody, within 6 months prior to the screening evaluation, prior treatment with any TNF antagonist, including Adalimumab, prior exposure to alkylating agents such as chlorambucil or cyclophosphamide"}, {"type": "EXCLUSION", "field": "lab", "operator": ">=", "value": 5, "unit": "mm", "evidence_text": "Positive TB skin test, RT23 dose skin test, \\>5 mm at 48 to 72 hours"}, {"type": "EXCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "Female who is pregnant or breast-feeding"}], "annotator_id": "annotator_c", "guideline_version": "m5-v1", "adjudicated": true, "adjudication_source": "parsing_relabel_round1"}
{"nct_id": "NCT00238069", "eligibility_text": "Inclusion Criteria:. * Adult (\\>18yrs at the time of recruitment). * Body mass index (BMI)  30. * Symptoms suggestive of sleep apnea. * Epworth Sleepiness Score (ESS) within range. * Positive sleep study for sleep apnea. Exclusion Criteria:. * Tobacco use within the last 3 months.. * Presence of other significant comorbid heart or lung disease. * Presence of another chronic inflammatory disease, such as connective-tissue disease, inflammatory bowel disease, or active infection.. * Use of systemic steroids, as defined as any prednisone use in the preceding 3 months.. * Use of leukotriene antagonists or theophylline within the preceding 6 weeks.. * Presence of severe or uncontrolled sinusitis, such that CPAP therapy will be difficult or uncomfortable.. * History of significant claustrophobia, uncontrolled psychiatric disease, or anticipated intolerance of CPAP therapy.. * Night shift workers, or other subjects with significantly altered sleep-wake cycles.. * Baseline post-bronchodilator FEV1 \\< 70% predicted.. * Severe gastroesophageal reflux disease.", "labeled_rules": [{"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "significantly altered sleep-wake cycles", "unit": null, "evidence_text": "* Night shift workers, or other subjects with significantly altered sleep-wake cycles"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "active infection", "unit": null, "evidence_text": "* Presence of another chronic inflammatory disease, such as connective-tissue disease, inflammatory bowel disease, or active infection"}, {"type": "EXCLUSION", "field": "history", "operator": "WITHIN_LAST", "value": 3, "unit": "months", "evidence_text": "* Tobacco use within the last 3 months"}]}
{"nct_id": "NCT00250445", "eligibility_text": "Inclusion Criteria:. * Patient has a clinical diagnosis of either Osteoarthritis or Rheumatoid Arthritis and in the opinion of the investigator will require chronic nonsteroidal anti-inflammatory or COX-2 inhibitor therapy for at least 1.5 years. Exclusion Criteria:. * Concurrent medical or arthritic disease that could confound or interfere with efficacy evaluation.. * Concomitant therapy of warfarin, heparin, high-dose aspirin (\\>100 mg/day).. * Impaired kidney function, clinical gastrointestinal malabsorption, congestive heart failure with symptoms that occur at rest, unstable angina, uncontrolled high blood pressure, active hepatitis/hepatic disease", "labeled_rules": [{"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "efficacy evaluation", "unit": null, "evidence_text": "* Concurrent medical or arthritic disease that could confound or interfere with efficacy evaluation"}]}
{"nct_id": "NCT00257283", "eligibility_text": "Inclusion Criteria:. * Males and females above 18 years of age. * Patients having been treated with chronic hemodialysis for at least 6 months. * Patients with documented cardiovascular disease, at least one of the following. 1. Angina pectoris. 2. Previous Acute myocardial infarction. 3. Previous PTCA/CABG or demonstated atheroclerosis after coronary angio. 4. Previous Transitory Cerebral Ischemia. 5. Previous Apoplexia Cerebri. 6. Symptoms of peripheral vascular disease. * Written informed consent. Exclusion Criteria:. * Active malignant disease, except basal cell carcinoma or spinocellular carcinoma. * Patients undergoing peritoneal dialysis. * Any condition associated with a risk of poor compliance, as judged by investigator. * Pregnant or breastfeeding. * Participation in other clinical studies involving treatment with drugs.", "labeled_rules": [{"type": "INCLUSION", "field": "age", "operator": ">=", "value": 18, "unit": "years", "evidence_text": "Males and females above 18 years of age"}, {"type": "INCLUSION", "field": "history", "operator": "IN", "value": "* Males and females above 18 years of age. * Patients having been treated with chronic hemodialysis for at least 6 mont", "unit": null, "evidence_text": "Males and females above 18 years of age"}, {"type": "INCLUSION", "field": "medication", "operator": "IN", "value": "* Males and females above 18 years of age. * Patients having been treated with chronic hemodialysis for at least 6 mont", "unit": null, "evidence_text": "Males and females above 18 years of age"}, {"type": "INCLUSION", "field": "other", "operator": "IN", "value": "* Males and females above 18 years of age. * Patients having been treated with chronic hemodialysis for at least 6 mont", "unit": null, "evidence_text": "Males and females above 18 years of age"}, {"type": "INCLUSION", "field": "procedure", "operator": "IN", "value": "* Males and females above 18 years of age. * Patients having been treated with chronic hemodialysis for at least 6 mont", "unit": null, "evidence_text": "Males and females above 18 years of age"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "been treated with chronic hemodialysis for at", "unit": null, "evidence_text": "Patients having been treated with chronic hemodialysis for at least 6 months"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "chronic hemodialysis for at least 6", "unit": null, "evidence_text": "Patients having been treated with chronic hemodialysis for at least 6 months"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "documented cardiovascular disease", "unit": null, "evidence_text": "Patients with documented cardiovascular disease, at least one of the following. 1. Angina pectoris. 2. Previous Acute myocardial infarction. 3. Previous PTCA/CABG or demonstated atheroclerosis after coronary angio. 4. Previous Transitory Cerebral Ischemia. 5. Previous Apoplexia Cerebri. 6. Symptoms of peripheral vascular disease"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "documented cardiovascular disease, at least one", "unit": null, "evidence_text": "Patients with documented cardiovascular disease, at least one of the following. 1. Angina pectoris. 2. Previous Acute myocardial infarction. 3. Previous PTCA/CABG or demonstated atheroclerosis after coronary angio. 4. Previous Transitory Cerebral Ischemia. 5. Previous Apoplexia Cerebri. 6. Symptoms of peripheral vascular disease"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "a risk of poor compliance", "unit": null, "evidence_text": "Any condition associated with a risk of poor compliance, as judged by investigator"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "a risk of poor compliance, as", "unit": null, "evidence_text": "Any condition associated with a risk of poor compliance, as judged by investigator"}, {"type": "EXCLUSION", "field": "sex", "operator": "=", "value": "all", "unit": null, "evidence_text": "Pregnant or breastfeeding"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "drugs", "unit": null, "evidence_text": "Participation in other clinical studies involving treatment with drugs"}], "annotator_id": "annotator_c", "guideline_version": "m5-v1", "adjudicated": true, "adjudication_source": "parsing_relabel_round1"}
{"nct_id": "NCT00264966", "eligibility_text": "Inclusion Criteria:. * Part 1: Men and women 18 to 65 years of age; generally good health; mild to moderate, stable, allergic asthma as defined by ATS criteria (1); history of episodic wheeze and shortness of breath; forced expiratory volume in 1 second (FEV1) at baseline 70% of the predicted value; able to comprehend and follow all required study procedures; willing and able to sign an informed consent form.. Part 2: Methacholine challenge at baseline (PC20 16 mg/mL); positive skin-prick test to common aeroallergens (cat, dust mite, grass, pollen) and positive allergen-induced early and late airway bronchoconstriction.. Exclusion Criteria:. * Part 1 and Part 2: Significant acute or chronic medical or psychiatric illness; known coagulopathy, worsening of asthma or respiratory infection in the preceding 6 weeks; use of inhaled or oral corticosteroids within the last 28 days, antihistamines, immunosuppressives, nonsteroidal anti-inflammatory drugs, or anticoagulants (intermittent doses of short-acting 2-agonist are allowed); use of medications that may interact with ASM8; investigational drug use within 30 days; any clinically significant abnormality on screening laboratory determinations; current tobacco use in previous 3 months or 10 pack-years; pregnant or lactating women; women actively seeking pregnancy or who are not using adequate contraception; history of serious adverse effect (SAE) or hypersensitivity to any drug; 20% decrease in FEV1 or FVC with baseline saline in methacholine challenge during screening.", "labeled_rules": [{"type": "INCLUSION", "field": "age", "operator": "<=", "value": 65, "unit": "years", "evidence_text": "Part 1: Men and women 18 to 65 years of age; generally good health; mild to moderate, stable, allergic asthma as defined by ATS criteria (1); history of episodic wheeze and shortness of breath; forced expiratory volume in 1 second (FEV1) at baseline 70% of the predicted value; able to comprehend and follow all required study procedures; willing and able to sign an informed consent form.. Part 2: Methacholine challenge at baseline (PC20 16 mg/mL); positive skin-prick test to common aeroallergens (cat, dust mite, grass, pollen) and positive allergen-induced early and late airway bronchoconstriction.. Exclusion Criteria:"}, {"type": "INCLUSION", "field": "age", "operator": ">=", "value": 18, "unit": "years", "evidence_text": "Part 1: Men and women 18 to 65 years of age; generally good health; mild to moderate, stable, allergic asthma as defined by ATS criteria (1); history of episodic wheeze and shortness of breath; forced expiratory volume in 1 second (FEV1) at baseline 70% of the predicted value; able to comprehend and follow all required study procedures; willing and able to sign an informed consent form.. Part 2: Methacholine challenge at baseline (PC20 16 mg/mL); positive skin-prick test to common aeroallergens (cat, dust mite, grass, pollen) and positive allergen-induced early and late airway bronchoconstriction.. Exclusion Criteria:"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "episodic wheeze and shortness of breath", "unit": null, "evidence_text": "Part 1: Men and women 18 to 65 years of age; generally good health; mild to moderate, stable, allergic asthma as defined by ATS criteria (1); history of episodic wheeze and shortness of breath; forced expiratory volume in 1 second (FEV1) at baseline 70% of the predicted value; able to comprehend and follow all required study procedures; willing and able to sign an informed consent form.. Part 2: Methacholine challenge at baseline (PC20 16 mg/mL); positive skin-prick test to common aeroallergens (cat, dust mite, grass, pollen) and positive allergen-induced early and late airway bronchoconstriction.. Exclusion Criteria:"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "mild to moderate, stable, allergic asthma as defined by ATS criteria (1)", "unit": null, "evidence_text": "Part 1: Men and women 18 to 65 years of age; generally good health; mild to moderate, stable, allergic asthma as defined by ATS criteria (1); history of episodic wheeze and shortness of breath; forced expiratory volume in 1 second (FEV1) at baseline 70% of the predicted value; able to comprehend and follow all required study procedures; willing and able to sign an informed consent form.. Part 2: Methacholine challenge at baseline (PC20 16 mg/mL); positive skin-prick test to common aeroallergens (cat, dust mite, grass, pollen) and positive allergen-induced early and late airway bronchoconstriction.. Exclusion Criteria:"}, {"type": "INCLUSION", "field": "history", "operator": "IN", "value": "history of episodic wheeze and shortness of breath", "unit": null, "evidence_text": "Part 1: Men and women 18 to 65 years of age; generally good health; mild to moderate, stable, allergic asthma as defined by ATS criteria (1); history of episodic wheeze and shortness of breath; forced expiratory volume in 1 second (FEV1) at baseline 70% of the predicted value; able to comprehend and follow all required study procedures; willing and able to sign an informed consent form.. Part 2: Methacholine challenge at baseline (PC20 16 mg/mL); positive skin-prick test to common aeroallergens (cat, dust mite, grass, pollen) and positive allergen-induced early and late airway bronchoconstriction.. Exclusion Criteria:"}, {"type": "INCLUSION", "field": "other", "operator": "IN", "value": "willing and able to sign an informed consent form.. Part 2: Methacholine challenge at baseline (PC20 16 mg/mL)", "unit": null, "evidence_text": "Part 1: Men and women 18 to 65 years of age; generally good health; mild to moderate, stable, allergic asthma as defined by ATS criteria (1); history of episodic wheeze and shortness of breath; forced expiratory volume in 1 second (FEV1) at baseline 70% of the predicted value; able to comprehend and follow all required study procedures; willing and able to sign an informed consent form.. Part 2: Methacholine challenge at baseline (PC20 16 mg/mL); positive skin-prick test to common aeroallergens (cat, dust mite, grass, pollen) and positive allergen-induced early and late airway bronchoconstriction.. Exclusion Criteria:"}, {"type": "INCLUSION", "field": "procedure", "operator": "IN", "value": "forced expiratory volume in 1 second (FEV1) at baseline 70% of the predicted value", "unit": null, "evidence_text": "Part 1: Men and women 18 to 65 years of age; generally good health; mild to moderate, stable, allergic asthma as defined by ATS criteria (1); history of episodic wheeze and shortness of breath; forced expiratory volume in 1 second (FEV1) at baseline 70% of the predicted value; able to comprehend and follow all required study procedures; willing and able to sign an informed consent form.. Part 2: Methacholine challenge at baseline (PC20 16 mg/mL); positive skin-prick test to common aeroallergens (cat, dust mite, grass, pollen) and positive allergen-induced early and late airway bronchoconstriction.. Exclusion Criteria:"}, {"type": "INCLUSION", "field": "procedure", "operator": "IN", "value": "positive skin-prick test to common aeroallergens (cat, dust mite, grass, pollen) and positive allergen-induced early and late airway broncho", "unit": null, "evidence_text": "Part 1: Men and women 18 to 65 years of age; generally good health; mild to moderate, stable, allergic asthma as defined by ATS criteria (1); history of episodic wheeze and shortness of breath; forced expiratory volume in 1 second (FEV1) at baseline 70% of the predicted value; able to comprehend and follow all required study procedures; willing and able to sign an informed consent form.. Part 2: Methacholine challenge at baseline (PC20 16 mg/mL); positive skin-prick test to common aeroallergens (cat, dust mite, grass, pollen) and positive allergen-induced early and late airway bronchoconstriction.. Exclusion Criteria:"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "asm8", "unit": null, "evidence_text": "Part 1 and Part 2: Significant acute or chronic medical or psychiatric illness; known coagulopathy, worsening of asthma or respiratory infection in the preceding 6 weeks; use of inhaled or oral corticosteroids within the last 28 days, antihistamines, immunosuppressives, nonsteroidal anti-inflammatory drugs, or anticoagulants (intermittent doses of short-acting 2-agonist are allowed); use of medications that may interact with ASM8; investigational drug use within 30 days; any clinically significant abnormality on screening laboratory determinations; current tobacco use in previous 3 months or 10 pack-years; pregnant or lactating women; women actively seeking pregnancy or who are not using adequate contraception; history of serious adverse effect (SAE) or hypersensitivity to any drug; 20% decrease in FEV1 or FVC with baseline saline in methacholine challenge during screening"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "baseline saline in methacholine challenge during screening", "unit": null, "evidence_text": "Part 1 and Part 2: Significant acute or chronic medical or psychiatric illness; known coagulopathy, worsening of asthma or respiratory infection in the preceding 6 weeks; use of inhaled or oral corticosteroids within the last 28 days, antihistamines, immunosuppressives, nonsteroidal anti-inflammatory drugs, or anticoagulants (intermittent doses of short-acting 2-agonist are allowed); use of medications that may interact with ASM8; investigational drug use within 30 days; any clinically significant abnormality on screening laboratory determinations; current tobacco use in previous 3 months or 10 pack-years; pregnant or lactating women; women actively seeking pregnancy or who are not using adequate contraception; history of serious adverse effect (SAE) or hypersensitivity to any drug; 20% decrease in FEV1 or FVC with baseline saline in methacholine challenge during screening"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "serious adverse effect (sae) or hypersensitivity to any drug", "unit": null, "evidence_text": "Part 1 and Part 2: Significant acute or chronic medical or psychiatric illness; known coagulopathy, worsening of asthma or respiratory infection in the preceding 6 weeks; use of inhaled or oral corticosteroids within the last 28 days, antihistamines, immunosuppressives, nonsteroidal anti-inflammatory drugs, or anticoagulants (intermittent doses of short-acting 2-agonist are allowed); use of medications that may interact with ASM8; investigational drug use within 30 days; any clinically significant abnormality on screening laboratory determinations; current tobacco use in previous 3 months or 10 pack-years; pregnant or lactating women; women actively seeking pregnancy or who are not using adequate contraception; history of serious adverse effect (SAE) or hypersensitivity to any drug; 20% decrease in FEV1 or FVC with baseline saline in methacholine challenge during screening"}, {"type": "EXCLUSION", "field": "history", "operator": "IN", "value": "current tobacco use in previous 3 months or 10 pack-years", "unit": null, "evidence_text": "Part 1 and Part 2: Significant acute or chronic medical or psychiatric illness; known coagulopathy, worsening of asthma or respiratory infection in the preceding 6 weeks; use of inhaled or oral corticosteroids within the last 28 days, antihistamines, immunosuppressives, nonsteroidal anti-inflammatory drugs, or anticoagulants (intermittent doses of short-acting 2-agonist are allowed); use of medications that may interact with ASM8; investigational drug use within 30 days; any clinically significant abnormality on screening laboratory determinations; current tobacco use in previous 3 months or 10 pack-years; pregnant or lactating women; women actively seeking pregnancy or who are not using adequate contraception; history of serious adverse effect (SAE) or hypersensitivity to any drug; 20% decrease in FEV1 or FVC with baseline saline in methacholine challenge during screening"}, {"type": "EXCLUSION", "field": "history", "operator": "IN", "value": "history of serious adverse effect (SAE) or hypersensitivity to any drug", "unit": null, "evidence_text": "Part 1 and Part 2: Significant acute or chronic medical or psychiatric illness; known coagulopathy, worsening of asthma or respiratory infection in the preceding 6 weeks; use of inhaled or oral corticosteroids within the last 28 days, antihistamines, immunosuppressives, nonsteroidal anti-inflammatory drugs, or anticoagulants (intermittent doses of short-acting 2-agonist are allowed); use of medications that may interact with ASM8; investigational drug use within 30 days; any clinically significant abnormality on screening laboratory determinations; current tobacco use in previous 3 months or 10 pack-years; pregnant or lactating women; women actively seeking pregnancy or who are not using adequate contraception; history of serious adverse effect (SAE) or hypersensitivity to any drug; 20% decrease in FEV1 or FVC with baseline saline in methacholine challenge during screening"}, {"type": "EXCLUSION", "field": "medication", "operator": "IN", "value": "history of serious adverse effect (SAE) or hypersensitivity to any drug", "unit": null, "evidence_text": "Part 1 and Part 2: Significant acute or chronic medical or psychiatric illness; known coagulopathy, worsening of asthma or respiratory infection in the preceding 6 weeks; use of inhaled or oral corticosteroids within the last 28 days, antihistamines, immunosuppressives, nonsteroidal anti-inflammatory drugs, or anticoagulants (intermittent doses of short-acting 2-agonist are allowed); use of medications that may interact with ASM8; investigational drug use within 30 days; any clinically significant abnormality on screening laboratory determinations; current tobacco use in previous 3 months or 10 pack-years; pregnant or lactating women; women actively seeking pregnancy or who are not using adequate contraception; history of serious adverse effect (SAE) or hypersensitivity to any drug; 20% decrease in FEV1 or FVC with baseline saline in methacholine challenge during screening"}, {"type": "EXCLUSION", "field": "medication", "operator": "IN", "value": "use of medications that may interact with ASM8", "unit": null, "evidence_text": "Part 1 and Part 2: Significant acute or chronic medical or psychiatric illness; known coagulopathy, worsening of asthma or respiratory infection in the preceding 6 weeks; use of inhaled or oral corticosteroids within the last 28 days, antihistamines, immunosuppressives, nonsteroidal anti-inflammatory drugs, or anticoagulants (intermittent doses of short-acting 2-agonist are allowed); use of medications that may interact with ASM8; investigational drug use within 30 days; any clinically significant abnormality on screening laboratory determinations; current tobacco use in previous 3 months or 10 pack-years; pregnant or lactating women; women actively seeking pregnancy or who are not using adequate contraception; history of serious adverse effect (SAE) or hypersensitivity to any drug; 20% decrease in FEV1 or FVC with baseline saline in methacholine challenge during screening"}, {"type": "EXCLUSION", "field": "medication", "operator": "WITHIN_LAST", "value": 28, "unit": "days", "evidence_text": "Part 1 and Part 2: Significant acute or chronic medical or psychiatric illness; known coagulopathy, worsening of asthma or respiratory infection in the preceding 6 weeks; use of inhaled or oral corticosteroids within the last 28 days, antihistamines, immunosuppressives, nonsteroidal anti-inflammatory drugs, or anticoagulants (intermittent doses of short-acting 2-agonist are allowed); use of medications that may interact with ASM8; investigational drug use within 30 days; any clinically significant abnormality on screening laboratory determinations; current tobacco use in previous 3 months or 10 pack-years; pregnant or lactating women; women actively seeking pregnancy or who are not using adequate contraception; history of serious adverse effect (SAE) or hypersensitivity to any drug; 20% decrease in FEV1 or FVC with baseline saline in methacholine challenge during screening"}, {"type": "EXCLUSION", "field": "medication", "operator": "WITHIN_LAST", "value": 30, "unit": "days", "evidence_text": "Part 1 and Part 2: Significant acute or chronic medical or psychiatric illness; known coagulopathy, worsening of asthma or respiratory infection in the preceding 6 weeks; use of inhaled or oral corticosteroids within the last 28 days, antihistamines, immunosuppressives, nonsteroidal anti-inflammatory drugs, or anticoagulants (intermittent doses of short-acting 2-agonist are allowed); use of medications that may interact with ASM8; investigational drug use within 30 days; any clinically significant abnormality on screening laboratory determinations; current tobacco use in previous 3 months or 10 pack-years; pregnant or lactating women; women actively seeking pregnancy or who are not using adequate contraception; history of serious adverse effect (SAE) or hypersensitivity to any drug; 20% decrease in FEV1 or FVC with baseline saline in methacholine challenge during screening"}, {"type": "EXCLUSION", "field": "procedure", "operator": "IN", "value": "history of serious adverse effect (SAE) or hypersensitivity to any drug", "unit": null, "evidence_text": "Part 1 and Part 2: Significant acute or chronic medical or psychiatric illness; known coagulopathy, worsening of asthma or respiratory infection in the preceding 6 weeks; use of inhaled or oral corticosteroids within the last 28 days, antihistamines, immunosuppressives, nonsteroidal anti-inflammatory drugs, or anticoagulants (intermittent doses of short-acting 2-agonist are allowed); use of medications that may interact with ASM8; investigational drug use within 30 days; any clinically significant abnormality on screening laboratory determinations; current tobacco use in previous 3 months or 10 pack-years; pregnant or lactating women; women actively seeking pregnancy or who are not using adequate contraception; history of serious adverse effect (SAE) or hypersensitivity to any drug; 20% decrease in FEV1 or FVC with baseline saline in methacholine challenge during screening"}, {"type": "EXCLUSION", "field": "procedure", "operator": "IN", "value": "known coagulopathy, worsening of asthma or respiratory infection in the preceding 6 weeks", "unit": null, "evidence_text": "Part 1 and Part 2: Significant acute or chronic medical or psychiatric illness; known coagulopathy, worsening of asthma or respiratory infection in the preceding 6 weeks; use of inhaled or oral corticosteroids within the last 28 days, antihistamines, immunosuppressives, nonsteroidal anti-inflammatory drugs, or anticoagulants (intermittent doses of short-acting 2-agonist are allowed); use of medications that may interact with ASM8; investigational drug use within 30 days; any clinically significant abnormality on screening laboratory determinations; current tobacco use in previous 3 months or 10 pack-years; pregnant or lactating women; women actively seeking pregnancy or who are not using adequate contraception; history of serious adverse effect (SAE) or hypersensitivity to any drug; 20% decrease in FEV1 or FVC with baseline saline in methacholine challenge during screening"}, {"type": "EXCLUSION", "field": "procedure", "operator": "IN", "value": "pregnant or lactating women", "unit": null, "evidence_text": "Part 1 and Part 2: Significant acute or chronic medical or psychiatric illness; known coagulopathy, worsening of asthma or respiratory infection in the preceding 6 weeks; use of inhaled or oral corticosteroids within the last 28 days, antihistamines, immunosuppressives, nonsteroidal anti-inflammatory drugs, or anticoagulants (intermittent doses of short-acting 2-agonist are allowed); use of medications that may interact with ASM8; investigational drug use within 30 days; any clinically significant abnormality on screening laboratory determinations; current tobacco use in previous 3 months or 10 pack-years; pregnant or lactating women; women actively seeking pregnancy or who are not using adequate contraception; history of serious adverse effect (SAE) or hypersensitivity to any drug; 20% decrease in FEV1 or FVC with baseline saline in methacholine challenge during screening"}, {"type": "EXCLUSION", "field": "procedure", "operator": "IN", "value": "use of medications that may interact with ASM8", "unit": null, "evidence_text": "Part 1 and Part 2: Significant acute or chronic medical or psychiatric illness; known coagulopathy, worsening of asthma or respiratory infection in the preceding 6 weeks; use of inhaled or oral corticosteroids within the last 28 days, antihistamines, immunosuppressives, nonsteroidal anti-inflammatory drugs, or anticoagulants (intermittent doses of short-acting 2-agonist are allowed); use of medications that may interact with ASM8; investigational drug use within 30 days; any clinically significant abnormality on screening laboratory determinations; current tobacco use in previous 3 months or 10 pack-years; pregnant or lactating women; women actively seeking pregnancy or who are not using adequate contraception; history of serious adverse effect (SAE) or hypersensitivity to any drug; 20% decrease in FEV1 or FVC with baseline saline in methacholine challenge during screening"}, {"type": "EXCLUSION", "field": "procedure", "operator": "IN", "value": "women actively seeking pregnancy or who are not using adequate contraception", "unit": null, "evidence_text": "Part 1 and Part 2: Significant acute or chronic medical or psychiatric illness; known coagulopathy, worsening of asthma or respiratory infection in the preceding 6 weeks; use of inhaled or oral corticosteroids within the last 28 days, antihistamines, immunosuppressives, nonsteroidal anti-inflammatory drugs, or anticoagulants (intermittent doses of short-acting 2-agonist are allowed); use of medications that may interact with ASM8; investigational drug use within 30 days; any clinically significant abnormality on screening laboratory determinations; current tobacco use in previous 3 months or 10 pack-years; pregnant or lactating women; women actively seeking pregnancy or who are not using adequate contraception; history of serious adverse effect (SAE) or hypersensitivity to any drug; 20% decrease in FEV1 or FVC with baseline saline in methacholine challenge during screening"}, {"type": "EXCLUSION", "field": "procedure", "operator": "WITHIN_LAST", "value": 28, "unit": "days", "evidence_text": "Part 1 and Part 2: Significant acute or chronic medical or psychiatric illness; known coagulopathy, worsening of asthma or respiratory infection in the preceding 6 weeks; use of inhaled or oral corticosteroids within the last 28 days, antihistamines, immunosuppressives, nonsteroidal anti-inflammatory drugs, or anticoagulants (intermittent doses of short-acting 2-agonist are allowed); use of medications that may interact with ASM8; investigational drug use within 30 days; any clinically significant abnormality on screening laboratory determinations; current tobacco use in previous 3 months or 10 pack-years; pregnant or lactating women; women actively seeking pregnancy or who are not using adequate contraception; history of serious adverse effect (SAE) or hypersensitivity to any drug; 20% decrease in FEV1 or FVC with baseline saline in methacholine challenge during screening"}, {"type": "EXCLUSION", "field": "sex", "operator": "=", "value": "all", "unit": null, "evidence_text": "Part 1 and Part 2: Significant acute or chronic medical or psychiatric illness; known coagulopathy, worsening of asthma or respiratory infection in the preceding 6 weeks; use of inhaled or oral corticosteroids within the last 28 days, antihistamines, immunosuppressives, nonsteroidal anti-inflammatory drugs, or anticoagulants (intermittent doses of short-acting 2-agonist are allowed); use of medications that may interact with ASM8; investigational drug use within 30 days; any clinically significant abnormality on screening laboratory determinations; current tobacco use in previous 3 months or 10 pack-years; pregnant or lactating women; women actively seeking pregnancy or who are not using adequate contraception; history of serious adverse effect (SAE) or hypersensitivity to any drug; 20% decrease in FEV1 or FVC with baseline saline in methacholine challenge during screening"}, {"type": "EXCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "Part 1 and Part 2: Significant acute or chronic medical or psychiatric illness; known coagulopathy, worsening of asthma or respiratory infection in the preceding 6 weeks; use of inhaled or oral corticosteroids within the last 28 days, antihistamines, immunosuppressives, nonsteroidal anti-inflammatory drugs, or anticoagulants (intermittent doses of short-acting 2-agonist are allowed); use of medications that may interact with ASM8; investigational drug use within 30 days; any clinically significant abnormality on screening laboratory determinations; current tobacco use in previous 3 months or 10 pack-years; pregnant or lactating women; women actively seeking pregnancy or who are not using adequate contraception; history of serious adverse effect (SAE) or hypersensitivity to any drug; 20% decrease in FEV1 or FVC with baseline saline in methacholine challenge during screening"}], "annotator_id": "annotator_c", "guideline_version": "m5-v1", "adjudicated": true, "adjudication_source": "parsing_relabel_round1"}
{"nct_id": "NCT00269867", "eligibility_text": "Inclusion Criteria:. * Patients with active Rheumatoid Arthritis despite treatment with methotrexate. * Diagnosed with Rheumatoid Arthritis at least 6 months prior to screening. * Having active disease at the time of screening and pre-infusion as defined by having at least 6 or more swollen joints and 6 or more tender joints. * Using methotrexate for at least 3 months prior to study enrollment. Exclusion Criteria:. * Patients having any systemic inflammatory condition. * Having Lyme disease or a rheumatic disease other than Rheumatoid Arthritis. * Who have used Disease-Modifying Antirheumatic Drugs (DMARDs) other than methotrexate within 4 weeks prior to screening. * Who have used corticosteroids within 4 weeks prior to screening. * Having received previous administration of infliximab", "labeled_rules": [{"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "rheumatoid arthritis at least 6 months prior", "unit": null, "evidence_text": "* Diagnosed with Rheumatoid Arthritis at least 6 months prior to screening"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "active rheumatoid arthritis despite treatment with methotrexate", "unit": null, "evidence_text": "* Patients with active Rheumatoid Arthritis despite treatment with methotrexate"}]}
{"nct_id": "NCT00270907", "eligibility_text": "Inclusion Criteria:. 1. Patients must have histologically confirmed breast cancer that is either metastatic or unresectable.. 2. Patients must have received anthracyclines as treatment of either early stage or metastatic breast cancer.. 3. Previous taxane therapy is allowed.. 4. Age \\>/= 18 years. There is limited data regarding the use of CT-2103 in children under 18 and they will be excluded from this combination dose finding study.. 5. Eastern Cooperative Oncology Group (ECOG) performance status \\</= 2 (Karnofsky \\>/= 60%).. 6. Measurable disease is not required.. 7. Previous endocrine therapies are allowed but should be discontinued prior to initiation of therapy.. 8. Patients must sign an informed consent indicating that they are aware of the investigational nature of the study, in keeping with institutional policy.. 9. The effects of CT-2103 on the developing human fetus are unknown. For this reason women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Females of childbearing potential are defined as females who have not undergone a hysterectomy or who have not been postmenopausal for at least 24 months.. 10. Patients must have normal organ and marrow function as defined below: leukocytes \\>/= 3,000/ul; absolute neutrophil count \\>/= 1,500/ul; platelets \\>/= 100,000/ul; total bilirubin within normal institutional limits; aspartate aminotransferase (AST or SGOT) and alanine aminotransferase (ALT or SGPT) \\</= 2.5 \\* institutional upper limit of normal; creatinine within normal institutional limits or creatinine clearance \\>/= 60 mL/min/1.73 m2 for patients with creatinine levels above institutional normal; coagulation prothrombin time (PT) and Partial thromboplastin time (PTT) within normal limits unless patients are already anti-coagulated for other reasons (i.e., atrial fibrillation, etc.).. 11. Patients with Her-2/neu positive tumors should have received prior trastuzumab if clinically appropriate.. Exclusion Criteria:. 1. Patients with preexisting neuropathy \\>/= grade 2.. 2. Patients may not be receiving any other investigational agents.. 3. Patients with known brain metastases should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events.. 4. History of allergic reactions attributed to compounds of similar chemical or biologic composition to CT-2103, gemcitabine or other agents used in study. History of typical paclitaxel- or docetaxel-induced Grade 1-2 hypersensitivity reactions is permitted.. 5. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.. 6. Patients who have had chemotherapy or radiotherapy within 4 weeks prior to entering the study.. 7. Previous history of stem cell transplantation.. 8. History of central nervous system metastases.. 9. While there is no strict exclusion based upon previous number of therapies, patients who experienced grade 3 or 4 hematologic toxicity requiring the use of white blood count (WBC) growth factor support during their most recent chemotherapy prior to enrollment are excluded. Exceptions to this would include patients who received growth factor support as mandated by a clinical study, and/or patients who have been off all chemotherapy for at least 6 months.", "labeled_rules": [{"type": "EXCLUSION", "field": "age", "operator": "<=", "value": 18, "unit": "years", "evidence_text": "Inclusion Criteria:. 1. Patients must have histologically confirmed breast cancer that is either metastatic or unresectable.. 2. Patients must have received anthracyclines as treatment of either early stage or metastatic breast cancer.. 3. Previous taxane therapy is allowed.. 4. Age \\>/= 18 years. There is limited data regarding the use of CT-2103 in children under 18 and they will be excluded from this combination dose finding study.. 5. Eastern Cooperative Oncology Group (ECOG) performance status \\</= 2 (Karnofsky \\>/= 60%).. 6. Measurable disease is not required.. 7. Previous endocrine therapies are allowed but should be discontinued prior to initiation of therapy.. 8. Patients must sign an informed consent indicating that they are aware of the investigational nature of the study, in keeping with institutional policy.. 9. The effects of CT-2103 on the developing human fetus are unknown. For this reason women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Females of childbearing potential are defined as females who have not undergone a hysterectomy or who have not been postmenopausal for at least 24 months.. 10. Patients must have normal organ and marrow function as defined below: leukocytes \\>/= 3,000/ul; absolute neutrophil count \\>/= 1,500/ul; platelets \\>/= 100,000/ul; total bilirubin within normal institutional limits; aspartate aminotransferase (AST or SGOT) and alanine aminotransferase (ALT or SGPT) \\</= 2.5 \\* institutional upper limit of normal; creatinine within normal institutional limits or creatinine clearance \\>/= 60 mL/min/1.73 m2 for patients with creatinine levels above institutional normal; coagulation prothrombin time (PT) and Partial thromboplastin time (PTT) within normal limits unless patients are already anti-coagulated for other reasons (i.e., atrial fibrillation, etc.).. 11. Patients with Her-2/neu positive tumors should have received prior trastuzumab if clinically appropriate.. Exclusion Criteria:. 1. Patients with preexisting neuropathy \\>/= grade 2.. 2. Patients may not be receiving any other investigational agents.. 3. Patients with known brain metastases should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events.. 4. History of allergic reactions attributed to compounds of similar chemical or biologic composition to CT-2103, gemcitabine or other agents used in study. History of typical paclitaxel- or docetaxel-induced Grade 1-2 hypersensitivity reactions is permitted.. 5. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.. 6. Patients who have had chemotherapy or radiotherapy within 4 weeks prior to entering the study.. 7. Previous history of stem cell transplantation.. 8. History of central nervous system metastases.. 9. While there is no strict exclusion based upon previous number of therapies, patients who experienced grade 3 or 4 hematologic toxicity requiring the use of white blood count (WBC) growth factor support during their most recent chemotherapy prior to enrollment are excluded. Exceptions to this would include patients who received growth factor support as mandated by a clinical study, and/or patients who have been off all chemotherapy for at least 6 months"}, {"type": "EXCLUSION", "field": "age", "operator": ">=", "value": 24, "unit": "years", "evidence_text": "Inclusion Criteria:. 1. Patients must have histologically confirmed breast cancer that is either metastatic or unresectable.. 2. Patients must have received anthracyclines as treatment of either early stage or metastatic breast cancer.. 3. Previous taxane therapy is allowed.. 4. Age \\>/= 18 years. There is limited data regarding the use of CT-2103 in children under 18 and they will be excluded from this combination dose finding study.. 5. Eastern Cooperative Oncology Group (ECOG) performance status \\</= 2 (Karnofsky \\>/= 60%).. 6. Measurable disease is not required.. 7. Previous endocrine therapies are allowed but should be discontinued prior to initiation of therapy.. 8. Patients must sign an informed consent indicating that they are aware of the investigational nature of the study, in keeping with institutional policy.. 9. The effects of CT-2103 on the developing human fetus are unknown. For this reason women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Females of childbearing potential are defined as females who have not undergone a hysterectomy or who have not been postmenopausal for at least 24 months.. 10. Patients must have normal organ and marrow function as defined below: leukocytes \\>/= 3,000/ul; absolute neutrophil count \\>/= 1,500/ul; platelets \\>/= 100,000/ul; total bilirubin within normal institutional limits; aspartate aminotransferase (AST or SGOT) and alanine aminotransferase (ALT or SGPT) \\</= 2.5 \\* institutional upper limit of normal; creatinine within normal institutional limits or creatinine clearance \\>/= 60 mL/min/1.73 m2 for patients with creatinine levels above institutional normal; coagulation prothrombin time (PT) and Partial thromboplastin time (PTT) within normal limits unless patients are already anti-coagulated for other reasons (i.e., atrial fibrillation, etc.).. 11. Patients with Her-2/neu positive tumors should have received prior trastuzumab if clinically appropriate.. Exclusion Criteria:. 1. Patients with preexisting neuropathy \\>/= grade 2.. 2. Patients may not be receiving any other investigational agents.. 3. Patients with known brain metastases should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events.. 4. History of allergic reactions attributed to compounds of similar chemical or biologic composition to CT-2103, gemcitabine or other agents used in study. History of typical paclitaxel- or docetaxel-induced Grade 1-2 hypersensitivity reactions is permitted.. 5. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.. 6. Patients who have had chemotherapy or radiotherapy within 4 weeks prior to entering the study.. 7. Previous history of stem cell transplantation.. 8. History of central nervous system metastases.. 9. While there is no strict exclusion based upon previous number of therapies, patients who experienced grade 3 or 4 hematologic toxicity requiring the use of white blood count (WBC) growth factor support during their most recent chemotherapy prior to enrollment are excluded. Exceptions to this would include patients who received growth factor support as mandated by a clinical study, and/or patients who have been off all chemotherapy for at least 6 months"}, {"type": "EXCLUSION", "field": "condition", "operator": "IN", "value": "creatinine levels above institutional normal", "unit": null, "evidence_text": "Inclusion Criteria:. 1. Patients must have histologically confirmed breast cancer that is either metastatic or unresectable.. 2. Patients must have received anthracyclines as treatment of either early stage or metastatic breast cancer.. 3. Previous taxane therapy is allowed.. 4. Age \\>/= 18 years. There is limited data regarding the use of CT-2103 in children under 18 and they will be excluded from this combination dose finding study.. 5. Eastern Cooperative Oncology Group (ECOG) performance status \\</= 2 (Karnofsky \\>/= 60%).. 6. Measurable disease is not required.. 7. Previous endocrine therapies are allowed but should be discontinued prior to initiation of therapy.. 8. Patients must sign an informed consent indicating that they are aware of the investigational nature of the study, in keeping with institutional policy.. 9. The effects of CT-2103 on the developing human fetus are unknown. For this reason women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Females of childbearing potential are defined as females who have not undergone a hysterectomy or who have not been postmenopausal for at least 24 months.. 10. Patients must have normal organ and marrow function as defined below: leukocytes \\>/= 3,000/ul; absolute neutrophil count \\>/= 1,500/ul; platelets \\>/= 100,000/ul; total bilirubin within normal institutional limits; aspartate aminotransferase (AST or SGOT) and alanine aminotransferase (ALT or SGPT) \\</= 2.5 \\* institutional upper limit of normal; creatinine within normal institutional limits or creatinine clearance \\>/= 60 mL/min/1.73 m2 for patients with creatinine levels above institutional normal; coagulation prothrombin time (PT) and Partial thromboplastin time (PTT) within normal limits unless patients are already anti-coagulated for other reasons (i.e., atrial fibrillation, etc.).. 11. Patients with Her-2/neu positive tumors should have received prior trastuzumab if clinically appropriate.. Exclusion Criteria:. 1. Patients with preexisting neuropathy \\>/= grade 2.. 2. Patients may not be receiving any other investigational agents.. 3. Patients with known brain metastases should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events.. 4. History of allergic reactions attributed to compounds of similar chemical or biologic composition to CT-2103, gemcitabine or other agents used in study. History of typical paclitaxel- or docetaxel-induced Grade 1-2 hypersensitivity reactions is permitted.. 5. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.. 6. Patients who have had chemotherapy or radiotherapy within 4 weeks prior to entering the study.. 7. Previous history of stem cell transplantation.. 8. History of central nervous system metastases.. 9. While there is no strict exclusion based upon previous number of therapies, patients who experienced grade 3 or 4 hematologic toxicity requiring the use of white blood count (WBC) growth factor support during their most recent chemotherapy prior to enrollment are excluded. Exceptions to this would include patients who received growth factor support as mandated by a clinical study, and/or patients who have been off all chemotherapy for at least 6 months"}, {"type": "EXCLUSION", "field": "condition", "operator": "IN", "value": "institutional policy", "unit": null, "evidence_text": "Inclusion Criteria:. 1. Patients must have histologically confirmed breast cancer that is either metastatic or unresectable.. 2. Patients must have received anthracyclines as treatment of either early stage or metastatic breast cancer.. 3. Previous taxane therapy is allowed.. 4. Age \\>/= 18 years. There is limited data regarding the use of CT-2103 in children under 18 and they will be excluded from this combination dose finding study.. 5. Eastern Cooperative Oncology Group (ECOG) performance status \\</= 2 (Karnofsky \\>/= 60%).. 6. Measurable disease is not required.. 7. Previous endocrine therapies are allowed but should be discontinued prior to initiation of therapy.. 8. Patients must sign an informed consent indicating that they are aware of the investigational nature of the study, in keeping with institutional policy.. 9. The effects of CT-2103 on the developing human fetus are unknown. For this reason women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Females of childbearing potential are defined as females who have not undergone a hysterectomy or who have not been postmenopausal for at least 24 months.. 10. Patients must have normal organ and marrow function as defined below: leukocytes \\>/= 3,000/ul; absolute neutrophil count \\>/= 1,500/ul; platelets \\>/= 100,000/ul; total bilirubin within normal institutional limits; aspartate aminotransferase (AST or SGOT) and alanine aminotransferase (ALT or SGPT) \\</= 2.5 \\* institutional upper limit of normal; creatinine within normal institutional limits or creatinine clearance \\>/= 60 mL/min/1.73 m2 for patients with creatinine levels above institutional normal; coagulation prothrombin time (PT) and Partial thromboplastin time (PTT) within normal limits unless patients are already anti-coagulated for other reasons (i.e., atrial fibrillation, etc.).. 11. Patients with Her-2/neu positive tumors should have received prior trastuzumab if clinically appropriate.. Exclusion Criteria:. 1. Patients with preexisting neuropathy \\>/= grade 2.. 2. Patients may not be receiving any other investigational agents.. 3. Patients with known brain metastases should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events.. 4. History of allergic reactions attributed to compounds of similar chemical or biologic composition to CT-2103, gemcitabine or other agents used in study. History of typical paclitaxel- or docetaxel-induced Grade 1-2 hypersensitivity reactions is permitted.. 5. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.. 6. Patients who have had chemotherapy or radiotherapy within 4 weeks prior to entering the study.. 7. Previous history of stem cell transplantation.. 8. History of central nervous system metastases.. 9. While there is no strict exclusion based upon previous number of therapies, patients who experienced grade 3 or 4 hematologic toxicity requiring the use of white blood count (WBC) growth factor support during their most recent chemotherapy prior to enrollment are excluded. Exceptions to this would include patients who received growth factor support as mandated by a clinical study, and/or patients who have been off all chemotherapy for at least 6 months"}, {"type": "EXCLUSION", "field": "condition", "operator": "IN", "value": "within normal limits unless", "unit": null, "evidence_text": "Inclusion Criteria:. 1. Patients must have histologically confirmed breast cancer that is either metastatic or unresectable.. 2. Patients must have received anthracyclines as treatment of either early stage or metastatic breast cancer.. 3. Previous taxane therapy is allowed.. 4. Age \\>/= 18 years. There is limited data regarding the use of CT-2103 in children under 18 and they will be excluded from this combination dose finding study.. 5. Eastern Cooperative Oncology Group (ECOG) performance status \\</= 2 (Karnofsky \\>/= 60%).. 6. Measurable disease is not required.. 7. Previous endocrine therapies are allowed but should be discontinued prior to initiation of therapy.. 8. Patients must sign an informed consent indicating that they are aware of the investigational nature of the study, in keeping with institutional policy.. 9. The effects of CT-2103 on the developing human fetus are unknown. For this reason women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Females of childbearing potential are defined as females who have not undergone a hysterectomy or who have not been postmenopausal for at least 24 months.. 10. Patients must have normal organ and marrow function as defined below: leukocytes \\>/= 3,000/ul; absolute neutrophil count \\>/= 1,500/ul; platelets \\>/= 100,000/ul; total bilirubin within normal institutional limits; aspartate aminotransferase (AST or SGOT) and alanine aminotransferase (ALT or SGPT) \\</= 2.5 \\* institutional upper limit of normal; creatinine within normal institutional limits or creatinine clearance \\>/= 60 mL/min/1.73 m2 for patients with creatinine levels above institutional normal; coagulation prothrombin time (PT) and Partial thromboplastin time (PTT) within normal limits unless patients are already anti-coagulated for other reasons (i.e., atrial fibrillation, etc.).. 11. Patients with Her-2/neu positive tumors should have received prior trastuzumab if clinically appropriate.. Exclusion Criteria:. 1. Patients with preexisting neuropathy \\>/= grade 2.. 2. Patients may not be receiving any other investigational agents.. 3. Patients with known brain metastases should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events.. 4. History of allergic reactions attributed to compounds of similar chemical or biologic composition to CT-2103, gemcitabine or other agents used in study. History of typical paclitaxel- or docetaxel-induced Grade 1-2 hypersensitivity reactions is permitted.. 5. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.. 6. Patients who have had chemotherapy or radiotherapy within 4 weeks prior to entering the study.. 7. Previous history of stem cell transplantation.. 8. History of central nervous system metastases.. 9. While there is no strict exclusion based upon previous number of therapies, patients who experienced grade 3 or 4 hematologic toxicity requiring the use of white blood count (WBC) growth factor support during their most recent chemotherapy prior to enrollment are excluded. Exceptions to this would include patients who received growth factor support as mandated by a clinical study, and/or patients who have been off all chemotherapy for at least 6 months"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "active infection", "unit": null, "evidence_text": "Inclusion Criteria:. 1. Patients must have histologically confirmed breast cancer that is either metastatic or unresectable.. 2. Patients must have received anthracyclines as treatment of either early stage or metastatic breast cancer.. 3. Previous taxane therapy is allowed.. 4. Age \\>/= 18 years. There is limited data regarding the use of CT-2103 in children under 18 and they will be excluded from this combination dose finding study.. 5. Eastern Cooperative Oncology Group (ECOG) performance status \\</= 2 (Karnofsky \\>/= 60%).. 6. Measurable disease is not required.. 7. Previous endocrine therapies are allowed but should be discontinued prior to initiation of therapy.. 8. Patients must sign an informed consent indicating that they are aware of the investigational nature of the study, in keeping with institutional policy.. 9. The effects of CT-2103 on the developing human fetus are unknown. For this reason women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Females of childbearing potential are defined as females who have not undergone a hysterectomy or who have not been postmenopausal for at least 24 months.. 10. Patients must have normal organ and marrow function as defined below: leukocytes \\>/= 3,000/ul; absolute neutrophil count \\>/= 1,500/ul; platelets \\>/= 100,000/ul; total bilirubin within normal institutional limits; aspartate aminotransferase (AST or SGOT) and alanine aminotransferase (ALT or SGPT) \\</= 2.5 \\* institutional upper limit of normal; creatinine within normal institutional limits or creatinine clearance \\>/= 60 mL/min/1.73 m2 for patients with creatinine levels above institutional normal; coagulation prothrombin time (PT) and Partial thromboplastin time (PTT) within normal limits unless patients are already anti-coagulated for other reasons (i.e., atrial fibrillation, etc.).. 11. Patients with Her-2/neu positive tumors should have received prior trastuzumab if clinically appropriate.. Exclusion Criteria:. 1. Patients with preexisting neuropathy \\>/= grade 2.. 2. Patients may not be receiving any other investigational agents.. 3. Patients with known brain metastases should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events.. 4. History of allergic reactions attributed to compounds of similar chemical or biologic composition to CT-2103, gemcitabine or other agents used in study. History of typical paclitaxel- or docetaxel-induced Grade 1-2 hypersensitivity reactions is permitted.. 5. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.. 6. Patients who have had chemotherapy or radiotherapy within 4 weeks prior to entering the study.. 7. Previous history of stem cell transplantation.. 8. History of central nervous system metastases.. 9. While there is no strict exclusion based upon previous number of therapies, patients who experienced grade 3 or 4 hematologic toxicity requiring the use of white blood count (WBC) growth factor support during their most recent chemotherapy prior to enrollment are excluded. Exceptions to this would include patients who received growth factor support as mandated by a clinical study, and/or patients who have been off all chemotherapy for at least 6 months"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "allergic reactions attributed to compounds of similar chemical or biologic composition to ct 2103, gemcitabine or other agents used in study", "unit": null, "evidence_text": "Inclusion Criteria:. 1. Patients must have histologically confirmed breast cancer that is either metastatic or unresectable.. 2. Patients must have received anthracyclines as treatment of either early stage or metastatic breast cancer.. 3. Previous taxane therapy is allowed.. 4. Age \\>/= 18 years. There is limited data regarding the use of CT-2103 in children under 18 and they will be excluded from this combination dose finding study.. 5. Eastern Cooperative Oncology Group (ECOG) performance status \\</= 2 (Karnofsky \\>/= 60%).. 6. Measurable disease is not required.. 7. Previous endocrine therapies are allowed but should be discontinued prior to initiation of therapy.. 8. Patients must sign an informed consent indicating that they are aware of the investigational nature of the study, in keeping with institutional policy.. 9. The effects of CT-2103 on the developing human fetus are unknown. For this reason women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Females of childbearing potential are defined as females who have not undergone a hysterectomy or who have not been postmenopausal for at least 24 months.. 10. Patients must have normal organ and marrow function as defined below: leukocytes \\>/= 3,000/ul; absolute neutrophil count \\>/= 1,500/ul; platelets \\>/= 100,000/ul; total bilirubin within normal institutional limits; aspartate aminotransferase (AST or SGOT) and alanine aminotransferase (ALT or SGPT) \\</= 2.5 \\* institutional upper limit of normal; creatinine within normal institutional limits or creatinine clearance \\>/= 60 mL/min/1.73 m2 for patients with creatinine levels above institutional normal; coagulation prothrombin time (PT) and Partial thromboplastin time (PTT) within normal limits unless patients are already anti-coagulated for other reasons (i.e., atrial fibrillation, etc.).. 11. Patients with Her-2/neu positive tumors should have received prior trastuzumab if clinically appropriate.. Exclusion Criteria:. 1. Patients with preexisting neuropathy \\>/= grade 2.. 2. Patients may not be receiving any other investigational agents.. 3. Patients with known brain metastases should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events.. 4. History of allergic reactions attributed to compounds of similar chemical or biologic composition to CT-2103, gemcitabine or other agents used in study. History of typical paclitaxel- or docetaxel-induced Grade 1-2 hypersensitivity reactions is permitted.. 5. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.. 6. Patients who have had chemotherapy or radiotherapy within 4 weeks prior to entering the study.. 7. Previous history of stem cell transplantation.. 8. History of central nervous system metastases.. 9. While there is no strict exclusion based upon previous number of therapies, patients who experienced grade 3 or 4 hematologic toxicity requiring the use of white blood count (WBC) growth factor support during their most recent chemotherapy prior to enrollment are excluded. Exceptions to this would include patients who received growth factor support as mandated by a clinical study, and/or patients who have been off all chemotherapy for at least 6 months"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "central nervous system metastases", "unit": null, "evidence_text": "Inclusion Criteria:. 1. Patients must have histologically confirmed breast cancer that is either metastatic or unresectable.. 2. Patients must have received anthracyclines as treatment of either early stage or metastatic breast cancer.. 3. Previous taxane therapy is allowed.. 4. Age \\>/= 18 years. There is limited data regarding the use of CT-2103 in children under 18 and they will be excluded from this combination dose finding study.. 5. Eastern Cooperative Oncology Group (ECOG) performance status \\</= 2 (Karnofsky \\>/= 60%).. 6. Measurable disease is not required.. 7. Previous endocrine therapies are allowed but should be discontinued prior to initiation of therapy.. 8. Patients must sign an informed consent indicating that they are aware of the investigational nature of the study, in keeping with institutional policy.. 9. The effects of CT-2103 on the developing human fetus are unknown. For this reason women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Females of childbearing potential are defined as females who have not undergone a hysterectomy or who have not been postmenopausal for at least 24 months.. 10. Patients must have normal organ and marrow function as defined below: leukocytes \\>/= 3,000/ul; absolute neutrophil count \\>/= 1,500/ul; platelets \\>/= 100,000/ul; total bilirubin within normal institutional limits; aspartate aminotransferase (AST or SGOT) and alanine aminotransferase (ALT or SGPT) \\</= 2.5 \\* institutional upper limit of normal; creatinine within normal institutional limits or creatinine clearance \\>/= 60 mL/min/1.73 m2 for patients with creatinine levels above institutional normal; coagulation prothrombin time (PT) and Partial thromboplastin time (PTT) within normal limits unless patients are already anti-coagulated for other reasons (i.e., atrial fibrillation, etc.).. 11. Patients with Her-2/neu positive tumors should have received prior trastuzumab if clinically appropriate.. Exclusion Criteria:. 1. Patients with preexisting neuropathy \\>/= grade 2.. 2. Patients may not be receiving any other investigational agents.. 3. Patients with known brain metastases should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events.. 4. History of allergic reactions attributed to compounds of similar chemical or biologic composition to CT-2103, gemcitabine or other agents used in study. History of typical paclitaxel- or docetaxel-induced Grade 1-2 hypersensitivity reactions is permitted.. 5. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.. 6. Patients who have had chemotherapy or radiotherapy within 4 weeks prior to entering the study.. 7. Previous history of stem cell transplantation.. 8. History of central nervous system metastases.. 9. While there is no strict exclusion based upon previous number of therapies, patients who experienced grade 3 or 4 hematologic toxicity requiring the use of white blood count (WBC) growth factor support during their most recent chemotherapy prior to enrollment are excluded. Exceptions to this would include patients who received growth factor support as mandated by a clinical study, and/or patients who have been off all chemotherapy for at least 6 months"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "exceptions to this would include", "unit": null, "evidence_text": "Inclusion Criteria:. 1. Patients must have histologically confirmed breast cancer that is either metastatic or unresectable.. 2. Patients must have received anthracyclines as treatment of either early stage or metastatic breast cancer.. 3. Previous taxane therapy is allowed.. 4. Age \\>/= 18 years. There is limited data regarding the use of CT-2103 in children under 18 and they will be excluded from this combination dose finding study.. 5. Eastern Cooperative Oncology Group (ECOG) performance status \\</= 2 (Karnofsky \\>/= 60%).. 6. Measurable disease is not required.. 7. Previous endocrine therapies are allowed but should be discontinued prior to initiation of therapy.. 8. Patients must sign an informed consent indicating that they are aware of the investigational nature of the study, in keeping with institutional policy.. 9. The effects of CT-2103 on the developing human fetus are unknown. For this reason women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Females of childbearing potential are defined as females who have not undergone a hysterectomy or who have not been postmenopausal for at least 24 months.. 10. Patients must have normal organ and marrow function as defined below: leukocytes \\>/= 3,000/ul; absolute neutrophil count \\>/= 1,500/ul; platelets \\>/= 100,000/ul; total bilirubin within normal institutional limits; aspartate aminotransferase (AST or SGOT) and alanine aminotransferase (ALT or SGPT) \\</= 2.5 \\* institutional upper limit of normal; creatinine within normal institutional limits or creatinine clearance \\>/= 60 mL/min/1.73 m2 for patients with creatinine levels above institutional normal; coagulation prothrombin time (PT) and Partial thromboplastin time (PTT) within normal limits unless patients are already anti-coagulated for other reasons (i.e., atrial fibrillation, etc.).. 11. Patients with Her-2/neu positive tumors should have received prior trastuzumab if clinically appropriate.. Exclusion Criteria:. 1. Patients with preexisting neuropathy \\>/= grade 2.. 2. Patients may not be receiving any other investigational agents.. 3. Patients with known brain metastases should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events.. 4. History of allergic reactions attributed to compounds of similar chemical or biologic composition to CT-2103, gemcitabine or other agents used in study. History of typical paclitaxel- or docetaxel-induced Grade 1-2 hypersensitivity reactions is permitted.. 5. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.. 6. Patients who have had chemotherapy or radiotherapy within 4 weeks prior to entering the study.. 7. Previous history of stem cell transplantation.. 8. History of central nervous system metastases.. 9. While there is no strict exclusion based upon previous number of therapies, patients who experienced grade 3 or 4 hematologic toxicity requiring the use of white blood count (WBC) growth factor support during their most recent chemotherapy prior to enrollment are excluded. Exceptions to this would include patients who received growth factor support as mandated by a clinical study, and/or patients who have been off all chemotherapy for at least 6 months"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "requirements", "unit": null, "evidence_text": "Inclusion Criteria:. 1. Patients must have histologically confirmed breast cancer that is either metastatic or unresectable.. 2. Patients must have received anthracyclines as treatment of either early stage or metastatic breast cancer.. 3. Previous taxane therapy is allowed.. 4. Age \\>/= 18 years. There is limited data regarding the use of CT-2103 in children under 18 and they will be excluded from this combination dose finding study.. 5. Eastern Cooperative Oncology Group (ECOG) performance status \\</= 2 (Karnofsky \\>/= 60%).. 6. Measurable disease is not required.. 7. Previous endocrine therapies are allowed but should be discontinued prior to initiation of therapy.. 8. Patients must sign an informed consent indicating that they are aware of the investigational nature of the study, in keeping with institutional policy.. 9. The effects of CT-2103 on the developing human fetus are unknown. For this reason women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Females of childbearing potential are defined as females who have not undergone a hysterectomy or who have not been postmenopausal for at least 24 months.. 10. Patients must have normal organ and marrow function as defined below: leukocytes \\>/= 3,000/ul; absolute neutrophil count \\>/= 1,500/ul; platelets \\>/= 100,000/ul; total bilirubin within normal institutional limits; aspartate aminotransferase (AST or SGOT) and alanine aminotransferase (ALT or SGPT) \\</= 2.5 \\* institutional upper limit of normal; creatinine within normal institutional limits or creatinine clearance \\>/= 60 mL/min/1.73 m2 for patients with creatinine levels above institutional normal; coagulation prothrombin time (PT) and Partial thromboplastin time (PTT) within normal limits unless patients are already anti-coagulated for other reasons (i.e., atrial fibrillation, etc.).. 11. Patients with Her-2/neu positive tumors should have received prior trastuzumab if clinically appropriate.. Exclusion Criteria:. 1. Patients with preexisting neuropathy \\>/= grade 2.. 2. Patients may not be receiving any other investigational agents.. 3. Patients with known brain metastases should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events.. 4. History of allergic reactions attributed to compounds of similar chemical or biologic composition to CT-2103, gemcitabine or other agents used in study. History of typical paclitaxel- or docetaxel-induced Grade 1-2 hypersensitivity reactions is permitted.. 5. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.. 6. Patients who have had chemotherapy or radiotherapy within 4 weeks prior to entering the study.. 7. Previous history of stem cell transplantation.. 8. History of central nervous system metastases.. 9. While there is no strict exclusion based upon previous number of therapies, patients who experienced grade 3 or 4 hematologic toxicity requiring the use of white blood count (WBC) growth factor support during their most recent chemotherapy prior to enrollment are excluded. Exceptions to this would include patients who received growth factor support as mandated by a clinical study, and/or patients who have been off all chemotherapy for at least 6 months"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "stem cell transplantation", "unit": null, "evidence_text": "Inclusion Criteria:. 1. Patients must have histologically confirmed breast cancer that is either metastatic or unresectable.. 2. Patients must have received anthracyclines as treatment of either early stage or metastatic breast cancer.. 3. Previous taxane therapy is allowed.. 4. Age \\>/= 18 years. There is limited data regarding the use of CT-2103 in children under 18 and they will be excluded from this combination dose finding study.. 5. Eastern Cooperative Oncology Group (ECOG) performance status \\</= 2 (Karnofsky \\>/= 60%).. 6. Measurable disease is not required.. 7. Previous endocrine therapies are allowed but should be discontinued prior to initiation of therapy.. 8. Patients must sign an informed consent indicating that they are aware of the investigational nature of the study, in keeping with institutional policy.. 9. The effects of CT-2103 on the developing human fetus are unknown. For this reason women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Females of childbearing potential are defined as females who have not undergone a hysterectomy or who have not been postmenopausal for at least 24 months.. 10. Patients must have normal organ and marrow function as defined below: leukocytes \\>/= 3,000/ul; absolute neutrophil count \\>/= 1,500/ul; platelets \\>/= 100,000/ul; total bilirubin within normal institutional limits; aspartate aminotransferase (AST or SGOT) and alanine aminotransferase (ALT or SGPT) \\</= 2.5 \\* institutional upper limit of normal; creatinine within normal institutional limits or creatinine clearance \\>/= 60 mL/min/1.73 m2 for patients with creatinine levels above institutional normal; coagulation prothrombin time (PT) and Partial thromboplastin time (PTT) within normal limits unless patients are already anti-coagulated for other reasons (i.e., atrial fibrillation, etc.).. 11. Patients with Her-2/neu positive tumors should have received prior trastuzumab if clinically appropriate.. Exclusion Criteria:. 1. Patients with preexisting neuropathy \\>/= grade 2.. 2. Patients may not be receiving any other investigational agents.. 3. Patients with known brain metastases should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events.. 4. History of allergic reactions attributed to compounds of similar chemical or biologic composition to CT-2103, gemcitabine or other agents used in study. History of typical paclitaxel- or docetaxel-induced Grade 1-2 hypersensitivity reactions is permitted.. 5. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.. 6. Patients who have had chemotherapy or radiotherapy within 4 weeks prior to entering the study.. 7. Previous history of stem cell transplantation.. 8. History of central nervous system metastases.. 9. While there is no strict exclusion based upon previous number of therapies, patients who experienced grade 3 or 4 hematologic toxicity requiring the use of white blood count (WBC) growth factor support during their most recent chemotherapy prior to enrollment are excluded. Exceptions to this would include patients who received growth factor support as mandated by a clinical study, and/or patients who have been off all chemotherapy for at least 6 months"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "study requirements", "unit": null, "evidence_text": "Inclusion Criteria:. 1. Patients must have histologically confirmed breast cancer that is either metastatic or unresectable.. 2. Patients must have received anthracyclines as treatment of either early stage or metastatic breast cancer.. 3. Previous taxane therapy is allowed.. 4. Age \\>/= 18 years. There is limited data regarding the use of CT-2103 in children under 18 and they will be excluded from this combination dose finding study.. 5. Eastern Cooperative Oncology Group (ECOG) performance status \\</= 2 (Karnofsky \\>/= 60%).. 6. Measurable disease is not required.. 7. Previous endocrine therapies are allowed but should be discontinued prior to initiation of therapy.. 8. Patients must sign an informed consent indicating that they are aware of the investigational nature of the study, in keeping with institutional policy.. 9. The effects of CT-2103 on the developing human fetus are unknown. For this reason women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Females of childbearing potential are defined as females who have not undergone a hysterectomy or who have not been postmenopausal for at least 24 months.. 10. Patients must have normal organ and marrow function as defined below: leukocytes \\>/= 3,000/ul; absolute neutrophil count \\>/= 1,500/ul; platelets \\>/= 100,000/ul; total bilirubin within normal institutional limits; aspartate aminotransferase (AST or SGOT) and alanine aminotransferase (ALT or SGPT) \\</= 2.5 \\* institutional upper limit of normal; creatinine within normal institutional limits or creatinine clearance \\>/= 60 mL/min/1.73 m2 for patients with creatinine levels above institutional normal; coagulation prothrombin time (PT) and Partial thromboplastin time (PTT) within normal limits unless patients are already anti-coagulated for other reasons (i.e., atrial fibrillation, etc.).. 11. Patients with Her-2/neu positive tumors should have received prior trastuzumab if clinically appropriate.. Exclusion Criteria:. 1. Patients with preexisting neuropathy \\>/= grade 2.. 2. Patients may not be receiving any other investigational agents.. 3. Patients with known brain metastases should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events.. 4. History of allergic reactions attributed to compounds of similar chemical or biologic composition to CT-2103, gemcitabine or other agents used in study. History of typical paclitaxel- or docetaxel-induced Grade 1-2 hypersensitivity reactions is permitted.. 5. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.. 6. Patients who have had chemotherapy or radiotherapy within 4 weeks prior to entering the study.. 7. Previous history of stem cell transplantation.. 8. History of central nervous system metastases.. 9. While there is no strict exclusion based upon previous number of therapies, patients who experienced grade 3 or 4 hematologic toxicity requiring the use of white blood count (WBC) growth factor support during their most recent chemotherapy prior to enrollment are excluded. Exceptions to this would include patients who received growth factor support as mandated by a clinical study, and/or patients who have been off all chemotherapy for at least 6 months"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "typical paclitaxel or docetaxel induced grade 1 2 hypersensitivity reactions is permitted", "unit": null, "evidence_text": "Inclusion Criteria:. 1. Patients must have histologically confirmed breast cancer that is either metastatic or unresectable.. 2. Patients must have received anthracyclines as treatment of either early stage or metastatic breast cancer.. 3. Previous taxane therapy is allowed.. 4. Age \\>/= 18 years. There is limited data regarding the use of CT-2103 in children under 18 and they will be excluded from this combination dose finding study.. 5. Eastern Cooperative Oncology Group (ECOG) performance status \\</= 2 (Karnofsky \\>/= 60%).. 6. Measurable disease is not required.. 7. Previous endocrine therapies are allowed but should be discontinued prior to initiation of therapy.. 8. Patients must sign an informed consent indicating that they are aware of the investigational nature of the study, in keeping with institutional policy.. 9. The effects of CT-2103 on the developing human fetus are unknown. For this reason women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Females of childbearing potential are defined as females who have not undergone a hysterectomy or who have not been postmenopausal for at least 24 months.. 10. Patients must have normal organ and marrow function as defined below: leukocytes \\>/= 3,000/ul; absolute neutrophil count \\>/= 1,500/ul; platelets \\>/= 100,000/ul; total bilirubin within normal institutional limits; aspartate aminotransferase (AST or SGOT) and alanine aminotransferase (ALT or SGPT) \\</= 2.5 \\* institutional upper limit of normal; creatinine within normal institutional limits or creatinine clearance \\>/= 60 mL/min/1.73 m2 for patients with creatinine levels above institutional normal; coagulation prothrombin time (PT) and Partial thromboplastin time (PTT) within normal limits unless patients are already anti-coagulated for other reasons (i.e., atrial fibrillation, etc.).. 11. Patients with Her-2/neu positive tumors should have received prior trastuzumab if clinically appropriate.. Exclusion Criteria:. 1. Patients with preexisting neuropathy \\>/= grade 2.. 2. Patients may not be receiving any other investigational agents.. 3. Patients with known brain metastases should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events.. 4. History of allergic reactions attributed to compounds of similar chemical or biologic composition to CT-2103, gemcitabine or other agents used in study. History of typical paclitaxel- or docetaxel-induced Grade 1-2 hypersensitivity reactions is permitted.. 5. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.. 6. Patients who have had chemotherapy or radiotherapy within 4 weeks prior to entering the study.. 7. Previous history of stem cell transplantation.. 8. History of central nervous system metastases.. 9. While there is no strict exclusion based upon previous number of therapies, patients who experienced grade 3 or 4 hematologic toxicity requiring the use of white blood count (WBC) growth factor support during their most recent chemotherapy prior to enrollment are excluded. Exceptions to this would include patients who received growth factor support as mandated by a clinical study, and/or patients who have been off all chemotherapy for at least 6 months"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "typical paclitaxel- or docetaxel-induced grade 1-2 hypersensitivity", "unit": null, "evidence_text": "Inclusion Criteria:. 1. Patients must have histologically confirmed breast cancer that is either metastatic or unresectable.. 2. Patients must have received anthracyclines as treatment of either early stage or metastatic breast cancer.. 3. Previous taxane therapy is allowed.. 4. Age \\>/= 18 years. There is limited data regarding the use of CT-2103 in children under 18 and they will be excluded from this combination dose finding study.. 5. Eastern Cooperative Oncology Group (ECOG) performance status \\</= 2 (Karnofsky \\>/= 60%).. 6. Measurable disease is not required.. 7. Previous endocrine therapies are allowed but should be discontinued prior to initiation of therapy.. 8. Patients must sign an informed consent indicating that they are aware of the investigational nature of the study, in keeping with institutional policy.. 9. The effects of CT-2103 on the developing human fetus are unknown. For this reason women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Females of childbearing potential are defined as females who have not undergone a hysterectomy or who have not been postmenopausal for at least 24 months.. 10. Patients must have normal organ and marrow function as defined below: leukocytes \\>/= 3,000/ul; absolute neutrophil count \\>/= 1,500/ul; platelets \\>/= 100,000/ul; total bilirubin within normal institutional limits; aspartate aminotransferase (AST or SGOT) and alanine aminotransferase (ALT or SGPT) \\</= 2.5 \\* institutional upper limit of normal; creatinine within normal institutional limits or creatinine clearance \\>/= 60 mL/min/1.73 m2 for patients with creatinine levels above institutional normal; coagulation prothrombin time (PT) and Partial thromboplastin time (PTT) within normal limits unless patients are already anti-coagulated for other reasons (i.e., atrial fibrillation, etc.).. 11. Patients with Her-2/neu positive tumors should have received prior trastuzumab if clinically appropriate.. Exclusion Criteria:. 1. Patients with preexisting neuropathy \\>/= grade 2.. 2. Patients may not be receiving any other investigational agents.. 3. Patients with known brain metastases should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events.. 4. History of allergic reactions attributed to compounds of similar chemical or biologic composition to CT-2103, gemcitabine or other agents used in study. History of typical paclitaxel- or docetaxel-induced Grade 1-2 hypersensitivity reactions is permitted.. 5. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.. 6. Patients who have had chemotherapy or radiotherapy within 4 weeks prior to entering the study.. 7. Previous history of stem cell transplantation.. 8. History of central nervous system metastases.. 9. While there is no strict exclusion based upon previous number of therapies, patients who experienced grade 3 or 4 hematologic toxicity requiring the use of white blood count (WBC) growth factor support during their most recent chemotherapy prior to enrollment are excluded. Exceptions to this would include patients who received growth factor support as mandated by a clinical study, and/or patients who have been off all chemotherapy for at least 6 months"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "while there is no strict exclusion based", "unit": null, "evidence_text": "Inclusion Criteria:. 1. Patients must have histologically confirmed breast cancer that is either metastatic or unresectable.. 2. Patients must have received anthracyclines as treatment of either early stage or metastatic breast cancer.. 3. Previous taxane therapy is allowed.. 4. Age \\>/= 18 years. There is limited data regarding the use of CT-2103 in children under 18 and they will be excluded from this combination dose finding study.. 5. Eastern Cooperative Oncology Group (ECOG) performance status \\</= 2 (Karnofsky \\>/= 60%).. 6. Measurable disease is not required.. 7. Previous endocrine therapies are allowed but should be discontinued prior to initiation of therapy.. 8. Patients must sign an informed consent indicating that they are aware of the investigational nature of the study, in keeping with institutional policy.. 9. The effects of CT-2103 on the developing human fetus are unknown. For this reason women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Females of childbearing potential are defined as females who have not undergone a hysterectomy or who have not been postmenopausal for at least 24 months.. 10. Patients must have normal organ and marrow function as defined below: leukocytes \\>/= 3,000/ul; absolute neutrophil count \\>/= 1,500/ul; platelets \\>/= 100,000/ul; total bilirubin within normal institutional limits; aspartate aminotransferase (AST or SGOT) and alanine aminotransferase (ALT or SGPT) \\</= 2.5 \\* institutional upper limit of normal; creatinine within normal institutional limits or creatinine clearance \\>/= 60 mL/min/1.73 m2 for patients with creatinine levels above institutional normal; coagulation prothrombin time (PT) and Partial thromboplastin time (PTT) within normal limits unless patients are already anti-coagulated for other reasons (i.e., atrial fibrillation, etc.).. 11. Patients with Her-2/neu positive tumors should have received prior trastuzumab if clinically appropriate.. Exclusion Criteria:. 1. Patients with preexisting neuropathy \\>/= grade 2.. 2. Patients may not be receiving any other investigational agents.. 3. Patients with known brain metastases should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events.. 4. History of allergic reactions attributed to compounds of similar chemical or biologic composition to CT-2103, gemcitabine or other agents used in study. History of typical paclitaxel- or docetaxel-induced Grade 1-2 hypersensitivity reactions is permitted.. 5. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.. 6. Patients who have had chemotherapy or radiotherapy within 4 weeks prior to entering the study.. 7. Previous history of stem cell transplantation.. 8. History of central nervous system metastases.. 9. While there is no strict exclusion based upon previous number of therapies, patients who experienced grade 3 or 4 hematologic toxicity requiring the use of white blood count (WBC) growth factor support during their most recent chemotherapy prior to enrollment are excluded. Exceptions to this would include patients who received growth factor support as mandated by a clinical study, and/or patients who have been off all chemotherapy for at least 6 months"}, {"type": "EXCLUSION", "field": "history", "operator": "IN", "value": "1. Patients must have histologically confirmed breast cancer that is either metastatic or unresectable.. 2. Patients mu", "unit": null, "evidence_text": "Inclusion Criteria:. 1. Patients must have histologically confirmed breast cancer that is either metastatic or unresectable.. 2. Patients must have received anthracyclines as treatment of either early stage or metastatic breast cancer.. 3. Previous taxane therapy is allowed.. 4. Age \\>/= 18 years. There is limited data regarding the use of CT-2103 in children under 18 and they will be excluded from this combination dose finding study.. 5. Eastern Cooperative Oncology Group (ECOG) performance status \\</= 2 (Karnofsky \\>/= 60%).. 6. Measurable disease is not required.. 7. Previous endocrine therapies are allowed but should be discontinued prior to initiation of therapy.. 8. Patients must sign an informed consent indicating that they are aware of the investigational nature of the study, in keeping with institutional policy.. 9. The effects of CT-2103 on the developing human fetus are unknown. For this reason women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Females of childbearing potential are defined as females who have not undergone a hysterectomy or who have not been postmenopausal for at least 24 months.. 10. Patients must have normal organ and marrow function as defined below: leukocytes \\>/= 3,000/ul; absolute neutrophil count \\>/= 1,500/ul; platelets \\>/= 100,000/ul; total bilirubin within normal institutional limits; aspartate aminotransferase (AST or SGOT) and alanine aminotransferase (ALT or SGPT) \\</= 2.5 \\* institutional upper limit of normal; creatinine within normal institutional limits or creatinine clearance \\>/= 60 mL/min/1.73 m2 for patients with creatinine levels above institutional normal; coagulation prothrombin time (PT) and Partial thromboplastin time (PTT) within normal limits unless patients are already anti-coagulated for other reasons (i.e., atrial fibrillation, etc.).. 11. Patients with Her-2/neu positive tumors should have received prior trastuzumab if clinically appropriate.. Exclusion Criteria:. 1. Patients with preexisting neuropathy \\>/= grade 2.. 2. Patients may not be receiving any other investigational agents.. 3. Patients with known brain metastases should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events.. 4. History of allergic reactions attributed to compounds of similar chemical or biologic composition to CT-2103, gemcitabine or other agents used in study. History of typical paclitaxel- or docetaxel-induced Grade 1-2 hypersensitivity reactions is permitted.. 5. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.. 6. Patients who have had chemotherapy or radiotherapy within 4 weeks prior to entering the study.. 7. Previous history of stem cell transplantation.. 8. History of central nervous system metastases.. 9. While there is no strict exclusion based upon previous number of therapies, patients who experienced grade 3 or 4 hematologic toxicity requiring the use of white blood count (WBC) growth factor support during their most recent chemotherapy prior to enrollment are excluded. Exceptions to this would include patients who received growth factor support as mandated by a clinical study, and/or patients who have been off all chemotherapy for at least 6 months"}, {"type": "EXCLUSION", "field": "history", "operator": "IN", "value": "coagulation prothrombin time (PT) and Partial thromboplastin time (PTT) within normal limits unless patients are already anti-coagulated for", "unit": null, "evidence_text": "Inclusion Criteria:. 1. Patients must have histologically confirmed breast cancer that is either metastatic or unresectable.. 2. Patients must have received anthracyclines as treatment of either early stage or metastatic breast cancer.. 3. Previous taxane therapy is allowed.. 4. Age \\>/= 18 years. There is limited data regarding the use of CT-2103 in children under 18 and they will be excluded from this combination dose finding study.. 5. Eastern Cooperative Oncology Group (ECOG) performance status \\</= 2 (Karnofsky \\>/= 60%).. 6. Measurable disease is not required.. 7. Previous endocrine therapies are allowed but should be discontinued prior to initiation of therapy.. 8. Patients must sign an informed consent indicating that they are aware of the investigational nature of the study, in keeping with institutional policy.. 9. The effects of CT-2103 on the developing human fetus are unknown. For this reason women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Females of childbearing potential are defined as females who have not undergone a hysterectomy or who have not been postmenopausal for at least 24 months.. 10. Patients must have normal organ and marrow function as defined below: leukocytes \\>/= 3,000/ul; absolute neutrophil count \\>/= 1,500/ul; platelets \\>/= 100,000/ul; total bilirubin within normal institutional limits; aspartate aminotransferase (AST or SGOT) and alanine aminotransferase (ALT or SGPT) \\</= 2.5 \\* institutional upper limit of normal; creatinine within normal institutional limits or creatinine clearance \\>/= 60 mL/min/1.73 m2 for patients with creatinine levels above institutional normal; coagulation prothrombin time (PT) and Partial thromboplastin time (PTT) within normal limits unless patients are already anti-coagulated for other reasons (i.e., atrial fibrillation, etc.).. 11. Patients with Her-2/neu positive tumors should have received prior trastuzumab if clinically appropriate.. Exclusion Criteria:. 1. Patients with preexisting neuropathy \\>/= grade 2.. 2. Patients may not be receiving any other investigational agents.. 3. Patients with known brain metastases should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events.. 4. History of allergic reactions attributed to compounds of similar chemical or biologic composition to CT-2103, gemcitabine or other agents used in study. History of typical paclitaxel- or docetaxel-induced Grade 1-2 hypersensitivity reactions is permitted.. 5. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.. 6. Patients who have had chemotherapy or radiotherapy within 4 weeks prior to entering the study.. 7. Previous history of stem cell transplantation.. 8. History of central nervous system metastases.. 9. While there is no strict exclusion based upon previous number of therapies, patients who experienced grade 3 or 4 hematologic toxicity requiring the use of white blood count (WBC) growth factor support during their most recent chemotherapy prior to enrollment are excluded. Exceptions to this would include patients who received growth factor support as mandated by a clinical study, and/or patients who have been off all chemotherapy for at least 6 months"}, {"type": "EXCLUSION", "field": "medication", "operator": "IN", "value": "1. Patients must have histologically confirmed breast cancer that is either metastatic or unresectable.. 2. Patients mu", "unit": null, "evidence_text": "Inclusion Criteria:. 1. Patients must have histologically confirmed breast cancer that is either metastatic or unresectable.. 2. Patients must have received anthracyclines as treatment of either early stage or metastatic breast cancer.. 3. Previous taxane therapy is allowed.. 4. Age \\>/= 18 years. There is limited data regarding the use of CT-2103 in children under 18 and they will be excluded from this combination dose finding study.. 5. Eastern Cooperative Oncology Group (ECOG) performance status \\</= 2 (Karnofsky \\>/= 60%).. 6. Measurable disease is not required.. 7. Previous endocrine therapies are allowed but should be discontinued prior to initiation of therapy.. 8. Patients must sign an informed consent indicating that they are aware of the investigational nature of the study, in keeping with institutional policy.. 9. The effects of CT-2103 on the developing human fetus are unknown. For this reason women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Females of childbearing potential are defined as females who have not undergone a hysterectomy or who have not been postmenopausal for at least 24 months.. 10. Patients must have normal organ and marrow function as defined below: leukocytes \\>/= 3,000/ul; absolute neutrophil count \\>/= 1,500/ul; platelets \\>/= 100,000/ul; total bilirubin within normal institutional limits; aspartate aminotransferase (AST or SGOT) and alanine aminotransferase (ALT or SGPT) \\</= 2.5 \\* institutional upper limit of normal; creatinine within normal institutional limits or creatinine clearance \\>/= 60 mL/min/1.73 m2 for patients with creatinine levels above institutional normal; coagulation prothrombin time (PT) and Partial thromboplastin time (PTT) within normal limits unless patients are already anti-coagulated for other reasons (i.e., atrial fibrillation, etc.).. 11. Patients with Her-2/neu positive tumors should have received prior trastuzumab if clinically appropriate.. Exclusion Criteria:. 1. Patients with preexisting neuropathy \\>/= grade 2.. 2. Patients may not be receiving any other investigational agents.. 3. Patients with known brain metastases should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events.. 4. History of allergic reactions attributed to compounds of similar chemical or biologic composition to CT-2103, gemcitabine or other agents used in study. History of typical paclitaxel- or docetaxel-induced Grade 1-2 hypersensitivity reactions is permitted.. 5. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.. 6. Patients who have had chemotherapy or radiotherapy within 4 weeks prior to entering the study.. 7. Previous history of stem cell transplantation.. 8. History of central nervous system metastases.. 9. While there is no strict exclusion based upon previous number of therapies, patients who experienced grade 3 or 4 hematologic toxicity requiring the use of white blood count (WBC) growth factor support during their most recent chemotherapy prior to enrollment are excluded. Exceptions to this would include patients who received growth factor support as mandated by a clinical study, and/or patients who have been off all chemotherapy for at least 6 months"}, {"type": "EXCLUSION", "field": "medication", "operator": "WITHIN_LAST", "value": 4, "unit": "weeks", "evidence_text": "Inclusion Criteria:. 1. Patients must have histologically confirmed breast cancer that is either metastatic or unresectable.. 2. Patients must have received anthracyclines as treatment of either early stage or metastatic breast cancer.. 3. Previous taxane therapy is allowed.. 4. Age \\>/= 18 years. There is limited data regarding the use of CT-2103 in children under 18 and they will be excluded from this combination dose finding study.. 5. Eastern Cooperative Oncology Group (ECOG) performance status \\</= 2 (Karnofsky \\>/= 60%).. 6. Measurable disease is not required.. 7. Previous endocrine therapies are allowed but should be discontinued prior to initiation of therapy.. 8. Patients must sign an informed consent indicating that they are aware of the investigational nature of the study, in keeping with institutional policy.. 9. The effects of CT-2103 on the developing human fetus are unknown. For this reason women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Females of childbearing potential are defined as females who have not undergone a hysterectomy or who have not been postmenopausal for at least 24 months.. 10. Patients must have normal organ and marrow function as defined below: leukocytes \\>/= 3,000/ul; absolute neutrophil count \\>/= 1,500/ul; platelets \\>/= 100,000/ul; total bilirubin within normal institutional limits; aspartate aminotransferase (AST or SGOT) and alanine aminotransferase (ALT or SGPT) \\</= 2.5 \\* institutional upper limit of normal; creatinine within normal institutional limits or creatinine clearance \\>/= 60 mL/min/1.73 m2 for patients with creatinine levels above institutional normal; coagulation prothrombin time (PT) and Partial thromboplastin time (PTT) within normal limits unless patients are already anti-coagulated for other reasons (i.e., atrial fibrillation, etc.).. 11. Patients with Her-2/neu positive tumors should have received prior trastuzumab if clinically appropriate.. Exclusion Criteria:. 1. Patients with preexisting neuropathy \\>/= grade 2.. 2. Patients may not be receiving any other investigational agents.. 3. Patients with known brain metastases should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events.. 4. History of allergic reactions attributed to compounds of similar chemical or biologic composition to CT-2103, gemcitabine or other agents used in study. History of typical paclitaxel- or docetaxel-induced Grade 1-2 hypersensitivity reactions is permitted.. 5. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.. 6. Patients who have had chemotherapy or radiotherapy within 4 weeks prior to entering the study.. 7. Previous history of stem cell transplantation.. 8. History of central nervous system metastases.. 9. While there is no strict exclusion based upon previous number of therapies, patients who experienced grade 3 or 4 hematologic toxicity requiring the use of white blood count (WBC) growth factor support during their most recent chemotherapy prior to enrollment are excluded. Exceptions to this would include patients who received growth factor support as mandated by a clinical study, and/or patients who have been off all chemotherapy for at least 6 months"}, {"type": "EXCLUSION", "field": "other", "operator": "IN", "value": "1. Patients must have histologically confirmed breast cancer that is either metastatic or unresectable.. 2. Patients mu", "unit": null, "evidence_text": "Inclusion Criteria:. 1. Patients must have histologically confirmed breast cancer that is either metastatic or unresectable.. 2. Patients must have received anthracyclines as treatment of either early stage or metastatic breast cancer.. 3. Previous taxane therapy is allowed.. 4. Age \\>/= 18 years. There is limited data regarding the use of CT-2103 in children under 18 and they will be excluded from this combination dose finding study.. 5. Eastern Cooperative Oncology Group (ECOG) performance status \\</= 2 (Karnofsky \\>/= 60%).. 6. Measurable disease is not required.. 7. Previous endocrine therapies are allowed but should be discontinued prior to initiation of therapy.. 8. Patients must sign an informed consent indicating that they are aware of the investigational nature of the study, in keeping with institutional policy.. 9. The effects of CT-2103 on the developing human fetus are unknown. For this reason women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Females of childbearing potential are defined as females who have not undergone a hysterectomy or who have not been postmenopausal for at least 24 months.. 10. Patients must have normal organ and marrow function as defined below: leukocytes \\>/= 3,000/ul; absolute neutrophil count \\>/= 1,500/ul; platelets \\>/= 100,000/ul; total bilirubin within normal institutional limits; aspartate aminotransferase (AST or SGOT) and alanine aminotransferase (ALT or SGPT) \\</= 2.5 \\* institutional upper limit of normal; creatinine within normal institutional limits or creatinine clearance \\>/= 60 mL/min/1.73 m2 for patients with creatinine levels above institutional normal; coagulation prothrombin time (PT) and Partial thromboplastin time (PTT) within normal limits unless patients are already anti-coagulated for other reasons (i.e., atrial fibrillation, etc.).. 11. Patients with Her-2/neu positive tumors should have received prior trastuzumab if clinically appropriate.. Exclusion Criteria:. 1. Patients with preexisting neuropathy \\>/= grade 2.. 2. Patients may not be receiving any other investigational agents.. 3. Patients with known brain metastases should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events.. 4. History of allergic reactions attributed to compounds of similar chemical or biologic composition to CT-2103, gemcitabine or other agents used in study. History of typical paclitaxel- or docetaxel-induced Grade 1-2 hypersensitivity reactions is permitted.. 5. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.. 6. Patients who have had chemotherapy or radiotherapy within 4 weeks prior to entering the study.. 7. Previous history of stem cell transplantation.. 8. History of central nervous system metastases.. 9. While there is no strict exclusion based upon previous number of therapies, patients who experienced grade 3 or 4 hematologic toxicity requiring the use of white blood count (WBC) growth factor support during their most recent chemotherapy prior to enrollment are excluded. Exceptions to this would include patients who received growth factor support as mandated by a clinical study, and/or patients who have been off all chemotherapy for at least 6 months"}, {"type": "EXCLUSION", "field": "procedure", "operator": "IN", "value": "1. Patients must have histologically confirmed breast cancer that is either metastatic or unresectable.. 2. Patients mu", "unit": null, "evidence_text": "Inclusion Criteria:. 1. Patients must have histologically confirmed breast cancer that is either metastatic or unresectable.. 2. Patients must have received anthracyclines as treatment of either early stage or metastatic breast cancer.. 3. Previous taxane therapy is allowed.. 4. Age \\>/= 18 years. There is limited data regarding the use of CT-2103 in children under 18 and they will be excluded from this combination dose finding study.. 5. Eastern Cooperative Oncology Group (ECOG) performance status \\</= 2 (Karnofsky \\>/= 60%).. 6. Measurable disease is not required.. 7. Previous endocrine therapies are allowed but should be discontinued prior to initiation of therapy.. 8. Patients must sign an informed consent indicating that they are aware of the investigational nature of the study, in keeping with institutional policy.. 9. The effects of CT-2103 on the developing human fetus are unknown. For this reason women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Females of childbearing potential are defined as females who have not undergone a hysterectomy or who have not been postmenopausal for at least 24 months.. 10. Patients must have normal organ and marrow function as defined below: leukocytes \\>/= 3,000/ul; absolute neutrophil count \\>/= 1,500/ul; platelets \\>/= 100,000/ul; total bilirubin within normal institutional limits; aspartate aminotransferase (AST or SGOT) and alanine aminotransferase (ALT or SGPT) \\</= 2.5 \\* institutional upper limit of normal; creatinine within normal institutional limits or creatinine clearance \\>/= 60 mL/min/1.73 m2 for patients with creatinine levels above institutional normal; coagulation prothrombin time (PT) and Partial thromboplastin time (PTT) within normal limits unless patients are already anti-coagulated for other reasons (i.e., atrial fibrillation, etc.).. 11. Patients with Her-2/neu positive tumors should have received prior trastuzumab if clinically appropriate.. Exclusion Criteria:. 1. Patients with preexisting neuropathy \\>/= grade 2.. 2. Patients may not be receiving any other investigational agents.. 3. Patients with known brain metastases should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events.. 4. History of allergic reactions attributed to compounds of similar chemical or biologic composition to CT-2103, gemcitabine or other agents used in study. History of typical paclitaxel- or docetaxel-induced Grade 1-2 hypersensitivity reactions is permitted.. 5. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.. 6. Patients who have had chemotherapy or radiotherapy within 4 weeks prior to entering the study.. 7. Previous history of stem cell transplantation.. 8. History of central nervous system metastases.. 9. While there is no strict exclusion based upon previous number of therapies, patients who experienced grade 3 or 4 hematologic toxicity requiring the use of white blood count (WBC) growth factor support during their most recent chemotherapy prior to enrollment are excluded. Exceptions to this would include patients who received growth factor support as mandated by a clinical study, and/or patients who have been off all chemotherapy for at least 6 months"}, {"type": "EXCLUSION", "field": "procedure", "operator": "IN", "value": "abstinence) prior to study entry and for the duration of study participation. Females of childbearing potential are defined as females who h", "unit": null, "evidence_text": "Inclusion Criteria:. 1. Patients must have histologically confirmed breast cancer that is either metastatic or unresectable.. 2. Patients must have received anthracyclines as treatment of either early stage or metastatic breast cancer.. 3. Previous taxane therapy is allowed.. 4. Age \\>/= 18 years. There is limited data regarding the use of CT-2103 in children under 18 and they will be excluded from this combination dose finding study.. 5. Eastern Cooperative Oncology Group (ECOG) performance status \\</= 2 (Karnofsky \\>/= 60%).. 6. Measurable disease is not required.. 7. Previous endocrine therapies are allowed but should be discontinued prior to initiation of therapy.. 8. Patients must sign an informed consent indicating that they are aware of the investigational nature of the study, in keeping with institutional policy.. 9. The effects of CT-2103 on the developing human fetus are unknown. For this reason women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Females of childbearing potential are defined as females who have not undergone a hysterectomy or who have not been postmenopausal for at least 24 months.. 10. Patients must have normal organ and marrow function as defined below: leukocytes \\>/= 3,000/ul; absolute neutrophil count \\>/= 1,500/ul; platelets \\>/= 100,000/ul; total bilirubin within normal institutional limits; aspartate aminotransferase (AST or SGOT) and alanine aminotransferase (ALT or SGPT) \\</= 2.5 \\* institutional upper limit of normal; creatinine within normal institutional limits or creatinine clearance \\>/= 60 mL/min/1.73 m2 for patients with creatinine levels above institutional normal; coagulation prothrombin time (PT) and Partial thromboplastin time (PTT) within normal limits unless patients are already anti-coagulated for other reasons (i.e., atrial fibrillation, etc.).. 11. Patients with Her-2/neu positive tumors should have received prior trastuzumab if clinically appropriate.. Exclusion Criteria:. 1. Patients with preexisting neuropathy \\>/= grade 2.. 2. Patients may not be receiving any other investigational agents.. 3. Patients with known brain metastases should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events.. 4. History of allergic reactions attributed to compounds of similar chemical or biologic composition to CT-2103, gemcitabine or other agents used in study. History of typical paclitaxel- or docetaxel-induced Grade 1-2 hypersensitivity reactions is permitted.. 5. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.. 6. Patients who have had chemotherapy or radiotherapy within 4 weeks prior to entering the study.. 7. Previous history of stem cell transplantation.. 8. History of central nervous system metastases.. 9. While there is no strict exclusion based upon previous number of therapies, patients who experienced grade 3 or 4 hematologic toxicity requiring the use of white blood count (WBC) growth factor support during their most recent chemotherapy prior to enrollment are excluded. Exceptions to this would include patients who received growth factor support as mandated by a clinical study, and/or patients who have been off all chemotherapy for at least 6 months"}, {"type": "EXCLUSION", "field": "procedure", "operator": "WITHIN_LAST", "value": 4, "unit": "weeks", "evidence_text": "Inclusion Criteria:. 1. Patients must have histologically confirmed breast cancer that is either metastatic or unresectable.. 2. Patients must have received anthracyclines as treatment of either early stage or metastatic breast cancer.. 3. Previous taxane therapy is allowed.. 4. Age \\>/= 18 years. There is limited data regarding the use of CT-2103 in children under 18 and they will be excluded from this combination dose finding study.. 5. Eastern Cooperative Oncology Group (ECOG) performance status \\</= 2 (Karnofsky \\>/= 60%).. 6. Measurable disease is not required.. 7. Previous endocrine therapies are allowed but should be discontinued prior to initiation of therapy.. 8. Patients must sign an informed consent indicating that they are aware of the investigational nature of the study, in keeping with institutional policy.. 9. The effects of CT-2103 on the developing human fetus are unknown. For this reason women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Females of childbearing potential are defined as females who have not undergone a hysterectomy or who have not been postmenopausal for at least 24 months.. 10. Patients must have normal organ and marrow function as defined below: leukocytes \\>/= 3,000/ul; absolute neutrophil count \\>/= 1,500/ul; platelets \\>/= 100,000/ul; total bilirubin within normal institutional limits; aspartate aminotransferase (AST or SGOT) and alanine aminotransferase (ALT or SGPT) \\</= 2.5 \\* institutional upper limit of normal; creatinine within normal institutional limits or creatinine clearance \\>/= 60 mL/min/1.73 m2 for patients with creatinine levels above institutional normal; coagulation prothrombin time (PT) and Partial thromboplastin time (PTT) within normal limits unless patients are already anti-coagulated for other reasons (i.e., atrial fibrillation, etc.).. 11. Patients with Her-2/neu positive tumors should have received prior trastuzumab if clinically appropriate.. Exclusion Criteria:. 1. Patients with preexisting neuropathy \\>/= grade 2.. 2. Patients may not be receiving any other investigational agents.. 3. Patients with known brain metastases should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events.. 4. History of allergic reactions attributed to compounds of similar chemical or biologic composition to CT-2103, gemcitabine or other agents used in study. History of typical paclitaxel- or docetaxel-induced Grade 1-2 hypersensitivity reactions is permitted.. 5. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.. 6. Patients who have had chemotherapy or radiotherapy within 4 weeks prior to entering the study.. 7. Previous history of stem cell transplantation.. 8. History of central nervous system metastases.. 9. While there is no strict exclusion based upon previous number of therapies, patients who experienced grade 3 or 4 hematologic toxicity requiring the use of white blood count (WBC) growth factor support during their most recent chemotherapy prior to enrollment are excluded. Exceptions to this would include patients who received growth factor support as mandated by a clinical study, and/or patients who have been off all chemotherapy for at least 6 months"}, {"type": "EXCLUSION", "field": "sex", "operator": "=", "value": "all", "unit": null, "evidence_text": "Inclusion Criteria:. 1. Patients must have histologically confirmed breast cancer that is either metastatic or unresectable.. 2. Patients must have received anthracyclines as treatment of either early stage or metastatic breast cancer.. 3. Previous taxane therapy is allowed.. 4. Age \\>/= 18 years. There is limited data regarding the use of CT-2103 in children under 18 and they will be excluded from this combination dose finding study.. 5. Eastern Cooperative Oncology Group (ECOG) performance status \\</= 2 (Karnofsky \\>/= 60%).. 6. Measurable disease is not required.. 7. Previous endocrine therapies are allowed but should be discontinued prior to initiation of therapy.. 8. Patients must sign an informed consent indicating that they are aware of the investigational nature of the study, in keeping with institutional policy.. 9. The effects of CT-2103 on the developing human fetus are unknown. For this reason women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Females of childbearing potential are defined as females who have not undergone a hysterectomy or who have not been postmenopausal for at least 24 months.. 10. Patients must have normal organ and marrow function as defined below: leukocytes \\>/= 3,000/ul; absolute neutrophil count \\>/= 1,500/ul; platelets \\>/= 100,000/ul; total bilirubin within normal institutional limits; aspartate aminotransferase (AST or SGOT) and alanine aminotransferase (ALT or SGPT) \\</= 2.5 \\* institutional upper limit of normal; creatinine within normal institutional limits or creatinine clearance \\>/= 60 mL/min/1.73 m2 for patients with creatinine levels above institutional normal; coagulation prothrombin time (PT) and Partial thromboplastin time (PTT) within normal limits unless patients are already anti-coagulated for other reasons (i.e., atrial fibrillation, etc.).. 11. Patients with Her-2/neu positive tumors should have received prior trastuzumab if clinically appropriate.. Exclusion Criteria:. 1. Patients with preexisting neuropathy \\>/= grade 2.. 2. Patients may not be receiving any other investigational agents.. 3. Patients with known brain metastases should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events.. 4. History of allergic reactions attributed to compounds of similar chemical or biologic composition to CT-2103, gemcitabine or other agents used in study. History of typical paclitaxel- or docetaxel-induced Grade 1-2 hypersensitivity reactions is permitted.. 5. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.. 6. Patients who have had chemotherapy or radiotherapy within 4 weeks prior to entering the study.. 7. Previous history of stem cell transplantation.. 8. History of central nervous system metastases.. 9. While there is no strict exclusion based upon previous number of therapies, patients who experienced grade 3 or 4 hematologic toxicity requiring the use of white blood count (WBC) growth factor support during their most recent chemotherapy prior to enrollment are excluded. Exceptions to this would include patients who received growth factor support as mandated by a clinical study, and/or patients who have been off all chemotherapy for at least 6 months"}, {"type": "EXCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "Inclusion Criteria:. 1. Patients must have histologically confirmed breast cancer that is either metastatic or unresectable.. 2. Patients must have received anthracyclines as treatment of either early stage or metastatic breast cancer.. 3. Previous taxane therapy is allowed.. 4. Age \\>/= 18 years. There is limited data regarding the use of CT-2103 in children under 18 and they will be excluded from this combination dose finding study.. 5. Eastern Cooperative Oncology Group (ECOG) performance status \\</= 2 (Karnofsky \\>/= 60%).. 6. Measurable disease is not required.. 7. Previous endocrine therapies are allowed but should be discontinued prior to initiation of therapy.. 8. Patients must sign an informed consent indicating that they are aware of the investigational nature of the study, in keeping with institutional policy.. 9. The effects of CT-2103 on the developing human fetus are unknown. For this reason women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Females of childbearing potential are defined as females who have not undergone a hysterectomy or who have not been postmenopausal for at least 24 months.. 10. Patients must have normal organ and marrow function as defined below: leukocytes \\>/= 3,000/ul; absolute neutrophil count \\>/= 1,500/ul; platelets \\>/= 100,000/ul; total bilirubin within normal institutional limits; aspartate aminotransferase (AST or SGOT) and alanine aminotransferase (ALT or SGPT) \\</= 2.5 \\* institutional upper limit of normal; creatinine within normal institutional limits or creatinine clearance \\>/= 60 mL/min/1.73 m2 for patients with creatinine levels above institutional normal; coagulation prothrombin time (PT) and Partial thromboplastin time (PTT) within normal limits unless patients are already anti-coagulated for other reasons (i.e., atrial fibrillation, etc.).. 11. Patients with Her-2/neu positive tumors should have received prior trastuzumab if clinically appropriate.. Exclusion Criteria:. 1. Patients with preexisting neuropathy \\>/= grade 2.. 2. Patients may not be receiving any other investigational agents.. 3. Patients with known brain metastases should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events.. 4. History of allergic reactions attributed to compounds of similar chemical or biologic composition to CT-2103, gemcitabine or other agents used in study. History of typical paclitaxel- or docetaxel-induced Grade 1-2 hypersensitivity reactions is permitted.. 5. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.. 6. Patients who have had chemotherapy or radiotherapy within 4 weeks prior to entering the study.. 7. Previous history of stem cell transplantation.. 8. History of central nervous system metastases.. 9. While there is no strict exclusion based upon previous number of therapies, patients who experienced grade 3 or 4 hematologic toxicity requiring the use of white blood count (WBC) growth factor support during their most recent chemotherapy prior to enrollment are excluded. Exceptions to this would include patients who received growth factor support as mandated by a clinical study, and/or patients who have been off all chemotherapy for at least 6 months"}], "annotator_id": "annotator_c", "guideline_version": "m5-v1", "adjudicated": true, "adjudication_source": "parsing_relabel_round1"}
{"nct_id": "NCT00289627", "eligibility_text": "Inclusion Criteria:. * Patients with previously treated Stage III (unresectable)or Stage IV melanoma", "labeled_rules": [{"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "study-specific condition", "unit": null, "evidence_text": "Inclusion Criteria:"}, {"type": "INCLUSION", "field": "history", "operator": "IN", "value": "* Patients with previously treated Stage III (unresectable)or Stage IV melanoma", "unit": null, "evidence_text": "Patients with previously treated Stage III (unresectable)or Stage IV melanoma"}, {"type": "INCLUSION", "field": "procedure", "operator": "IN", "value": "* Patients with previously treated Stage III (unresectable)or Stage IV melanoma", "unit": null, "evidence_text": "Patients with previously treated Stage III (unresectable)or Stage IV melanoma"}], "annotator_id": "annotator_c", "guideline_version": "m5-v1", "adjudicated": true, "adjudication_source": "parsing_relabel_round1"}
{"nct_id": "NCT00289822", "eligibility_text": "Inclusion Criteria:. * Patients aged 18 to 80. * Patients post-myocardial infarction (\\> 3 months old) or with diffuse ischemic CHD. * Signed informed consent. Exclusion Criteria:. \\- Existing neoplastic disease or signs of tumor recurrence within the last 5 years. * Active infection. * Active internal bleeding. * Stroke within the past 2 years. * Surgery or trauma within the past two months. * Uncontrolled hypertension over 160/100. * Arteriovenous malformations or aneurysms. * HIV infection. * Signs of significant kidney or liver failure (creatinine \\> 2.0 mg/dL, GOT \\> 2 x upper standard value). * Thrombopenia (\\< 100,000). * Anemia (hemoglobin \\< 8.5 g/dL). * Mental retardation. * Participation in another clinical study. * Women of childbearing age. * Chronic inflammatory disease", "labeled_rules": [{"type": "EXCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "* Women of childbearing age"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "hiv positive", "unit": null, "evidence_text": "* HIV infection"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "active infection", "unit": null, "evidence_text": "* Active infection"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "diffuse ischemic chd", "unit": null, "evidence_text": "* Patients post-myocardial infarction (\\> 3 months old) or with diffuse ischemic CHD"}, {"type": "EXCLUSION", "field": "history", "operator": "WITHIN_LAST", "value": 5, "unit": "years", "evidence_text": "\\- Existing neoplastic disease or signs of tumor recurrence within the last 5 years"}]}
{"nct_id": "NCT00291577", "eligibility_text": "Inclusion Criteria:. * Breast cancer with evidence of unresectable, locally recurrent or metastatic disease. * Candidate for treatment with docetaxel. Exclusion Criteria:. * Prior chemotherapy in the advanced disease setting. * Inflammatory breast cancer. * HER2 positive disease", "labeled_rules": [{"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "evidence of unresectable", "unit": null, "evidence_text": "Breast cancer with evidence of unresectable, locally recurrent or metastatic disease"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "evidence of unresectable, locally recurrent or metastatic", "unit": null, "evidence_text": "Breast cancer with evidence of unresectable, locally recurrent or metastatic disease"}, {"type": "INCLUSION", "field": "medication", "operator": "IN", "value": "* Breast cancer with evidence of unresectable, locally recurrent or metastatic disease. * Candidate for treatment with", "unit": null, "evidence_text": "Breast cancer with evidence of unresectable, locally recurrent or metastatic disease"}, {"type": "INCLUSION", "field": "procedure", "operator": "IN", "value": "* Breast cancer with evidence of unresectable, locally recurrent or metastatic disease. * Candidate for treatment with", "unit": null, "evidence_text": "Breast cancer with evidence of unresectable, locally recurrent or metastatic disease"}, {"type": "EXCLUSION", "field": "condition", "operator": "IN", "value": "docetaxel", "unit": null, "evidence_text": "Candidate for treatment with docetaxel. Exclusion Criteria:"}], "annotator_id": "annotator_c", "guideline_version": "m5-v1", "adjudicated": true, "adjudication_source": "parsing_relabel_round1"}
{"nct_id": "NCT00292175", "eligibility_text": "Inclusion Criteria:. * petients with colitis who meet surveillance criteria. * patients over 18 years of age. Exclusion Criteria:. * pregnant patients. * unable or unwilling to give informed consent. * patients with severe active colitis who would be unsafe to endoscope", "labeled_rules": [{"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "colitis who meet surveillance", "unit": null, "evidence_text": "petients with colitis who meet surveillance criteria"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "colitis who meet surveillance criteria", "unit": null, "evidence_text": "petients with colitis who meet surveillance criteria"}, {"type": "INCLUSION", "field": "other", "operator": "IN", "value": "petients with colitis who meet surveillance criteria", "unit": null, "evidence_text": "petients with colitis who meet surveillance criteria"}, {"type": "INCLUSION", "field": "procedure", "operator": "IN", "value": "petients with colitis who meet surveillance criteria", "unit": null, "evidence_text": "petients with colitis who meet surveillance criteria"}, {"type": "EXCLUSION", "field": "age", "operator": ">=", "value": 18, "unit": "years", "evidence_text": "patients over 18 years of age. Exclusion Criteria:"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "pregnant", "unit": null, "evidence_text": "pregnant patients"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "severe active colitis who would be unsafe", "unit": null, "evidence_text": "patients with severe active colitis who would be unsafe to endoscope"}], "annotator_id": "annotator_c", "guideline_version": "m5-v1", "adjudicated": true, "adjudication_source": "parsing_relabel_round1"}
{"nct_id": "NCT00320034", "eligibility_text": "Inclusion Criteria:. * Male or female (medically or surgically postmenopausal or practicing an accepted form of barrier or hormonal contraception) subjects age 18-55.. * Stable, mild atopic asthma with forced expiratory volume in one second (FEV1.0) greater than 70% of predicted for age and height, and not requiring any medical treatment other than short acting inhaled beta-agonists as needed.. * No recent or significant history of cigarette smoking (no cigarettes within six months prior to entry into the study; less than 10 pack-years cumulative history of cigarette smoking).. * Peak decrease in FEV1 in both early (0-2 hour) and late (3-7 hour) allergen-provoked response of \\> 15% compared with the baseline (pre-allergen challenge) spirometric determination.. * Signed written informed consent to participate in the protocol; ability to return to the outpatient clinic for repeated clinic visits.. * No history of asthma exacerbations or acute intercurrent respiratory illness (viral respiratory syndrome, bronchitis, pneumonia) for a six week period preceding entry into the screening phase of the study.. Exclusion Criteria:. * Significant gastrointestinal (including hepatic), hematological, cardiovascular, cerebrovascular or other body system disorder.. * History of an acute exacerbation, or of a respiratory tract infection at any time during the past 6 weeks.. * Baseline AST or ALT (indicators of liver damage) greater than twice the upper limit of the normal range for the local laboratory.. * History of allergy or hypersensitivity to short-acting beta-agonists.. * Inability to discontinue asthma medications for the duration of the study or receipt of oral or inhaled corticosteroids or leukotriene receptor antagonist in the three weeks prior to entry into the screening phase of the study.. * Recent (within the past 2 months) or planned (within the study period) lung volume reduction surgery.. * Psychosis, alcoholism, active substance abuse, or any personality disorder which would make compliance with this protocol problematic.. * Pregnant or nursing females.. * Any other medical or social condition which, in the opinion of the investigator, could confound the interpretation of the data derived from this study.", "labeled_rules": [{"type": "INCLUSION", "field": "history", "operator": "IN", "value": "* Male or female (medically or surgically postmenopausal or practicing an accepted form of barrier or hormonal contrace", "unit": null, "evidence_text": "Male or female (medically or surgically postmenopausal or practicing an accepted form of barrier or hormonal contraception) subjects age 18-55"}, {"type": "INCLUSION", "field": "medication", "operator": "IN", "value": "* Male or female (medically or surgically postmenopausal or practicing an accepted form of barrier or hormonal contrace", "unit": null, "evidence_text": "Male or female (medically or surgically postmenopausal or practicing an accepted form of barrier or hormonal contraception) subjects age 18-55"}, {"type": "INCLUSION", "field": "procedure", "operator": "IN", "value": "* Male or female (medically or surgically postmenopausal or practicing an accepted form of barrier or hormonal contrace", "unit": null, "evidence_text": "Male or female (medically or surgically postmenopausal or practicing an accepted form of barrier or hormonal contraception) subjects age 18-55"}, {"type": "INCLUSION", "field": "sex", "operator": "=", "value": "all", "unit": null, "evidence_text": "Male or female (medically or surgically postmenopausal or practicing an accepted form of barrier or hormonal contraception) subjects age 18-55"}, {"type": "INCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "Male or female (medically or surgically postmenopausal or practicing an accepted form of barrier or hormonal contraception) subjects age 18-55"}, {"type": "INCLUSION", "field": "lab", "operator": ">=", "value": 70, "unit": "%", "evidence_text": "Stable, mild atopic asthma with forced expiratory volume in one second (FEV1.0) greater than 70% of predicted for age and height, and not requiring any medical treatment other than short acting inhaled beta-agonists as needed"}, {"type": "INCLUSION", "field": "history", "operator": "IN", "value": "less than 10 pack-years cumulative history of cigarette smoking).. * Peak decrease in FEV1 in both early (0-2 hour) and late (3-7 hour) alle", "unit": null, "evidence_text": "No recent or significant history of cigarette smoking (no cigarettes within six months prior to entry into the study; less than 10 pack-years cumulative history of cigarette smoking)"}, {"type": "INCLUSION", "field": "other", "operator": "IN", "value": "less than 10 pack-years cumulative history of cigarette smoking).. * Peak decrease in FEV1 in both early (0-2 hour) and late (3-7 hour) alle", "unit": null, "evidence_text": "No recent or significant history of cigarette smoking (no cigarettes within six months prior to entry into the study; less than 10 pack-years cumulative history of cigarette smoking)"}, {"type": "INCLUSION", "field": "history", "operator": "IN", "value": "ability to return to the outpatient clinic for repeated clinic visits.. * No history of asthma exacerbations or acute intercurrent respirato", "unit": null, "evidence_text": "Signed written informed consent to participate in the protocol; ability to return to the outpatient clinic for repeated clinic visits"}, {"type": "INCLUSION", "field": "other", "operator": "IN", "value": "ability to return to the outpatient clinic for repeated clinic visits.. * No history of asthma exacerbations or acute intercurrent respirato", "unit": null, "evidence_text": "Signed written informed consent to participate in the protocol; ability to return to the outpatient clinic for repeated clinic visits"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "acute exacerbation, or of a respiratory tract infection at any time during the past 6 weeks", "unit": null, "evidence_text": "History of an acute exacerbation, or of a respiratory tract infection at any time during the past 6 weeks"}, {"type": "EXCLUSION", "field": "medication", "operator": "WITHIN_LAST", "value": 6, "unit": "weeks", "evidence_text": "History of an acute exacerbation, or of a respiratory tract infection at any time during the past 6 weeks"}, {"type": "EXCLUSION", "field": "procedure", "operator": "WITHIN_LAST", "value": 6, "unit": "weeks", "evidence_text": "History of an acute exacerbation, or of a respiratory tract infection at any time during the past 6 weeks"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "allergy or hypersensitivity to short-acting beta-agonists", "unit": null, "evidence_text": "History of allergy or hypersensitivity to short-acting beta-agonists"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "this protocol problematic", "unit": null, "evidence_text": "Psychosis, alcoholism, active substance abuse, or any personality disorder which would make compliance with this protocol problematic"}], "annotator_id": "annotator_c", "guideline_version": "m5-v1", "adjudicated": true, "adjudication_source": "parsing_relabel_round1"}
{"nct_id": "NCT00322517", "eligibility_text": "Inclusion Criteria:. * Histologically or cytologically proven diagnosis of metastatic breast adenocarcinoma that is not amenable to surgery, radiation, or combined modality therapy with curative intent.. * Must have received prior treatment with an anthracycline and a taxane either concurrently or sequentially in the adjuvant and/or advanced disease treatment settings. Patients may have received as many as 2 other chemotherapy regimens in the advanced disease setting. Patients whose tumors are Her-2-positive must have received prior trastuzumab therapy. Prior hormonal therapy or immunotherapy in the adjuvant and/or advanced/metastatic disease settings is permitted. Prior treatment with surgery, radiotherapy, chemoembolization therapy, or cryotherapy is allowed if these therapies did not affect the areas of measurable disease.. Exclusion Criteria:. * Prior treatment with \\>/= 3 regimens of chemotherapy in the metastatic disease setting beyond those containing anthracyclines and taxanes. * Uncontrolled brain metastases, spinal cord compression, or carcinomatous meningitis, or new evidence of brain or leptomeningeal disease. Patients should have completed surgery or radiation therapy for existing brain metastases, should not have documented increase in size over the previous 3 months and should be asymptomatic", "labeled_rules": [{"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "curative intent", "unit": null, "evidence_text": "Histologically or cytologically proven diagnosis of metastatic breast adenocarcinoma that is not amenable to surgery, radiation, or combined modality therapy with curative intent"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "histologically or cytologically proven", "unit": null, "evidence_text": "Histologically or cytologically proven diagnosis of metastatic breast adenocarcinoma that is not amenable to surgery, radiation, or combined modality therapy with curative intent"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "surgery", "unit": null, "evidence_text": "Histologically or cytologically proven diagnosis of metastatic breast adenocarcinoma that is not amenable to surgery, radiation, or combined modality therapy with curative intent"}, {"type": "INCLUSION", "field": "history", "operator": "IN", "value": "* Histologically or cytologically proven diagnosis of metastatic breast adenocarcinoma that is not amenable to surgery", "unit": null, "evidence_text": "Histologically or cytologically proven diagnosis of metastatic breast adenocarcinoma that is not amenable to surgery, radiation, or combined modality therapy with curative intent"}, {"type": "INCLUSION", "field": "medication", "operator": "IN", "value": "* Histologically or cytologically proven diagnosis of metastatic breast adenocarcinoma that is not amenable to surgery", "unit": null, "evidence_text": "Histologically or cytologically proven diagnosis of metastatic breast adenocarcinoma that is not amenable to surgery, radiation, or combined modality therapy with curative intent"}, {"type": "INCLUSION", "field": "procedure", "operator": "IN", "value": "* Histologically or cytologically proven diagnosis of metastatic breast adenocarcinoma that is not amenable to surgery", "unit": null, "evidence_text": "Histologically or cytologically proven diagnosis of metastatic breast adenocarcinoma that is not amenable to surgery, radiation, or combined modality therapy with curative intent"}], "annotator_id": "annotator_c", "guideline_version": "m5-v1", "adjudicated": true, "adjudication_source": "parsing_relabel_round1"}
{"nct_id": "NCT00329732", "eligibility_text": "Inclusion Criteria:. * Subjects, male or female, between the ages of 18 and 80 years old (inclusive) with a previous diagnosis fulfilling IHS criteria for episodic migraine. * Presenting to clinic in migraine status, meaning the migraine has continued for greater than or equal to 3 days but less than 3 months.. * Pain must be reported as at least moderate pain level at time of injections. Exclusion Criteria:. A subject is ineligible to participate in this study if he/she satisfies any of the following criteria:. * Subjects who have received greater occipital nerve blocks in the past. * Subjects who in their own or the investigator's opinion are unable to describe their symptoms. * Subjects who are pregnant or lactating", "labeled_rules": [{"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "a previous diagnosis fulfilling ihs criteria for", "unit": null, "evidence_text": "Subjects, male or female, between the ages of 18 and 80 years old (inclusive) with a previous diagnosis fulfilling IHS criteria for episodic migraine"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "a previous diagnosis fulfilling ihs for episodic", "unit": null, "evidence_text": "Subjects, male or female, between the ages of 18 and 80 years old (inclusive) with a previous diagnosis fulfilling IHS criteria for episodic migraine"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "with a previous", "unit": null, "evidence_text": "Subjects, male or female, between the ages of 18 and 80 years old (inclusive) with a previous diagnosis fulfilling IHS criteria for episodic migraine"}, {"type": "INCLUSION", "field": "history", "operator": "IN", "value": "* Subjects, male or female, between the ages of 18 and 80 years old (inclusive) with a previous diagnosis fulfilling IH", "unit": null, "evidence_text": "Subjects, male or female, between the ages of 18 and 80 years old (inclusive) with a previous diagnosis fulfilling IHS criteria for episodic migraine"}, {"type": "INCLUSION", "field": "other", "operator": "IN", "value": "* Subjects, male or female, between the ages of 18 and 80 years old (inclusive) with a previous diagnosis fulfilling IH", "unit": null, "evidence_text": "Subjects, male or female, between the ages of 18 and 80 years old (inclusive) with a previous diagnosis fulfilling IHS criteria for episodic migraine"}, {"type": "INCLUSION", "field": "procedure", "operator": "IN", "value": "* Subjects, male or female, between the ages of 18 and 80 years old (inclusive) with a previous diagnosis fulfilling IH", "unit": null, "evidence_text": "Subjects, male or female, between the ages of 18 and 80 years old (inclusive) with a previous diagnosis fulfilling IHS criteria for episodic migraine"}, {"type": "INCLUSION", "field": "sex", "operator": "=", "value": "all", "unit": null, "evidence_text": "Subjects, male or female, between the ages of 18 and 80 years old (inclusive) with a previous diagnosis fulfilling IHS criteria for episodic migraine"}, {"type": "INCLUSION", "field": "lab", "operator": ">=", "value": 3, "unit": "days", "evidence_text": "Presenting to clinic in migraine status, meaning the migraine has continued for greater than or equal to 3 days but less than 3 months"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "s opinion are unable to describe their", "unit": null, "evidence_text": "Subjects who in their own or the investigator's opinion are unable to describe their symptoms"}], "annotator_id": "annotator_c", "guideline_version": "m5-v1", "adjudicated": true, "adjudication_source": "parsing_relabel_round1"}
{"nct_id": "NCT00339703", "eligibility_text": "Inclusion Criteria:. * Inclusion criteria for the asthmatic group will consist of the following: (a) male or non-pregnant female, (b) 18-65 years of age, (c) asthma defined as moderate or severe persistent by NHLBI guidelines, and characterized by at least daily symptoms, night symptoms at least once weekly, and a FEV1 between 60-80% of predicted. Newly diagnosed asthmatics, poorly controlled asthmatics, and hospitalized patients with asthma flares may also be considered in separate arms of this study.. * Inclusion criteria for the control group will consist of the following: (a) male or non-pregnant female, (b) 18-65 years of age.. Exclusion Criteria:. * Exlusion criteria for the asthmatic group will consist of the following: (a) current use of oral steroids or statins, (b) any serious concurrent disease process such as, but not limited to diabetes, coronary artery disease, or vasculitis, that would have effects on levels of systemic inflammation.. * Exclusion criteria for the control group will consist of the following: (a) current use of oral steroids or statins, (b) prior diagnosis of asthma, or clinical symptoms consistent with asthma or reactive airway disease, (c) any serious concurrent disease process such as, but not limited to diabetes, coronary artery disease, or vasculitis, that would have effects on levels of systemic inflammation.", "labeled_rules": [{"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "and characterized by at least daily", "unit": null, "evidence_text": "Inclusion criteria for the asthmatic group will consist of the following: (a) male or non-pregnant female, (b) 18-65 years of age, (c) asthma defined as moderate or severe persistent by NHLBI guidelines, and characterized by at least daily symptoms, night symptoms at least once weekly, and a FEV1 between 60-80% of predicted. Newly diagnosed asthmatics, poorly controlled asthmatics, and hospitalized patients with asthma flares may also be considered in separate arms of this study"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "asthma flares may also be considered in", "unit": null, "evidence_text": "Inclusion criteria for the asthmatic group will consist of the following: (a) male or non-pregnant female, (b) 18-65 years of age, (c) asthma defined as moderate or severe persistent by NHLBI guidelines, and characterized by at least daily symptoms, night symptoms at least once weekly, and a FEV1 between 60-80% of predicted. Newly diagnosed asthmatics, poorly controlled asthmatics, and hospitalized patients with asthma flares may also be considered in separate arms of this study"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "night", "unit": null, "evidence_text": "Inclusion criteria for the asthmatic group will consist of the following: (a) male or non-pregnant female, (b) 18-65 years of age, (c) asthma defined as moderate or severe persistent by NHLBI guidelines, and characterized by at least daily symptoms, night symptoms at least once weekly, and a FEV1 between 60-80% of predicted. Newly diagnosed asthmatics, poorly controlled asthmatics, and hospitalized patients with asthma flares may also be considered in separate arms of this study"}, {"type": "EXCLUSION", "field": "age", "operator": "<=", "value": 65, "unit": "years", "evidence_text": "Inclusion criteria for the control group will consist of the following: (a) male or non-pregnant female, (b) 18-65 years of age.. Exclusion Criteria:"}, {"type": "EXCLUSION", "field": "age", "operator": ">=", "value": 18, "unit": "years", "evidence_text": "Inclusion criteria for the control group will consist of the following: (a) male or non-pregnant female, (b) 18-65 years of age.. Exclusion Criteria:"}, {"type": "EXCLUSION", "field": "sex", "operator": "=", "value": "all", "unit": null, "evidence_text": "Inclusion criteria for the control group will consist of the following: (a) male or non-pregnant female, (b) 18-65 years of age.. Exclusion Criteria:"}, {"type": "INCLUSION", "field": "medication", "operator": "IN", "value": "Exlusion criteria for the asthmatic group will consist of the following: (a) current use of oral steroids or statins, (b) any serious concurrent disease process such as, but not limited to diabetes, coronary artery disease, or vasculitis, that would have effects on levels of systemic inflammation", "unit": null, "evidence_text": "Exlusion criteria for the asthmatic group will consist of the following: (a) current use of oral steroids or statins, (b) any serious concurrent disease process such as, but not limited to diabetes, coronary artery disease, or vasculitis, that would have effects on levels of systemic inflammation"}, {"type": "INCLUSION", "field": "procedure", "operator": "IN", "value": "Exlusion criteria for the asthmatic group will consist of the following: (a) current use of oral steroids or statins, (b) any serious concurrent disease process such as, but not limited to diabetes, coronary artery disease, or vasculitis, that would have effects on levels of systemic inflammation", "unit": null, "evidence_text": "Exlusion criteria for the asthmatic group will consist of the following: (a) current use of oral steroids or statins, (b) any serious concurrent disease process such as, but not limited to diabetes, coronary artery disease, or vasculitis, that would have effects on levels of systemic inflammation"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "asthma or reactive airway disease", "unit": null, "evidence_text": "Exclusion criteria for the control group will consist of the following: (a) current use of oral steroids or statins, (b) prior diagnosis of asthma, or clinical symptoms consistent with asthma or reactive airway disease, (c) any serious concurrent disease process such as, but not limited to diabetes, coronary artery disease, or vasculitis, that would have effects on levels of systemic inflammation"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "or clinical", "unit": null, "evidence_text": "Exclusion criteria for the control group will consist of the following: (a) current use of oral steroids or statins, (b) prior diagnosis of asthma, or clinical symptoms consistent with asthma or reactive airway disease, (c) any serious concurrent disease process such as, but not limited to diabetes, coronary artery disease, or vasculitis, that would have effects on levels of systemic inflammation"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "prior", "unit": null, "evidence_text": "Exclusion criteria for the control group will consist of the following: (a) current use of oral steroids or statins, (b) prior diagnosis of asthma, or clinical symptoms consistent with asthma or reactive airway disease, (c) any serious concurrent disease process such as, but not limited to diabetes, coronary artery disease, or vasculitis, that would have effects on levels of systemic inflammation"}], "annotator_id": "annotator_c", "guideline_version": "m5-v1", "adjudicated": true, "adjudication_source": "parsing_relabel_round1"}
{"nct_id": "NCT00345748", "eligibility_text": "Inclusion Criteria:. * patients with active Rheumatoid Arthritis while on methotrexate having 12 tender and 10 swollen joints at randomization. Exclusion Criteria:. * no current infection or other evolutive or uncontrolled disease", "labeled_rules": [{"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "study-specific condition", "unit": null, "evidence_text": "Inclusion Criteria:"}]}
{"nct_id": "NCT00349427", "eligibility_text": "Inclusion:. * Patients with type 2 Diabetes mellitus on a minimum dose of 30 units/day insulin monotherapy continuously for at least 8 weeks. * If Patients are taking another oral antidiabetic agent may stop their oral agent and adjust their insulin dose properly over 8 weeks prior to screening if they are asked by doctor who considers him/her suitable for study in all other respects, and the HbA1c level\\>7.5%.. Exclusion:. * Fasting plasma glucose \\>13 mmol/L at screening. * Ongoing edema or history of peripheral edema requiring pharmacological treatment within 12 months. * Drug abuse. * Women pregnant or lactating. * Use any rosiglitazone like drug in 3 months. * Use more than one oral antidiabetic agent in 2 months. * Uncontrolled hypertension. * Chronic heart failure. * Anemia", "labeled_rules": [{"type": "INCLUSION", "field": "history", "operator": "IN", "value": "Inclusion:. * Patients with type 2 Diabetes mellitus on a minimum dose of 30 units/day insulin monotherapy continuously for at least 8 weeks", "unit": null, "evidence_text": "Patients with type 2 Diabetes mellitus on a minimum dose of 30 units/day insulin monotherapy continuously for at least 8 weeks"}, {"type": "INCLUSION", "field": "lab", "operator": ">=", "value": 7.5, "unit": "%", "evidence_text": "If Patients are taking another oral antidiabetic agent may stop their oral agent and adjust their insulin dose properly over 8 weeks prior to screening if they are asked by doctor who considers him/her suitable for study in all other respects, and the HbA1c level\\>7.5%.. Exclusion:"}, {"type": "INCLUSION", "field": "lab", "operator": ">=", "value": 13, "unit": "mmol/l", "evidence_text": "Fasting plasma glucose \\>13 mmol/L at screening"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "peripheral edema requiring pharmacological treatment within 12", "unit": null, "evidence_text": "Ongoing edema or history of peripheral edema requiring pharmacological treatment within 12 months"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "peripheral edema requiring pharmacological treatment within 12 months", "unit": null, "evidence_text": "Ongoing edema or history of peripheral edema requiring pharmacological treatment within 12 months"}, {"type": "EXCLUSION", "field": "history", "operator": "WITHIN_LAST", "value": 12, "unit": "months", "evidence_text": "Ongoing edema or history of peripheral edema requiring pharmacological treatment within 12 months"}, {"type": "INCLUSION", "field": "medication", "operator": "WITHIN_LAST", "value": 12, "unit": "months", "evidence_text": "Ongoing edema or history of peripheral edema requiring pharmacological treatment within 12 months"}, {"type": "INCLUSION", "field": "procedure", "operator": "WITHIN_LAST", "value": 12, "unit": "months", "evidence_text": "Ongoing edema or history of peripheral edema requiring pharmacological treatment within 12 months"}, {"type": "EXCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "Women pregnant or lactating"}, {"type": "INCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "Women pregnant or lactating"}], "annotator_id": "annotator_c", "guideline_version": "m5-v1", "adjudicated": true, "adjudication_source": "parsing_relabel_round1"}
{"nct_id": "NCT00351988", "eligibility_text": "Inclusion Criteria:. 1. Caregiver inclusion criteria includes: provides care and/or assistance to a patient receiving new or current treatment - Single or combined chemotherapy, radiotherapy, and/or targeted therapy for advanced solid tumors (lung, breast, cervical, and other).. 2. 18 years of age or older;. 3. self-identified as African-American/Black, Latino, or white, non-Latino;. 4. able to speak English or Spanish (as applicable);. 5. able to read and complete forms or be willing to have the forms read to them by a trained interviewer;. 6. accessible through personal or telephone contact for the duration of the study.. 7. Patient inclusion criteria: Receiving new or current treatment - Single or combined - chemotherapy, radiotherapy, and/or targeted therapy for advanced solid tumors (lung, breast, cervical, and others). Criteria 2-6 are the same as listed under Caregiver Criteria.. Exclusion Criteria: None", "labeled_rules": [{"type": "EXCLUSION", "field": "age", "operator": ">=", "value": 18, "unit": "years", "evidence_text": "Inclusion Criteria:. 1. Caregiver inclusion criteria includes: provides care and/or assistance to a patient receiving new or current treatment - Single or combined chemotherapy, radiotherapy, and/or targeted therapy for advanced solid tumors (lung, breast, cervical, and other).. 2. 18 years of age or older;. 3. self-identified as African-American/Black, Latino, or white, non-Latino;. 4. able to speak English or Spanish (as applicable);. 5. able to read and complete forms or be willing to have the forms read to them by a trained interviewer;. 6. accessible through personal or telephone contact for the duration of the study.. 7. Patient inclusion criteria: Receiving new or current treatment - Single or combined - chemotherapy, radiotherapy, and/or targeted therapy for advanced solid tumors (lung, breast, cervical, and others). Criteria 2-6 are the same as listed under Caregiver Criteria.. Exclusion Criteria: None"}, {"type": "EXCLUSION", "field": "condition", "operator": "IN", "value": "study-specific condition", "unit": null, "evidence_text": "Inclusion Criteria:. 1. Caregiver inclusion criteria includes: provides care and/or assistance to a patient receiving new or current treatment - Single or combined chemotherapy, radiotherapy, and/or targeted therapy for advanced solid tumors (lung, breast, cervical, and other).. 2. 18 years of age or older;. 3. self-identified as African-American/Black, Latino, or white, non-Latino;. 4. able to speak English or Spanish (as applicable);. 5. able to read and complete forms or be willing to have the forms read to them by a trained interviewer;. 6. accessible through personal or telephone contact for the duration of the study.. 7. Patient inclusion criteria: Receiving new or current treatment - Single or combined - chemotherapy, radiotherapy, and/or targeted therapy for advanced solid tumors (lung, breast, cervical, and others). Criteria 2-6 are the same as listed under Caregiver Criteria.. Exclusion Criteria: None"}, {"type": "EXCLUSION", "field": "medication", "operator": "IN", "value": "1. Caregiver inclusion criteria includes: provides care and/or assistance to a patient receiving new or current treatment - Single or combined chemotherapy, radiotherapy, and/or targeted therapy for advanced solid tumors (lung, breast, cervical, and other).. 2. 18 years of age or older;. 3. self-identified as African-American/Black, Latino, or white, non-Latino;. 4. able to speak English or Spanish (as applicable);. 5. able to read and complete forms or be willing to have the forms read to them by a trained interviewer;. 6. accessible through personal or telephone contact for the duration of the study.. 7. Patient inclusion criteria: Receiving new or current treatment - Single or combined - chemotherapy, radiotherapy, and/or targeted therapy for advanced solid tumors (lung, breast, cervical, and others). Criteria 2-6 are the same as listed under Caregiver Criteria.. Exclusion Criteria: None", "unit": null, "evidence_text": "Inclusion Criteria:. 1. Caregiver inclusion criteria includes: provides care and/or assistance to a patient receiving new or current treatment - Single or combined chemotherapy, radiotherapy, and/or targeted therapy for advanced solid tumors (lung, breast, cervical, and other).. 2. 18 years of age or older;. 3. self-identified as African-American/Black, Latino, or white, non-Latino;. 4. able to speak English or Spanish (as applicable);. 5. able to read and complete forms or be willing to have the forms read to them by a trained interviewer;. 6. accessible through personal or telephone contact for the duration of the study.. 7. Patient inclusion criteria: Receiving new or current treatment - Single or combined - chemotherapy, radiotherapy, and/or targeted therapy for advanced solid tumors (lung, breast, cervical, and others). Criteria 2-6 are the same as listed under Caregiver Criteria.. Exclusion Criteria: None"}, {"type": "EXCLUSION", "field": "other", "operator": "IN", "value": "5. able to read and complete forms or be willing to have the forms read to them by a trained interviewer", "unit": null, "evidence_text": "Inclusion Criteria:. 1. Caregiver inclusion criteria includes: provides care and/or assistance to a patient receiving new or current treatment - Single or combined chemotherapy, radiotherapy, and/or targeted therapy for advanced solid tumors (lung, breast, cervical, and other).. 2. 18 years of age or older;. 3. self-identified as African-American/Black, Latino, or white, non-Latino;. 4. able to speak English or Spanish (as applicable);. 5. able to read and complete forms or be willing to have the forms read to them by a trained interviewer;. 6. accessible through personal or telephone contact for the duration of the study.. 7. Patient inclusion criteria: Receiving new or current treatment - Single or combined - chemotherapy, radiotherapy, and/or targeted therapy for advanced solid tumors (lung, breast, cervical, and others). Criteria 2-6 are the same as listed under Caregiver Criteria.. Exclusion Criteria: None"}, {"type": "EXCLUSION", "field": "other", "operator": "IN", "value": "1. Caregiver inclusion criteria includes: provides care and/or assistance to a patient receiving new or current treatment - Single or combined chemotherapy, radiotherapy, and/or targeted therapy for advanced solid tumors (lung, breast, cervical, and other).. 2. 18 years of age or older;. 3. self-identified as African-American/Black, Latino, or white, non-Latino;. 4. able to speak English or Spanish (as applicable);. 5. able to read and complete forms or be willing to have the forms read to them by a trained interviewer;. 6. accessible through personal or telephone contact for the duration of the study.. 7. Patient inclusion criteria: Receiving new or current treatment - Single or combined - chemotherapy, radiotherapy, and/or targeted therapy for advanced solid tumors (lung, breast, cervical, and others). Criteria 2-6 are the same as listed under Caregiver Criteria.. Exclusion Criteria: None", "unit": null, "evidence_text": "Inclusion Criteria:. 1. Caregiver inclusion criteria includes: provides care and/or assistance to a patient receiving new or current treatment - Single or combined chemotherapy, radiotherapy, and/or targeted therapy for advanced solid tumors (lung, breast, cervical, and other).. 2. 18 years of age or older;. 3. self-identified as African-American/Black, Latino, or white, non-Latino;. 4. able to speak English or Spanish (as applicable);. 5. able to read and complete forms or be willing to have the forms read to them by a trained interviewer;. 6. accessible through personal or telephone contact for the duration of the study.. 7. Patient inclusion criteria: Receiving new or current treatment - Single or combined - chemotherapy, radiotherapy, and/or targeted therapy for advanced solid tumors (lung, breast, cervical, and others). Criteria 2-6 are the same as listed under Caregiver Criteria.. Exclusion Criteria: None"}, {"type": "EXCLUSION", "field": "procedure", "operator": "IN", "value": "1. Caregiver inclusion criteria includes: provides care and/or assistance to a patient receiving new or current treatment - Single or combined chemotherapy, radiotherapy, and/or targeted therapy for advanced solid tumors (lung, breast, cervical, and other).. 2. 18 years of age or older;. 3. self-identified as African-American/Black, Latino, or white, non-Latino;. 4. able to speak English or Spanish (as applicable);. 5. able to read and complete forms or be willing to have the forms read to them by a trained interviewer;. 6. accessible through personal or telephone contact for the duration of the study.. 7. Patient inclusion criteria: Receiving new or current treatment - Single or combined - chemotherapy, radiotherapy, and/or targeted therapy for advanced solid tumors (lung, breast, cervical, and others). Criteria 2-6 are the same as listed under Caregiver Criteria.. Exclusion Criteria: None", "unit": null, "evidence_text": "Inclusion Criteria:. 1. Caregiver inclusion criteria includes: provides care and/or assistance to a patient receiving new or current treatment - Single or combined chemotherapy, radiotherapy, and/or targeted therapy for advanced solid tumors (lung, breast, cervical, and other).. 2. 18 years of age or older;. 3. self-identified as African-American/Black, Latino, or white, non-Latino;. 4. able to speak English or Spanish (as applicable);. 5. able to read and complete forms or be willing to have the forms read to them by a trained interviewer;. 6. accessible through personal or telephone contact for the duration of the study.. 7. Patient inclusion criteria: Receiving new or current treatment - Single or combined - chemotherapy, radiotherapy, and/or targeted therapy for advanced solid tumors (lung, breast, cervical, and others). Criteria 2-6 are the same as listed under Caregiver Criteria.. Exclusion Criteria: None"}], "annotator_id": "annotator_c", "guideline_version": "m5-v1", "adjudicated": true, "adjudication_source": "parsing_relabel_round1"}
{"nct_id": "NCT00356629", "eligibility_text": "Inclusion criteria. * Subjects suffering from CF, COPD, asthma and tobacco exposure (groups 1 to 4) and controls (group 5). * aged more or equal to 18. * stable disease. * able to perform PFTs. * informed consent signed. * affiliated to french social insurance. Exclusion Criteria:. * acute exacerbation of the disease during the last 2 weeks. * IV or oral steroids or antibiotics during the last 2 weeks. * hospitalization during the last 2 weeks. * colonization by S aureus methicillin resistant and/or Burkholderia cepacia", "labeled_rules": [{"type": "INCLUSION", "field": "other", "operator": "IN", "value": "* Subjects suffering from CF, COPD, asthma and tobacco exposure (groups 1 to 4) and controls (group 5). * aged more or e", "unit": null, "evidence_text": "Subjects suffering from CF, COPD, asthma and tobacco exposure (groups 1 to 4) and controls (group 5)"}, {"type": "EXCLUSION", "field": "history", "operator": "WITHIN_LAST", "value": 2, "unit": "weeks", "evidence_text": "hospitalization during the last 2 weeks"}, {"type": "INCLUSION", "field": "medication", "operator": "WITHIN_LAST", "value": 2, "unit": "weeks", "evidence_text": "hospitalization during the last 2 weeks"}, {"type": "INCLUSION", "field": "procedure", "operator": "WITHIN_LAST", "value": 2, "unit": "weeks", "evidence_text": "hospitalization during the last 2 weeks"}], "annotator_id": "annotator_c", "guideline_version": "m5-v1", "adjudicated": true, "adjudication_source": "parsing_relabel_round1"}
{"nct_id": "NCT00369499", "eligibility_text": "Inclusion Criteria:. * Migraine history of at least 1 year.. * Migraine patients experiencing at least 2 migraine attacks per month.. * Migraine patients experiencing at least 1 migraine attack with aura per month.. * Failure of or intolerance to at least 2 classes of prophylactic migraine medication evaluated in adequate, approved medication trials. At least one of the classes shall come from beta-blockers, anticonvulsants, calcium channel blockers and tricyclic antidepressants.. * Aged 18 - 50 years and of legal age in the host country.. * The patient or legal guardian has signed a study specific informed consent form agreeing to data collection and follow-up requirements.. * The patient agrees to abstain from starting prophylactic migraine medication or agrees to maintain existing prophylactic migraine medication without changing dose or drug from entering the baseline period throughout the duration of the study until final assessments.. * Documented right to left shunt that is suitable for device closure.. Exclusion Criteria:. * Taking migraine preventative medication for conditions other than migraine.. * History of 15 or more headache days per month.. * 8 or more non-migraine headache days per month.. * Overuse of acute headache medication (use on 10 or more days per month).. * Patient has severe central nervous system disease such as seizure disorder, inflammatory disease of the central nervous system, or a previous stroke.. * Previous surgical or device closure of a PFO or ASD.. * Artificial heart valve.. * Pacemaker or ICD implanted within past 3 months.. * Anatomic variant that could affect successful deployment such as coronary sinus, pulmonary veins, Chiari network.. * Uncontrolled bacteremias or dental or surgical procedure within past 30 days or planned within study period.. * Allergy to contrast media, and/or to any component of the device to be used.. * Contraindicated for any medication used during or after the procedure.. * History of atrial fibrillation or atrial flutter (chronic or paroxysmal).. * Patient is enrolled or intends to participate in another clinical study (of an investigational drug or device, new indication for an approved drug or device, or requirement of additional testing beyond standard clinical practice) during the study or within four weeks prior to his/her enrollment in the study.. * Patient is undergoing dialysis for renal failure.. * Patient has NYHA class 3 or 4 cardiac failure.. * Patient is pregnant, or intends to become pregnant during the trial period.. * Patient requires anticoagulation therapy for a concomitant condition.", "labeled_rules": [{"type": "INCLUSION", "field": "age", "operator": ">=", "value": 1, "unit": "years", "evidence_text": "Migraine history of at least 1 year"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "at least 1 year", "unit": null, "evidence_text": "Migraine history of at least 1 year"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "migraine", "unit": null, "evidence_text": "Migraine history of at least 1 year"}, {"type": "INCLUSION", "field": "history", "operator": "IN", "value": "* Migraine history of at least 1 year.. * Migraine patients experiencing at least 2 migraine attacks per month.. * Migr", "unit": null, "evidence_text": "Migraine history of at least 1 year"}, {"type": "INCLUSION", "field": "other", "operator": "IN", "value": "* Migraine history of at least 1 year.. * Migraine patients experiencing at least 2 migraine attacks per month.. * Migr", "unit": null, "evidence_text": "Migraine history of at least 1 year"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "aura per month", "unit": null, "evidence_text": "Migraine patients experiencing at least 1 migraine attack with aura per month"}, {"type": "INCLUSION", "field": "age", "operator": "<=", "value": 50, "unit": "years", "evidence_text": "Aged 18 - 50 years and of legal age in the host country"}, {"type": "INCLUSION", "field": "age", "operator": ">=", "value": 18, "unit": "years", "evidence_text": "Aged 18 - 50 years and of legal age in the host country"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "15 or more headache days per month", "unit": null, "evidence_text": "History of 15 or more headache days per month"}, {"type": "INCLUSION", "field": "medication", "operator": "WITHIN_LAST", "value": 3, "unit": "months", "evidence_text": "Pacemaker or ICD implanted within past 3 months"}, {"type": "INCLUSION", "field": "procedure", "operator": "WITHIN_LAST", "value": 3, "unit": "months", "evidence_text": "Pacemaker or ICD implanted within past 3 months"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "atrial fibrillation or atrial flutter (chronic or paroxysmal)", "unit": null, "evidence_text": "History of atrial fibrillation or atrial flutter (chronic or paroxysmal)"}], "annotator_id": "annotator_c", "guideline_version": "m5-v1", "adjudicated": true, "adjudication_source": "parsing_relabel_round1"}
{"nct_id": "NCT00383968", "eligibility_text": "Inclusion criteria:. * Known hypertensives aged 40 and above with microalbuminuria and/or elevated serum creatinine on first evaluation.. * Hypertension: Systolic blood pressure 140, and /or diastolic blood pressure  90 with or without antihypertensive drugs.. * Microalbuminuria:. * Albumin concentration of 20-200mg/L, with albumin-to-creatinine ratio of 3-30mg/mmol or 30-300mg/g. * Female: 3.0-30.0mg/mmol or 30-300mg/g. * Male: 2.0-20.0mg/mmol or 20. * Elevated Serum creatinine:. * Female: \\>1.2mg/dl. * Male: \\>1.4mg/dl. Exclusion Criteria:. * Known diabetics will be excluded.. * unable to give informed consent", "labeled_rules": [{"type": "INCLUSION", "field": "medication", "operator": "IN", "value": "* Known hypertensives aged 40 and above with microalbuminuria and/or elevated serum creatinine on first evaluation.. *", "unit": null, "evidence_text": "Known hypertensives aged 40 and above with microalbuminuria and/or elevated serum creatinine on first evaluation"}, {"type": "INCLUSION", "field": "other", "operator": "IN", "value": "* Known hypertensives aged 40 and above with microalbuminuria and/or elevated serum creatinine on first evaluation.. *", "unit": null, "evidence_text": "Known hypertensives aged 40 and above with microalbuminuria and/or elevated serum creatinine on first evaluation"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "or without antihypertensive drugs", "unit": null, "evidence_text": "Hypertension: Systolic blood pressure 140, and /or diastolic blood pressure  90 with or without antihypertensive drugs"}, {"type": "INCLUSION", "field": "lab", "operator": ">=", "value": 1.2, "unit": "mg/dl", "evidence_text": "Female: \\>1.2mg/dl"}, {"type": "INCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "Female: \\>1.2mg/dl"}, {"type": "INCLUSION", "field": "sex", "operator": "=", "value": "male", "unit": null, "evidence_text": "Female: \\>1.2mg/dl"}, {"type": "INCLUSION", "field": "sex", "operator": "=", "value": "all", "unit": null, "evidence_text": "Female: \\>1.2mg/dl"}, {"type": "EXCLUSION", "field": "lab", "operator": ">=", "value": 1.4, "unit": "mg/dl", "evidence_text": "Male: \\>1.4mg/dl. Exclusion Criteria:"}], "annotator_id": "annotator_c", "guideline_version": "m5-v1", "adjudicated": true, "adjudication_source": "parsing_relabel_round1"}
{"nct_id": "NCT00384722", "eligibility_text": "Inclusion Criteria:. * Must be indicated for a Guidant CRT-P or CRT-D device. * Creatinine \\< 2.5 mg/dL obtained no more than two weeks prior to enrollment. * Age 18 or above, or of legal age to give informed consent specific to state and national law. * Willing and capable of providing informed consent, undergoing a device implant, participating in all testing associated with this clinical investigation at an approved clinical investigation center and at the intervals defined by this protocol. * Geographically stable residents who are available for follow-up. Exclusion Criteria:. * Have a known hypersensitivity to a 0.5 mg nominal dose of dexamethasone acetate. * Have or had previous cardiac resynchronization therapy, a coronary venous pace/sense lead or attempted LV lead placement. * Have pre-existing cardioversion/defibrillation leads or right ventricular pacing leads other than those specified in the investigational plan (unless the investigator intends to replace them with permitted cardioversion/defibrillation leads). * Currently requiring dialysis. * Have had a myocardial infarct, unstable angina, percutaneous coronary intervention, or coronary artery bypass graft during the preceding 30 days prior to enrollment. * Have hypertrophic obstructive cardiomyopathy or infiltrative cardiomyopathy (e.g., amyloidosis, sarcoidosis). * Documented life expectancy of less than six months or expected to undergo heart transplant within the next six months. * Enrolled or participating in any concurrent study, including drug investigations, without Guidant written approval, that may confound the results of this study. * Have a pre-existing unipolar pacemaker that will not be explanted/abandoned. * Have a mechanical tricuspid heart valve. * Women who are pregnant or plan to become pregnant. Note: Women of childbearing potential must have a negative pregnancy test within seven days of enrollment.", "labeled_rules": [{"type": "INCLUSION", "field": "history", "operator": "IN", "value": "* Must be indicated for a Guidant CRT-P or CRT-D device. * Creatinine \\< 2.5 mg/dL obtained no more than two weeks prio", "unit": null, "evidence_text": "Must be indicated for a Guidant CRT-P or CRT-D device"}, {"type": "INCLUSION", "field": "medication", "operator": "IN", "value": "* Must be indicated for a Guidant CRT-P or CRT-D device. * Creatinine \\< 2.5 mg/dL obtained no more than two weeks prio", "unit": null, "evidence_text": "Must be indicated for a Guidant CRT-P or CRT-D device"}, {"type": "INCLUSION", "field": "other", "operator": "IN", "value": "* Must be indicated for a Guidant CRT-P or CRT-D device. * Creatinine \\< 2.5 mg/dL obtained no more than two weeks prio", "unit": null, "evidence_text": "Must be indicated for a Guidant CRT-P or CRT-D device"}, {"type": "INCLUSION", "field": "procedure", "operator": "IN", "value": "* Must be indicated for a Guidant CRT-P or CRT-D device. * Creatinine \\< 2.5 mg/dL obtained no more than two weeks prio", "unit": null, "evidence_text": "Must be indicated for a Guidant CRT-P or CRT-D device"}, {"type": "INCLUSION", "field": "lab", "operator": "<=", "value": 2.5, "unit": "mg/dl", "evidence_text": "Creatinine \\< 2.5 mg/dL obtained no more than two weeks prior to enrollment"}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "pregnancy", "unit": null, "evidence_text": "Women who are pregnant or plan to become pregnant. Note: Women of childbearing potential must have a negative pregnancy test within seven days of enrollment"}, {"type": "INCLUSION", "field": "lab", "operator": "IN", "value": "negative pregnancy test", "unit": null, "evidence_text": "Women who are pregnant or plan to become pregnant. Note: Women of childbearing potential must have a negative pregnancy test within seven days of enrollment"}, {"type": "EXCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "Women who are pregnant or plan to become pregnant. Note: Women of childbearing potential must have a negative pregnancy test within seven days of enrollment"}, {"type": "INCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "Women who are pregnant or plan to become pregnant. Note: Women of childbearing potential must have a negative pregnancy test within seven days of enrollment"}], "annotator_id": "annotator_c", "guideline_version": "m5-v1", "adjudicated": true, "adjudication_source": "parsing_relabel_round1"}
{"nct_id": "NCT00398645", "eligibility_text": "Inclusion criteria:. * Type of Subject: Outpatient. * Age: 12 years of age or older at Visit 1 (or 18 years of age or older if local regulations or the regulatory status of study medication permit enrollment of adults only).. * Gender: Male or eligible female - Females are eligible to participate only if they are currently non-pregnant and non-lactating. To be eligible for entry into the study, females of childbearing potential must commit to consistent and correct use of an acceptable method of birth control, as defined by the following: Male partner who is sterile prior to the female subject's entry into the study and is the sole sexual partner for that female subject, Implants of levonorgestrel, Injectable progestogen, Oral contraceptive (either combined estrogen/progestin or progestin only), Any intrauterine device (IUD) with a documented failure rate of less than 1% per year, Double-barrier method - spermicide plus a mechanical barrier (e.g., spermicide plus a male condom or a spermicide and female diaphragm), The contraceptive transdermal patch, Ortho Evra (if the subject is less than 198 pounds), Female subjects should not be enrolled if they plan to become pregnant during the time of study participation. A urine pregnancy test is required for all subjects at all visits, Female subjects should not be enrolled if they plan to become pregnant during the time of study participation. A urine pregnancy test is required for all subjects at all visits, Female subjects should not be enrolled if they plan to become pregnant during the time of study participation. A urine pregnancy test is required for all subjects at all visits, Females of childbearing potential who are not sexually active must commit to complete abstinence from intercourse throughout the clinical trial, and for a period after the trial to account for elimination of the drug (minimum of six days),. * Asthma Diagnosis: Asthma as defined by the National Institutes of Health \\[National Institutes of Health, 2002; GINA, 2005\\].. * Severity of Disease: A best AM FEV1 of 50% to 80% of the predicted value during Visit 1 based on the Standardization of Lung Function Tests \\[European Respiratory Society, 1993\\] standards for 18 years and older or Polgar \\[Polgar, 1971\\] standards for 12 to 17 years and race adjusted for African-Americans \\[American Thoracic Society, 1991\\].. * Reversibility of Disease: Demonstrated 12% and 200mL reversibility of FEV1 within 30 minutes following 200 to 400mcg of albuterol/salbutamol inhalation aerosol (or one nebulized albuterol/salbutamol treatment) at Visit 1. If a subject fails to demonstrate an increase in FEV1 of 12% and 200mL, the subject is not eligible for the study and will not be allowed to re-screen.. * Concurrent Anti-Asthma Therapy: Subjects must be using an inhaled corticosteroid for at least 3 months prior to Visit 1 and be maintained on a stable dose for four weeks prior to Visit 1 at one of the following doses: Anti-Asthma Therapy Maximum Daily Dose (mcg/day) Fluticasone propionate MDI CFC/HFA 220mcg1/250mcg2 Fluticasone propionate DPI 200mcg Beclomethasone dipropionate 420mcg1/500mcg2 Beclomethasone dipropionate HFA 160mcg1/200mcg2 Budesonide DPI 400mcg Flunisolide 1000mcg Triamcinolone acetonide 1000mcg Mometasone furoate 200mcg Ciclesonide 160mcg1/200mcg2. 1. Ex-actuator dose: dose delivered to the lungs. 2. Ex-valve dose: dose expressed from the valve. * Short-Acting Beta2-Agonist: All subjects must be able to replace short-acting beta2-agonists with albuterol/salbutamol inhalation aerosol at Visit 1 for use as-needed for the duration of the study. Subjects must be able to withhold all inhaled short-acting beta-sympathomimetic bronchodilators for at least 6 hours prior to study visits.Note: Nebulized albuterol/salbutamol will not be allowed during the study with the exception of its use during reversibility testing at Visit 1. The use of albuterol/salbutamol through the DISKUS/ACCUHALER device will not be allowed during the study.. * Informed Consent: All subjects must be able and willing to give written informed consent to take part in the study.. * Compliance: Subjects must be able to comply with all the study requirements.. Exclusion criteria:. * History of Life-Threatening Asthma: History of life-threatening asthma, defined as an asthma episode that required intubation and/or was associated with hypercapnia, respiratory arrest or hypoxic seizures.. * Anti-Asthma Medications: Asthma medications listed below must not have been used prior to Visit 1 for the required interval listed below, and not taken during the study: Within 24 hours of Visit 1: Oral short-acting beta2-agonists: Within 2 weeks of Visit 1:Combination therapy containing inhaled beta2-agonists and ICS for asthma (e.g., fluticasone propionate/salmeterol combination, budesonide/formoterol combination);Slow-release bronchodilators (e.g., aminophylline, theophylline);Anticholinergics; Long-acting beta2-agonists (e.g., salmeterol); Ketotifen; Nedocromil sodium; Sodium cromoglycate; Oral long-acting beta2-agonists. Within 4 weeks of Visit 1: Anti-leukotrienes including suppressors of leukotriene production and antagonists. Within 12 weeks of Visit 1: Systemic, oral, parenteral, or depot corticosteroids; Anti-IgE (e.g., omalizumab).. * Other Medications: The medications listed below must not have been used prior to Visit 1 for the required interval indicated below, and not taken during the study: Within 4 weeks of Visit 1: Known potent inhibitors of CYP3A4 (e.g., ritonavir, ketoconazole). * Respiratory Infection: History of a respiratory tract infection within 4 weeks of Visit 1. In addition, the subject must be excluded, if such infection occurs between Visits 1 and 2.. * Asthma Exacerbation: History of a an asthma exacerbation within 4 weeks of Visit 1, any asthma exacerbation requiring oral corticosteroids within 3 months of Visit 1, or any hospitalization due to asthma exacerbation within 6 months of Visit 1.. * Investigational Medications: A subject must not have used any investigational drug within 30 days prior to Visit 1 or within ten half-lives (t1/2) of the prior investigational study (which ever is longer of the two) or concurrently during the study.. * Concurrent Diseases/Abnormalities: Historical or current evidence of clinically significant uncontrolled disease including, but not limited to: cardiovascular disease, malignancy, hepatic disease, renal disease, hematological disease, neurological disease, or pulmonary disease (including, but not confined to chronic bronchitis, emphysema, bronchiectasis with the need of treatment, cystic fibrosis, bronchopulmonary dysplasia, and chronic obstructive pulmonary disease). Significant is defined as any disease that, in the opinion of the investigator, would put the safety of the subject at risk through participation, or which would affect the efficacy or safety analysis if the disease/condition exacerbated during the study.. * Oropharyngeal Examination: A subject will not be eligible for the run-in if he/she has evidence of oropharyngeal candidiasis at Visit 1.. * Drug Allergy: Any adverse reaction including immediate or delayed hypersensitivity to any beta2-agonist, sympathomimetic drug, or any intranasal, inhaled, or systemic corticosteroid therapy.. * Milk Protein Allergy: History of severe milk protein allergy.. * Immunosuppressive Medications: A subject must not be using, or require use of, immunosuppressive medications during the study.. Note: Immunotherapy for the treatment of allergies is allowed during the study provided that it was initiated prior to Visit 1 and the subject is maintained on a stable daily dose throughout the study period.. * Attendance: A subject will not be eligible if he/she or his/her parent or legal guardian has any infirmity, disability, or geographical location which seems likely (in the opinion of the Investigator) to impair compliance with any aspect of this study protocol or scheduled visits to the study center and compliance with study medication or procedures (e.g., completion of daily diary). Neurological or psychiatric disease or history of drug or alcohol abuse which would interfere with the subject's proper completion of the protocol requirements excludes study participation.. * Tobacco Use: A subject may not have used tobacco products within the past one year (i.e., cigarettes, cigars, or pipe tobacco) and must not have historical use of \\>10 pack years (e.g., 20 cigarettes/day for 10 years).. * Affiliation with Investigator's Site: A subject will not be eligible for this study if he/she is an immediate family member of the participating investigator, sub-investigator, study coordinator, or employee of the participating investigator.", "labeled_rules": [{"type": "INCLUSION", "field": "age", "operator": ">=", "value": 12, "unit": "years", "evidence_text": "Age: 12 years of age or older at Visit 1 (or 18 years of age or older if local regulations or the regulatory status of study medication permit enrollment of adults only)"}, {"type": "INCLUSION", "field": "medication", "operator": "IN", "value": "* Type of Subject: Outpatient. * Age: 12 years of age or older at Visit 1 (or 18 years of age or older if local regula", "unit": null, "evidence_text": "Age: 12 years of age or older at Visit 1 (or 18 years of age or older if local regulations or the regulatory status of study medication permit enrollment of adults only)"}, {"type": "INCLUSION", "field": "other", "operator": "IN", "value": "* Type of Subject: Outpatient. * Age: 12 years of age or older at Visit 1 (or 18 years of age or older if local regula", "unit": null, "evidence_text": "Age: 12 years of age or older at Visit 1 (or 18 years of age or older if local regulations or the regulatory status of study medication permit enrollment of adults only)"}, {"type": "INCLUSION", "field": "procedure", "operator": "IN", "value": "* Type of Subject: Outpatient. * Age: 12 years of age or older at Visit 1 (or 18 years of age or older if local regula", "unit": null, "evidence_text": "Age: 12 years of age or older at Visit 1 (or 18 years of age or older if local regulations or the regulatory status of study medication permit enrollment of adults only)"}, {"type": "EXCLUSION", "field": "sex", "operator": "=", "value": "all", "unit": null, "evidence_text": "Gender: Male or eligible female - Females are eligible to participate only if they are currently non-pregnant and non-lactating. To be eligible for entry into the study, females of childbearing potential must commit to consistent and correct use of an acceptable method of birth control, as defined by the following: Male partner who is sterile prior to the female subject's entry into the study and is the sole sexual partner for that female subject, Implants of levonorgestrel, Injectable progestogen, Oral contraceptive (either combined estrogen/progestin or progestin only), Any intrauterine device (IUD) with a documented failure rate of less than 1% per year, Double-barrier method - spermicide plus a mechanical barrier (e.g., spermicide plus a male condom or a spermicide and female diaphragm), The contraceptive transdermal patch, Ortho Evra (if the subject is less than 198 pounds), Female subjects should not be enrolled if they plan to become pregnant during the time of study participation. A urine pregnancy test is required for all subjects at all visits, Female subjects should not be enrolled if they plan to become pregnant during the time of study participation. A urine pregnancy test is required for all subjects at all visits, Female subjects should not be enrolled if they plan to become pregnant during the time of study participation. A urine pregnancy test is required for all subjects at all visits, Females of childbearing potential who are not sexually active must commit to complete abstinence from intercourse throughout the clinical trial, and for a period after the trial to account for elimination of the drug (minimum of six days),"}, {"type": "EXCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "Gender: Male or eligible female - Females are eligible to participate only if they are currently non-pregnant and non-lactating. To be eligible for entry into the study, females of childbearing potential must commit to consistent and correct use of an acceptable method of birth control, as defined by the following: Male partner who is sterile prior to the female subject's entry into the study and is the sole sexual partner for that female subject, Implants of levonorgestrel, Injectable progestogen, Oral contraceptive (either combined estrogen/progestin or progestin only), Any intrauterine device (IUD) with a documented failure rate of less than 1% per year, Double-barrier method - spermicide plus a mechanical barrier (e.g., spermicide plus a male condom or a spermicide and female diaphragm), The contraceptive transdermal patch, Ortho Evra (if the subject is less than 198 pounds), Female subjects should not be enrolled if they plan to become pregnant during the time of study participation. A urine pregnancy test is required for all subjects at all visits, Female subjects should not be enrolled if they plan to become pregnant during the time of study participation. A urine pregnancy test is required for all subjects at all visits, Female subjects should not be enrolled if they plan to become pregnant during the time of study participation. A urine pregnancy test is required for all subjects at all visits, Females of childbearing potential who are not sexually active must commit to complete abstinence from intercourse throughout the clinical trial, and for a period after the trial to account for elimination of the drug (minimum of six days),"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "asthma", "unit": null, "evidence_text": "Asthma Diagnosis: Asthma as defined by the National Institutes of Health \\[National Institutes of Health, 2002; GINA, 2005\\]"}, {"type": "INCLUSION", "field": "age", "operator": "<=", "value": 17, "unit": "years", "evidence_text": "Severity of Disease: A best AM FEV1 of 50% to 80% of the predicted value during Visit 1 based on the Standardization of Lung Function Tests \\[European Respiratory Society, 1993\\] standards for 18 years and older or Polgar \\[Polgar, 1971\\] standards for 12 to 17 years and race adjusted for African-Americans \\[American Thoracic Society, 1991\\]"}, {"type": "INCLUSION", "field": "history", "operator": "IN", "value": "GINA, 2005\\].. * Severity of Disease: A best AM FEV1 of 50% to 80% of the predicted value during Visit 1 based on the Standardization of Lun", "unit": null, "evidence_text": "Severity of Disease: A best AM FEV1 of 50% to 80% of the predicted value during Visit 1 based on the Standardization of Lung Function Tests \\[European Respiratory Society, 1993\\] standards for 18 years and older or Polgar \\[Polgar, 1971\\] standards for 12 to 17 years and race adjusted for African-Americans \\[American Thoracic Society, 1991\\]"}, {"type": "INCLUSION", "field": "other", "operator": "IN", "value": "GINA, 2005\\].. * Severity of Disease: A best AM FEV1 of 50% to 80% of the predicted value during Visit 1 based on the Standardization of Lun", "unit": null, "evidence_text": "Severity of Disease: A best AM FEV1 of 50% to 80% of the predicted value during Visit 1 based on the Standardization of Lung Function Tests \\[European Respiratory Society, 1993\\] standards for 18 years and older or Polgar \\[Polgar, 1971\\] standards for 12 to 17 years and race adjusted for African-Americans \\[American Thoracic Society, 1991\\]"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "the exception of its use during reversibility", "unit": null, "evidence_text": "Short-Acting Beta2-Agonist: All subjects must be able to replace short-acting beta2-agonists with albuterol/salbutamol inhalation aerosol at Visit 1 for use as-needed for the duration of the study. Subjects must be able to withhold all inhaled short-acting beta-sympathomimetic bronchodilators for at least 6 hours prior to study visits.Note: Nebulized albuterol/salbutamol will not be allowed during the study with the exception of its use during reversibility testing at Visit 1. The use of albuterol/salbutamol through the DISKUS/ACCUHALER device will not be allowed during the study"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "all the requirements", "unit": null, "evidence_text": "Informed Consent: All subjects must be able and willing to give written informed consent to take part in the study"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "all the study requirements", "unit": null, "evidence_text": "Compliance: Subjects must be able to comply with all the study requirements.. Exclusion criteria:"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "hypercapnia", "unit": null, "evidence_text": "History of Life-Threatening Asthma: History of life-threatening asthma, defined as an asthma episode that required intubation and/or was associated with hypercapnia, respiratory arrest or hypoxic seizures"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "hypercapnia, respiratory arrest or hypoxic seizures", "unit": null, "evidence_text": "History of Life-Threatening Asthma: History of life-threatening asthma, defined as an asthma episode that required intubation and/or was associated with hypercapnia, respiratory arrest or hypoxic seizures"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "life threatening asthma: history of life threatening asthma, defined as an asthma episode that required intubation and/or was associated with hypercapnia, respiratory arrest or hypoxic seizures", "unit": null, "evidence_text": "History of Life-Threatening Asthma: History of life-threatening asthma, defined as an asthma episode that required intubation and/or was associated with hypercapnia, respiratory arrest or hypoxic seizures"}, {"type": "EXCLUSION", "field": "medication", "operator": "IN", "value": "Anticholinergics", "unit": null, "evidence_text": "Anti-Asthma Medications: Asthma medications listed below must not have been used prior to Visit 1 for the required interval listed below, and not taken during the study: Within 24 hours of Visit 1: Oral short-acting beta2-agonists: Within 2 weeks of Visit 1:Combination therapy containing inhaled beta2-agonists and ICS for asthma (e.g., fluticasone propionate/salmeterol combination, budesonide/formoterol combination);Slow-release bronchodilators (e.g., aminophylline, theophylline);Anticholinergics; Long-acting beta2-agonists (e.g., salmeterol); Ketotifen; Nedocromil sodium; Sodium cromoglycate; Oral long-acting beta2-agonists. Within 4 weeks of Visit 1: Anti-leukotrienes including suppressors of leukotriene production and antagonists. Within 12 weeks of Visit 1: Systemic, oral, parenteral, or depot corticosteroids; Anti-IgE (e.g., omalizumab)"}, {"type": "EXCLUSION", "field": "procedure", "operator": "IN", "value": "Long-acting beta2-agonists (e.g., salmeterol)", "unit": null, "evidence_text": "Anti-Asthma Medications: Asthma medications listed below must not have been used prior to Visit 1 for the required interval listed below, and not taken during the study: Within 24 hours of Visit 1: Oral short-acting beta2-agonists: Within 2 weeks of Visit 1:Combination therapy containing inhaled beta2-agonists and ICS for asthma (e.g., fluticasone propionate/salmeterol combination, budesonide/formoterol combination);Slow-release bronchodilators (e.g., aminophylline, theophylline);Anticholinergics; Long-acting beta2-agonists (e.g., salmeterol); Ketotifen; Nedocromil sodium; Sodium cromoglycate; Oral long-acting beta2-agonists. Within 4 weeks of Visit 1: Anti-leukotrienes including suppressors of leukotriene production and antagonists. Within 12 weeks of Visit 1: Systemic, oral, parenteral, or depot corticosteroids; Anti-IgE (e.g., omalizumab)"}, {"type": "EXCLUSION", "field": "history", "operator": "IN", "value": "Anti-IgE (e.g., omalizumab).. * Other Medications: The medications listed below must not have been used prior to Visit 1 for the required in", "unit": null, "evidence_text": "Other Medications: The medications listed below must not have been used prior to Visit 1 for the required interval indicated below, and not taken during the study: Within 4 weeks of Visit 1: Known potent inhibitors of CYP3A4 (e.g., ritonavir, ketoconazole)"}, {"type": "EXCLUSION", "field": "other", "operator": "IN", "value": "Anti-IgE (e.g., omalizumab).. * Other Medications: The medications listed below must not have been used prior to Visit 1 for the required in", "unit": null, "evidence_text": "Other Medications: The medications listed below must not have been used prior to Visit 1 for the required interval indicated below, and not taken during the study: Within 4 weeks of Visit 1: Known potent inhibitors of CYP3A4 (e.g., ritonavir, ketoconazole)"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "a respiratory tract infection within 4 weeks", "unit": null, "evidence_text": "Respiratory Infection: History of a respiratory tract infection within 4 weeks of Visit 1. In addition, the subject must be excluded, if such infection occurs between Visits 1 and 2"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "respiratory tract infection within 4 weeks of visit 1", "unit": null, "evidence_text": "Respiratory Infection: History of a respiratory tract infection within 4 weeks of Visit 1. In addition, the subject must be excluded, if such infection occurs between Visits 1 and 2"}, {"type": "EXCLUSION", "field": "history", "operator": "WITHIN_LAST", "value": 4, "unit": "weeks", "evidence_text": "Respiratory Infection: History of a respiratory tract infection within 4 weeks of Visit 1. In addition, the subject must be excluded, if such infection occurs between Visits 1 and 2"}, {"type": "EXCLUSION", "field": "medication", "operator": "WITHIN_LAST", "value": 2, "unit": "weeks", "evidence_text": "Respiratory Infection: History of a respiratory tract infection within 4 weeks of Visit 1. In addition, the subject must be excluded, if such infection occurs between Visits 1 and 2"}, {"type": "EXCLUSION", "field": "medication", "operator": "WITHIN_LAST", "value": 4, "unit": "weeks", "evidence_text": "Respiratory Infection: History of a respiratory tract infection within 4 weeks of Visit 1. In addition, the subject must be excluded, if such infection occurs between Visits 1 and 2"}, {"type": "EXCLUSION", "field": "procedure", "operator": "WITHIN_LAST", "value": 2, "unit": "weeks", "evidence_text": "Respiratory Infection: History of a respiratory tract infection within 4 weeks of Visit 1. In addition, the subject must be excluded, if such infection occurs between Visits 1 and 2"}, {"type": "EXCLUSION", "field": "procedure", "operator": "WITHIN_LAST", "value": 4, "unit": "weeks", "evidence_text": "Respiratory Infection: History of a respiratory tract infection within 4 weeks of Visit 1. In addition, the subject must be excluded, if such infection occurs between Visits 1 and 2"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "an asthma exacerbation within 4 weeks of visit 1, any asthma exacerbation requiring oral corticosteroids within 3 months of visit 1, or any hospitalization due to asthma exacerbation within 6 months of visit 1", "unit": null, "evidence_text": "Asthma Exacerbation: History of a an asthma exacerbation within 4 weeks of Visit 1, any asthma exacerbation requiring oral corticosteroids within 3 months of Visit 1, or any hospitalization due to asthma exacerbation within 6 months of Visit 1"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "the need of treatment", "unit": null, "evidence_text": "Concurrent Diseases/Abnormalities: Historical or current evidence of clinically significant uncontrolled disease including, but not limited to: cardiovascular disease, malignancy, hepatic disease, renal disease, hematological disease, neurological disease, or pulmonary disease (including, but not confined to chronic bronchitis, emphysema, bronchiectasis with the need of treatment, cystic fibrosis, bronchopulmonary dysplasia, and chronic obstructive pulmonary disease). Significant is defined as any disease that, in the opinion of the investigator, would put the safety of the subject at risk through participation, or which would affect the efficacy or safety analysis if the disease/condition exacerbated during the study"}, {"type": "EXCLUSION", "field": "lab", "operator": "<=", "value": 1, "unit": "%", "evidence_text": "Oropharyngeal Examination: A subject will not be eligible for the run-in if he/she has evidence of oropharyngeal candidiasis at Visit 1"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "severe milk protein allergy", "unit": null, "evidence_text": "Milk Protein Allergy: History of severe milk protein allergy"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "drug or alcohol abuse which would interfere with the subject's proper completion of the protocol requirements excludes study participation", "unit": null, "evidence_text": "Attendance: A subject will not be eligible if he/she or his/her parent or legal guardian has any infirmity, disability, or geographical location which seems likely (in the opinion of the Investigator) to impair compliance with any aspect of this study protocol or scheduled visits to the study center and compliance with study medication or procedures (e.g., completion of daily diary). Neurological or psychiatric disease or history of drug or alcohol abuse which would interfere with the subject's proper completion of the protocol requirements excludes study participation"}, {"type": "EXCLUSION", "field": "lab", "operator": ">=", "value": 10, "unit": "pack", "evidence_text": "Tobacco Use: A subject may not have used tobacco products within the past one year (i.e., cigarettes, cigars, or pipe tobacco) and must not have historical use of \\>10 pack years (e.g., 20 cigarettes/day for 10 years)"}], "annotator_id": "annotator_c", "guideline_version": "m5-v1", "adjudicated": true, "adjudication_source": "parsing_relabel_round1"}
{"nct_id": "NCT00400491", "eligibility_text": "Inclusion Criteria:. * Type 2 diabetes for at least 1 year. * age 21-75 years. * long-acting insulin at bedtime. * metformin during the day. * for women of child bearing age use of reliable method of birth control. Exclusion Criteria:. * serum creatinine above 130 umol/l for men and above 110 for women. * systolic blood pressure \\> 175 or diastolic \\> 104 mmHg. * heart disease. * serum calcium \\> 2.54 mmol/l. * history of renal stones", "labeled_rules": [{"type": "INCLUSION", "field": "history", "operator": "IN", "value": "* Type 2 diabetes for at least 1 year. * age 21-75 years. * long-acting insulin at bedtime. * metformin during the day", "unit": null, "evidence_text": "Type 2 diabetes for at least 1 year"}, {"type": "INCLUSION", "field": "procedure", "operator": "IN", "value": "* Type 2 diabetes for at least 1 year. * age 21-75 years. * long-acting insulin at bedtime. * metformin during the day", "unit": null, "evidence_text": "Type 2 diabetes for at least 1 year"}, {"type": "INCLUSION", "field": "age", "operator": "<=", "value": 75, "unit": "years", "evidence_text": "age 21-75 years"}, {"type": "INCLUSION", "field": "age", "operator": ">=", "value": 21, "unit": "years", "evidence_text": "age 21-75 years"}, {"type": "INCLUSION", "field": "age", "operator": ">=", "value": 1, "unit": "years", "evidence_text": "age 21-75 years"}, {"type": "EXCLUSION", "field": "sex", "operator": "=", "value": "all", "unit": null, "evidence_text": "serum creatinine above 130 umol/l for men and above 110 for women"}, {"type": "INCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "serum creatinine above 130 umol/l for men and above 110 for women"}, {"type": "INCLUSION", "field": "sex", "operator": "=", "value": "all", "unit": null, "evidence_text": "serum creatinine above 130 umol/l for men and above 110 for women"}, {"type": "INCLUSION", "field": "lab", "operator": ">=", "value": 104, "unit": "mmhg", "evidence_text": "systolic blood pressure \\> 175 or diastolic \\> 104 mmHg"}, {"type": "INCLUSION", "field": "lab", "operator": ">=", "value": 175, "unit": "or", "evidence_text": "systolic blood pressure \\> 175 or diastolic \\> 104 mmHg"}, {"type": "INCLUSION", "field": "lab", "operator": ">=", "value": 2.54, "unit": "mmol/l", "evidence_text": "serum calcium \\> 2.54 mmol/l"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "renal stones", "unit": null, "evidence_text": "history of renal stones"}], "annotator_id": "annotator_c", "guideline_version": "m5-v1", "adjudicated": true, "adjudication_source": "parsing_relabel_round1"}
{"nct_id": "NCT00420290", "eligibility_text": "Inclusion Criteria:. 1. Patients on CHD for more than 3 months;. 2. Ability to read and sign the consent form;. 3. Have acceptable dialysis adequacy (Kt/V \\> 1.2);. 4. Use biocompatible hemodialysis membrane;. 5. Have a patent, well functioning, arteriovenous dialysis access;. 6. Signs of chronic inflammation (the average of three consecutive CRP measurements  5 mg/L).. Exclusion Criteria:. 1. Patients with residual renal function \\> 5 ml/min or urine output \\> 100 ml/day;. 2. Pregnancy;. 3. Intolerance to the study medication or contraindication to the study medication: Hypersensitivity to E. coli-derived proteins, anakinra, or any component of the formulation; patients with active infections (including chronic or local infection);. 4. Severe, unstable, active, or chronic inflammatory disease (active infection, active connective tissue disorder, active cancer or cancer history in the prior 5 years, HIV, liver disease including positive test or history of Hepatitis B or C);. 5. Hospitalization within 1 month prior to the study;. 6. Malfunctioning arterial-venous vascular access \\[recirculation and/or blood flow \\< 500 ml/min for an arterial-venous graft (AVG) or \\< 400 ml/min for an arterial-venous fistula (AVF)\\];. 7. Patients receiving steroids and/or other immunosuppressive agents;. 8. Life-expectancy less than 6 months;. 9. Age greater than 75 or less than 18 years old;. 10. Hypersensitivity to organic nitrates, isosorbide, or nitroglycerin.. 11. Presence of active infections or a history of pulmonary TB infection with or without documented adequate therapy. Subjects with current active TB, or recent close exposure to an individual with active TB, are excluded from the study.", "labeled_rules": [{"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "active infection", "unit": null, "evidence_text": "Inclusion Criteria:. 1. Patients on CHD for more than 3 months;. 2. Ability to read and sign the consent form;. 3. Have acceptable dialysis adequacy (Kt/V \\> 1.2);. 4. Use biocompatible hemodialysis membrane;. 5. Have a patent, well functioning, arteriovenous dialysis access;. 6. Signs of chronic inflammation (the average of three consecutive CRP measurements  5 mg/L).. Exclusion Criteria:. 1. Patients with residual renal function \\> 5 ml/min or urine output \\> 100 ml/day;. 2. Pregnancy;. 3. Intolerance to the study medication or contraindication to the study medication: Hypersensitivity to E. coli-derived proteins, anakinra, or any component of the formulation; patients with active infections (including chronic or local infection);. 4. Severe, unstable, active, or chronic inflammatory disease (active infection, active connective tissue disorder, active cancer or cancer history in the prior 5 years, HIV, liver disease including positive test or history of Hepatitis B or C);. 5. Hospitalization within 1 month prior to the study;. 6. Malfunctioning arterial-venous vascular access \\[recirculation and/or blood flow \\< 500 ml/min for an arterial-venous graft (AVG) or \\< 400 ml/min for an arterial-venous fistula (AVF)\\];. 7. Patients receiving steroids and/or other immunosuppressive agents;. 8. Life-expectancy less than 6 months;. 9. Age greater than 75 or less than 18 years old;. 10. Hypersensitivity to organic nitrates, isosorbide, or nitroglycerin.. 11. Presence of active infections or a history of pulmonary TB infection with or without documented adequate therapy. Subjects with current active TB, or recent close exposure to an individual with active TB, are excluded from the study"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "active tb", "unit": null, "evidence_text": "Inclusion Criteria:. 1. Patients on CHD for more than 3 months;. 2. Ability to read and sign the consent form;. 3. Have acceptable dialysis adequacy (Kt/V \\> 1.2);. 4. Use biocompatible hemodialysis membrane;. 5. Have a patent, well functioning, arteriovenous dialysis access;. 6. Signs of chronic inflammation (the average of three consecutive CRP measurements  5 mg/L).. Exclusion Criteria:. 1. Patients with residual renal function \\> 5 ml/min or urine output \\> 100 ml/day;. 2. Pregnancy;. 3. Intolerance to the study medication or contraindication to the study medication: Hypersensitivity to E. coli-derived proteins, anakinra, or any component of the formulation; patients with active infections (including chronic or local infection);. 4. Severe, unstable, active, or chronic inflammatory disease (active infection, active connective tissue disorder, active cancer or cancer history in the prior 5 years, HIV, liver disease including positive test or history of Hepatitis B or C);. 5. Hospitalization within 1 month prior to the study;. 6. Malfunctioning arterial-venous vascular access \\[recirculation and/or blood flow \\< 500 ml/min for an arterial-venous graft (AVG) or \\< 400 ml/min for an arterial-venous fistula (AVF)\\];. 7. Patients receiving steroids and/or other immunosuppressive agents;. 8. Life-expectancy less than 6 months;. 9. Age greater than 75 or less than 18 years old;. 10. Hypersensitivity to organic nitrates, isosorbide, or nitroglycerin.. 11. Presence of active infections or a history of pulmonary TB infection with or without documented adequate therapy. Subjects with current active TB, or recent close exposure to an individual with active TB, are excluded from the study"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "active tb, are excluded from the", "unit": null, "evidence_text": "Inclusion Criteria:. 1. Patients on CHD for more than 3 months;. 2. Ability to read and sign the consent form;. 3. Have acceptable dialysis adequacy (Kt/V \\> 1.2);. 4. Use biocompatible hemodialysis membrane;. 5. Have a patent, well functioning, arteriovenous dialysis access;. 6. Signs of chronic inflammation (the average of three consecutive CRP measurements  5 mg/L).. Exclusion Criteria:. 1. Patients with residual renal function \\> 5 ml/min or urine output \\> 100 ml/day;. 2. Pregnancy;. 3. Intolerance to the study medication or contraindication to the study medication: Hypersensitivity to E. coli-derived proteins, anakinra, or any component of the formulation; patients with active infections (including chronic or local infection);. 4. Severe, unstable, active, or chronic inflammatory disease (active infection, active connective tissue disorder, active cancer or cancer history in the prior 5 years, HIV, liver disease including positive test or history of Hepatitis B or C);. 5. Hospitalization within 1 month prior to the study;. 6. Malfunctioning arterial-venous vascular access \\[recirculation and/or blood flow \\< 500 ml/min for an arterial-venous graft (AVG) or \\< 400 ml/min for an arterial-venous fistula (AVF)\\];. 7. Patients receiving steroids and/or other immunosuppressive agents;. 8. Life-expectancy less than 6 months;. 9. Age greater than 75 or less than 18 years old;. 10. Hypersensitivity to organic nitrates, isosorbide, or nitroglycerin.. 11. Presence of active infections or a history of pulmonary TB infection with or without documented adequate therapy. Subjects with current active TB, or recent close exposure to an individual with active TB, are excluded from the study"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "current active tb", "unit": null, "evidence_text": "Inclusion Criteria:. 1. Patients on CHD for more than 3 months;. 2. Ability to read and sign the consent form;. 3. Have acceptable dialysis adequacy (Kt/V \\> 1.2);. 4. Use biocompatible hemodialysis membrane;. 5. Have a patent, well functioning, arteriovenous dialysis access;. 6. Signs of chronic inflammation (the average of three consecutive CRP measurements  5 mg/L).. Exclusion Criteria:. 1. Patients with residual renal function \\> 5 ml/min or urine output \\> 100 ml/day;. 2. Pregnancy;. 3. Intolerance to the study medication or contraindication to the study medication: Hypersensitivity to E. coli-derived proteins, anakinra, or any component of the formulation; patients with active infections (including chronic or local infection);. 4. Severe, unstable, active, or chronic inflammatory disease (active infection, active connective tissue disorder, active cancer or cancer history in the prior 5 years, HIV, liver disease including positive test or history of Hepatitis B or C);. 5. Hospitalization within 1 month prior to the study;. 6. Malfunctioning arterial-venous vascular access \\[recirculation and/or blood flow \\< 500 ml/min for an arterial-venous graft (AVG) or \\< 400 ml/min for an arterial-venous fistula (AVF)\\];. 7. Patients receiving steroids and/or other immunosuppressive agents;. 8. Life-expectancy less than 6 months;. 9. Age greater than 75 or less than 18 years old;. 10. Hypersensitivity to organic nitrates, isosorbide, or nitroglycerin.. 11. Presence of active infections or a history of pulmonary TB infection with or without documented adequate therapy. Subjects with current active TB, or recent close exposure to an individual with active TB, are excluded from the study"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "hepatitis b or c)", "unit": null, "evidence_text": "Inclusion Criteria:. 1. Patients on CHD for more than 3 months;. 2. Ability to read and sign the consent form;. 3. Have acceptable dialysis adequacy (Kt/V \\> 1.2);. 4. Use biocompatible hemodialysis membrane;. 5. Have a patent, well functioning, arteriovenous dialysis access;. 6. Signs of chronic inflammation (the average of three consecutive CRP measurements  5 mg/L).. Exclusion Criteria:. 1. Patients with residual renal function \\> 5 ml/min or urine output \\> 100 ml/day;. 2. Pregnancy;. 3. Intolerance to the study medication or contraindication to the study medication: Hypersensitivity to E. coli-derived proteins, anakinra, or any component of the formulation; patients with active infections (including chronic or local infection);. 4. Severe, unstable, active, or chronic inflammatory disease (active infection, active connective tissue disorder, active cancer or cancer history in the prior 5 years, HIV, liver disease including positive test or history of Hepatitis B or C);. 5. Hospitalization within 1 month prior to the study;. 6. Malfunctioning arterial-venous vascular access \\[recirculation and/or blood flow \\< 500 ml/min for an arterial-venous graft (AVG) or \\< 400 ml/min for an arterial-venous fistula (AVF)\\];. 7. Patients receiving steroids and/or other immunosuppressive agents;. 8. Life-expectancy less than 6 months;. 9. Age greater than 75 or less than 18 years old;. 10. Hypersensitivity to organic nitrates, isosorbide, or nitroglycerin.. 11. Presence of active infections or a history of pulmonary TB infection with or without documented adequate therapy. Subjects with current active TB, or recent close exposure to an individual with active TB, are excluded from the study"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "hiv positive", "unit": null, "evidence_text": "Inclusion Criteria:. 1. Patients on CHD for more than 3 months;. 2. Ability to read and sign the consent form;. 3. Have acceptable dialysis adequacy (Kt/V \\> 1.2);. 4. Use biocompatible hemodialysis membrane;. 5. Have a patent, well functioning, arteriovenous dialysis access;. 6. Signs of chronic inflammation (the average of three consecutive CRP measurements  5 mg/L).. Exclusion Criteria:. 1. Patients with residual renal function \\> 5 ml/min or urine output \\> 100 ml/day;. 2. Pregnancy;. 3. Intolerance to the study medication or contraindication to the study medication: Hypersensitivity to E. coli-derived proteins, anakinra, or any component of the formulation; patients with active infections (including chronic or local infection);. 4. Severe, unstable, active, or chronic inflammatory disease (active infection, active connective tissue disorder, active cancer or cancer history in the prior 5 years, HIV, liver disease including positive test or history of Hepatitis B or C);. 5. Hospitalization within 1 month prior to the study;. 6. Malfunctioning arterial-venous vascular access \\[recirculation and/or blood flow \\< 500 ml/min for an arterial-venous graft (AVG) or \\< 400 ml/min for an arterial-venous fistula (AVF)\\];. 7. Patients receiving steroids and/or other immunosuppressive agents;. 8. Life-expectancy less than 6 months;. 9. Age greater than 75 or less than 18 years old;. 10. Hypersensitivity to organic nitrates, isosorbide, or nitroglycerin.. 11. Presence of active infections or a history of pulmonary TB infection with or without documented adequate therapy. Subjects with current active TB, or recent close exposure to an individual with active TB, are excluded from the study"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "or without documented adequate therapy", "unit": null, "evidence_text": "Inclusion Criteria:. 1. Patients on CHD for more than 3 months;. 2. Ability to read and sign the consent form;. 3. Have acceptable dialysis adequacy (Kt/V \\> 1.2);. 4. Use biocompatible hemodialysis membrane;. 5. Have a patent, well functioning, arteriovenous dialysis access;. 6. Signs of chronic inflammation (the average of three consecutive CRP measurements  5 mg/L).. Exclusion Criteria:. 1. Patients with residual renal function \\> 5 ml/min or urine output \\> 100 ml/day;. 2. Pregnancy;. 3. Intolerance to the study medication or contraindication to the study medication: Hypersensitivity to E. coli-derived proteins, anakinra, or any component of the formulation; patients with active infections (including chronic or local infection);. 4. Severe, unstable, active, or chronic inflammatory disease (active infection, active connective tissue disorder, active cancer or cancer history in the prior 5 years, HIV, liver disease including positive test or history of Hepatitis B or C);. 5. Hospitalization within 1 month prior to the study;. 6. Malfunctioning arterial-venous vascular access \\[recirculation and/or blood flow \\< 500 ml/min for an arterial-venous graft (AVG) or \\< 400 ml/min for an arterial-venous fistula (AVF)\\];. 7. Patients receiving steroids and/or other immunosuppressive agents;. 8. Life-expectancy less than 6 months;. 9. Age greater than 75 or less than 18 years old;. 10. Hypersensitivity to organic nitrates, isosorbide, or nitroglycerin.. 11. Presence of active infections or a history of pulmonary TB infection with or without documented adequate therapy. Subjects with current active TB, or recent close exposure to an individual with active TB, are excluded from the study"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "pulmonary tb infection with or without documented", "unit": null, "evidence_text": "Inclusion Criteria:. 1. Patients on CHD for more than 3 months;. 2. Ability to read and sign the consent form;. 3. Have acceptable dialysis adequacy (Kt/V \\> 1.2);. 4. Use biocompatible hemodialysis membrane;. 5. Have a patent, well functioning, arteriovenous dialysis access;. 6. Signs of chronic inflammation (the average of three consecutive CRP measurements  5 mg/L).. Exclusion Criteria:. 1. Patients with residual renal function \\> 5 ml/min or urine output \\> 100 ml/day;. 2. Pregnancy;. 3. Intolerance to the study medication or contraindication to the study medication: Hypersensitivity to E. coli-derived proteins, anakinra, or any component of the formulation; patients with active infections (including chronic or local infection);. 4. Severe, unstable, active, or chronic inflammatory disease (active infection, active connective tissue disorder, active cancer or cancer history in the prior 5 years, HIV, liver disease including positive test or history of Hepatitis B or C);. 5. Hospitalization within 1 month prior to the study;. 6. Malfunctioning arterial-venous vascular access \\[recirculation and/or blood flow \\< 500 ml/min for an arterial-venous graft (AVG) or \\< 400 ml/min for an arterial-venous fistula (AVF)\\];. 7. Patients receiving steroids and/or other immunosuppressive agents;. 8. Life-expectancy less than 6 months;. 9. Age greater than 75 or less than 18 years old;. 10. Hypersensitivity to organic nitrates, isosorbide, or nitroglycerin.. 11. Presence of active infections or a history of pulmonary TB infection with or without documented adequate therapy. Subjects with current active TB, or recent close exposure to an individual with active TB, are excluded from the study"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "pulmonary tb infection with or without documented adequate therapy", "unit": null, "evidence_text": "Inclusion Criteria:. 1. Patients on CHD for more than 3 months;. 2. Ability to read and sign the consent form;. 3. Have acceptable dialysis adequacy (Kt/V \\> 1.2);. 4. Use biocompatible hemodialysis membrane;. 5. Have a patent, well functioning, arteriovenous dialysis access;. 6. Signs of chronic inflammation (the average of three consecutive CRP measurements  5 mg/L).. Exclusion Criteria:. 1. Patients with residual renal function \\> 5 ml/min or urine output \\> 100 ml/day;. 2. Pregnancy;. 3. Intolerance to the study medication or contraindication to the study medication: Hypersensitivity to E. coli-derived proteins, anakinra, or any component of the formulation; patients with active infections (including chronic or local infection);. 4. Severe, unstable, active, or chronic inflammatory disease (active infection, active connective tissue disorder, active cancer or cancer history in the prior 5 years, HIV, liver disease including positive test or history of Hepatitis B or C);. 5. Hospitalization within 1 month prior to the study;. 6. Malfunctioning arterial-venous vascular access \\[recirculation and/or blood flow \\< 500 ml/min for an arterial-venous graft (AVG) or \\< 400 ml/min for an arterial-venous fistula (AVF)\\];. 7. Patients receiving steroids and/or other immunosuppressive agents;. 8. Life-expectancy less than 6 months;. 9. Age greater than 75 or less than 18 years old;. 10. Hypersensitivity to organic nitrates, isosorbide, or nitroglycerin.. 11. Presence of active infections or a history of pulmonary TB infection with or without documented adequate therapy. Subjects with current active TB, or recent close exposure to an individual with active TB, are excluded from the study"}, {"type": "EXCLUSION", "field": "history", "operator": "IN", "value": "10. Hypersensitivity to organic nitrates, isosorbide, or nitroglycerin.. 11. Presence of active infections or a history of pulmonary TB in", "unit": null, "evidence_text": "Inclusion Criteria:. 1. Patients on CHD for more than 3 months;. 2. Ability to read and sign the consent form;. 3. Have acceptable dialysis adequacy (Kt/V \\> 1.2);. 4. Use biocompatible hemodialysis membrane;. 5. Have a patent, well functioning, arteriovenous dialysis access;. 6. Signs of chronic inflammation (the average of three consecutive CRP measurements  5 mg/L).. Exclusion Criteria:. 1. Patients with residual renal function \\> 5 ml/min or urine output \\> 100 ml/day;. 2. Pregnancy;. 3. Intolerance to the study medication or contraindication to the study medication: Hypersensitivity to E. coli-derived proteins, anakinra, or any component of the formulation; patients with active infections (including chronic or local infection);. 4. Severe, unstable, active, or chronic inflammatory disease (active infection, active connective tissue disorder, active cancer or cancer history in the prior 5 years, HIV, liver disease including positive test or history of Hepatitis B or C);. 5. Hospitalization within 1 month prior to the study;. 6. Malfunctioning arterial-venous vascular access \\[recirculation and/or blood flow \\< 500 ml/min for an arterial-venous graft (AVG) or \\< 400 ml/min for an arterial-venous fistula (AVF)\\];. 7. Patients receiving steroids and/or other immunosuppressive agents;. 8. Life-expectancy less than 6 months;. 9. Age greater than 75 or less than 18 years old;. 10. Hypersensitivity to organic nitrates, isosorbide, or nitroglycerin.. 11. Presence of active infections or a history of pulmonary TB infection with or without documented adequate therapy. Subjects with current active TB, or recent close exposure to an individual with active TB, are excluded from the study"}, {"type": "EXCLUSION", "field": "history", "operator": "IN", "value": "4. Severe, unstable, active, or chronic inflammatory disease (active infection, active connective tissue disorder, active cancer or cancer", "unit": null, "evidence_text": "Inclusion Criteria:. 1. Patients on CHD for more than 3 months;. 2. Ability to read and sign the consent form;. 3. Have acceptable dialysis adequacy (Kt/V \\> 1.2);. 4. Use biocompatible hemodialysis membrane;. 5. Have a patent, well functioning, arteriovenous dialysis access;. 6. Signs of chronic inflammation (the average of three consecutive CRP measurements  5 mg/L).. Exclusion Criteria:. 1. Patients with residual renal function \\> 5 ml/min or urine output \\> 100 ml/day;. 2. Pregnancy;. 3. Intolerance to the study medication or contraindication to the study medication: Hypersensitivity to E. coli-derived proteins, anakinra, or any component of the formulation; patients with active infections (including chronic or local infection);. 4. Severe, unstable, active, or chronic inflammatory disease (active infection, active connective tissue disorder, active cancer or cancer history in the prior 5 years, HIV, liver disease including positive test or history of Hepatitis B or C);. 5. Hospitalization within 1 month prior to the study;. 6. Malfunctioning arterial-venous vascular access \\[recirculation and/or blood flow \\< 500 ml/min for an arterial-venous graft (AVG) or \\< 400 ml/min for an arterial-venous fistula (AVF)\\];. 7. Patients receiving steroids and/or other immunosuppressive agents;. 8. Life-expectancy less than 6 months;. 9. Age greater than 75 or less than 18 years old;. 10. Hypersensitivity to organic nitrates, isosorbide, or nitroglycerin.. 11. Presence of active infections or a history of pulmonary TB infection with or without documented adequate therapy. Subjects with current active TB, or recent close exposure to an individual with active TB, are excluded from the study"}, {"type": "EXCLUSION", "field": "lab", "operator": "<=", "value": 6, "unit": "months", "evidence_text": "Inclusion Criteria:. 1. Patients on CHD for more than 3 months;. 2. Ability to read and sign the consent form;. 3. Have acceptable dialysis adequacy (Kt/V \\> 1.2);. 4. Use biocompatible hemodialysis membrane;. 5. Have a patent, well functioning, arteriovenous dialysis access;. 6. Signs of chronic inflammation (the average of three consecutive CRP measurements  5 mg/L).. Exclusion Criteria:. 1. Patients with residual renal function \\> 5 ml/min or urine output \\> 100 ml/day;. 2. Pregnancy;. 3. Intolerance to the study medication or contraindication to the study medication: Hypersensitivity to E. coli-derived proteins, anakinra, or any component of the formulation; patients with active infections (including chronic or local infection);. 4. Severe, unstable, active, or chronic inflammatory disease (active infection, active connective tissue disorder, active cancer or cancer history in the prior 5 years, HIV, liver disease including positive test or history of Hepatitis B or C);. 5. Hospitalization within 1 month prior to the study;. 6. Malfunctioning arterial-venous vascular access \\[recirculation and/or blood flow \\< 500 ml/min for an arterial-venous graft (AVG) or \\< 400 ml/min for an arterial-venous fistula (AVF)\\];. 7. Patients receiving steroids and/or other immunosuppressive agents;. 8. Life-expectancy less than 6 months;. 9. Age greater than 75 or less than 18 years old;. 10. Hypersensitivity to organic nitrates, isosorbide, or nitroglycerin.. 11. Presence of active infections or a history of pulmonary TB infection with or without documented adequate therapy. Subjects with current active TB, or recent close exposure to an individual with active TB, are excluded from the study"}, {"type": "EXCLUSION", "field": "medication", "operator": "IN", "value": "10. Hypersensitivity to organic nitrates, isosorbide, or nitroglycerin.. 11. Presence of active infections or a history of pulmonary TB in", "unit": null, "evidence_text": "Inclusion Criteria:. 1. Patients on CHD for more than 3 months;. 2. Ability to read and sign the consent form;. 3. Have acceptable dialysis adequacy (Kt/V \\> 1.2);. 4. Use biocompatible hemodialysis membrane;. 5. Have a patent, well functioning, arteriovenous dialysis access;. 6. Signs of chronic inflammation (the average of three consecutive CRP measurements  5 mg/L).. Exclusion Criteria:. 1. Patients with residual renal function \\> 5 ml/min or urine output \\> 100 ml/day;. 2. Pregnancy;. 3. Intolerance to the study medication or contraindication to the study medication: Hypersensitivity to E. coli-derived proteins, anakinra, or any component of the formulation; patients with active infections (including chronic or local infection);. 4. Severe, unstable, active, or chronic inflammatory disease (active infection, active connective tissue disorder, active cancer or cancer history in the prior 5 years, HIV, liver disease including positive test or history of Hepatitis B or C);. 5. Hospitalization within 1 month prior to the study;. 6. Malfunctioning arterial-venous vascular access \\[recirculation and/or blood flow \\< 500 ml/min for an arterial-venous graft (AVG) or \\< 400 ml/min for an arterial-venous fistula (AVF)\\];. 7. Patients receiving steroids and/or other immunosuppressive agents;. 8. Life-expectancy less than 6 months;. 9. Age greater than 75 or less than 18 years old;. 10. Hypersensitivity to organic nitrates, isosorbide, or nitroglycerin.. 11. Presence of active infections or a history of pulmonary TB infection with or without documented adequate therapy. Subjects with current active TB, or recent close exposure to an individual with active TB, are excluded from the study"}, {"type": "EXCLUSION", "field": "medication", "operator": "IN", "value": "3. Intolerance to the study medication or contraindication to the study medication: Hypersensitivity to E. coli-derived proteins, anakinra", "unit": null, "evidence_text": "Inclusion Criteria:. 1. Patients on CHD for more than 3 months;. 2. Ability to read and sign the consent form;. 3. Have acceptable dialysis adequacy (Kt/V \\> 1.2);. 4. Use biocompatible hemodialysis membrane;. 5. Have a patent, well functioning, arteriovenous dialysis access;. 6. Signs of chronic inflammation (the average of three consecutive CRP measurements  5 mg/L).. Exclusion Criteria:. 1. Patients with residual renal function \\> 5 ml/min or urine output \\> 100 ml/day;. 2. Pregnancy;. 3. Intolerance to the study medication or contraindication to the study medication: Hypersensitivity to E. coli-derived proteins, anakinra, or any component of the formulation; patients with active infections (including chronic or local infection);. 4. Severe, unstable, active, or chronic inflammatory disease (active infection, active connective tissue disorder, active cancer or cancer history in the prior 5 years, HIV, liver disease including positive test or history of Hepatitis B or C);. 5. Hospitalization within 1 month prior to the study;. 6. Malfunctioning arterial-venous vascular access \\[recirculation and/or blood flow \\< 500 ml/min for an arterial-venous graft (AVG) or \\< 400 ml/min for an arterial-venous fistula (AVF)\\];. 7. Patients receiving steroids and/or other immunosuppressive agents;. 8. Life-expectancy less than 6 months;. 9. Age greater than 75 or less than 18 years old;. 10. Hypersensitivity to organic nitrates, isosorbide, or nitroglycerin.. 11. Presence of active infections or a history of pulmonary TB infection with or without documented adequate therapy. Subjects with current active TB, or recent close exposure to an individual with active TB, are excluded from the study"}, {"type": "EXCLUSION", "field": "medication", "operator": "IN", "value": "7. Patients receiving steroids and/or other immunosuppressive agents", "unit": null, "evidence_text": "Inclusion Criteria:. 1. Patients on CHD for more than 3 months;. 2. Ability to read and sign the consent form;. 3. Have acceptable dialysis adequacy (Kt/V \\> 1.2);. 4. Use biocompatible hemodialysis membrane;. 5. Have a patent, well functioning, arteriovenous dialysis access;. 6. Signs of chronic inflammation (the average of three consecutive CRP measurements  5 mg/L).. Exclusion Criteria:. 1. Patients with residual renal function \\> 5 ml/min or urine output \\> 100 ml/day;. 2. Pregnancy;. 3. Intolerance to the study medication or contraindication to the study medication: Hypersensitivity to E. coli-derived proteins, anakinra, or any component of the formulation; patients with active infections (including chronic or local infection);. 4. Severe, unstable, active, or chronic inflammatory disease (active infection, active connective tissue disorder, active cancer or cancer history in the prior 5 years, HIV, liver disease including positive test or history of Hepatitis B or C);. 5. Hospitalization within 1 month prior to the study;. 6. Malfunctioning arterial-venous vascular access \\[recirculation and/or blood flow \\< 500 ml/min for an arterial-venous graft (AVG) or \\< 400 ml/min for an arterial-venous fistula (AVF)\\];. 7. Patients receiving steroids and/or other immunosuppressive agents;. 8. Life-expectancy less than 6 months;. 9. Age greater than 75 or less than 18 years old;. 10. Hypersensitivity to organic nitrates, isosorbide, or nitroglycerin.. 11. Presence of active infections or a history of pulmonary TB infection with or without documented adequate therapy. Subjects with current active TB, or recent close exposure to an individual with active TB, are excluded from the study"}, {"type": "EXCLUSION", "field": "other", "operator": "IN", "value": "2. Ability to read and sign the consent form", "unit": null, "evidence_text": "Inclusion Criteria:. 1. Patients on CHD for more than 3 months;. 2. Ability to read and sign the consent form;. 3. Have acceptable dialysis adequacy (Kt/V \\> 1.2);. 4. Use biocompatible hemodialysis membrane;. 5. Have a patent, well functioning, arteriovenous dialysis access;. 6. Signs of chronic inflammation (the average of three consecutive CRP measurements  5 mg/L).. Exclusion Criteria:. 1. Patients with residual renal function \\> 5 ml/min or urine output \\> 100 ml/day;. 2. Pregnancy;. 3. Intolerance to the study medication or contraindication to the study medication: Hypersensitivity to E. coli-derived proteins, anakinra, or any component of the formulation; patients with active infections (including chronic or local infection);. 4. Severe, unstable, active, or chronic inflammatory disease (active infection, active connective tissue disorder, active cancer or cancer history in the prior 5 years, HIV, liver disease including positive test or history of Hepatitis B or C);. 5. Hospitalization within 1 month prior to the study;. 6. Malfunctioning arterial-venous vascular access \\[recirculation and/or blood flow \\< 500 ml/min for an arterial-venous graft (AVG) or \\< 400 ml/min for an arterial-venous fistula (AVF)\\];. 7. Patients receiving steroids and/or other immunosuppressive agents;. 8. Life-expectancy less than 6 months;. 9. Age greater than 75 or less than 18 years old;. 10. Hypersensitivity to organic nitrates, isosorbide, or nitroglycerin.. 11. Presence of active infections or a history of pulmonary TB infection with or without documented adequate therapy. Subjects with current active TB, or recent close exposure to an individual with active TB, are excluded from the study"}, {"type": "EXCLUSION", "field": "other", "operator": "IN", "value": "5. Have a patent, well functioning, arteriovenous dialysis access", "unit": null, "evidence_text": "Inclusion Criteria:. 1. Patients on CHD for more than 3 months;. 2. Ability to read and sign the consent form;. 3. Have acceptable dialysis adequacy (Kt/V \\> 1.2);. 4. Use biocompatible hemodialysis membrane;. 5. Have a patent, well functioning, arteriovenous dialysis access;. 6. Signs of chronic inflammation (the average of three consecutive CRP measurements  5 mg/L).. Exclusion Criteria:. 1. Patients with residual renal function \\> 5 ml/min or urine output \\> 100 ml/day;. 2. Pregnancy;. 3. Intolerance to the study medication or contraindication to the study medication: Hypersensitivity to E. coli-derived proteins, anakinra, or any component of the formulation; patients with active infections (including chronic or local infection);. 4. Severe, unstable, active, or chronic inflammatory disease (active infection, active connective tissue disorder, active cancer or cancer history in the prior 5 years, HIV, liver disease including positive test or history of Hepatitis B or C);. 5. Hospitalization within 1 month prior to the study;. 6. Malfunctioning arterial-venous vascular access \\[recirculation and/or blood flow \\< 500 ml/min for an arterial-venous graft (AVG) or \\< 400 ml/min for an arterial-venous fistula (AVF)\\];. 7. Patients receiving steroids and/or other immunosuppressive agents;. 8. Life-expectancy less than 6 months;. 9. Age greater than 75 or less than 18 years old;. 10. Hypersensitivity to organic nitrates, isosorbide, or nitroglycerin.. 11. Presence of active infections or a history of pulmonary TB infection with or without documented adequate therapy. Subjects with current active TB, or recent close exposure to an individual with active TB, are excluded from the study"}, {"type": "EXCLUSION", "field": "other", "operator": "IN", "value": "6. Malfunctioning arterial-venous vascular access \\[recirculation and/or blood flow \\< 500 ml/min for an arterial-venous graft (AVG) or \\<", "unit": null, "evidence_text": "Inclusion Criteria:. 1. Patients on CHD for more than 3 months;. 2. Ability to read and sign the consent form;. 3. Have acceptable dialysis adequacy (Kt/V \\> 1.2);. 4. Use biocompatible hemodialysis membrane;. 5. Have a patent, well functioning, arteriovenous dialysis access;. 6. Signs of chronic inflammation (the average of three consecutive CRP measurements  5 mg/L).. Exclusion Criteria:. 1. Patients with residual renal function \\> 5 ml/min or urine output \\> 100 ml/day;. 2. Pregnancy;. 3. Intolerance to the study medication or contraindication to the study medication: Hypersensitivity to E. coli-derived proteins, anakinra, or any component of the formulation; patients with active infections (including chronic or local infection);. 4. Severe, unstable, active, or chronic inflammatory disease (active infection, active connective tissue disorder, active cancer or cancer history in the prior 5 years, HIV, liver disease including positive test or history of Hepatitis B or C);. 5. Hospitalization within 1 month prior to the study;. 6. Malfunctioning arterial-venous vascular access \\[recirculation and/or blood flow \\< 500 ml/min for an arterial-venous graft (AVG) or \\< 400 ml/min for an arterial-venous fistula (AVF)\\];. 7. Patients receiving steroids and/or other immunosuppressive agents;. 8. Life-expectancy less than 6 months;. 9. Age greater than 75 or less than 18 years old;. 10. Hypersensitivity to organic nitrates, isosorbide, or nitroglycerin.. 11. Presence of active infections or a history of pulmonary TB infection with or without documented adequate therapy. Subjects with current active TB, or recent close exposure to an individual with active TB, are excluded from the study"}, {"type": "EXCLUSION", "field": "procedure", "operator": "IN", "value": "1. Patients on CHD for more than 3 months;. 2. Ability to read and sign the consent form;. 3. Have acceptable dialysis adequacy (Kt/V \\> 1.2);. 4. Use biocompatible hemodialysis membrane;. 5. Have a patent, well functioning, arteriovenous dialysis access;. 6. Signs of chronic inflammation (the average of three consecutive CRP measurements  5 mg/L).. Exclusion Criteria:. 1. Patients with residual renal function \\> 5 ml/min or urine output \\> 100 ml/day;. 2. Pregnancy;. 3. Intolerance to the study medication or contraindication to the study medication: Hypersensitivity to E. coli-derived proteins, anakinra, or any component of the formulation; patients with active infections (including chronic or local infection);. 4. Severe, unstable, active, or chronic inflammatory disease (active infection, active connective tissue disorder, active cancer or cancer history in the prior 5 years, HIV, liver disease including positive test or history of Hepatitis B or C);. 5. Hospitalization within 1 month prior to the study;. 6. Malfunctioning arterial-venous vascular access \\[recirculation and/or blood flow \\< 500 ml/min for an arterial-venous graft (AVG) or \\< 400 ml/min for an arterial-venous fistula (AVF)\\];. 7. Patients receiving steroids and/or other immunosuppressive agents;. 8. Life-expectancy less than 6 months;. 9. Age greater than 75 or less than 18 years old;. 10. Hypersensitivity to organic nitrates, isosorbide, or nitroglycerin.. 11. Presence of active infections or a history of pulmonary TB infection with or without documented adequate therapy. Subjects with current active TB, or recent close exposure to an individual with active TB, are excluded from the study", "unit": null, "evidence_text": "Inclusion Criteria:. 1. Patients on CHD for more than 3 months;. 2. Ability to read and sign the consent form;. 3. Have acceptable dialysis adequacy (Kt/V \\> 1.2);. 4. Use biocompatible hemodialysis membrane;. 5. Have a patent, well functioning, arteriovenous dialysis access;. 6. Signs of chronic inflammation (the average of three consecutive CRP measurements  5 mg/L).. Exclusion Criteria:. 1. Patients with residual renal function \\> 5 ml/min or urine output \\> 100 ml/day;. 2. Pregnancy;. 3. Intolerance to the study medication or contraindication to the study medication: Hypersensitivity to E. coli-derived proteins, anakinra, or any component of the formulation; patients with active infections (including chronic or local infection);. 4. Severe, unstable, active, or chronic inflammatory disease (active infection, active connective tissue disorder, active cancer or cancer history in the prior 5 years, HIV, liver disease including positive test or history of Hepatitis B or C);. 5. Hospitalization within 1 month prior to the study;. 6. Malfunctioning arterial-venous vascular access \\[recirculation and/or blood flow \\< 500 ml/min for an arterial-venous graft (AVG) or \\< 400 ml/min for an arterial-venous fistula (AVF)\\];. 7. Patients receiving steroids and/or other immunosuppressive agents;. 8. Life-expectancy less than 6 months;. 9. Age greater than 75 or less than 18 years old;. 10. Hypersensitivity to organic nitrates, isosorbide, or nitroglycerin.. 11. Presence of active infections or a history of pulmonary TB infection with or without documented adequate therapy. Subjects with current active TB, or recent close exposure to an individual with active TB, are excluded from the study"}, {"type": "EXCLUSION", "field": "procedure", "operator": "IN", "value": "10. Hypersensitivity to organic nitrates, isosorbide, or nitroglycerin.. 11. Presence of active infections or a history of pulmonary TB in", "unit": null, "evidence_text": "Inclusion Criteria:. 1. Patients on CHD for more than 3 months;. 2. Ability to read and sign the consent form;. 3. Have acceptable dialysis adequacy (Kt/V \\> 1.2);. 4. Use biocompatible hemodialysis membrane;. 5. Have a patent, well functioning, arteriovenous dialysis access;. 6. Signs of chronic inflammation (the average of three consecutive CRP measurements  5 mg/L).. Exclusion Criteria:. 1. Patients with residual renal function \\> 5 ml/min or urine output \\> 100 ml/day;. 2. Pregnancy;. 3. Intolerance to the study medication or contraindication to the study medication: Hypersensitivity to E. coli-derived proteins, anakinra, or any component of the formulation; patients with active infections (including chronic or local infection);. 4. Severe, unstable, active, or chronic inflammatory disease (active infection, active connective tissue disorder, active cancer or cancer history in the prior 5 years, HIV, liver disease including positive test or history of Hepatitis B or C);. 5. Hospitalization within 1 month prior to the study;. 6. Malfunctioning arterial-venous vascular access \\[recirculation and/or blood flow \\< 500 ml/min for an arterial-venous graft (AVG) or \\< 400 ml/min for an arterial-venous fistula (AVF)\\];. 7. Patients receiving steroids and/or other immunosuppressive agents;. 8. Life-expectancy less than 6 months;. 9. Age greater than 75 or less than 18 years old;. 10. Hypersensitivity to organic nitrates, isosorbide, or nitroglycerin.. 11. Presence of active infections or a history of pulmonary TB infection with or without documented adequate therapy. Subjects with current active TB, or recent close exposure to an individual with active TB, are excluded from the study"}, {"type": "EXCLUSION", "field": "procedure", "operator": "IN", "value": "3. Have acceptable dialysis adequacy (Kt/V \\> 1.2)", "unit": null, "evidence_text": "Inclusion Criteria:. 1. Patients on CHD for more than 3 months;. 2. Ability to read and sign the consent form;. 3. Have acceptable dialysis adequacy (Kt/V \\> 1.2);. 4. Use biocompatible hemodialysis membrane;. 5. Have a patent, well functioning, arteriovenous dialysis access;. 6. Signs of chronic inflammation (the average of three consecutive CRP measurements  5 mg/L).. Exclusion Criteria:. 1. Patients with residual renal function \\> 5 ml/min or urine output \\> 100 ml/day;. 2. Pregnancy;. 3. Intolerance to the study medication or contraindication to the study medication: Hypersensitivity to E. coli-derived proteins, anakinra, or any component of the formulation; patients with active infections (including chronic or local infection);. 4. Severe, unstable, active, or chronic inflammatory disease (active infection, active connective tissue disorder, active cancer or cancer history in the prior 5 years, HIV, liver disease including positive test or history of Hepatitis B or C);. 5. Hospitalization within 1 month prior to the study;. 6. Malfunctioning arterial-venous vascular access \\[recirculation and/or blood flow \\< 500 ml/min for an arterial-venous graft (AVG) or \\< 400 ml/min for an arterial-venous fistula (AVF)\\];. 7. Patients receiving steroids and/or other immunosuppressive agents;. 8. Life-expectancy less than 6 months;. 9. Age greater than 75 or less than 18 years old;. 10. Hypersensitivity to organic nitrates, isosorbide, or nitroglycerin.. 11. Presence of active infections or a history of pulmonary TB infection with or without documented adequate therapy. Subjects with current active TB, or recent close exposure to an individual with active TB, are excluded from the study"}, {"type": "EXCLUSION", "field": "procedure", "operator": "IN", "value": "4. Severe, unstable, active, or chronic inflammatory disease (active infection, active connective tissue disorder, active cancer or cancer", "unit": null, "evidence_text": "Inclusion Criteria:. 1. Patients on CHD for more than 3 months;. 2. Ability to read and sign the consent form;. 3. Have acceptable dialysis adequacy (Kt/V \\> 1.2);. 4. Use biocompatible hemodialysis membrane;. 5. Have a patent, well functioning, arteriovenous dialysis access;. 6. Signs of chronic inflammation (the average of three consecutive CRP measurements  5 mg/L).. Exclusion Criteria:. 1. Patients with residual renal function \\> 5 ml/min or urine output \\> 100 ml/day;. 2. Pregnancy;. 3. Intolerance to the study medication or contraindication to the study medication: Hypersensitivity to E. coli-derived proteins, anakinra, or any component of the formulation; patients with active infections (including chronic or local infection);. 4. Severe, unstable, active, or chronic inflammatory disease (active infection, active connective tissue disorder, active cancer or cancer history in the prior 5 years, HIV, liver disease including positive test or history of Hepatitis B or C);. 5. Hospitalization within 1 month prior to the study;. 6. Malfunctioning arterial-venous vascular access \\[recirculation and/or blood flow \\< 500 ml/min for an arterial-venous graft (AVG) or \\< 400 ml/min for an arterial-venous fistula (AVF)\\];. 7. Patients receiving steroids and/or other immunosuppressive agents;. 8. Life-expectancy less than 6 months;. 9. Age greater than 75 or less than 18 years old;. 10. Hypersensitivity to organic nitrates, isosorbide, or nitroglycerin.. 11. Presence of active infections or a history of pulmonary TB infection with or without documented adequate therapy. Subjects with current active TB, or recent close exposure to an individual with active TB, are excluded from the study"}, {"type": "EXCLUSION", "field": "procedure", "operator": "IN", "value": "4. Use biocompatible hemodialysis membrane", "unit": null, "evidence_text": "Inclusion Criteria:. 1. Patients on CHD for more than 3 months;. 2. Ability to read and sign the consent form;. 3. Have acceptable dialysis adequacy (Kt/V \\> 1.2);. 4. Use biocompatible hemodialysis membrane;. 5. Have a patent, well functioning, arteriovenous dialysis access;. 6. Signs of chronic inflammation (the average of three consecutive CRP measurements  5 mg/L).. Exclusion Criteria:. 1. Patients with residual renal function \\> 5 ml/min or urine output \\> 100 ml/day;. 2. Pregnancy;. 3. Intolerance to the study medication or contraindication to the study medication: Hypersensitivity to E. coli-derived proteins, anakinra, or any component of the formulation; patients with active infections (including chronic or local infection);. 4. Severe, unstable, active, or chronic inflammatory disease (active infection, active connective tissue disorder, active cancer or cancer history in the prior 5 years, HIV, liver disease including positive test or history of Hepatitis B or C);. 5. Hospitalization within 1 month prior to the study;. 6. Malfunctioning arterial-venous vascular access \\[recirculation and/or blood flow \\< 500 ml/min for an arterial-venous graft (AVG) or \\< 400 ml/min for an arterial-venous fistula (AVF)\\];. 7. Patients receiving steroids and/or other immunosuppressive agents;. 8. Life-expectancy less than 6 months;. 9. Age greater than 75 or less than 18 years old;. 10. Hypersensitivity to organic nitrates, isosorbide, or nitroglycerin.. 11. Presence of active infections or a history of pulmonary TB infection with or without documented adequate therapy. Subjects with current active TB, or recent close exposure to an individual with active TB, are excluded from the study"}, {"type": "EXCLUSION", "field": "procedure", "operator": "IN", "value": "5. Have a patent, well functioning, arteriovenous dialysis access", "unit": null, "evidence_text": "Inclusion Criteria:. 1. Patients on CHD for more than 3 months;. 2. Ability to read and sign the consent form;. 3. Have acceptable dialysis adequacy (Kt/V \\> 1.2);. 4. Use biocompatible hemodialysis membrane;. 5. Have a patent, well functioning, arteriovenous dialysis access;. 6. Signs of chronic inflammation (the average of three consecutive CRP measurements  5 mg/L).. Exclusion Criteria:. 1. Patients with residual renal function \\> 5 ml/min or urine output \\> 100 ml/day;. 2. Pregnancy;. 3. Intolerance to the study medication or contraindication to the study medication: Hypersensitivity to E. coli-derived proteins, anakinra, or any component of the formulation; patients with active infections (including chronic or local infection);. 4. Severe, unstable, active, or chronic inflammatory disease (active infection, active connective tissue disorder, active cancer or cancer history in the prior 5 years, HIV, liver disease including positive test or history of Hepatitis B or C);. 5. Hospitalization within 1 month prior to the study;. 6. Malfunctioning arterial-venous vascular access \\[recirculation and/or blood flow \\< 500 ml/min for an arterial-venous graft (AVG) or \\< 400 ml/min for an arterial-venous fistula (AVF)\\];. 7. Patients receiving steroids and/or other immunosuppressive agents;. 8. Life-expectancy less than 6 months;. 9. Age greater than 75 or less than 18 years old;. 10. Hypersensitivity to organic nitrates, isosorbide, or nitroglycerin.. 11. Presence of active infections or a history of pulmonary TB infection with or without documented adequate therapy. Subjects with current active TB, or recent close exposure to an individual with active TB, are excluded from the study"}, {"type": "EXCLUSION", "field": "procedure", "operator": "IN", "value": "6. Malfunctioning arterial-venous vascular access \\[recirculation and/or blood flow \\< 500 ml/min for an arterial-venous graft (AVG) or \\<", "unit": null, "evidence_text": "Inclusion Criteria:. 1. Patients on CHD for more than 3 months;. 2. Ability to read and sign the consent form;. 3. Have acceptable dialysis adequacy (Kt/V \\> 1.2);. 4. Use biocompatible hemodialysis membrane;. 5. Have a patent, well functioning, arteriovenous dialysis access;. 6. Signs of chronic inflammation (the average of three consecutive CRP measurements  5 mg/L).. Exclusion Criteria:. 1. Patients with residual renal function \\> 5 ml/min or urine output \\> 100 ml/day;. 2. Pregnancy;. 3. Intolerance to the study medication or contraindication to the study medication: Hypersensitivity to E. coli-derived proteins, anakinra, or any component of the formulation; patients with active infections (including chronic or local infection);. 4. Severe, unstable, active, or chronic inflammatory disease (active infection, active connective tissue disorder, active cancer or cancer history in the prior 5 years, HIV, liver disease including positive test or history of Hepatitis B or C);. 5. Hospitalization within 1 month prior to the study;. 6. Malfunctioning arterial-venous vascular access \\[recirculation and/or blood flow \\< 500 ml/min for an arterial-venous graft (AVG) or \\< 400 ml/min for an arterial-venous fistula (AVF)\\];. 7. Patients receiving steroids and/or other immunosuppressive agents;. 8. Life-expectancy less than 6 months;. 9. Age greater than 75 or less than 18 years old;. 10. Hypersensitivity to organic nitrates, isosorbide, or nitroglycerin.. 11. Presence of active infections or a history of pulmonary TB infection with or without documented adequate therapy. Subjects with current active TB, or recent close exposure to an individual with active TB, are excluded from the study"}, {"type": "EXCLUSION", "field": "procedure", "operator": "IN", "value": "8. Life-expectancy less than 6 months", "unit": null, "evidence_text": "Inclusion Criteria:. 1. Patients on CHD for more than 3 months;. 2. Ability to read and sign the consent form;. 3. Have acceptable dialysis adequacy (Kt/V \\> 1.2);. 4. Use biocompatible hemodialysis membrane;. 5. Have a patent, well functioning, arteriovenous dialysis access;. 6. Signs of chronic inflammation (the average of three consecutive CRP measurements  5 mg/L).. Exclusion Criteria:. 1. Patients with residual renal function \\> 5 ml/min or urine output \\> 100 ml/day;. 2. Pregnancy;. 3. Intolerance to the study medication or contraindication to the study medication: Hypersensitivity to E. coli-derived proteins, anakinra, or any component of the formulation; patients with active infections (including chronic or local infection);. 4. Severe, unstable, active, or chronic inflammatory disease (active infection, active connective tissue disorder, active cancer or cancer history in the prior 5 years, HIV, liver disease including positive test or history of Hepatitis B or C);. 5. Hospitalization within 1 month prior to the study;. 6. Malfunctioning arterial-venous vascular access \\[recirculation and/or blood flow \\< 500 ml/min for an arterial-venous graft (AVG) or \\< 400 ml/min for an arterial-venous fistula (AVF)\\];. 7. Patients receiving steroids and/or other immunosuppressive agents;. 8. Life-expectancy less than 6 months;. 9. Age greater than 75 or less than 18 years old;. 10. Hypersensitivity to organic nitrates, isosorbide, or nitroglycerin.. 11. Presence of active infections or a history of pulmonary TB infection with or without documented adequate therapy. Subjects with current active TB, or recent close exposure to an individual with active TB, are excluded from the study"}, {"type": "EXCLUSION", "field": "procedure", "operator": "IN", "value": "patients with active infections (including chronic or local infection)", "unit": null, "evidence_text": "Inclusion Criteria:. 1. Patients on CHD for more than 3 months;. 2. Ability to read and sign the consent form;. 3. Have acceptable dialysis adequacy (Kt/V \\> 1.2);. 4. Use biocompatible hemodialysis membrane;. 5. Have a patent, well functioning, arteriovenous dialysis access;. 6. Signs of chronic inflammation (the average of three consecutive CRP measurements  5 mg/L).. Exclusion Criteria:. 1. Patients with residual renal function \\> 5 ml/min or urine output \\> 100 ml/day;. 2. Pregnancy;. 3. Intolerance to the study medication or contraindication to the study medication: Hypersensitivity to E. coli-derived proteins, anakinra, or any component of the formulation; patients with active infections (including chronic or local infection);. 4. Severe, unstable, active, or chronic inflammatory disease (active infection, active connective tissue disorder, active cancer or cancer history in the prior 5 years, HIV, liver disease including positive test or history of Hepatitis B or C);. 5. Hospitalization within 1 month prior to the study;. 6. Malfunctioning arterial-venous vascular access \\[recirculation and/or blood flow \\< 500 ml/min for an arterial-venous graft (AVG) or \\< 400 ml/min for an arterial-venous fistula (AVF)\\];. 7. Patients receiving steroids and/or other immunosuppressive agents;. 8. Life-expectancy less than 6 months;. 9. Age greater than 75 or less than 18 years old;. 10. Hypersensitivity to organic nitrates, isosorbide, or nitroglycerin.. 11. Presence of active infections or a history of pulmonary TB infection with or without documented adequate therapy. Subjects with current active TB, or recent close exposure to an individual with active TB, are excluded from the study"}], "annotator_id": "annotator_c", "guideline_version": "m5-v1", "adjudicated": true, "adjudication_source": "parsing_relabel_round1"}
{"nct_id": "NCT00421642", "eligibility_text": "Inclusion Criteria. 1. Males and females 18 years of age and older. 2. Female subjects must utilize a highly effective method of birth control throughout the study and for 70 days after study completion, or female subjects must not be of childbearing potential, defined as postmenopausal at least two years, or surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy).. 3. A diagnosis of UC for greater than 3 months.. 4. UC diagnosis confirmed by endoscopy with exclusion of infectious cause.. 5. Active ulcerative colitis with a Mayo Clinic Score (see Appendix C) of 6 to 12 points with moderately-to-severely active disease on sigmoidoscopy (endoscopic subscore of at least 2) despite concurrent treatment with corticosteroids, and/or azathioprine or 6 mercaptopurine and/or 5-aminosalicylate-containing medications. Patients who previously have not responded to or could not tolerate corticosteroids (within the past 18 months), or azathioprine or 6 mercaptopurine (both within the past 5 years), or 5 aminosalicylate-containing medications (within the past 18 months) will not required to be taking concurrent therapy at enrollment.. 6. Either anti-TNF agent nave or those with previous clinical response to infliximab therapy for UC with subsequent loss of response AND/OR are unable to tolerate further infliximab therapy for UC due to acute or delayed reactions, as defined by the investigator.. 7. Subjects must be able and willing to give written informed consent and to comply with the requirements of this study protocol.. 8. Adequate cardiac, renal and hepatic function as determined by principal investigator and demonstrated by screening laboratory evaluations, questionnaires, and physical examination results that are within normal limits.. Exclusion Criteria. 1. History of cancer or lymphoproliferative disease other than a successfully and completely treated squamous cell or basal cell carcinoma of the skin.. 2. Subjects with a history of Listeria, Hepatitis B infection, central nervous system (CNS) demyelinating disease, or human immunodeficiency virus (HIV) or a history of previously untreated TB. See Appendix B.. 3. Subjects with Crohn?s Disease. 4. Subjects with symptomatic obstructive strictures. 5. Subjects who have had subtotal colectomy with ileorectostomy or colectomy with ileoanal pouch, Kock pouch, or ileostomy for ulcerative colitis or are planning subtotal colectomy or colectomy within 8 weeks of starting the study medication.. 6. Subjects who are currently receiving total parenteral nutrition (TPN).. 7. Any investigational chemical agent in the past 30 days or 5 half-lives prior to screening (whichever is longer). Patients who have previously been treated with infliximab and responded, and then become intolerant to infliximab or lost response, can be treated \\>/= 4 weeks from their last infliximab dose.. 8. Antibiotic treatment for any systemic infection within 3 weeks prior to screening.. 9. Female subjects who are pregnant or breast-feeding.. 10. History of clinically significant drug or alcohol abuse in the prior year.. 11. Poorly controlled medical condition, including but not limited to diabetes with documented history of recurrent infections or cerebrovascular accidents (within 3 months).. 12. Subjects who have been on cyclosporine or tacrolimus within 4 weeks of screening.. 13. Subjects who have been on methotrexate within 4 weeks of screening.", "labeled_rules": [{"type": "EXCLUSION", "field": "age", "operator": ">=", "value": 18, "unit": "years", "evidence_text": "Inclusion Criteria. 1. Males and females 18 years of age and older. 2. Female subjects must utilize a highly effective method of birth control throughout the study and for 70 days after study completion, or female subjects must not be of childbearing potential, defined as postmenopausal at least two years, or surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy).. 3. A diagnosis of UC for greater than 3 months.. 4. UC diagnosis confirmed by endoscopy with exclusion of infectious cause.. 5. Active ulcerative colitis with a Mayo Clinic Score (see Appendix C) of 6 to 12 points with moderately-to-severely active disease on sigmoidoscopy (endoscopic subscore of at least 2) despite concurrent treatment with corticosteroids, and/or azathioprine or 6 mercaptopurine and/or 5-aminosalicylate-containing medications. Patients who previously have not responded to or could not tolerate corticosteroids (within the past 18 months), or azathioprine or 6 mercaptopurine (both within the past 5 years), or 5 aminosalicylate-containing medications (within the past 18 months) will not required to be taking concurrent therapy at enrollment.. 6. Either anti-TNF agent nave or those with previous clinical response to infliximab therapy for UC with subsequent loss of response AND/OR are unable to tolerate further infliximab therapy for UC due to acute or delayed reactions, as defined by the investigator.. 7. Subjects must be able and willing to give written informed consent and to comply with the requirements of this study protocol.. 8. Adequate cardiac, renal and hepatic function as determined by principal investigator and demonstrated by screening laboratory evaluations, questionnaires, and physical examination results that are within normal limits.. Exclusion Criteria. 1. History of cancer or lymphoproliferative disease other than a successfully and completely treated squamous cell or basal cell carcinoma of the skin.. 2. Subjects with a history of Listeria, Hepatitis B infection, central nervous system (CNS) demyelinating disease, or human immunodeficiency virus (HIV) or a history of previously untreated TB. See Appendix B.. 3. Subjects with Crohn?s Disease. 4. Subjects with symptomatic obstructive strictures. 5. Subjects who have had subtotal colectomy with ileorectostomy or colectomy with ileoanal pouch, Kock pouch, or ileostomy for ulcerative colitis or are planning subtotal colectomy or colectomy within 8 weeks of starting the study medication.. 6. Subjects who are currently receiving total parenteral nutrition (TPN).. 7. Any investigational chemical agent in the past 30 days or 5 half-lives prior to screening (whichever is longer). Patients who have previously been treated with infliximab and responded, and then become intolerant to infliximab or lost response, can be treated \\>/= 4 weeks from their last infliximab dose.. 8. Antibiotic treatment for any systemic infection within 3 weeks prior to screening.. 9. Female subjects who are pregnant or breast-feeding.. 10. History of clinically significant drug or alcohol abuse in the prior year.. 11. Poorly controlled medical condition, including but not limited to diabetes with documented history of recurrent infections or cerebrovascular accidents (within 3 months).. 12. Subjects who have been on cyclosporine or tacrolimus within 4 weeks of screening.. 13. Subjects who have been on methotrexate within 4 weeks of screening"}, {"type": "EXCLUSION", "field": "age", "operator": ">=", "value": 2, "unit": "years", "evidence_text": "Inclusion Criteria. 1. Males and females 18 years of age and older. 2. Female subjects must utilize a highly effective method of birth control throughout the study and for 70 days after study completion, or female subjects must not be of childbearing potential, defined as postmenopausal at least two years, or surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy).. 3. A diagnosis of UC for greater than 3 months.. 4. UC diagnosis confirmed by endoscopy with exclusion of infectious cause.. 5. Active ulcerative colitis with a Mayo Clinic Score (see Appendix C) of 6 to 12 points with moderately-to-severely active disease on sigmoidoscopy (endoscopic subscore of at least 2) despite concurrent treatment with corticosteroids, and/or azathioprine or 6 mercaptopurine and/or 5-aminosalicylate-containing medications. Patients who previously have not responded to or could not tolerate corticosteroids (within the past 18 months), or azathioprine or 6 mercaptopurine (both within the past 5 years), or 5 aminosalicylate-containing medications (within the past 18 months) will not required to be taking concurrent therapy at enrollment.. 6. Either anti-TNF agent nave or those with previous clinical response to infliximab therapy for UC with subsequent loss of response AND/OR are unable to tolerate further infliximab therapy for UC due to acute or delayed reactions, as defined by the investigator.. 7. Subjects must be able and willing to give written informed consent and to comply with the requirements of this study protocol.. 8. Adequate cardiac, renal and hepatic function as determined by principal investigator and demonstrated by screening laboratory evaluations, questionnaires, and physical examination results that are within normal limits.. Exclusion Criteria. 1. History of cancer or lymphoproliferative disease other than a successfully and completely treated squamous cell or basal cell carcinoma of the skin.. 2. Subjects with a history of Listeria, Hepatitis B infection, central nervous system (CNS) demyelinating disease, or human immunodeficiency virus (HIV) or a history of previously untreated TB. See Appendix B.. 3. Subjects with Crohn?s Disease. 4. Subjects with symptomatic obstructive strictures. 5. Subjects who have had subtotal colectomy with ileorectostomy or colectomy with ileoanal pouch, Kock pouch, or ileostomy for ulcerative colitis or are planning subtotal colectomy or colectomy within 8 weeks of starting the study medication.. 6. Subjects who are currently receiving total parenteral nutrition (TPN).. 7. Any investigational chemical agent in the past 30 days or 5 half-lives prior to screening (whichever is longer). Patients who have previously been treated with infliximab and responded, and then become intolerant to infliximab or lost response, can be treated \\>/= 4 weeks from their last infliximab dose.. 8. Antibiotic treatment for any systemic infection within 3 weeks prior to screening.. 9. Female subjects who are pregnant or breast-feeding.. 10. History of clinically significant drug or alcohol abuse in the prior year.. 11. Poorly controlled medical condition, including but not limited to diabetes with documented history of recurrent infections or cerebrovascular accidents (within 3 months).. 12. Subjects who have been on cyclosporine or tacrolimus within 4 weeks of screening.. 13. Subjects who have been on methotrexate within 4 weeks of screening"}, {"type": "EXCLUSION", "field": "condition", "operator": "IN", "value": "a history of listeria", "unit": null, "evidence_text": "Inclusion Criteria. 1. Males and females 18 years of age and older. 2. Female subjects must utilize a highly effective method of birth control throughout the study and for 70 days after study completion, or female subjects must not be of childbearing potential, defined as postmenopausal at least two years, or surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy).. 3. A diagnosis of UC for greater than 3 months.. 4. UC diagnosis confirmed by endoscopy with exclusion of infectious cause.. 5. Active ulcerative colitis with a Mayo Clinic Score (see Appendix C) of 6 to 12 points with moderately-to-severely active disease on sigmoidoscopy (endoscopic subscore of at least 2) despite concurrent treatment with corticosteroids, and/or azathioprine or 6 mercaptopurine and/or 5-aminosalicylate-containing medications. Patients who previously have not responded to or could not tolerate corticosteroids (within the past 18 months), or azathioprine or 6 mercaptopurine (both within the past 5 years), or 5 aminosalicylate-containing medications (within the past 18 months) will not required to be taking concurrent therapy at enrollment.. 6. Either anti-TNF agent nave or those with previous clinical response to infliximab therapy for UC with subsequent loss of response AND/OR are unable to tolerate further infliximab therapy for UC due to acute or delayed reactions, as defined by the investigator.. 7. Subjects must be able and willing to give written informed consent and to comply with the requirements of this study protocol.. 8. Adequate cardiac, renal and hepatic function as determined by principal investigator and demonstrated by screening laboratory evaluations, questionnaires, and physical examination results that are within normal limits.. Exclusion Criteria. 1. History of cancer or lymphoproliferative disease other than a successfully and completely treated squamous cell or basal cell carcinoma of the skin.. 2. Subjects with a history of Listeria, Hepatitis B infection, central nervous system (CNS) demyelinating disease, or human immunodeficiency virus (HIV) or a history of previously untreated TB. See Appendix B.. 3. Subjects with Crohn?s Disease. 4. Subjects with symptomatic obstructive strictures. 5. Subjects who have had subtotal colectomy with ileorectostomy or colectomy with ileoanal pouch, Kock pouch, or ileostomy for ulcerative colitis or are planning subtotal colectomy or colectomy within 8 weeks of starting the study medication.. 6. Subjects who are currently receiving total parenteral nutrition (TPN).. 7. Any investigational chemical agent in the past 30 days or 5 half-lives prior to screening (whichever is longer). Patients who have previously been treated with infliximab and responded, and then become intolerant to infliximab or lost response, can be treated \\>/= 4 weeks from their last infliximab dose.. 8. Antibiotic treatment for any systemic infection within 3 weeks prior to screening.. 9. Female subjects who are pregnant or breast-feeding.. 10. History of clinically significant drug or alcohol abuse in the prior year.. 11. Poorly controlled medical condition, including but not limited to diabetes with documented history of recurrent infections or cerebrovascular accidents (within 3 months).. 12. Subjects who have been on cyclosporine or tacrolimus within 4 weeks of screening.. 13. Subjects who have been on methotrexate within 4 weeks of screening"}, {"type": "EXCLUSION", "field": "condition", "operator": "IN", "value": "corticosteroids", "unit": null, "evidence_text": "Inclusion Criteria. 1. Males and females 18 years of age and older. 2. Female subjects must utilize a highly effective method of birth control throughout the study and for 70 days after study completion, or female subjects must not be of childbearing potential, defined as postmenopausal at least two years, or surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy).. 3. A diagnosis of UC for greater than 3 months.. 4. UC diagnosis confirmed by endoscopy with exclusion of infectious cause.. 5. Active ulcerative colitis with a Mayo Clinic Score (see Appendix C) of 6 to 12 points with moderately-to-severely active disease on sigmoidoscopy (endoscopic subscore of at least 2) despite concurrent treatment with corticosteroids, and/or azathioprine or 6 mercaptopurine and/or 5-aminosalicylate-containing medications. Patients who previously have not responded to or could not tolerate corticosteroids (within the past 18 months), or azathioprine or 6 mercaptopurine (both within the past 5 years), or 5 aminosalicylate-containing medications (within the past 18 months) will not required to be taking concurrent therapy at enrollment.. 6. Either anti-TNF agent nave or those with previous clinical response to infliximab therapy for UC with subsequent loss of response AND/OR are unable to tolerate further infliximab therapy for UC due to acute or delayed reactions, as defined by the investigator.. 7. Subjects must be able and willing to give written informed consent and to comply with the requirements of this study protocol.. 8. Adequate cardiac, renal and hepatic function as determined by principal investigator and demonstrated by screening laboratory evaluations, questionnaires, and physical examination results that are within normal limits.. Exclusion Criteria. 1. History of cancer or lymphoproliferative disease other than a successfully and completely treated squamous cell or basal cell carcinoma of the skin.. 2. Subjects with a history of Listeria, Hepatitis B infection, central nervous system (CNS) demyelinating disease, or human immunodeficiency virus (HIV) or a history of previously untreated TB. See Appendix B.. 3. Subjects with Crohn?s Disease. 4. Subjects with symptomatic obstructive strictures. 5. Subjects who have had subtotal colectomy with ileorectostomy or colectomy with ileoanal pouch, Kock pouch, or ileostomy for ulcerative colitis or are planning subtotal colectomy or colectomy within 8 weeks of starting the study medication.. 6. Subjects who are currently receiving total parenteral nutrition (TPN).. 7. Any investigational chemical agent in the past 30 days or 5 half-lives prior to screening (whichever is longer). Patients who have previously been treated with infliximab and responded, and then become intolerant to infliximab or lost response, can be treated \\>/= 4 weeks from their last infliximab dose.. 8. Antibiotic treatment for any systemic infection within 3 weeks prior to screening.. 9. Female subjects who are pregnant or breast-feeding.. 10. History of clinically significant drug or alcohol abuse in the prior year.. 11. Poorly controlled medical condition, including but not limited to diabetes with documented history of recurrent infections or cerebrovascular accidents (within 3 months).. 12. Subjects who have been on cyclosporine or tacrolimus within 4 weeks of screening.. 13. Subjects who have been on methotrexate within 4 weeks of screening"}, {"type": "EXCLUSION", "field": "condition", "operator": "IN", "value": "exclusion of infectious cause", "unit": null, "evidence_text": "Inclusion Criteria. 1. Males and females 18 years of age and older. 2. Female subjects must utilize a highly effective method of birth control throughout the study and for 70 days after study completion, or female subjects must not be of childbearing potential, defined as postmenopausal at least two years, or surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy).. 3. A diagnosis of UC for greater than 3 months.. 4. UC diagnosis confirmed by endoscopy with exclusion of infectious cause.. 5. Active ulcerative colitis with a Mayo Clinic Score (see Appendix C) of 6 to 12 points with moderately-to-severely active disease on sigmoidoscopy (endoscopic subscore of at least 2) despite concurrent treatment with corticosteroids, and/or azathioprine or 6 mercaptopurine and/or 5-aminosalicylate-containing medications. Patients who previously have not responded to or could not tolerate corticosteroids (within the past 18 months), or azathioprine or 6 mercaptopurine (both within the past 5 years), or 5 aminosalicylate-containing medications (within the past 18 months) will not required to be taking concurrent therapy at enrollment.. 6. Either anti-TNF agent nave or those with previous clinical response to infliximab therapy for UC with subsequent loss of response AND/OR are unable to tolerate further infliximab therapy for UC due to acute or delayed reactions, as defined by the investigator.. 7. Subjects must be able and willing to give written informed consent and to comply with the requirements of this study protocol.. 8. Adequate cardiac, renal and hepatic function as determined by principal investigator and demonstrated by screening laboratory evaluations, questionnaires, and physical examination results that are within normal limits.. Exclusion Criteria. 1. History of cancer or lymphoproliferative disease other than a successfully and completely treated squamous cell or basal cell carcinoma of the skin.. 2. Subjects with a history of Listeria, Hepatitis B infection, central nervous system (CNS) demyelinating disease, or human immunodeficiency virus (HIV) or a history of previously untreated TB. See Appendix B.. 3. Subjects with Crohn?s Disease. 4. Subjects with symptomatic obstructive strictures. 5. Subjects who have had subtotal colectomy with ileorectostomy or colectomy with ileoanal pouch, Kock pouch, or ileostomy for ulcerative colitis or are planning subtotal colectomy or colectomy within 8 weeks of starting the study medication.. 6. Subjects who are currently receiving total parenteral nutrition (TPN).. 7. Any investigational chemical agent in the past 30 days or 5 half-lives prior to screening (whichever is longer). Patients who have previously been treated with infliximab and responded, and then become intolerant to infliximab or lost response, can be treated \\>/= 4 weeks from their last infliximab dose.. 8. Antibiotic treatment for any systemic infection within 3 weeks prior to screening.. 9. Female subjects who are pregnant or breast-feeding.. 10. History of clinically significant drug or alcohol abuse in the prior year.. 11. Poorly controlled medical condition, including but not limited to diabetes with documented history of recurrent infections or cerebrovascular accidents (within 3 months).. 12. Subjects who have been on cyclosporine or tacrolimus within 4 weeks of screening.. 13. Subjects who have been on methotrexate within 4 weeks of screening"}, {"type": "EXCLUSION", "field": "condition", "operator": "IN", "value": "ileorectostomy or colectomy with ileoanal pouch", "unit": null, "evidence_text": "Inclusion Criteria. 1. Males and females 18 years of age and older. 2. Female subjects must utilize a highly effective method of birth control throughout the study and for 70 days after study completion, or female subjects must not be of childbearing potential, defined as postmenopausal at least two years, or surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy).. 3. A diagnosis of UC for greater than 3 months.. 4. UC diagnosis confirmed by endoscopy with exclusion of infectious cause.. 5. Active ulcerative colitis with a Mayo Clinic Score (see Appendix C) of 6 to 12 points with moderately-to-severely active disease on sigmoidoscopy (endoscopic subscore of at least 2) despite concurrent treatment with corticosteroids, and/or azathioprine or 6 mercaptopurine and/or 5-aminosalicylate-containing medications. Patients who previously have not responded to or could not tolerate corticosteroids (within the past 18 months), or azathioprine or 6 mercaptopurine (both within the past 5 years), or 5 aminosalicylate-containing medications (within the past 18 months) will not required to be taking concurrent therapy at enrollment.. 6. Either anti-TNF agent nave or those with previous clinical response to infliximab therapy for UC with subsequent loss of response AND/OR are unable to tolerate further infliximab therapy for UC due to acute or delayed reactions, as defined by the investigator.. 7. Subjects must be able and willing to give written informed consent and to comply with the requirements of this study protocol.. 8. Adequate cardiac, renal and hepatic function as determined by principal investigator and demonstrated by screening laboratory evaluations, questionnaires, and physical examination results that are within normal limits.. Exclusion Criteria. 1. History of cancer or lymphoproliferative disease other than a successfully and completely treated squamous cell or basal cell carcinoma of the skin.. 2. Subjects with a history of Listeria, Hepatitis B infection, central nervous system (CNS) demyelinating disease, or human immunodeficiency virus (HIV) or a history of previously untreated TB. See Appendix B.. 3. Subjects with Crohn?s Disease. 4. Subjects with symptomatic obstructive strictures. 5. Subjects who have had subtotal colectomy with ileorectostomy or colectomy with ileoanal pouch, Kock pouch, or ileostomy for ulcerative colitis or are planning subtotal colectomy or colectomy within 8 weeks of starting the study medication.. 6. Subjects who are currently receiving total parenteral nutrition (TPN).. 7. Any investigational chemical agent in the past 30 days or 5 half-lives prior to screening (whichever is longer). Patients who have previously been treated with infliximab and responded, and then become intolerant to infliximab or lost response, can be treated \\>/= 4 weeks from their last infliximab dose.. 8. Antibiotic treatment for any systemic infection within 3 weeks prior to screening.. 9. Female subjects who are pregnant or breast-feeding.. 10. History of clinically significant drug or alcohol abuse in the prior year.. 11. Poorly controlled medical condition, including but not limited to diabetes with documented history of recurrent infections or cerebrovascular accidents (within 3 months).. 12. Subjects who have been on cyclosporine or tacrolimus within 4 weeks of screening.. 13. Subjects who have been on methotrexate within 4 weeks of screening"}, {"type": "EXCLUSION", "field": "condition", "operator": "IN", "value": "infliximab and responded", "unit": null, "evidence_text": "Inclusion Criteria. 1. Males and females 18 years of age and older. 2. Female subjects must utilize a highly effective method of birth control throughout the study and for 70 days after study completion, or female subjects must not be of childbearing potential, defined as postmenopausal at least two years, or surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy).. 3. A diagnosis of UC for greater than 3 months.. 4. UC diagnosis confirmed by endoscopy with exclusion of infectious cause.. 5. Active ulcerative colitis with a Mayo Clinic Score (see Appendix C) of 6 to 12 points with moderately-to-severely active disease on sigmoidoscopy (endoscopic subscore of at least 2) despite concurrent treatment with corticosteroids, and/or azathioprine or 6 mercaptopurine and/or 5-aminosalicylate-containing medications. Patients who previously have not responded to or could not tolerate corticosteroids (within the past 18 months), or azathioprine or 6 mercaptopurine (both within the past 5 years), or 5 aminosalicylate-containing medications (within the past 18 months) will not required to be taking concurrent therapy at enrollment.. 6. Either anti-TNF agent nave or those with previous clinical response to infliximab therapy for UC with subsequent loss of response AND/OR are unable to tolerate further infliximab therapy for UC due to acute or delayed reactions, as defined by the investigator.. 7. Subjects must be able and willing to give written informed consent and to comply with the requirements of this study protocol.. 8. Adequate cardiac, renal and hepatic function as determined by principal investigator and demonstrated by screening laboratory evaluations, questionnaires, and physical examination results that are within normal limits.. Exclusion Criteria. 1. History of cancer or lymphoproliferative disease other than a successfully and completely treated squamous cell or basal cell carcinoma of the skin.. 2. Subjects with a history of Listeria, Hepatitis B infection, central nervous system (CNS) demyelinating disease, or human immunodeficiency virus (HIV) or a history of previously untreated TB. See Appendix B.. 3. Subjects with Crohn?s Disease. 4. Subjects with symptomatic obstructive strictures. 5. Subjects who have had subtotal colectomy with ileorectostomy or colectomy with ileoanal pouch, Kock pouch, or ileostomy for ulcerative colitis or are planning subtotal colectomy or colectomy within 8 weeks of starting the study medication.. 6. Subjects who are currently receiving total parenteral nutrition (TPN).. 7. Any investigational chemical agent in the past 30 days or 5 half-lives prior to screening (whichever is longer). Patients who have previously been treated with infliximab and responded, and then become intolerant to infliximab or lost response, can be treated \\>/= 4 weeks from their last infliximab dose.. 8. Antibiotic treatment for any systemic infection within 3 weeks prior to screening.. 9. Female subjects who are pregnant or breast-feeding.. 10. History of clinically significant drug or alcohol abuse in the prior year.. 11. Poorly controlled medical condition, including but not limited to diabetes with documented history of recurrent infections or cerebrovascular accidents (within 3 months).. 12. Subjects who have been on cyclosporine or tacrolimus within 4 weeks of screening.. 13. Subjects who have been on methotrexate within 4 weeks of screening"}, {"type": "EXCLUSION", "field": "condition", "operator": "IN", "value": "symptomatic obstructive strictures", "unit": null, "evidence_text": "Inclusion Criteria. 1. Males and females 18 years of age and older. 2. Female subjects must utilize a highly effective method of birth control throughout the study and for 70 days after study completion, or female subjects must not be of childbearing potential, defined as postmenopausal at least two years, or surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy).. 3. A diagnosis of UC for greater than 3 months.. 4. UC diagnosis confirmed by endoscopy with exclusion of infectious cause.. 5. Active ulcerative colitis with a Mayo Clinic Score (see Appendix C) of 6 to 12 points with moderately-to-severely active disease on sigmoidoscopy (endoscopic subscore of at least 2) despite concurrent treatment with corticosteroids, and/or azathioprine or 6 mercaptopurine and/or 5-aminosalicylate-containing medications. Patients who previously have not responded to or could not tolerate corticosteroids (within the past 18 months), or azathioprine or 6 mercaptopurine (both within the past 5 years), or 5 aminosalicylate-containing medications (within the past 18 months) will not required to be taking concurrent therapy at enrollment.. 6. Either anti-TNF agent nave or those with previous clinical response to infliximab therapy for UC with subsequent loss of response AND/OR are unable to tolerate further infliximab therapy for UC due to acute or delayed reactions, as defined by the investigator.. 7. Subjects must be able and willing to give written informed consent and to comply with the requirements of this study protocol.. 8. Adequate cardiac, renal and hepatic function as determined by principal investigator and demonstrated by screening laboratory evaluations, questionnaires, and physical examination results that are within normal limits.. Exclusion Criteria. 1. History of cancer or lymphoproliferative disease other than a successfully and completely treated squamous cell or basal cell carcinoma of the skin.. 2. Subjects with a history of Listeria, Hepatitis B infection, central nervous system (CNS) demyelinating disease, or human immunodeficiency virus (HIV) or a history of previously untreated TB. See Appendix B.. 3. Subjects with Crohn?s Disease. 4. Subjects with symptomatic obstructive strictures. 5. Subjects who have had subtotal colectomy with ileorectostomy or colectomy with ileoanal pouch, Kock pouch, or ileostomy for ulcerative colitis or are planning subtotal colectomy or colectomy within 8 weeks of starting the study medication.. 6. Subjects who are currently receiving total parenteral nutrition (TPN).. 7. Any investigational chemical agent in the past 30 days or 5 half-lives prior to screening (whichever is longer). Patients who have previously been treated with infliximab and responded, and then become intolerant to infliximab or lost response, can be treated \\>/= 4 weeks from their last infliximab dose.. 8. Antibiotic treatment for any systemic infection within 3 weeks prior to screening.. 9. Female subjects who are pregnant or breast-feeding.. 10. History of clinically significant drug or alcohol abuse in the prior year.. 11. Poorly controlled medical condition, including but not limited to diabetes with documented history of recurrent infections or cerebrovascular accidents (within 3 months).. 12. Subjects who have been on cyclosporine or tacrolimus within 4 weeks of screening.. 13. Subjects who have been on methotrexate within 4 weeks of screening"}, {"type": "EXCLUSION", "field": "condition", "operator": "IN", "value": "the requirements of this protocol", "unit": null, "evidence_text": "Inclusion Criteria. 1. Males and females 18 years of age and older. 2. Female subjects must utilize a highly effective method of birth control throughout the study and for 70 days after study completion, or female subjects must not be of childbearing potential, defined as postmenopausal at least two years, or surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy).. 3. A diagnosis of UC for greater than 3 months.. 4. UC diagnosis confirmed by endoscopy with exclusion of infectious cause.. 5. Active ulcerative colitis with a Mayo Clinic Score (see Appendix C) of 6 to 12 points with moderately-to-severely active disease on sigmoidoscopy (endoscopic subscore of at least 2) despite concurrent treatment with corticosteroids, and/or azathioprine or 6 mercaptopurine and/or 5-aminosalicylate-containing medications. Patients who previously have not responded to or could not tolerate corticosteroids (within the past 18 months), or azathioprine or 6 mercaptopurine (both within the past 5 years), or 5 aminosalicylate-containing medications (within the past 18 months) will not required to be taking concurrent therapy at enrollment.. 6. Either anti-TNF agent nave or those with previous clinical response to infliximab therapy for UC with subsequent loss of response AND/OR are unable to tolerate further infliximab therapy for UC due to acute or delayed reactions, as defined by the investigator.. 7. Subjects must be able and willing to give written informed consent and to comply with the requirements of this study protocol.. 8. Adequate cardiac, renal and hepatic function as determined by principal investigator and demonstrated by screening laboratory evaluations, questionnaires, and physical examination results that are within normal limits.. Exclusion Criteria. 1. History of cancer or lymphoproliferative disease other than a successfully and completely treated squamous cell or basal cell carcinoma of the skin.. 2. Subjects with a history of Listeria, Hepatitis B infection, central nervous system (CNS) demyelinating disease, or human immunodeficiency virus (HIV) or a history of previously untreated TB. See Appendix B.. 3. Subjects with Crohn?s Disease. 4. Subjects with symptomatic obstructive strictures. 5. Subjects who have had subtotal colectomy with ileorectostomy or colectomy with ileoanal pouch, Kock pouch, or ileostomy for ulcerative colitis or are planning subtotal colectomy or colectomy within 8 weeks of starting the study medication.. 6. Subjects who are currently receiving total parenteral nutrition (TPN).. 7. Any investigational chemical agent in the past 30 days or 5 half-lives prior to screening (whichever is longer). Patients who have previously been treated with infliximab and responded, and then become intolerant to infliximab or lost response, can be treated \\>/= 4 weeks from their last infliximab dose.. 8. Antibiotic treatment for any systemic infection within 3 weeks prior to screening.. 9. Female subjects who are pregnant or breast-feeding.. 10. History of clinically significant drug or alcohol abuse in the prior year.. 11. Poorly controlled medical condition, including but not limited to diabetes with documented history of recurrent infections or cerebrovascular accidents (within 3 months).. 12. Subjects who have been on cyclosporine or tacrolimus within 4 weeks of screening.. 13. Subjects who have been on methotrexate within 4 weeks of screening"}, {"type": "EXCLUSION", "field": "condition", "operator": "IN", "value": "the requirements of this study protocol", "unit": null, "evidence_text": "Inclusion Criteria. 1. Males and females 18 years of age and older. 2. Female subjects must utilize a highly effective method of birth control throughout the study and for 70 days after study completion, or female subjects must not be of childbearing potential, defined as postmenopausal at least two years, or surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy).. 3. A diagnosis of UC for greater than 3 months.. 4. UC diagnosis confirmed by endoscopy with exclusion of infectious cause.. 5. Active ulcerative colitis with a Mayo Clinic Score (see Appendix C) of 6 to 12 points with moderately-to-severely active disease on sigmoidoscopy (endoscopic subscore of at least 2) despite concurrent treatment with corticosteroids, and/or azathioprine or 6 mercaptopurine and/or 5-aminosalicylate-containing medications. Patients who previously have not responded to or could not tolerate corticosteroids (within the past 18 months), or azathioprine or 6 mercaptopurine (both within the past 5 years), or 5 aminosalicylate-containing medications (within the past 18 months) will not required to be taking concurrent therapy at enrollment.. 6. Either anti-TNF agent nave or those with previous clinical response to infliximab therapy for UC with subsequent loss of response AND/OR are unable to tolerate further infliximab therapy for UC due to acute or delayed reactions, as defined by the investigator.. 7. Subjects must be able and willing to give written informed consent and to comply with the requirements of this study protocol.. 8. Adequate cardiac, renal and hepatic function as determined by principal investigator and demonstrated by screening laboratory evaluations, questionnaires, and physical examination results that are within normal limits.. Exclusion Criteria. 1. History of cancer or lymphoproliferative disease other than a successfully and completely treated squamous cell or basal cell carcinoma of the skin.. 2. Subjects with a history of Listeria, Hepatitis B infection, central nervous system (CNS) demyelinating disease, or human immunodeficiency virus (HIV) or a history of previously untreated TB. See Appendix B.. 3. Subjects with Crohn?s Disease. 4. Subjects with symptomatic obstructive strictures. 5. Subjects who have had subtotal colectomy with ileorectostomy or colectomy with ileoanal pouch, Kock pouch, or ileostomy for ulcerative colitis or are planning subtotal colectomy or colectomy within 8 weeks of starting the study medication.. 6. Subjects who are currently receiving total parenteral nutrition (TPN).. 7. Any investigational chemical agent in the past 30 days or 5 half-lives prior to screening (whichever is longer). Patients who have previously been treated with infliximab and responded, and then become intolerant to infliximab or lost response, can be treated \\>/= 4 weeks from their last infliximab dose.. 8. Antibiotic treatment for any systemic infection within 3 weeks prior to screening.. 9. Female subjects who are pregnant or breast-feeding.. 10. History of clinically significant drug or alcohol abuse in the prior year.. 11. Poorly controlled medical condition, including but not limited to diabetes with documented history of recurrent infections or cerebrovascular accidents (within 3 months).. 12. Subjects who have been on cyclosporine or tacrolimus within 4 weeks of screening.. 13. Subjects who have been on methotrexate within 4 weeks of screening"}, {"type": "EXCLUSION", "field": "condition", "operator": "IN", "value": "uc for greater than 3 months", "unit": null, "evidence_text": "Inclusion Criteria. 1. Males and females 18 years of age and older. 2. Female subjects must utilize a highly effective method of birth control throughout the study and for 70 days after study completion, or female subjects must not be of childbearing potential, defined as postmenopausal at least two years, or surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy).. 3. A diagnosis of UC for greater than 3 months.. 4. UC diagnosis confirmed by endoscopy with exclusion of infectious cause.. 5. Active ulcerative colitis with a Mayo Clinic Score (see Appendix C) of 6 to 12 points with moderately-to-severely active disease on sigmoidoscopy (endoscopic subscore of at least 2) despite concurrent treatment with corticosteroids, and/or azathioprine or 6 mercaptopurine and/or 5-aminosalicylate-containing medications. Patients who previously have not responded to or could not tolerate corticosteroids (within the past 18 months), or azathioprine or 6 mercaptopurine (both within the past 5 years), or 5 aminosalicylate-containing medications (within the past 18 months) will not required to be taking concurrent therapy at enrollment.. 6. Either anti-TNF agent nave or those with previous clinical response to infliximab therapy for UC with subsequent loss of response AND/OR are unable to tolerate further infliximab therapy for UC due to acute or delayed reactions, as defined by the investigator.. 7. Subjects must be able and willing to give written informed consent and to comply with the requirements of this study protocol.. 8. Adequate cardiac, renal and hepatic function as determined by principal investigator and demonstrated by screening laboratory evaluations, questionnaires, and physical examination results that are within normal limits.. Exclusion Criteria. 1. History of cancer or lymphoproliferative disease other than a successfully and completely treated squamous cell or basal cell carcinoma of the skin.. 2. Subjects with a history of Listeria, Hepatitis B infection, central nervous system (CNS) demyelinating disease, or human immunodeficiency virus (HIV) or a history of previously untreated TB. See Appendix B.. 3. Subjects with Crohn?s Disease. 4. Subjects with symptomatic obstructive strictures. 5. Subjects who have had subtotal colectomy with ileorectostomy or colectomy with ileoanal pouch, Kock pouch, or ileostomy for ulcerative colitis or are planning subtotal colectomy or colectomy within 8 weeks of starting the study medication.. 6. Subjects who are currently receiving total parenteral nutrition (TPN).. 7. Any investigational chemical agent in the past 30 days or 5 half-lives prior to screening (whichever is longer). Patients who have previously been treated with infliximab and responded, and then become intolerant to infliximab or lost response, can be treated \\>/= 4 weeks from their last infliximab dose.. 8. Antibiotic treatment for any systemic infection within 3 weeks prior to screening.. 9. Female subjects who are pregnant or breast-feeding.. 10. History of clinically significant drug or alcohol abuse in the prior year.. 11. Poorly controlled medical condition, including but not limited to diabetes with documented history of recurrent infections or cerebrovascular accidents (within 3 months).. 12. Subjects who have been on cyclosporine or tacrolimus within 4 weeks of screening.. 13. Subjects who have been on methotrexate within 4 weeks of screening"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "clinically significant drug or alcohol abuse in", "unit": null, "evidence_text": "Inclusion Criteria. 1. Males and females 18 years of age and older. 2. Female subjects must utilize a highly effective method of birth control throughout the study and for 70 days after study completion, or female subjects must not be of childbearing potential, defined as postmenopausal at least two years, or surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy).. 3. A diagnosis of UC for greater than 3 months.. 4. UC diagnosis confirmed by endoscopy with exclusion of infectious cause.. 5. Active ulcerative colitis with a Mayo Clinic Score (see Appendix C) of 6 to 12 points with moderately-to-severely active disease on sigmoidoscopy (endoscopic subscore of at least 2) despite concurrent treatment with corticosteroids, and/or azathioprine or 6 mercaptopurine and/or 5-aminosalicylate-containing medications. Patients who previously have not responded to or could not tolerate corticosteroids (within the past 18 months), or azathioprine or 6 mercaptopurine (both within the past 5 years), or 5 aminosalicylate-containing medications (within the past 18 months) will not required to be taking concurrent therapy at enrollment.. 6. Either anti-TNF agent nave or those with previous clinical response to infliximab therapy for UC with subsequent loss of response AND/OR are unable to tolerate further infliximab therapy for UC due to acute or delayed reactions, as defined by the investigator.. 7. Subjects must be able and willing to give written informed consent and to comply with the requirements of this study protocol.. 8. Adequate cardiac, renal and hepatic function as determined by principal investigator and demonstrated by screening laboratory evaluations, questionnaires, and physical examination results that are within normal limits.. Exclusion Criteria. 1. History of cancer or lymphoproliferative disease other than a successfully and completely treated squamous cell or basal cell carcinoma of the skin.. 2. Subjects with a history of Listeria, Hepatitis B infection, central nervous system (CNS) demyelinating disease, or human immunodeficiency virus (HIV) or a history of previously untreated TB. See Appendix B.. 3. Subjects with Crohn?s Disease. 4. Subjects with symptomatic obstructive strictures. 5. Subjects who have had subtotal colectomy with ileorectostomy or colectomy with ileoanal pouch, Kock pouch, or ileostomy for ulcerative colitis or are planning subtotal colectomy or colectomy within 8 weeks of starting the study medication.. 6. Subjects who are currently receiving total parenteral nutrition (TPN).. 7. Any investigational chemical agent in the past 30 days or 5 half-lives prior to screening (whichever is longer). Patients who have previously been treated with infliximab and responded, and then become intolerant to infliximab or lost response, can be treated \\>/= 4 weeks from their last infliximab dose.. 8. Antibiotic treatment for any systemic infection within 3 weeks prior to screening.. 9. Female subjects who are pregnant or breast-feeding.. 10. History of clinically significant drug or alcohol abuse in the prior year.. 11. Poorly controlled medical condition, including but not limited to diabetes with documented history of recurrent infections or cerebrovascular accidents (within 3 months).. 12. Subjects who have been on cyclosporine or tacrolimus within 4 weeks of screening.. 13. Subjects who have been on methotrexate within 4 weeks of screening"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "hiv positive", "unit": null, "evidence_text": "Inclusion Criteria. 1. Males and females 18 years of age and older. 2. Female subjects must utilize a highly effective method of birth control throughout the study and for 70 days after study completion, or female subjects must not be of childbearing potential, defined as postmenopausal at least two years, or surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy).. 3. A diagnosis of UC for greater than 3 months.. 4. UC diagnosis confirmed by endoscopy with exclusion of infectious cause.. 5. Active ulcerative colitis with a Mayo Clinic Score (see Appendix C) of 6 to 12 points with moderately-to-severely active disease on sigmoidoscopy (endoscopic subscore of at least 2) despite concurrent treatment with corticosteroids, and/or azathioprine or 6 mercaptopurine and/or 5-aminosalicylate-containing medications. Patients who previously have not responded to or could not tolerate corticosteroids (within the past 18 months), or azathioprine or 6 mercaptopurine (both within the past 5 years), or 5 aminosalicylate-containing medications (within the past 18 months) will not required to be taking concurrent therapy at enrollment.. 6. Either anti-TNF agent nave or those with previous clinical response to infliximab therapy for UC with subsequent loss of response AND/OR are unable to tolerate further infliximab therapy for UC due to acute or delayed reactions, as defined by the investigator.. 7. Subjects must be able and willing to give written informed consent and to comply with the requirements of this study protocol.. 8. Adequate cardiac, renal and hepatic function as determined by principal investigator and demonstrated by screening laboratory evaluations, questionnaires, and physical examination results that are within normal limits.. Exclusion Criteria. 1. History of cancer or lymphoproliferative disease other than a successfully and completely treated squamous cell or basal cell carcinoma of the skin.. 2. Subjects with a history of Listeria, Hepatitis B infection, central nervous system (CNS) demyelinating disease, or human immunodeficiency virus (HIV) or a history of previously untreated TB. See Appendix B.. 3. Subjects with Crohn?s Disease. 4. Subjects with symptomatic obstructive strictures. 5. Subjects who have had subtotal colectomy with ileorectostomy or colectomy with ileoanal pouch, Kock pouch, or ileostomy for ulcerative colitis or are planning subtotal colectomy or colectomy within 8 weeks of starting the study medication.. 6. Subjects who are currently receiving total parenteral nutrition (TPN).. 7. Any investigational chemical agent in the past 30 days or 5 half-lives prior to screening (whichever is longer). Patients who have previously been treated with infliximab and responded, and then become intolerant to infliximab or lost response, can be treated \\>/= 4 weeks from their last infliximab dose.. 8. Antibiotic treatment for any systemic infection within 3 weeks prior to screening.. 9. Female subjects who are pregnant or breast-feeding.. 10. History of clinically significant drug or alcohol abuse in the prior year.. 11. Poorly controlled medical condition, including but not limited to diabetes with documented history of recurrent infections or cerebrovascular accidents (within 3 months).. 12. Subjects who have been on cyclosporine or tacrolimus within 4 weeks of screening.. 13. Subjects who have been on methotrexate within 4 weeks of screening"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "previously untreated tb", "unit": null, "evidence_text": "Inclusion Criteria. 1. Males and females 18 years of age and older. 2. Female subjects must utilize a highly effective method of birth control throughout the study and for 70 days after study completion, or female subjects must not be of childbearing potential, defined as postmenopausal at least two years, or surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy).. 3. A diagnosis of UC for greater than 3 months.. 4. UC diagnosis confirmed by endoscopy with exclusion of infectious cause.. 5. Active ulcerative colitis with a Mayo Clinic Score (see Appendix C) of 6 to 12 points with moderately-to-severely active disease on sigmoidoscopy (endoscopic subscore of at least 2) despite concurrent treatment with corticosteroids, and/or azathioprine or 6 mercaptopurine and/or 5-aminosalicylate-containing medications. Patients who previously have not responded to or could not tolerate corticosteroids (within the past 18 months), or azathioprine or 6 mercaptopurine (both within the past 5 years), or 5 aminosalicylate-containing medications (within the past 18 months) will not required to be taking concurrent therapy at enrollment.. 6. Either anti-TNF agent nave or those with previous clinical response to infliximab therapy for UC with subsequent loss of response AND/OR are unable to tolerate further infliximab therapy for UC due to acute or delayed reactions, as defined by the investigator.. 7. Subjects must be able and willing to give written informed consent and to comply with the requirements of this study protocol.. 8. Adequate cardiac, renal and hepatic function as determined by principal investigator and demonstrated by screening laboratory evaluations, questionnaires, and physical examination results that are within normal limits.. Exclusion Criteria. 1. History of cancer or lymphoproliferative disease other than a successfully and completely treated squamous cell or basal cell carcinoma of the skin.. 2. Subjects with a history of Listeria, Hepatitis B infection, central nervous system (CNS) demyelinating disease, or human immunodeficiency virus (HIV) or a history of previously untreated TB. See Appendix B.. 3. Subjects with Crohn?s Disease. 4. Subjects with symptomatic obstructive strictures. 5. Subjects who have had subtotal colectomy with ileorectostomy or colectomy with ileoanal pouch, Kock pouch, or ileostomy for ulcerative colitis or are planning subtotal colectomy or colectomy within 8 weeks of starting the study medication.. 6. Subjects who are currently receiving total parenteral nutrition (TPN).. 7. Any investigational chemical agent in the past 30 days or 5 half-lives prior to screening (whichever is longer). Patients who have previously been treated with infliximab and responded, and then become intolerant to infliximab or lost response, can be treated \\>/= 4 weeks from their last infliximab dose.. 8. Antibiotic treatment for any systemic infection within 3 weeks prior to screening.. 9. Female subjects who are pregnant or breast-feeding.. 10. History of clinically significant drug or alcohol abuse in the prior year.. 11. Poorly controlled medical condition, including but not limited to diabetes with documented history of recurrent infections or cerebrovascular accidents (within 3 months).. 12. Subjects who have been on cyclosporine or tacrolimus within 4 weeks of screening.. 13. Subjects who have been on methotrexate within 4 weeks of screening"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "symptomatic obstructive strictures", "unit": null, "evidence_text": "Inclusion Criteria. 1. Males and females 18 years of age and older. 2. Female subjects must utilize a highly effective method of birth control throughout the study and for 70 days after study completion, or female subjects must not be of childbearing potential, defined as postmenopausal at least two years, or surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy).. 3. A diagnosis of UC for greater than 3 months.. 4. UC diagnosis confirmed by endoscopy with exclusion of infectious cause.. 5. Active ulcerative colitis with a Mayo Clinic Score (see Appendix C) of 6 to 12 points with moderately-to-severely active disease on sigmoidoscopy (endoscopic subscore of at least 2) despite concurrent treatment with corticosteroids, and/or azathioprine or 6 mercaptopurine and/or 5-aminosalicylate-containing medications. Patients who previously have not responded to or could not tolerate corticosteroids (within the past 18 months), or azathioprine or 6 mercaptopurine (both within the past 5 years), or 5 aminosalicylate-containing medications (within the past 18 months) will not required to be taking concurrent therapy at enrollment.. 6. Either anti-TNF agent nave or those with previous clinical response to infliximab therapy for UC with subsequent loss of response AND/OR are unable to tolerate further infliximab therapy for UC due to acute or delayed reactions, as defined by the investigator.. 7. Subjects must be able and willing to give written informed consent and to comply with the requirements of this study protocol.. 8. Adequate cardiac, renal and hepatic function as determined by principal investigator and demonstrated by screening laboratory evaluations, questionnaires, and physical examination results that are within normal limits.. Exclusion Criteria. 1. History of cancer or lymphoproliferative disease other than a successfully and completely treated squamous cell or basal cell carcinoma of the skin.. 2. Subjects with a history of Listeria, Hepatitis B infection, central nervous system (CNS) demyelinating disease, or human immunodeficiency virus (HIV) or a history of previously untreated TB. See Appendix B.. 3. Subjects with Crohn?s Disease. 4. Subjects with symptomatic obstructive strictures. 5. Subjects who have had subtotal colectomy with ileorectostomy or colectomy with ileoanal pouch, Kock pouch, or ileostomy for ulcerative colitis or are planning subtotal colectomy or colectomy within 8 weeks of starting the study medication.. 6. Subjects who are currently receiving total parenteral nutrition (TPN).. 7. Any investigational chemical agent in the past 30 days or 5 half-lives prior to screening (whichever is longer). Patients who have previously been treated with infliximab and responded, and then become intolerant to infliximab or lost response, can be treated \\>/= 4 weeks from their last infliximab dose.. 8. Antibiotic treatment for any systemic infection within 3 weeks prior to screening.. 9. Female subjects who are pregnant or breast-feeding.. 10. History of clinically significant drug or alcohol abuse in the prior year.. 11. Poorly controlled medical condition, including but not limited to diabetes with documented history of recurrent infections or cerebrovascular accidents (within 3 months).. 12. Subjects who have been on cyclosporine or tacrolimus within 4 weeks of screening.. 13. Subjects who have been on methotrexate within 4 weeks of screening"}, {"type": "EXCLUSION", "field": "history", "operator": "IN", "value": "1. Males and females 18 years of age and older. 2. Female subjects must utilize a highly effective method of birth contr", "unit": null, "evidence_text": "Inclusion Criteria. 1. Males and females 18 years of age and older. 2. Female subjects must utilize a highly effective method of birth control throughout the study and for 70 days after study completion, or female subjects must not be of childbearing potential, defined as postmenopausal at least two years, or surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy).. 3. A diagnosis of UC for greater than 3 months.. 4. UC diagnosis confirmed by endoscopy with exclusion of infectious cause.. 5. Active ulcerative colitis with a Mayo Clinic Score (see Appendix C) of 6 to 12 points with moderately-to-severely active disease on sigmoidoscopy (endoscopic subscore of at least 2) despite concurrent treatment with corticosteroids, and/or azathioprine or 6 mercaptopurine and/or 5-aminosalicylate-containing medications. Patients who previously have not responded to or could not tolerate corticosteroids (within the past 18 months), or azathioprine or 6 mercaptopurine (both within the past 5 years), or 5 aminosalicylate-containing medications (within the past 18 months) will not required to be taking concurrent therapy at enrollment.. 6. Either anti-TNF agent nave or those with previous clinical response to infliximab therapy for UC with subsequent loss of response AND/OR are unable to tolerate further infliximab therapy for UC due to acute or delayed reactions, as defined by the investigator.. 7. Subjects must be able and willing to give written informed consent and to comply with the requirements of this study protocol.. 8. Adequate cardiac, renal and hepatic function as determined by principal investigator and demonstrated by screening laboratory evaluations, questionnaires, and physical examination results that are within normal limits.. Exclusion Criteria. 1. History of cancer or lymphoproliferative disease other than a successfully and completely treated squamous cell or basal cell carcinoma of the skin.. 2. Subjects with a history of Listeria, Hepatitis B infection, central nervous system (CNS) demyelinating disease, or human immunodeficiency virus (HIV) or a history of previously untreated TB. See Appendix B.. 3. Subjects with Crohn?s Disease. 4. Subjects with symptomatic obstructive strictures. 5. Subjects who have had subtotal colectomy with ileorectostomy or colectomy with ileoanal pouch, Kock pouch, or ileostomy for ulcerative colitis or are planning subtotal colectomy or colectomy within 8 weeks of starting the study medication.. 6. Subjects who are currently receiving total parenteral nutrition (TPN).. 7. Any investigational chemical agent in the past 30 days or 5 half-lives prior to screening (whichever is longer). Patients who have previously been treated with infliximab and responded, and then become intolerant to infliximab or lost response, can be treated \\>/= 4 weeks from their last infliximab dose.. 8. Antibiotic treatment for any systemic infection within 3 weeks prior to screening.. 9. Female subjects who are pregnant or breast-feeding.. 10. History of clinically significant drug or alcohol abuse in the prior year.. 11. Poorly controlled medical condition, including but not limited to diabetes with documented history of recurrent infections or cerebrovascular accidents (within 3 months).. 12. Subjects who have been on cyclosporine or tacrolimus within 4 weeks of screening.. 13. Subjects who have been on methotrexate within 4 weeks of screening"}, {"type": "EXCLUSION", "field": "lab", "operator": ">=", "value": 3, "unit": "months", "evidence_text": "Inclusion Criteria. 1. Males and females 18 years of age and older. 2. Female subjects must utilize a highly effective method of birth control throughout the study and for 70 days after study completion, or female subjects must not be of childbearing potential, defined as postmenopausal at least two years, or surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy).. 3. A diagnosis of UC for greater than 3 months.. 4. UC diagnosis confirmed by endoscopy with exclusion of infectious cause.. 5. Active ulcerative colitis with a Mayo Clinic Score (see Appendix C) of 6 to 12 points with moderately-to-severely active disease on sigmoidoscopy (endoscopic subscore of at least 2) despite concurrent treatment with corticosteroids, and/or azathioprine or 6 mercaptopurine and/or 5-aminosalicylate-containing medications. Patients who previously have not responded to or could not tolerate corticosteroids (within the past 18 months), or azathioprine or 6 mercaptopurine (both within the past 5 years), or 5 aminosalicylate-containing medications (within the past 18 months) will not required to be taking concurrent therapy at enrollment.. 6. Either anti-TNF agent nave or those with previous clinical response to infliximab therapy for UC with subsequent loss of response AND/OR are unable to tolerate further infliximab therapy for UC due to acute or delayed reactions, as defined by the investigator.. 7. Subjects must be able and willing to give written informed consent and to comply with the requirements of this study protocol.. 8. Adequate cardiac, renal and hepatic function as determined by principal investigator and demonstrated by screening laboratory evaluations, questionnaires, and physical examination results that are within normal limits.. Exclusion Criteria. 1. History of cancer or lymphoproliferative disease other than a successfully and completely treated squamous cell or basal cell carcinoma of the skin.. 2. Subjects with a history of Listeria, Hepatitis B infection, central nervous system (CNS) demyelinating disease, or human immunodeficiency virus (HIV) or a history of previously untreated TB. See Appendix B.. 3. Subjects with Crohn?s Disease. 4. Subjects with symptomatic obstructive strictures. 5. Subjects who have had subtotal colectomy with ileorectostomy or colectomy with ileoanal pouch, Kock pouch, or ileostomy for ulcerative colitis or are planning subtotal colectomy or colectomy within 8 weeks of starting the study medication.. 6. Subjects who are currently receiving total parenteral nutrition (TPN).. 7. Any investigational chemical agent in the past 30 days or 5 half-lives prior to screening (whichever is longer). Patients who have previously been treated with infliximab and responded, and then become intolerant to infliximab or lost response, can be treated \\>/= 4 weeks from their last infliximab dose.. 8. Antibiotic treatment for any systemic infection within 3 weeks prior to screening.. 9. Female subjects who are pregnant or breast-feeding.. 10. History of clinically significant drug or alcohol abuse in the prior year.. 11. Poorly controlled medical condition, including but not limited to diabetes with documented history of recurrent infections or cerebrovascular accidents (within 3 months).. 12. Subjects who have been on cyclosporine or tacrolimus within 4 weeks of screening.. 13. Subjects who have been on methotrexate within 4 weeks of screening"}, {"type": "EXCLUSION", "field": "medication", "operator": "WITHIN_LAST", "value": 18, "unit": "months", "evidence_text": "Inclusion Criteria. 1. Males and females 18 years of age and older. 2. Female subjects must utilize a highly effective method of birth control throughout the study and for 70 days after study completion, or female subjects must not be of childbearing potential, defined as postmenopausal at least two years, or surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy).. 3. A diagnosis of UC for greater than 3 months.. 4. UC diagnosis confirmed by endoscopy with exclusion of infectious cause.. 5. Active ulcerative colitis with a Mayo Clinic Score (see Appendix C) of 6 to 12 points with moderately-to-severely active disease on sigmoidoscopy (endoscopic subscore of at least 2) despite concurrent treatment with corticosteroids, and/or azathioprine or 6 mercaptopurine and/or 5-aminosalicylate-containing medications. Patients who previously have not responded to or could not tolerate corticosteroids (within the past 18 months), or azathioprine or 6 mercaptopurine (both within the past 5 years), or 5 aminosalicylate-containing medications (within the past 18 months) will not required to be taking concurrent therapy at enrollment.. 6. Either anti-TNF agent nave or those with previous clinical response to infliximab therapy for UC with subsequent loss of response AND/OR are unable to tolerate further infliximab therapy for UC due to acute or delayed reactions, as defined by the investigator.. 7. Subjects must be able and willing to give written informed consent and to comply with the requirements of this study protocol.. 8. Adequate cardiac, renal and hepatic function as determined by principal investigator and demonstrated by screening laboratory evaluations, questionnaires, and physical examination results that are within normal limits.. Exclusion Criteria. 1. History of cancer or lymphoproliferative disease other than a successfully and completely treated squamous cell or basal cell carcinoma of the skin.. 2. Subjects with a history of Listeria, Hepatitis B infection, central nervous system (CNS) demyelinating disease, or human immunodeficiency virus (HIV) or a history of previously untreated TB. See Appendix B.. 3. Subjects with Crohn?s Disease. 4. Subjects with symptomatic obstructive strictures. 5. Subjects who have had subtotal colectomy with ileorectostomy or colectomy with ileoanal pouch, Kock pouch, or ileostomy for ulcerative colitis or are planning subtotal colectomy or colectomy within 8 weeks of starting the study medication.. 6. Subjects who are currently receiving total parenteral nutrition (TPN).. 7. Any investigational chemical agent in the past 30 days or 5 half-lives prior to screening (whichever is longer). Patients who have previously been treated with infliximab and responded, and then become intolerant to infliximab or lost response, can be treated \\>/= 4 weeks from their last infliximab dose.. 8. Antibiotic treatment for any systemic infection within 3 weeks prior to screening.. 9. Female subjects who are pregnant or breast-feeding.. 10. History of clinically significant drug or alcohol abuse in the prior year.. 11. Poorly controlled medical condition, including but not limited to diabetes with documented history of recurrent infections or cerebrovascular accidents (within 3 months).. 12. Subjects who have been on cyclosporine or tacrolimus within 4 weeks of screening.. 13. Subjects who have been on methotrexate within 4 weeks of screening"}, {"type": "EXCLUSION", "field": "other", "operator": "IN", "value": "1. Males and females 18 years of age and older. 2. Female subjects must utilize a highly effective method of birth contr", "unit": null, "evidence_text": "Inclusion Criteria. 1. Males and females 18 years of age and older. 2. Female subjects must utilize a highly effective method of birth control throughout the study and for 70 days after study completion, or female subjects must not be of childbearing potential, defined as postmenopausal at least two years, or surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy).. 3. A diagnosis of UC for greater than 3 months.. 4. UC diagnosis confirmed by endoscopy with exclusion of infectious cause.. 5. Active ulcerative colitis with a Mayo Clinic Score (see Appendix C) of 6 to 12 points with moderately-to-severely active disease on sigmoidoscopy (endoscopic subscore of at least 2) despite concurrent treatment with corticosteroids, and/or azathioprine or 6 mercaptopurine and/or 5-aminosalicylate-containing medications. Patients who previously have not responded to or could not tolerate corticosteroids (within the past 18 months), or azathioprine or 6 mercaptopurine (both within the past 5 years), or 5 aminosalicylate-containing medications (within the past 18 months) will not required to be taking concurrent therapy at enrollment.. 6. Either anti-TNF agent nave or those with previous clinical response to infliximab therapy for UC with subsequent loss of response AND/OR are unable to tolerate further infliximab therapy for UC due to acute or delayed reactions, as defined by the investigator.. 7. Subjects must be able and willing to give written informed consent and to comply with the requirements of this study protocol.. 8. Adequate cardiac, renal and hepatic function as determined by principal investigator and demonstrated by screening laboratory evaluations, questionnaires, and physical examination results that are within normal limits.. Exclusion Criteria. 1. History of cancer or lymphoproliferative disease other than a successfully and completely treated squamous cell or basal cell carcinoma of the skin.. 2. Subjects with a history of Listeria, Hepatitis B infection, central nervous system (CNS) demyelinating disease, or human immunodeficiency virus (HIV) or a history of previously untreated TB. See Appendix B.. 3. Subjects with Crohn?s Disease. 4. Subjects with symptomatic obstructive strictures. 5. Subjects who have had subtotal colectomy with ileorectostomy or colectomy with ileoanal pouch, Kock pouch, or ileostomy for ulcerative colitis or are planning subtotal colectomy or colectomy within 8 weeks of starting the study medication.. 6. Subjects who are currently receiving total parenteral nutrition (TPN).. 7. Any investigational chemical agent in the past 30 days or 5 half-lives prior to screening (whichever is longer). Patients who have previously been treated with infliximab and responded, and then become intolerant to infliximab or lost response, can be treated \\>/= 4 weeks from their last infliximab dose.. 8. Antibiotic treatment for any systemic infection within 3 weeks prior to screening.. 9. Female subjects who are pregnant or breast-feeding.. 10. History of clinically significant drug or alcohol abuse in the prior year.. 11. Poorly controlled medical condition, including but not limited to diabetes with documented history of recurrent infections or cerebrovascular accidents (within 3 months).. 12. Subjects who have been on cyclosporine or tacrolimus within 4 weeks of screening.. 13. Subjects who have been on methotrexate within 4 weeks of screening"}, {"type": "EXCLUSION", "field": "procedure", "operator": "WITHIN_LAST", "value": 18, "unit": "months", "evidence_text": "Inclusion Criteria. 1. Males and females 18 years of age and older. 2. Female subjects must utilize a highly effective method of birth control throughout the study and for 70 days after study completion, or female subjects must not be of childbearing potential, defined as postmenopausal at least two years, or surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy).. 3. A diagnosis of UC for greater than 3 months.. 4. UC diagnosis confirmed by endoscopy with exclusion of infectious cause.. 5. Active ulcerative colitis with a Mayo Clinic Score (see Appendix C) of 6 to 12 points with moderately-to-severely active disease on sigmoidoscopy (endoscopic subscore of at least 2) despite concurrent treatment with corticosteroids, and/or azathioprine or 6 mercaptopurine and/or 5-aminosalicylate-containing medications. Patients who previously have not responded to or could not tolerate corticosteroids (within the past 18 months), or azathioprine or 6 mercaptopurine (both within the past 5 years), or 5 aminosalicylate-containing medications (within the past 18 months) will not required to be taking concurrent therapy at enrollment.. 6. Either anti-TNF agent nave or those with previous clinical response to infliximab therapy for UC with subsequent loss of response AND/OR are unable to tolerate further infliximab therapy for UC due to acute or delayed reactions, as defined by the investigator.. 7. Subjects must be able and willing to give written informed consent and to comply with the requirements of this study protocol.. 8. Adequate cardiac, renal and hepatic function as determined by principal investigator and demonstrated by screening laboratory evaluations, questionnaires, and physical examination results that are within normal limits.. Exclusion Criteria. 1. History of cancer or lymphoproliferative disease other than a successfully and completely treated squamous cell or basal cell carcinoma of the skin.. 2. Subjects with a history of Listeria, Hepatitis B infection, central nervous system (CNS) demyelinating disease, or human immunodeficiency virus (HIV) or a history of previously untreated TB. See Appendix B.. 3. Subjects with Crohn?s Disease. 4. Subjects with symptomatic obstructive strictures. 5. Subjects who have had subtotal colectomy with ileorectostomy or colectomy with ileoanal pouch, Kock pouch, or ileostomy for ulcerative colitis or are planning subtotal colectomy or colectomy within 8 weeks of starting the study medication.. 6. Subjects who are currently receiving total parenteral nutrition (TPN).. 7. Any investigational chemical agent in the past 30 days or 5 half-lives prior to screening (whichever is longer). Patients who have previously been treated with infliximab and responded, and then become intolerant to infliximab or lost response, can be treated \\>/= 4 weeks from their last infliximab dose.. 8. Antibiotic treatment for any systemic infection within 3 weeks prior to screening.. 9. Female subjects who are pregnant or breast-feeding.. 10. History of clinically significant drug or alcohol abuse in the prior year.. 11. Poorly controlled medical condition, including but not limited to diabetes with documented history of recurrent infections or cerebrovascular accidents (within 3 months).. 12. Subjects who have been on cyclosporine or tacrolimus within 4 weeks of screening.. 13. Subjects who have been on methotrexate within 4 weeks of screening"}, {"type": "EXCLUSION", "field": "sex", "operator": "=", "value": "all", "unit": null, "evidence_text": "Inclusion Criteria. 1. Males and females 18 years of age and older. 2. Female subjects must utilize a highly effective method of birth control throughout the study and for 70 days after study completion, or female subjects must not be of childbearing potential, defined as postmenopausal at least two years, or surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy).. 3. A diagnosis of UC for greater than 3 months.. 4. UC diagnosis confirmed by endoscopy with exclusion of infectious cause.. 5. Active ulcerative colitis with a Mayo Clinic Score (see Appendix C) of 6 to 12 points with moderately-to-severely active disease on sigmoidoscopy (endoscopic subscore of at least 2) despite concurrent treatment with corticosteroids, and/or azathioprine or 6 mercaptopurine and/or 5-aminosalicylate-containing medications. Patients who previously have not responded to or could not tolerate corticosteroids (within the past 18 months), or azathioprine or 6 mercaptopurine (both within the past 5 years), or 5 aminosalicylate-containing medications (within the past 18 months) will not required to be taking concurrent therapy at enrollment.. 6. Either anti-TNF agent nave or those with previous clinical response to infliximab therapy for UC with subsequent loss of response AND/OR are unable to tolerate further infliximab therapy for UC due to acute or delayed reactions, as defined by the investigator.. 7. Subjects must be able and willing to give written informed consent and to comply with the requirements of this study protocol.. 8. Adequate cardiac, renal and hepatic function as determined by principal investigator and demonstrated by screening laboratory evaluations, questionnaires, and physical examination results that are within normal limits.. Exclusion Criteria. 1. History of cancer or lymphoproliferative disease other than a successfully and completely treated squamous cell or basal cell carcinoma of the skin.. 2. Subjects with a history of Listeria, Hepatitis B infection, central nervous system (CNS) demyelinating disease, or human immunodeficiency virus (HIV) or a history of previously untreated TB. See Appendix B.. 3. Subjects with Crohn?s Disease. 4. Subjects with symptomatic obstructive strictures. 5. Subjects who have had subtotal colectomy with ileorectostomy or colectomy with ileoanal pouch, Kock pouch, or ileostomy for ulcerative colitis or are planning subtotal colectomy or colectomy within 8 weeks of starting the study medication.. 6. Subjects who are currently receiving total parenteral nutrition (TPN).. 7. Any investigational chemical agent in the past 30 days or 5 half-lives prior to screening (whichever is longer). Patients who have previously been treated with infliximab and responded, and then become intolerant to infliximab or lost response, can be treated \\>/= 4 weeks from their last infliximab dose.. 8. Antibiotic treatment for any systemic infection within 3 weeks prior to screening.. 9. Female subjects who are pregnant or breast-feeding.. 10. History of clinically significant drug or alcohol abuse in the prior year.. 11. Poorly controlled medical condition, including but not limited to diabetes with documented history of recurrent infections or cerebrovascular accidents (within 3 months).. 12. Subjects who have been on cyclosporine or tacrolimus within 4 weeks of screening.. 13. Subjects who have been on methotrexate within 4 weeks of screening"}, {"type": "EXCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "Inclusion Criteria. 1. Males and females 18 years of age and older. 2. Female subjects must utilize a highly effective method of birth control throughout the study and for 70 days after study completion, or female subjects must not be of childbearing potential, defined as postmenopausal at least two years, or surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy).. 3. A diagnosis of UC for greater than 3 months.. 4. UC diagnosis confirmed by endoscopy with exclusion of infectious cause.. 5. Active ulcerative colitis with a Mayo Clinic Score (see Appendix C) of 6 to 12 points with moderately-to-severely active disease on sigmoidoscopy (endoscopic subscore of at least 2) despite concurrent treatment with corticosteroids, and/or azathioprine or 6 mercaptopurine and/or 5-aminosalicylate-containing medications. Patients who previously have not responded to or could not tolerate corticosteroids (within the past 18 months), or azathioprine or 6 mercaptopurine (both within the past 5 years), or 5 aminosalicylate-containing medications (within the past 18 months) will not required to be taking concurrent therapy at enrollment.. 6. Either anti-TNF agent nave or those with previous clinical response to infliximab therapy for UC with subsequent loss of response AND/OR are unable to tolerate further infliximab therapy for UC due to acute or delayed reactions, as defined by the investigator.. 7. Subjects must be able and willing to give written informed consent and to comply with the requirements of this study protocol.. 8. Adequate cardiac, renal and hepatic function as determined by principal investigator and demonstrated by screening laboratory evaluations, questionnaires, and physical examination results that are within normal limits.. Exclusion Criteria. 1. History of cancer or lymphoproliferative disease other than a successfully and completely treated squamous cell or basal cell carcinoma of the skin.. 2. Subjects with a history of Listeria, Hepatitis B infection, central nervous system (CNS) demyelinating disease, or human immunodeficiency virus (HIV) or a history of previously untreated TB. See Appendix B.. 3. Subjects with Crohn?s Disease. 4. Subjects with symptomatic obstructive strictures. 5. Subjects who have had subtotal colectomy with ileorectostomy or colectomy with ileoanal pouch, Kock pouch, or ileostomy for ulcerative colitis or are planning subtotal colectomy or colectomy within 8 weeks of starting the study medication.. 6. Subjects who are currently receiving total parenteral nutrition (TPN).. 7. Any investigational chemical agent in the past 30 days or 5 half-lives prior to screening (whichever is longer). Patients who have previously been treated with infliximab and responded, and then become intolerant to infliximab or lost response, can be treated \\>/= 4 weeks from their last infliximab dose.. 8. Antibiotic treatment for any systemic infection within 3 weeks prior to screening.. 9. Female subjects who are pregnant or breast-feeding.. 10. History of clinically significant drug or alcohol abuse in the prior year.. 11. Poorly controlled medical condition, including but not limited to diabetes with documented history of recurrent infections or cerebrovascular accidents (within 3 months).. 12. Subjects who have been on cyclosporine or tacrolimus within 4 weeks of screening.. 13. Subjects who have been on methotrexate within 4 weeks of screening"}], "annotator_id": "annotator_c", "guideline_version": "m5-v1", "adjudicated": true, "adjudication_source": "parsing_relabel_round1"}
{"nct_id": "NCT00422513", "eligibility_text": "Inclusion Criteria:. * adult patients, \\>=18 years of age;. * CKD (stage V) on outpatient hemodialysis therapy for \\>= 3 months;. * CKD-related anemia treated with epoetin alfa iv 3x/week for \\>= 3 months;. * average hemoglobin (Hb) 10-12 g/dL over last 3 months.. Exclusion Criteria:. * failed renal transplant within 12 months prior to screening;. * poorly controlled hypertension;. * previous treatment with Mircera.", "labeled_rules": [{"type": "INCLUSION", "field": "age", "operator": ">=", "value": 18, "unit": "years", "evidence_text": "adult patients, \\>=18 years of age"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "adult", "unit": null, "evidence_text": "adult patients, \\>=18 years of age"}, {"type": "INCLUSION", "field": "medication", "operator": "IN", "value": "* CKD (stage V) on outpatient hemodialysis therapy for \\>= 3 months", "unit": null, "evidence_text": "CKD (stage V) on outpatient hemodialysis therapy for \\>= 3 months"}, {"type": "INCLUSION", "field": "procedure", "operator": "IN", "value": "* CKD (stage V) on outpatient hemodialysis therapy for \\>= 3 months", "unit": null, "evidence_text": "CKD (stage V) on outpatient hemodialysis therapy for \\>= 3 months"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "* CKD-related anemia treated with epoetin alfa iv 3x/week for \\>= 3 months", "unit": null, "evidence_text": "CKD-related anemia treated with epoetin alfa iv 3x/week for \\>= 3 months"}, {"type": "INCLUSION", "field": "procedure", "operator": "WITHIN_LAST", "value": 12, "unit": "months", "evidence_text": "failed renal transplant within 12 months prior to screening"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "mircera", "unit": null, "evidence_text": "previous treatment with Mircera"}, {"type": "INCLUSION", "field": "history", "operator": "IN", "value": "* previous treatment with Mircera", "unit": null, "evidence_text": "previous treatment with Mircera"}, {"type": "INCLUSION", "field": "medication", "operator": "IN", "value": "* previous treatment with Mircera", "unit": null, "evidence_text": "previous treatment with Mircera"}], "annotator_id": "annotator_c", "guideline_version": "m5-v1", "adjudicated": true, "adjudication_source": "parsing_relabel_round1"}
{"nct_id": "NCT00437723", "eligibility_text": "Inclusion Criteria:. * adult patients,18-75 years of age;. * end-stage renal disease, not on dialysis;. * Hb \\<110g/L.. Exclusion Criteria:. * unstable hypertension;. * acute infections;. * use of i.v. NeoRecormon, or use of any other ESA beside NeoRecormon;. * myocardial infarction, unstable angina or venous thrombosis within 6 months before start of treatment.", "labeled_rules": [{"type": "INCLUSION", "field": "age", "operator": ">=", "value": 18, "unit": "years", "evidence_text": "* adult patients,18-75 years of age"}, {"type": "INCLUSION", "field": "age", "operator": "<=", "value": 75, "unit": "years", "evidence_text": "* adult patients,18-75 years of age"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "adult", "unit": null, "evidence_text": "* adult patients,18-75 years of age"}]}
{"nct_id": "NCT00438984", "eligibility_text": "Inclusion Criteria:. * Histopathological documentation of melanoma concurrent with the diagnosis of metastatic disease. * Expression of HLA-A2, B44, or A3 as determined by Fred Hutchinson Cancer Research Center (FHCRC) human leukocyte antigen (HLA) typing lab. * Zubrod performance status of 0-1. * Bi-dimensionally measurable disease by palpation on clinical exam, or radiographic imaging (X-ray, CT scan). * Normal cardiac stress test within 182 days prior to enrollment is required of all patients over 50 years old or those with an abnormal electrocardiogram (ECG), any history of cardiac disease, a family history of cardiac disease, hypercholesterolemia or hypertension. * FOR LEUKAPHERESIS:. * Pulse \\> 45 or \\< 120. * Weight \\>= 45 kg. * White blood cell count (WBC) \\>= 3,000. * Temperature =\\< 38C (=\\< 100.4 F). * Hematocrit (HCT) \\>= 30%. * Platelets \\>= 100,000. * FOR T CELL INFUSION: Patients must be willing and able to discontinue the use of all anti-hypertensive medications 24 hours prior to and during IL-2 therapy. Exclusion Criteria:. * Pregnant women, nursing mothers, men or women of reproductive ability who are unwilling to use effective contraception or abstinence; women of childbearing potential must have a negative pregnancy test within two weeks prior to entry. * Serum creatinine \\> 1.6 mg/dL or Creatinine clearance \\< 75 ml/min. * Serum glutamic oxaloacetic transaminase (SGOT) \\> 150 IU or \\> 3x upper limit of normal. * Bilirubin \\> 1.6 mg/dL. * Prothrombin time \\> 1.5 x control. * Clinically significant pulmonary dysfunction, as determined by medical history and physical exam; patients so identified will undergo pulmonary functions testing and those with forced expiratory volume in one second (FEV1) \\< 2.0 L or carbon monoxide diffusing capacity (DLco) (corr for Hgb) \\< 75% will be excluded. * Significant cardiovascular abnormalities as defined by any one of the following:. * Congestive heart failure;. * Clinically significant hypotension;. * Symptoms of coronary artery disease;. * Presence of cardiac arrhythmias on electrocardiograph (EKG) requiring drug therapy;. * Ejection fraction \\< 50 % (echocardiogram or multi gated acquisition scan \\[MUGA\\]). * Symptomatic central nervous system metastases greater than 1 cm at the time of therapy; patients with 1-2 asymptomatic, less than 1 cm brain/central nervous system (CNS) metastases without significant edema may be considered for treatment; if sub-centimeter CNS lesions are noted at study entry, than a repeat imaging will be performed if more than 3 weeks have elapsed from the last scan; patients will not be treated if CNS lesions are \\> 1 cm or if patient is symptomatic from brain metastasis. * Patients with active infections or oral temperature \\> 38.2 C within 72 hours of study entry or systemic infection requiring chronic maintenance or suppressive therapy. * Chemotherapeutic agents (standard or experimental), radiation therapy, or other immunosuppressive therapies less than 3 weeks prior to T cell therapy; (patients with bulky disease may undergo cytoreductive chemotherapy but treatment will be discontinued at least 3 weeks prior to T cell therapy). * Clinically significant autoimmune disorders or conditions of immunosuppression; patients with acquired immune deficiency syndrome (AIDS) or human immunodeficiency virus (HIV)-1 associated complex or known to HIV antibody seropositive or known to be recently polymerase chain reaction (PCR)+ for hepatitis are not eligible for this study; virology testing will be done within 6 months of T cell infusion; the severely depressed immune system found in these infected patients and the possibility of premature death would compromise study objectives. * FOR T CELL INFUSION: Patients with active infections or oral temperature \\> 38.2 C within 72 hours of study entry or systemic infection requiring chronic maintenance or suppressive therapy. * FOR T CELL INFUSION: Chemotherapeutic agents (standard or experimental), radiation therapy, or other immunosuppressive therapies less than 3 weeks prior to T cell therapy. * FOR T CELL INFUSION: Current treatment with steroids. * FOR T CELL INFUSION: Patients must not be receiving any other experimental drugs within 3 weeks of the initiation of the protocol and must have recovered from all side effects of such therapy", "labeled_rules": [{"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "histopathological documentation of melanoma concurrent with the", "unit": null, "evidence_text": "Histopathological documentation of melanoma concurrent with the diagnosis of metastatic disease"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "the diagnosis of metastatic disease", "unit": null, "evidence_text": "Histopathological documentation of melanoma concurrent with the diagnosis of metastatic disease"}, {"type": "INCLUSION", "field": "history", "operator": "IN", "value": "* Histopathological documentation of melanoma concurrent with the diagnosis of metastatic disease. * Expression of HLA", "unit": null, "evidence_text": "Histopathological documentation of melanoma concurrent with the diagnosis of metastatic disease"}, {"type": "INCLUSION", "field": "other", "operator": "IN", "value": "* Histopathological documentation of melanoma concurrent with the diagnosis of metastatic disease. * Expression of HLA", "unit": null, "evidence_text": "Histopathological documentation of melanoma concurrent with the diagnosis of metastatic disease"}, {"type": "INCLUSION", "field": "age", "operator": ">=", "value": 50, "unit": "years", "evidence_text": "Normal cardiac stress test within 182 days prior to enrollment is required of all patients over 50 years old or those with an abnormal electrocardiogram (ECG), any history of cardiac disease, a family history of cardiac disease, hypercholesterolemia or hypertension"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "cardiac disease, a family history of cardiac", "unit": null, "evidence_text": "Normal cardiac stress test within 182 days prior to enrollment is required of all patients over 50 years old or those with an abnormal electrocardiogram (ECG), any history of cardiac disease, a family history of cardiac disease, hypercholesterolemia or hypertension"}, {"type": "INCLUSION", "field": "medication", "operator": "WITHIN_LAST", "value": 182, "unit": "days", "evidence_text": "Normal cardiac stress test within 182 days prior to enrollment is required of all patients over 50 years old or those with an abnormal electrocardiogram (ECG), any history of cardiac disease, a family history of cardiac disease, hypercholesterolemia or hypertension"}, {"type": "INCLUSION", "field": "procedure", "operator": "WITHIN_LAST", "value": 182, "unit": "days", "evidence_text": "Normal cardiac stress test within 182 days prior to enrollment is required of all patients over 50 years old or those with an abnormal electrocardiogram (ECG), any history of cardiac disease, a family history of cardiac disease, hypercholesterolemia or hypertension"}, {"type": "INCLUSION", "field": "lab", "operator": "<=", "value": 1, "unit": "cm", "evidence_text": "Pulse \\> 45 or \\< 120"}, {"type": "INCLUSION", "field": "lab", "operator": "<=", "value": 120, "unit": null, "evidence_text": "Pulse \\> 45 or \\< 120"}, {"type": "INCLUSION", "field": "lab", "operator": ">=", "value": 1, "unit": "cm", "evidence_text": "Pulse \\> 45 or \\< 120"}, {"type": "INCLUSION", "field": "lab", "operator": ">=", "value": 100000, "unit": null, "evidence_text": "Weight \\>= 45 kg"}, {"type": "INCLUSION", "field": "lab", "operator": ">=", "value": 3000, "unit": null, "evidence_text": "Weight \\>= 45 kg"}, {"type": "INCLUSION", "field": "lab", "operator": ">=", "value": 45, "unit": "kg", "evidence_text": "Weight \\>= 45 kg"}, {"type": "INCLUSION", "field": "lab", "operator": ">=", "value": 45, "unit": "or", "evidence_text": "Weight \\>= 45 kg"}, {"type": "INCLUSION", "field": "lab", "operator": "<=", "value": 100.4, "unit": "f", "evidence_text": "Temperature =\\< 38C (=\\< 100.4 F)"}, {"type": "INCLUSION", "field": "lab", "operator": "<=", "value": 38, "unit": "c", "evidence_text": "Temperature =\\< 38C (=\\< 100.4 F)"}, {"type": "INCLUSION", "field": "lab", "operator": ">=", "value": 3, "unit": "x", "evidence_text": "Hematocrit (HCT) \\>= 30%"}, {"type": "INCLUSION", "field": "lab", "operator": ">=", "value": 30, "unit": "%", "evidence_text": "Hematocrit (HCT) \\>= 30%"}, {"type": "EXCLUSION", "field": "history", "operator": "IN", "value": "women of childbearing potential must have a negative pregnancy test within two weeks prior to entry. * Serum creatinine \\> 1.6 mg/dL or Crea", "unit": null, "evidence_text": "Pregnant women, nursing mothers, men or women of reproductive ability who are unwilling to use effective contraception or abstinence; women of childbearing potential must have a negative pregnancy test within two weeks prior to entry"}, {"type": "EXCLUSION", "field": "history", "operator": "NO_HISTORY", "value": "pregnancy", "unit": null, "evidence_text": "Pregnant women, nursing mothers, men or women of reproductive ability who are unwilling to use effective contraception or abstinence; women of childbearing potential must have a negative pregnancy test within two weeks prior to entry"}, {"type": "EXCLUSION", "field": "lab", "operator": "IN", "value": "negative pregnancy test", "unit": null, "evidence_text": "Pregnant women, nursing mothers, men or women of reproductive ability who are unwilling to use effective contraception or abstinence; women of childbearing potential must have a negative pregnancy test within two weeks prior to entry"}, {"type": "EXCLUSION", "field": "procedure", "operator": "IN", "value": "women of childbearing potential must have a negative pregnancy test within two weeks prior to entry. * Serum creatinine \\> 1.6 mg/dL or Crea", "unit": null, "evidence_text": "Pregnant women, nursing mothers, men or women of reproductive ability who are unwilling to use effective contraception or abstinence; women of childbearing potential must have a negative pregnancy test within two weeks prior to entry"}, {"type": "EXCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "Pregnant women, nursing mothers, men or women of reproductive ability who are unwilling to use effective contraception or abstinence; women of childbearing potential must have a negative pregnancy test within two weeks prior to entry"}, {"type": "EXCLUSION", "field": "lab", "operator": "<=", "value": 75, "unit": "ml/min", "evidence_text": "Serum creatinine \\> 1.6 mg/dL or Creatinine clearance \\< 75 ml/min"}, {"type": "EXCLUSION", "field": "lab", "operator": ">=", "value": 150, "unit": "iu", "evidence_text": "Serum glutamic oxaloacetic transaminase (SGOT) \\> 150 IU or \\> 3x upper limit of normal"}, {"type": "EXCLUSION", "field": "lab", "operator": ">=", "value": 1.6, "unit": "mg/dl", "evidence_text": "Bilirubin \\> 1.6 mg/dL"}, {"type": "EXCLUSION", "field": "lab", "operator": ">=", "value": 1.5, "unit": "x", "evidence_text": "Prothrombin time \\> 1.5 x control"}, {"type": "EXCLUSION", "field": "procedure", "operator": "IN", "value": "patients so identified will undergo pulmonary functions testing and those with forced expiratory volume in one second (FEV1) \\< 2.0 L or car", "unit": null, "evidence_text": "Clinically significant pulmonary dysfunction, as determined by medical history and physical exam; patients so identified will undergo pulmonary functions testing and those with forced expiratory volume in one second (FEV1) \\< 2.0 L or carbon monoxide diffusing capacity (DLco) (corr for Hgb) \\< 75% will be excluded"}, {"type": "EXCLUSION", "field": "condition", "operator": "IN", "value": "* Clinically significant hypotension", "unit": null, "evidence_text": "Clinically significant hypotension"}, {"type": "EXCLUSION", "field": "sex", "operator": "=", "value": "all", "unit": null, "evidence_text": "Clinically significant hypotension"}, {"type": "EXCLUSION", "field": "condition", "operator": "IN", "value": "* Symptoms of coronary artery disease", "unit": null, "evidence_text": "Symptoms of coronary artery disease"}, {"type": "EXCLUSION", "field": "medication", "operator": "IN", "value": "* Presence of cardiac arrhythmias on electrocardiograph (EKG) requiring drug therapy", "unit": null, "evidence_text": "Presence of cardiac arrhythmias on electrocardiograph (EKG) requiring drug therapy"}, {"type": "EXCLUSION", "field": "procedure", "operator": "IN", "value": "* Presence of cardiac arrhythmias on electrocardiograph (EKG) requiring drug therapy", "unit": null, "evidence_text": "Presence of cardiac arrhythmias on electrocardiograph (EKG) requiring drug therapy"}, {"type": "EXCLUSION", "field": "lab", "operator": "<=", "value": 50, "unit": "%", "evidence_text": "Ejection fraction \\< 50 % (echocardiogram or multi gated acquisition scan \\[MUGA\\])"}, {"type": "EXCLUSION", "field": "medication", "operator": "IN", "value": "* Ejection fraction \\< 50 % (echocardiogram or multi gated acquisition scan \\[MUGA\\]). * Symptomatic central nervous system metastases gre", "unit": null, "evidence_text": "Ejection fraction \\< 50 % (echocardiogram or multi gated acquisition scan \\[MUGA\\])"}, {"type": "EXCLUSION", "field": "procedure", "operator": "IN", "value": "* Ejection fraction \\< 50 % (echocardiogram or multi gated acquisition scan \\[MUGA\\]). * Symptomatic central nervous system metastases gre", "unit": null, "evidence_text": "Ejection fraction \\< 50 % (echocardiogram or multi gated acquisition scan \\[MUGA\\])"}, {"type": "EXCLUSION", "field": "medication", "operator": "IN", "value": "patients will not be treated if CNS lesions are \\> 1 cm or if patient is symptomatic from brain metastasis. * Patients with active infection", "unit": null, "evidence_text": "Symptomatic central nervous system metastases greater than 1 cm at the time of therapy; patients with 1-2 asymptomatic, less than 1 cm brain/central nervous system (CNS) metastases without significant edema may be considered for treatment; if sub-centimeter CNS lesions are noted at study entry, than a repeat imaging will be performed if more than 3 weeks have elapsed from the last scan; patients will not be treated if CNS lesions are \\> 1 cm or if patient is symptomatic from brain metastasis"}, {"type": "EXCLUSION", "field": "medication", "operator": "IN", "value": "patients with 1-2 asymptomatic, less than 1 cm brain/central nervous system (CNS) metastases without significant edema may be considered for", "unit": null, "evidence_text": "Symptomatic central nervous system metastases greater than 1 cm at the time of therapy; patients with 1-2 asymptomatic, less than 1 cm brain/central nervous system (CNS) metastases without significant edema may be considered for treatment; if sub-centimeter CNS lesions are noted at study entry, than a repeat imaging will be performed if more than 3 weeks have elapsed from the last scan; patients will not be treated if CNS lesions are \\> 1 cm or if patient is symptomatic from brain metastasis"}, {"type": "EXCLUSION", "field": "procedure", "operator": "IN", "value": "if sub-centimeter CNS lesions are noted at study entry, than a repeat imaging will be performed if more than 3 weeks have elapsed from the l", "unit": null, "evidence_text": "Symptomatic central nervous system metastases greater than 1 cm at the time of therapy; patients with 1-2 asymptomatic, less than 1 cm brain/central nervous system (CNS) metastases without significant edema may be considered for treatment; if sub-centimeter CNS lesions are noted at study entry, than a repeat imaging will be performed if more than 3 weeks have elapsed from the last scan; patients will not be treated if CNS lesions are \\> 1 cm or if patient is symptomatic from brain metastasis"}, {"type": "EXCLUSION", "field": "procedure", "operator": "IN", "value": "patients will not be treated if CNS lesions are \\> 1 cm or if patient is symptomatic from brain metastasis. * Patients with active infection", "unit": null, "evidence_text": "Symptomatic central nervous system metastases greater than 1 cm at the time of therapy; patients with 1-2 asymptomatic, less than 1 cm brain/central nervous system (CNS) metastases without significant edema may be considered for treatment; if sub-centimeter CNS lesions are noted at study entry, than a repeat imaging will be performed if more than 3 weeks have elapsed from the last scan; patients will not be treated if CNS lesions are \\> 1 cm or if patient is symptomatic from brain metastasis"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "active infection", "unit": null, "evidence_text": "Patients with active infections or oral temperature \\> 38.2 C within 72 hours of study entry or systemic infection requiring chronic maintenance or suppressive therapy"}, {"type": "EXCLUSION", "field": "lab", "operator": ">=", "value": 38.2, "unit": "c", "evidence_text": "Patients with active infections or oral temperature \\> 38.2 C within 72 hours of study entry or systemic infection requiring chronic maintenance or suppressive therapy"}, {"type": "EXCLUSION", "field": "medication", "operator": "WITHIN_LAST", "value": 3, "unit": "weeks", "evidence_text": "Patients with active infections or oral temperature \\> 38.2 C within 72 hours of study entry or systemic infection requiring chronic maintenance or suppressive therapy"}, {"type": "EXCLUSION", "field": "procedure", "operator": "WITHIN_LAST", "value": 3, "unit": "weeks", "evidence_text": "Patients with active infections or oral temperature \\> 38.2 C within 72 hours of study entry or systemic infection requiring chronic maintenance or suppressive therapy"}, {"type": "EXCLUSION", "field": "medication", "operator": "IN", "value": "(patients with bulky disease may undergo cytoreductive chemotherapy but treatment will be discontinued at least 3 weeks prior to T cell ther", "unit": null, "evidence_text": "Chemotherapeutic agents (standard or experimental), radiation therapy, or other immunosuppressive therapies less than 3 weeks prior to T cell therapy; (patients with bulky disease may undergo cytoreductive chemotherapy but treatment will be discontinued at least 3 weeks prior to T cell therapy)"}, {"type": "EXCLUSION", "field": "procedure", "operator": "IN", "value": "(patients with bulky disease may undergo cytoreductive chemotherapy but treatment will be discontinued at least 3 weeks prior to T cell ther", "unit": null, "evidence_text": "Chemotherapeutic agents (standard or experimental), radiation therapy, or other immunosuppressive therapies less than 3 weeks prior to T cell therapy; (patients with bulky disease may undergo cytoreductive chemotherapy but treatment will be discontinued at least 3 weeks prior to T cell therapy)"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "hiv positive", "unit": null, "evidence_text": "Clinically significant autoimmune disorders or conditions of immunosuppression; patients with acquired immune deficiency syndrome (AIDS) or human immunodeficiency virus (HIV)-1 associated complex or known to HIV antibody seropositive or known to be recently polymerase chain reaction (PCR)+ for hepatitis are not eligible for this study; virology testing will be done within 6 months of T cell infusion; the severely depressed immune system found in these infected patients and the possibility of premature death would compromise study objectives"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "the severely depressed immune system found in", "unit": null, "evidence_text": "Clinically significant autoimmune disorders or conditions of immunosuppression; patients with acquired immune deficiency syndrome (AIDS) or human immunodeficiency virus (HIV)-1 associated complex or known to HIV antibody seropositive or known to be recently polymerase chain reaction (PCR)+ for hepatitis are not eligible for this study; virology testing will be done within 6 months of T cell infusion; the severely depressed immune system found in these infected patients and the possibility of premature death would compromise study objectives"}, {"type": "EXCLUSION", "field": "medication", "operator": "IN", "value": "patients with acquired immune deficiency syndrome (AIDS) or human immunodeficiency virus (HIV)-1 associated complex or known to HIV antibody", "unit": null, "evidence_text": "Clinically significant autoimmune disorders or conditions of immunosuppression; patients with acquired immune deficiency syndrome (AIDS) or human immunodeficiency virus (HIV)-1 associated complex or known to HIV antibody seropositive or known to be recently polymerase chain reaction (PCR)+ for hepatitis are not eligible for this study; virology testing will be done within 6 months of T cell infusion; the severely depressed immune system found in these infected patients and the possibility of premature death would compromise study objectives"}, {"type": "EXCLUSION", "field": "procedure", "operator": "IN", "value": "patients with acquired immune deficiency syndrome (AIDS) or human immunodeficiency virus (HIV)-1 associated complex or known to HIV antibody", "unit": null, "evidence_text": "Clinically significant autoimmune disorders or conditions of immunosuppression; patients with acquired immune deficiency syndrome (AIDS) or human immunodeficiency virus (HIV)-1 associated complex or known to HIV antibody seropositive or known to be recently polymerase chain reaction (PCR)+ for hepatitis are not eligible for this study; virology testing will be done within 6 months of T cell infusion; the severely depressed immune system found in these infected patients and the possibility of premature death would compromise study objectives"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "steroids", "unit": null, "evidence_text": "FOR T CELL INFUSION: Current treatment with steroids"}], "annotator_id": "annotator_c", "guideline_version": "m5-v1", "adjudicated": true, "adjudication_source": "parsing_relabel_round1"}
{"nct_id": "NCT00440817", "eligibility_text": "Inclusion Criteria:. * Patients with Crohns disease or rheumatoid arthritis who participate in the specified registries will be included in the analysis. For the lymphoma analysis, patients must be recorded as having a lymphoma during their participation in one of these registries. Exclusion Criteria:. * Patients who do not have Crohns disease or rheumatoid arthritis and who did not participate in one of the identified registries will be excluded from the study", "labeled_rules": [{"type": "EXCLUSION", "field": "condition", "operator": "IN", "value": "a lymphoma during their participation in one", "unit": null, "evidence_text": "Patients with Crohns disease or rheumatoid arthritis who participate in the specified registries will be included in the analysis. For the lymphoma analysis, patients must be recorded as having a lymphoma during their participation in one of these registries. Exclusion Criteria:"}, {"type": "EXCLUSION", "field": "condition", "operator": "IN", "value": "for the lymphoma analysis", "unit": null, "evidence_text": "Patients with Crohns disease or rheumatoid arthritis who participate in the specified registries will be included in the analysis. For the lymphoma analysis, patients must be recorded as having a lymphoma during their participation in one of these registries. Exclusion Criteria:"}, {"type": "EXCLUSION", "field": "condition", "operator": "IN", "value": "* Patients with Crohns disease or rheumatoid arthritis who participate in the specified registries will be included in", "unit": null, "evidence_text": "Patients who do not have Crohns disease or rheumatoid arthritis and who did not participate in one of the identified registries will be excluded from the study"}, {"type": "EXCLUSION", "field": "other", "operator": "IN", "value": "* Patients with Crohns disease or rheumatoid arthritis who participate in the specified registries will be included in", "unit": null, "evidence_text": "Patients who do not have Crohns disease or rheumatoid arthritis and who did not participate in one of the identified registries will be excluded from the study"}], "annotator_id": "annotator_c", "guideline_version": "m5-v1", "adjudicated": true, "adjudication_source": "parsing_relabel_round1"}
{"nct_id": "NCT00454805", "eligibility_text": "Inclusion Criteria:. * Written informed consent. * Females with histological/cytological confirmation of hormone sensitive breast cancer with evidence of metastatic disease. * One or more evaluable lesions. Exclusion Criteria:. * Prior hormonal therapy with fulvestrant. * More than one course of prior systemic cytotoxic chemotherapy for metastatic breast cancer. * Prior biologic therapy for ABC including Anti-VEGF agents. * Radiation therapy within 4 weeks prior to provision of consent", "labeled_rules": [{"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "fulvestrant", "unit": null, "evidence_text": "* Prior hormonal therapy with fulvestrant"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "evidence of metastatic disease", "unit": null, "evidence_text": "* Females with histological/cytological confirmation of hormone sensitive breast cancer with evidence of metastatic disease"}]}
{"nct_id": "NCT00457600", "eligibility_text": "Inclusion Criteria:. * Age less than 12 years with head trauma. * Age less than 12 years with ear pain. * Ages less than 12 years with concern for UTI. * 1 year - 12 years with asthma history and respiratory chief complaint. * 3 months - 2 years with fever. * Parent speaks English or Spanish. * Triage status is non-emergent", "labeled_rules": [{"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "fever", "unit": null, "evidence_text": "* 3 months - 2 years with fever"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "ear pain", "unit": null, "evidence_text": "* Age less than 12 years with ear pain"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "head trauma", "unit": null, "evidence_text": "* Age less than 12 years with head trauma"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "concern for uti", "unit": null, "evidence_text": "* Ages less than 12 years with concern for UTI"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "asthma history and respiratory chief complaint", "unit": null, "evidence_text": "* 1 year - 12 years with asthma history and respiratory chief complaint"}]}
{"nct_id": "NCT00468039", "eligibility_text": "Inclusion Criteria:. * Male or female (non-fertile or of childbearing potential using a medically approved birth control method) patients with type 2 diabetes. * Diagnosis of type 2 diabetes for at least 4 weeks prior to study entry. * Body mass index 22-40 kg/meter squared. * HbA1c \\> 11% and/or FPG \\>270 mg/dL. Exclusion Criteria:. * Pregnant or lactating female. * History of type 1 diabetes. * Evidence of significant diabetic complications. * Treatment with insulin or any other oral antidiabetic agent. Other protocol-defined inclusion/exclusion criteria may apply.", "labeled_rules": [{"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "fertile", "unit": null, "evidence_text": "Male or female (non-fertile or of childbearing potential using a medically approved birth control method) patients with type 2 diabetes"}, {"type": "INCLUSION", "field": "history", "operator": "IN", "value": "* Male or female (non-fertile or of childbearing potential using a medically approved birth control method) patients wi", "unit": null, "evidence_text": "Male or female (non-fertile or of childbearing potential using a medically approved birth control method) patients with type 2 diabetes"}, {"type": "INCLUSION", "field": "medication", "operator": "IN", "value": "* Male or female (non-fertile or of childbearing potential using a medically approved birth control method) patients wi", "unit": null, "evidence_text": "Male or female (non-fertile or of childbearing potential using a medically approved birth control method) patients with type 2 diabetes"}, {"type": "INCLUSION", "field": "procedure", "operator": "IN", "value": "* Male or female (non-fertile or of childbearing potential using a medically approved birth control method) patients wi", "unit": null, "evidence_text": "Male or female (non-fertile or of childbearing potential using a medically approved birth control method) patients with type 2 diabetes"}, {"type": "INCLUSION", "field": "sex", "operator": "=", "value": "all", "unit": null, "evidence_text": "Male or female (non-fertile or of childbearing potential using a medically approved birth control method) patients with type 2 diabetes"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "type 2 diabetes", "unit": null, "evidence_text": "Diagnosis of type 2 diabetes for at least 4 weeks prior to study entry"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "type 2 diabetes for at least 4", "unit": null, "evidence_text": "Diagnosis of type 2 diabetes for at least 4 weeks prior to study entry"}, {"type": "EXCLUSION", "field": "lab", "operator": ">=", "value": 11, "unit": "%", "evidence_text": "HbA1c \\> 11% and/or FPG \\>270 mg/dL. Exclusion Criteria:"}, {"type": "EXCLUSION", "field": "lab", "operator": ">=", "value": 270, "unit": "mg/dl", "evidence_text": "HbA1c \\> 11% and/or FPG \\>270 mg/dL. Exclusion Criteria:"}, {"type": "EXCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "Pregnant or lactating female"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "type 1 diabetes", "unit": null, "evidence_text": "History of type 1 diabetes"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "insulin or any other oral antidiabetic agent", "unit": null, "evidence_text": "Treatment with insulin or any other oral antidiabetic agent. Other protocol-defined inclusion/exclusion criteria may apply"}], "annotator_id": "annotator_c", "guideline_version": "m5-v1", "adjudicated": true, "adjudication_source": "parsing_relabel_round1"}
{"nct_id": "NCT00483301", "eligibility_text": "Inclusion Criteria:. * Histologically confirmed diagnosis of melanoma with measurable disease. * Patients with stage IV, previously untreated, refractory to initial therapy or progressing after response to initial therapy. * Patients with unresectable stage III, including unresectable in-transit metastases. * Two prior chemotherapy regimen is allowed. * One prior immunotherapy regimen is allowed. * No other concurrent investigational therapy. * Radiation therapy to non-target lesions or to one of multiple target lesions may be allowed on a case-by-case basis. * Patients must be past the nadir from previous cytotoxic therapy. * Age at least 18 years. * ECOG performance status 0-2. * Hemoglobin \\> 9.0 g/dl, absolute neutrophil count (ANC) \\> 1,500/mm3, platelet count \\> 100,000/mm3. * Total bilirubin within normal limits, ALT and AST \\< 2.0 x the ULN ( \\< 5 x ULN for patients with liver involvement), INR \\< 1.5 and aPTT within normal limits. Patients who receive anti-coagulation treatment with an agent such as warfarin or heparin may be allowed to participate. For patients on warfarin, close monitoring of at least weekly evaluations will be performed until INR is stable based on a measurement at pre dose, as defined by the local standard of care.. * Creatinine \\< 1.5 x ULN, serum calcium within normal limits. * Patients with stable brain metastasis who have been treated with either whole brain radiation or Gamma Knife and have been off steroids for \\> 4 weeks. * Women of childbearing potential and men must agree to use adequate contraception (barrier method of birth control) prior to study entry and for the duration of study participation. Men and women should use adequate birth control for at least three months after the last administration of protocol drugs. Women of childbearing potential must have a negative serum pregnancy test performed within 7 days prior to the start of treatment.. * Ability to understand and sign a written informed consent document. All patients must have a signed informed consent before registration and initiation of therapy. Exclusion Criteria:. * Cardiac disease: Congestive heart failure \\> class II NYHA.. * Patients must not have unstable angina (anginal symptoms at rest) or new onset angina (began within the last 3 months) or myocardial infarction within the past 6 months.. * Cardiac ventricular arrhythmias requiring anti-arrhythmic therapy.. * Uncontrolled hypertension defined as systolic blood pressure \\> 150 mmHg or diastolic pressure \\> 90 mmHg, despite optimal medical management.. * No known severe hypersensitivity or suspected allergy to sorafenib, ABI-007 or any of the excipients. * Patients with neurological symptoms must undergo a CT scan/MRI of the brain to exclude progressing brain metastasis.. * Peripheral neuropathy greater than grade II. * Serious intercurrent medical or psychiatric illness, including serious active infection. * Known human immunodeficiency virus (HIV) infection or chronic Hepatitis B or C.. * Thrombotic or embolic events such as a cerebrovascular accident including transient ischemic attacks within the past 6 months.. * Pulmonary hemorrhage/bleeding event \\> CTCAE Grade 2 within 4 weeks of first dose of study drug.. * Any other hemorrhage/bleeding event \\> CTCAE Grade 3 within 4 weeks of first dose of study drug.. * Serious non-healing wound, ulcer, or bone fracture.. * Evidence or history of bleeding diathesis or coagulopathy. * Major surgery, open biopsy or significant traumatic injury within 4 weeks of first study drug.. * Use of St. John's Wort or rifampin (rifampicin). * Any condition that impairs patient's ability to swallow whole pills.. * Any malabsorption problem. * No treatment for melanoma within the previous 4 weeks.", "labeled_rules": [{"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "histologically confirmed", "unit": null, "evidence_text": "Histologically confirmed diagnosis of melanoma with measurable disease"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "measurable disease", "unit": null, "evidence_text": "Histologically confirmed diagnosis of melanoma with measurable disease"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "melanoma with measurable disease", "unit": null, "evidence_text": "Histologically confirmed diagnosis of melanoma with measurable disease"}, {"type": "INCLUSION", "field": "history", "operator": "IN", "value": "* Histologically confirmed diagnosis of melanoma with measurable disease. * Patients with stage IV, previously untreate", "unit": null, "evidence_text": "Histologically confirmed diagnosis of melanoma with measurable disease"}, {"type": "INCLUSION", "field": "other", "operator": "IN", "value": "* Histologically confirmed diagnosis of melanoma with measurable disease. * Patients with stage IV, previously untreate", "unit": null, "evidence_text": "Histologically confirmed diagnosis of melanoma with measurable disease"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "stage iv", "unit": null, "evidence_text": "Patients with stage IV, previously untreated, refractory to initial therapy or progressing after response to initial therapy"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "unresectable stage iii", "unit": null, "evidence_text": "Patients with unresectable stage III, including unresectable in-transit metastases"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "unresectable stage iii, including unresectable in-transit metastases", "unit": null, "evidence_text": "Patients with unresectable stage III, including unresectable in-transit metastases"}, {"type": "INCLUSION", "field": "sex", "operator": "=", "value": "all", "unit": null, "evidence_text": "Two prior chemotherapy regimen is allowed"}, {"type": "INCLUSION", "field": "age", "operator": ">=", "value": 18, "unit": "years", "evidence_text": "Age at least 18 years"}, {"type": "INCLUSION", "field": "lab", "operator": ">=", "value": 100000, "unit": "/mm3", "evidence_text": "Age at least 18 years"}, {"type": "INCLUSION", "field": "lab", "operator": ">=", "value": 1500, "unit": "/mm3", "evidence_text": "Age at least 18 years"}, {"type": "INCLUSION", "field": "lab", "operator": "<=", "value": 2, "unit": "x", "evidence_text": "ECOG performance status 0-2"}, {"type": "INCLUSION", "field": "lab", "operator": ">=", "value": 9, "unit": "g/dl", "evidence_text": "Hemoglobin \\> 9.0 g/dl, absolute neutrophil count (ANC) \\> 1,500/mm3, platelet count \\> 100,000/mm3"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "an agent such as warfarin or heparin", "unit": null, "evidence_text": "Total bilirubin within normal limits, ALT and AST \\< 2.0 x the ULN ( \\< 5 x ULN for patients with liver involvement), INR \\< 1.5 and aPTT within normal limits. Patients who receive anti-coagulation treatment with an agent such as warfarin or heparin may be allowed to participate. For patients on warfarin, close monitoring of at least weekly evaluations will be performed until INR is stable based on a measurement at pre dose, as defined by the local standard of care"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "x uln for", "unit": null, "evidence_text": "Total bilirubin within normal limits, ALT and AST \\< 2.0 x the ULN ( \\< 5 x ULN for patients with liver involvement), INR \\< 1.5 and aPTT within normal limits. Patients who receive anti-coagulation treatment with an agent such as warfarin or heparin may be allowed to participate. For patients on warfarin, close monitoring of at least weekly evaluations will be performed until INR is stable based on a measurement at pre dose, as defined by the local standard of care"}, {"type": "INCLUSION", "field": "lab", "operator": "<=", "value": 1.5, "unit": "and", "evidence_text": "Creatinine \\< 1.5 x ULN, serum calcium within normal limits"}, {"type": "INCLUSION", "field": "lab", "operator": "<=", "value": 1.5, "unit": "x", "evidence_text": "Creatinine \\< 1.5 x ULN, serum calcium within normal limits"}, {"type": "INCLUSION", "field": "lab", "operator": "<=", "value": 5, "unit": "x", "evidence_text": "Creatinine \\< 1.5 x ULN, serum calcium within normal limits"}, {"type": "INCLUSION", "field": "lab", "operator": "IN", "value": "negative pregnancy test", "unit": null, "evidence_text": "Women of childbearing potential and men must agree to use adequate contraception (barrier method of birth control) prior to study entry and for the duration of study participation. Men and women should use adequate birth control for at least three months after the last administration of protocol drugs. Women of childbearing potential must have a negative serum pregnancy test performed within 7 days prior to the start of treatment"}, {"type": "INCLUSION", "field": "medication", "operator": "WITHIN_LAST", "value": 7, "unit": "days", "evidence_text": "Women of childbearing potential and men must agree to use adequate contraception (barrier method of birth control) prior to study entry and for the duration of study participation. Men and women should use adequate birth control for at least three months after the last administration of protocol drugs. Women of childbearing potential must have a negative serum pregnancy test performed within 7 days prior to the start of treatment"}, {"type": "INCLUSION", "field": "procedure", "operator": "WITHIN_LAST", "value": 7, "unit": "days", "evidence_text": "Women of childbearing potential and men must agree to use adequate contraception (barrier method of birth control) prior to study entry and for the duration of study participation. Men and women should use adequate birth control for at least three months after the last administration of protocol drugs. Women of childbearing potential must have a negative serum pregnancy test performed within 7 days prior to the start of treatment"}, {"type": "INCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "Women of childbearing potential and men must agree to use adequate contraception (barrier method of birth control) prior to study entry and for the duration of study participation. Men and women should use adequate birth control for at least three months after the last administration of protocol drugs. Women of childbearing potential must have a negative serum pregnancy test performed within 7 days prior to the start of treatment"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "anginal", "unit": null, "evidence_text": "Patients must not have unstable angina (anginal symptoms at rest) or new onset angina (began within the last 3 months) or myocardial infarction within the past 6 months"}, {"type": "EXCLUSION", "field": "lab", "operator": ">=", "value": 150, "unit": "mmhg", "evidence_text": "Uncontrolled hypertension defined as systolic blood pressure \\> 150 mmHg or diastolic pressure \\> 90 mmHg, despite optimal medical management"}, {"type": "EXCLUSION", "field": "lab", "operator": ">=", "value": 90, "unit": "mmhg", "evidence_text": "Uncontrolled hypertension defined as systolic blood pressure \\> 150 mmHg or diastolic pressure \\> 90 mmHg, despite optimal medical management"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "neurological", "unit": null, "evidence_text": "Patients with neurological symptoms must undergo a CT scan/MRI of the brain to exclude progressing brain metastasis"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "active infection", "unit": null, "evidence_text": "Serious intercurrent medical or psychiatric illness, including serious active infection"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "hiv positive", "unit": null, "evidence_text": "Known human immunodeficiency virus (HIV) infection or chronic Hepatitis B or C"}, {"type": "EXCLUSION", "field": "history", "operator": "WITHIN_LAST", "value": 3, "unit": "months", "evidence_text": "Any other hemorrhage/bleeding event \\> CTCAE Grade 3 within 4 weeks of first dose of study drug"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "bleeding diathesis or coagulopathy", "unit": null, "evidence_text": "Evidence or history of bleeding diathesis or coagulopathy"}, {"type": "EXCLUSION", "field": "lab", "operator": ">=", "value": 4, "unit": "weeks", "evidence_text": "No treatment for melanoma within the previous 4 weeks"}], "annotator_id": "annotator_c", "guideline_version": "m5-v1", "adjudicated": true, "adjudication_source": "parsing_relabel_round1"}
{"nct_id": "NCT00502853", "eligibility_text": "Inclusion Criteria:. * adult patients, 18-75 years of age;. * rheumatoid arthritis for \\>=3 months and \\<=10 years;. * inadequate response to methotrexate (12.5-25mg/week) for \\>=3 months;. * evidence of erosive disease and/or clinical synovitis in a signal joint.. Exclusion Criteria:. * autoimmune rheumatic diseases other than RA;. * surgical operations on bones/joints in 12 weeks prior to baseline visit;. * concomitant treatment with biologic agents;. * previous treatment with more than one biologic agent approved for RA, or with cell-depleting therapies.", "labeled_rules": [{"type": "INCLUSION", "field": "age", "operator": "<=", "value": 75, "unit": "years", "evidence_text": "adult patients, 18-75 years of age"}, {"type": "INCLUSION", "field": "age", "operator": ">=", "value": 18, "unit": "years", "evidence_text": "adult patients, 18-75 years of age"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "adult", "unit": null, "evidence_text": "adult patients, 18-75 years of age"}, {"type": "INCLUSION", "field": "age", "operator": "<=", "value": 10, "unit": "years", "evidence_text": "rheumatoid arthritis for \\>=3 months and \\<=10 years"}, {"type": "INCLUSION", "field": "age", "operator": ">=", "value": 3, "unit": "years", "evidence_text": "rheumatoid arthritis for \\>=3 months and \\<=10 years"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "* rheumatoid arthritis for \\>=3 months and \\<=10 years", "unit": null, "evidence_text": "rheumatoid arthritis for \\>=3 months and \\<=10 years"}, {"type": "EXCLUSION", "field": "condition", "operator": "IN", "value": "evidence of erosive disease and/or clinical synovitis in a signal joint.. Exclusion Criteria", "unit": null, "evidence_text": "evidence of erosive disease and/or clinical synovitis in a signal joint.. Exclusion Criteria:"}, {"type": "INCLUSION", "field": "procedure", "operator": "IN", "value": "* surgical operations on bones/joints in 12 weeks prior to baseline visit", "unit": null, "evidence_text": "surgical operations on bones/joints in 12 weeks prior to baseline visit"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "biologic agents", "unit": null, "evidence_text": "concomitant treatment with biologic agents"}, {"type": "INCLUSION", "field": "medication", "operator": "IN", "value": "* concomitant treatment with biologic agents", "unit": null, "evidence_text": "concomitant treatment with biologic agents"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "cell depleting therapies", "unit": null, "evidence_text": "previous treatment with more than one biologic agent approved for RA, or with cell-depleting therapies"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "more than one biologic agent approved for", "unit": null, "evidence_text": "previous treatment with more than one biologic agent approved for RA, or with cell-depleting therapies"}, {"type": "INCLUSION", "field": "history", "operator": "IN", "value": "* previous treatment with more than one biologic agent approved for RA, or with cell-depleting therapies", "unit": null, "evidence_text": "previous treatment with more than one biologic agent approved for RA, or with cell-depleting therapies"}, {"type": "INCLUSION", "field": "medication", "operator": "IN", "value": "* previous treatment with more than one biologic agent approved for RA, or with cell-depleting therapies", "unit": null, "evidence_text": "previous treatment with more than one biologic agent approved for RA, or with cell-depleting therapies"}], "annotator_id": "annotator_c", "guideline_version": "m5-v1", "adjudicated": true, "adjudication_source": "parsing_relabel_round1"}
{"nct_id": "NCT00510302", "eligibility_text": "Inclusion Criteria:. * (FDRs will include siblings and adult children.) Melanoma patients are eligible if they were diagnosed with in situ, localized, or regional melanoma after January 1, 1997.. * Melanoma patients, their spouses/partners, and their first-degree relatives (FDRs) 18 years of age or older are eligible.. * Melanoma patients, their spouses/partners, and FDRs are eligible if they can speak, read, and write English.. * Melanoma patients, their spouses/partners, and FDRs are eligible if they provide informed consent.. * Spouses/partners and FDRs of melanoma patients are eligible if the patient gives permission for them to be contacted for recruitment.. * A melanoma patient's FDR is eligible if he/she is a sibling or child of the melanoma patient.. Exclusion Criteria:. * Melanoma patients, spouses/partners of patients, and FDRs of patients are not eligible if they cannot provide informed consent.", "labeled_rules": [{"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "in situ", "unit": null, "evidence_text": "(FDRs will include siblings and adult children.) Melanoma patients are eligible if they were diagnosed with in situ, localized, or regional melanoma after January 1, 1997"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "in situ, localized, or regional melanoma after", "unit": null, "evidence_text": "(FDRs will include siblings and adult children.) Melanoma patients are eligible if they were diagnosed with in situ, localized, or regional melanoma after January 1, 1997"}, {"type": "INCLUSION", "field": "other", "operator": "IN", "value": "* (FDRs will include siblings and adult children.) Melanoma patients are eligible if they were diagnosed with in situ", "unit": null, "evidence_text": "(FDRs will include siblings and adult children.) Melanoma patients are eligible if they were diagnosed with in situ, localized, or regional melanoma after January 1, 1997"}, {"type": "INCLUSION", "field": "procedure", "operator": "IN", "value": "* (FDRs will include siblings and adult children.) Melanoma patients are eligible if they were diagnosed with in situ", "unit": null, "evidence_text": "(FDRs will include siblings and adult children.) Melanoma patients are eligible if they were diagnosed with in situ, localized, or regional melanoma after January 1, 1997"}, {"type": "INCLUSION", "field": "age", "operator": ">=", "value": 18, "unit": "years", "evidence_text": "Melanoma patients, their spouses/partners, and their first-degree relatives (FDRs) 18 years of age or older are eligible"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "melanoma", "unit": null, "evidence_text": "Melanoma patients, their spouses/partners, and FDRs are eligible if they provide informed consent"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "melanoma", "unit": null, "evidence_text": "Melanoma patients, their spouses/partners, and FDRs are eligible if they provide informed consent"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "partners and fdrs of melanoma", "unit": null, "evidence_text": "Spouses/partners and FDRs of melanoma patients are eligible if the patient gives permission for them to be contacted for recruitment"}], "annotator_id": "annotator_c", "guideline_version": "m5-v1", "adjudicated": true, "adjudication_source": "parsing_relabel_round1"}
{"nct_id": "NCT00516776", "eligibility_text": "Inclusion Criteria:. * Presence of ulcerative colitis. * Presence of Crohn's disease. * Healthy (no sign of inflammatory bowel disease). Exclusion Criteria:. * Anticoagulation. * Cardiac valvular disease. * Intravascular prosthesis. * Coagulation disorders. * Gastrointestinal malignancy", "labeled_rules": [{"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "study-specific condition", "unit": null, "evidence_text": "Inclusion Criteria:"}]}
{"nct_id": "NCT00548574", "eligibility_text": "Inclusion Criteria:. * newly diagnosed or relapsing mild to moderate UC (score of 4-10 (inclusive) on the UC-DAI scale, with a sigmoidoscopy score of =\\> 1 and a PGA \\<=2) with compatible histology. * females eligible if post--menopausal, surgically sterile or if they had a negative urine pregnancy test at screening and were on adequate contraception. Exclusion Criteria:. * subjects with relapsing UC who were in relapse for \\> 6 weeks prior to baseline. * subjects who relapsed on maintenace therapy with doses of mesalazine =\\> 2g/day. * subjects who had unsuccessfully treated their current relapse with steroids or a mesalazine dose of \\> 2g/day. * subjects with Crohn's disease, proctitis, bleeding disorders, active peptic ulcer disease, previous colonic surgery, or those at an immediate risk of toxic megacolon or a stool culture positive for enteric pathogens. * subjects who had used systemic or rectal steroids within the last 4 weeks, immunosuppressants wihtin the last 6 weeks or anti-inflammatory drugs on a repeat basis within 7 days prior to the baseline visit. * subjects with hypersensitivity to salicylates and subjects with moderate/severe renal impairment", "labeled_rules": [{"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "compatible histology", "unit": null, "evidence_text": "newly diagnosed or relapsing mild to moderate UC (score of 4-10 (inclusive) on the UC-DAI scale, with a sigmoidoscopy score of =\\> 1 and a PGA \\<=2) with compatible histology"}, {"type": "INCLUSION", "field": "history", "operator": "IN", "value": "* newly diagnosed or relapsing mild to moderate UC (score of 4-10 (inclusive) on the UC-DAI scale, with a sigmoidoscopy", "unit": null, "evidence_text": "newly diagnosed or relapsing mild to moderate UC (score of 4-10 (inclusive) on the UC-DAI scale, with a sigmoidoscopy score of =\\> 1 and a PGA \\<=2) with compatible histology"}, {"type": "INCLUSION", "field": "lab", "operator": ">=", "value": 1, "unit": "and", "evidence_text": "newly diagnosed or relapsing mild to moderate UC (score of 4-10 (inclusive) on the UC-DAI scale, with a sigmoidoscopy score of =\\> 1 and a PGA \\<=2) with compatible histology"}, {"type": "EXCLUSION", "field": "lab", "operator": "IN", "value": "negative pregnancy test", "unit": null, "evidence_text": "females eligible if post--menopausal, surgically sterile or if they had a negative urine pregnancy test at screening and were on adequate contraception. Exclusion Criteria:"}, {"type": "EXCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "females eligible if post--menopausal, surgically sterile or if they had a negative urine pregnancy test at screening and were on adequate contraception. Exclusion Criteria:"}, {"type": "INCLUSION", "field": "lab", "operator": ">=", "value": 6, "unit": "weeks", "evidence_text": "subjects with relapsing UC who were in relapse for \\> 6 weeks prior to baseline"}, {"type": "INCLUSION", "field": "lab", "operator": "<=", "value": 2, "unit": null, "evidence_text": "subjects who relapsed on maintenace therapy with doses of mesalazine =\\> 2g/day"}, {"type": "INCLUSION", "field": "lab", "operator": ">=", "value": 2, "unit": "g/day", "evidence_text": "subjects who relapsed on maintenace therapy with doses of mesalazine =\\> 2g/day"}, {"type": "EXCLUSION", "field": "medication", "operator": "WITHIN_LAST", "value": 4, "unit": "weeks", "evidence_text": "subjects who had used systemic or rectal steroids within the last 4 weeks, immunosuppressants wihtin the last 6 weeks or anti-inflammatory drugs on a repeat basis within 7 days prior to the baseline visit"}, {"type": "INCLUSION", "field": "medication", "operator": "WITHIN_LAST", "value": 4, "unit": "weeks", "evidence_text": "subjects who had used systemic or rectal steroids within the last 4 weeks, immunosuppressants wihtin the last 6 weeks or anti-inflammatory drugs on a repeat basis within 7 days prior to the baseline visit"}, {"type": "INCLUSION", "field": "procedure", "operator": "WITHIN_LAST", "value": 4, "unit": "weeks", "evidence_text": "subjects who had used systemic or rectal steroids within the last 4 weeks, immunosuppressants wihtin the last 6 weeks or anti-inflammatory drugs on a repeat basis within 7 days prior to the baseline visit"}], "annotator_id": "annotator_c", "guideline_version": "m5-v1", "adjudicated": true, "adjudication_source": "parsing_relabel_round1"}
{"nct_id": "NCT00550758", "eligibility_text": "Inclusion Criteria:. * age 3- to 6-years. * respiratory diseases who were highly indicative of asthma diagnosis according to GINA guidelines \\[9\\]. * cough duration of more than 4 weeks. * normal chest auscultation and baseline FEV1\\>75% predicted for healthy preschool children, on the day of testing.. Exclusion Criteria:. * presence of other chronic respiratory conditions. * emergency room visit or the presence of respiratory infection within the last month. * oral or inhaled steroids or other anti-inflammatory medication taken in the last two weeks. * bronchodilator taken within 24-hours prior to the test.", "labeled_rules": [{"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "respiratory diseases", "unit": null, "evidence_text": "respiratory diseases who were highly indicative of asthma diagnosis according to GINA guidelines \\[9\\]"}, {"type": "INCLUSION", "field": "medication", "operator": "IN", "value": "* age 3- to 6-years. * respiratory diseases who were highly indicative of asthma diagnosis according to GINA guidelines", "unit": null, "evidence_text": "respiratory diseases who were highly indicative of asthma diagnosis according to GINA guidelines \\[9\\]"}, {"type": "INCLUSION", "field": "procedure", "operator": "IN", "value": "* age 3- to 6-years. * respiratory diseases who were highly indicative of asthma diagnosis according to GINA guidelines", "unit": null, "evidence_text": "respiratory diseases who were highly indicative of asthma diagnosis according to GINA guidelines \\[9\\]"}, {"type": "EXCLUSION", "field": "lab", "operator": ">=", "value": 75, "unit": "%", "evidence_text": "normal chest auscultation and baseline FEV1\\>75% predicted for healthy preschool children, on the day of testing.. Exclusion Criteria:"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "study-specific condition", "unit": null, "evidence_text": "presence of other chronic respiratory conditions"}], "annotator_id": "annotator_c", "guideline_version": "m5-v1", "adjudicated": true, "adjudication_source": "parsing_relabel_round1"}
{"nct_id": "NCT00552903", "eligibility_text": "Inclusion Criteria:. * Diagnosis of type 2 diabetes (medication and HbA1c\\>7% and no cardiovascular disease), coronary artery disease (history of myocardial infarction or revascularisation) or heart failure (NYHA II-III and admitted in a hospital for the condition within 2 years). * Aged 45 years or older. * Resident in the Pijt-Hme health care district. Exclusion Criteria:. * Classified as ineligible by primary care physician. * Unable to co-operate or participate in health coaching. * Major elective surgery planned within 6 months. * History of major surgery within past 2 years. * Life expectancy \\<1 year. * Pregnancy", "labeled_rules": [{"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "major surgery within past 2 years", "unit": null, "evidence_text": "* History of major surgery within past 2 years"}]}
{"nct_id": "NCT00576069", "eligibility_text": "Inclusion Criteria:. * Current non-smoking (\\<10 pack yr smoking history). * Stable, treated asthmatics. * Age 12-95 yr. * post 180ug albuterol by MDI: FEV 1/FVC \\< 70% and FEV 1 \\<80% predicted. Exclusion Criteria:. * Pregnancy", "labeled_rules": [{"type": "INCLUSION", "field": "age", "operator": ">=", "value": 12, "unit": "years", "evidence_text": "* Age 12-95 yr"}, {"type": "INCLUSION", "field": "age", "operator": "<=", "value": 95, "unit": "years", "evidence_text": "* Age 12-95 yr"}]}
{"nct_id": "NCT00584350", "eligibility_text": "Inclusion Criteria:. * minimum 18 years old. * chronic renal insufficiency with a calculated creatinine clearance below 60 cc /min. (estimated with the MDRD formula). * hemodynamically stable. Exclusion Criteria:. * Acute renal failure or in recuperation of acute renal failure. * urgent coronary angiogram. * moderate to severe valvulopathy or presence of a valvular prosthesis. * diagnostic of multiple myeloma. * dialysis before test. * having had a test with contrast product in the 2 weeks preceding. * receiving a nephrotoxic in the last month.", "labeled_rules": [{"type": "INCLUSION", "field": "procedure", "operator": "IN", "value": "* minimum 18 years old. * chronic renal insufficiency with a calculated creatinine clearance below 60 cc /min. (estimat", "unit": null, "evidence_text": "minimum 18 years old"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "contrast product in the 2 weeks preceding", "unit": null, "evidence_text": "having had a test with contrast product in the 2 weeks preceding"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "had a test with contrast product in", "unit": null, "evidence_text": "having had a test with contrast product in the 2 weeks preceding"}], "annotator_id": "annotator_c", "guideline_version": "m5-v1", "adjudicated": true, "adjudication_source": "parsing_relabel_round1"}
{"nct_id": "NCT00595361", "eligibility_text": "Inclusion Criteria:. * Both male and female. * 18 to 50 years of age. * Resting FEV1  65% of predicted normal. * Exercise-induced bronchoconstriction defined as a decrease in FEV1 of  20% following a standardized exercise challenge when compared to pre-exercise baseline FEV1 value measured 5 minutes before exercise. * Must be Arg/Arg or Gly/Gly genotype. Exclusion Criteria:. * Long-acting beta agonist use within 12 weeks of the first exercise challenge. * Smoking within past 12 months. * Greater than 10-pack years smoking history. * Unresolved signs and/or symptoms of an upper respiratory tract infection within 4 weeks of first exercise challenge. * Asthma exacerbation within 4 weeks of first exercise challenge requiring change in type, dose or frequency of medications and/or an unscheduled visit to an health care provider, including emergency room or hospital. * Subject has exercised or performed strenuous activity within 72 hours of the first exercise challenge. * Subject has been exposed to cold air sufficient to provoke symptoms of bronchospasm within 2 hours of exercise challenge. * In addition to asthma, the subject has an active, acute or chronic pulmonary disorder documented by history, physical examination, or chest x-ray. * Subject has evidence of ischemic, valvular, hypertrophic, familial or other forms of heart disease that would put the subject at risk during exercise testing or that would interfere with the ability to achieve protocol-specified heart rates during exercise testing. * Subject has used systemic corticosteroids within 1 month of first exercise challenge", "labeled_rules": [{"type": "INCLUSION", "field": "history", "operator": "IN", "value": "* Both male and female. * 18 to 50 years of age. * Resting FEV1  65% of predicted normal. * Exercise-induced bronchoco", "unit": null, "evidence_text": "Both male and female"}, {"type": "INCLUSION", "field": "other", "operator": "IN", "value": "* Both male and female. * 18 to 50 years of age. * Resting FEV1  65% of predicted normal. * Exercise-induced bronchoco", "unit": null, "evidence_text": "Both male and female"}, {"type": "INCLUSION", "field": "age", "operator": "<=", "value": 50, "unit": "years", "evidence_text": "18 to 50 years of age"}, {"type": "INCLUSION", "field": "age", "operator": ">=", "value": 18, "unit": "years", "evidence_text": "18 to 50 years of age"}, {"type": "INCLUSION", "field": "sex", "operator": "=", "value": "all", "unit": null, "evidence_text": "Long-acting beta agonist use within 12 weeks of the first exercise challenge"}, {"type": "INCLUSION", "field": "medication", "operator": "WITHIN_LAST", "value": 12, "unit": "weeks", "evidence_text": "Smoking within past 12 months"}, {"type": "INCLUSION", "field": "procedure", "operator": "WITHIN_LAST", "value": 12, "unit": "weeks", "evidence_text": "Smoking within past 12 months"}, {"type": "INCLUSION", "field": "lab", "operator": ">=", "value": 10, "unit": "pack", "evidence_text": "Greater than 10-pack years smoking history"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "subject has been exposed to cold air", "unit": null, "evidence_text": "Subject has been exposed to cold air sufficient to provoke symptoms of bronchospasm within 2 hours of exercise challenge"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "the ability to achieve protocol-specified heart rates", "unit": null, "evidence_text": "Subject has evidence of ischemic, valvular, hypertrophic, familial or other forms of heart disease that would put the subject at risk during exercise testing or that would interfere with the ability to achieve protocol-specified heart rates during exercise testing"}], "annotator_id": "annotator_c", "guideline_version": "m5-v1", "adjudicated": true, "adjudication_source": "parsing_relabel_round1"}
{"nct_id": "NCT00628095", "eligibility_text": "Inclusion Criteria:. * Active rheumatoid arthritis. * Incomplete response to methotrexate. Exclusion Criteria:. * Must not be on biologic therapies. * No recent infections", "labeled_rules": [{"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "study-specific condition", "unit": null, "evidence_text": "Inclusion Criteria:"}]}
{"nct_id": "NCT00642564", "eligibility_text": "Inclusion Criteria:. * Patients diagnosed with epilepsy. * Patients or parent(s)/caregiver(s) have signed and dated an informed consent.. Exclusion Criteria:. * Patients who have non-epileptic events in addition to epilepsy, such as pseudoseizures or an acute symptomatic cause of seizures (e.g., a metabolic disturbance, toxic exposure, active CNS infection). * Patients with progressive or degenerative neurological disorder. * Patients with an active malignancy. * Patients or parents/caregivers with known or suspected psychotic disease, mental retardation, or any mental situation which may cause the concern to properly complete this survey.", "labeled_rules": [{"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "an active malignancy", "unit": null, "evidence_text": "* Patients with an active malignancy"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "progressive or degenerative neurological disorder", "unit": null, "evidence_text": "* Patients with progressive or degenerative neurological disorder"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "epilepsy", "unit": null, "evidence_text": "* Patients diagnosed with epilepsy"}]}
{"nct_id": "NCT00649922", "eligibility_text": "Inclusion Criteria:. * Male/Females at least 20 years of age.. * Females post-menopausal for at least 1 year, surgically sterile, or practicing acceptable methods of birth control.. * Females have a negative pregnancy test at screening.. * Diagnosis of RA and met ACR criteria.. * Must discontinue any TNF at least 2 months prior to baseline.. * In condition of general good health.. Exclusion Criteria:. * History of significant sensitivity to any drug; clinically significant drug or alcohol abuse within the past year; active infection with Listeria or TB; lymphoma or leukemia; sickle-cell disease, splenectomy, other malignancy within 5 years with the exception of successfully treated non-metastatic basal cell or squamous cell carcinoma of skin or localized carcinoma in situ of the cervix.. * History of current acute inflammatory joint disease.. * Use of TAMIFLU or Symmetrel within 3 months of study drug administration.. * Recent (3 month) history of influenza or pneumococcal bacterial infection.. * Known positive human immunodeficiency virus (HIV) status.. * Positive hepatitis B or hepatitis C virus.. * Positive PPD \\>5 mm.. * Chest x-ray with calcified granulomas and/or pleural scarring or significant abnormalities.", "labeled_rules": [{"type": "INCLUSION", "field": "age", "operator": ">=", "value": 20, "unit": "years", "evidence_text": "Male/Females at least 20 years of age"}, {"type": "INCLUSION", "field": "history", "operator": "IN", "value": "* Male/Females at least 20 years of age.. * Females post-menopausal for at least 1 year, surgically sterile, or practic", "unit": null, "evidence_text": "Male/Females at least 20 years of age"}, {"type": "INCLUSION", "field": "medication", "operator": "IN", "value": "* Male/Females at least 20 years of age.. * Females post-menopausal for at least 1 year, surgically sterile, or practic", "unit": null, "evidence_text": "Male/Females at least 20 years of age"}, {"type": "INCLUSION", "field": "procedure", "operator": "IN", "value": "* Male/Females at least 20 years of age.. * Females post-menopausal for at least 1 year, surgically sterile, or practic", "unit": null, "evidence_text": "Male/Females at least 20 years of age"}, {"type": "INCLUSION", "field": "age", "operator": ">=", "value": 1, "unit": "years", "evidence_text": "Females post-menopausal for at least 1 year, surgically sterile, or practicing acceptable methods of birth control"}, {"type": "INCLUSION", "field": "sex", "operator": "=", "value": "all", "unit": null, "evidence_text": "Females post-menopausal for at least 1 year, surgically sterile, or practicing acceptable methods of birth control"}, {"type": "INCLUSION", "field": "lab", "operator": "IN", "value": "negative pregnancy test", "unit": null, "evidence_text": "Females have a negative pregnancy test at screening"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "ra and met acr", "unit": null, "evidence_text": "Diagnosis of RA and met ACR criteria"}, {"type": "EXCLUSION", "field": "condition", "operator": "IN", "value": "lymphoma or leukemia", "unit": null, "evidence_text": "History of significant sensitivity to any drug; clinically significant drug or alcohol abuse within the past year; active infection with Listeria or TB; lymphoma or leukemia; sickle-cell disease, splenectomy, other malignancy within 5 years with the exception of successfully treated non-metastatic basal cell or squamous cell carcinoma of skin or localized carcinoma in situ of the cervix"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "active infection", "unit": null, "evidence_text": "History of significant sensitivity to any drug; clinically significant drug or alcohol abuse within the past year; active infection with Listeria or TB; lymphoma or leukemia; sickle-cell disease, splenectomy, other malignancy within 5 years with the exception of successfully treated non-metastatic basal cell or squamous cell carcinoma of skin or localized carcinoma in situ of the cervix"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "listeria or tb", "unit": null, "evidence_text": "History of significant sensitivity to any drug; clinically significant drug or alcohol abuse within the past year; active infection with Listeria or TB; lymphoma or leukemia; sickle-cell disease, splenectomy, other malignancy within 5 years with the exception of successfully treated non-metastatic basal cell or squamous cell carcinoma of skin or localized carcinoma in situ of the cervix"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "significant sensitivity to any drug", "unit": null, "evidence_text": "History of significant sensitivity to any drug; clinically significant drug or alcohol abuse within the past year; active infection with Listeria or TB; lymphoma or leukemia; sickle-cell disease, splenectomy, other malignancy within 5 years with the exception of successfully treated non-metastatic basal cell or squamous cell carcinoma of skin or localized carcinoma in situ of the cervix"}, {"type": "EXCLUSION", "field": "history", "operator": "IN", "value": "sickle-cell disease, splenectomy, other malignancy within 5 years with the exception of successfully treated non-metastatic basal cell or sq", "unit": null, "evidence_text": "History of significant sensitivity to any drug; clinically significant drug or alcohol abuse within the past year; active infection with Listeria or TB; lymphoma or leukemia; sickle-cell disease, splenectomy, other malignancy within 5 years with the exception of successfully treated non-metastatic basal cell or squamous cell carcinoma of skin or localized carcinoma in situ of the cervix"}, {"type": "EXCLUSION", "field": "history", "operator": "WITHIN_LAST", "value": 5, "unit": "years", "evidence_text": "History of significant sensitivity to any drug; clinically significant drug or alcohol abuse within the past year; active infection with Listeria or TB; lymphoma or leukemia; sickle-cell disease, splenectomy, other malignancy within 5 years with the exception of successfully treated non-metastatic basal cell or squamous cell carcinoma of skin or localized carcinoma in situ of the cervix"}, {"type": "EXCLUSION", "field": "medication", "operator": "IN", "value": "clinically significant drug or alcohol abuse within the past year", "unit": null, "evidence_text": "History of significant sensitivity to any drug; clinically significant drug or alcohol abuse within the past year; active infection with Listeria or TB; lymphoma or leukemia; sickle-cell disease, splenectomy, other malignancy within 5 years with the exception of successfully treated non-metastatic basal cell or squamous cell carcinoma of skin or localized carcinoma in situ of the cervix"}, {"type": "EXCLUSION", "field": "medication", "operator": "WITHIN_LAST", "value": 5, "unit": "years", "evidence_text": "History of significant sensitivity to any drug; clinically significant drug or alcohol abuse within the past year; active infection with Listeria or TB; lymphoma or leukemia; sickle-cell disease, splenectomy, other malignancy within 5 years with the exception of successfully treated non-metastatic basal cell or squamous cell carcinoma of skin or localized carcinoma in situ of the cervix"}, {"type": "EXCLUSION", "field": "procedure", "operator": "IN", "value": "active infection with Listeria or TB", "unit": null, "evidence_text": "History of significant sensitivity to any drug; clinically significant drug or alcohol abuse within the past year; active infection with Listeria or TB; lymphoma or leukemia; sickle-cell disease, splenectomy, other malignancy within 5 years with the exception of successfully treated non-metastatic basal cell or squamous cell carcinoma of skin or localized carcinoma in situ of the cervix"}, {"type": "EXCLUSION", "field": "procedure", "operator": "WITHIN_LAST", "value": 5, "unit": "years", "evidence_text": "History of significant sensitivity to any drug; clinically significant drug or alcohol abuse within the past year; active infection with Listeria or TB; lymphoma or leukemia; sickle-cell disease, splenectomy, other malignancy within 5 years with the exception of successfully treated non-metastatic basal cell or squamous cell carcinoma of skin or localized carcinoma in situ of the cervix"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "current acute inflammatory joint disease", "unit": null, "evidence_text": "History of current acute inflammatory joint disease"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "influenza or pneumococcal bacterial infection", "unit": null, "evidence_text": "Recent (3 month) history of influenza or pneumococcal bacterial infection"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "hiv positive", "unit": null, "evidence_text": "Known positive human immunodeficiency virus (HIV) status"}, {"type": "EXCLUSION", "field": "lab", "operator": ">=", "value": 5, "unit": "mm", "evidence_text": "Positive PPD \\>5 mm"}], "annotator_id": "annotator_c", "guideline_version": "m5-v1", "adjudicated": true, "adjudication_source": "parsing_relabel_round1"}
{"nct_id": "NCT00685425", "eligibility_text": "Inclusion Criteria:. * Subject, male or female, must be at least 12 years of age at the time of consent.. * Female subjects 12-60 years of age must have a negative serum pregnancy test.. * Women of child bearing potential must be using an acceptable method of birth control throughout the study.. * Subject must have a documented diagnosis of asthma for a minimum of 6 months prior to study start. * Subject must be in good health with the exception of their reversible airways disease and not suffering from any chronic condition that might affect their respiratory function.. * Subject must have a chest X-ray for the study or within 12 months prior to randomization.. * Subject must be able to complete the diary cards and medical event calendars reliably on a daily basis and understand dosing instructions. Any minor subject who is not able to do this must have a parent/legal guardian who can assist them during the study with these activities.. Exclusion Criteria:. * Female subject who is pregnant or lactating.. * Subject who has participated in an investigational drug study within 30 days of study start, or who is currently participating in another clinical trial.. * Subject whose schedule prevents him or her from starting study visits before 12 PM.. * Subject who is unwilling or physically unable to perform the exercise challenges as described in the protocol.. * Subject who has travel commitments during the study that would interfere with trial measurements or compliance or both.. * Subject who has a history of hospitalization for asthma within 4 weeks prior to study start, or who is scheduled for in-patient hospitalization, including elective surgery during the course of the trial.. * Subject with a known sensitivity to levalbuterol or racemic albuterol, or any of the excipients contained in any of these formulations.. * Subject using any prescription drug with which albuterol sulfate administration is contraindicated.. * Subject with currently diagnosed life-threatening asthma defined as a history of asthma episodes requiring intubation, associated with hypercapnia, respiratory arrest, or hypoxic seizures within 12 months prior to study start.. * Subject with a history of cancer (exception: basal cell carcinoma in remission).. * Subject with hyperthyroidism, diabetes, hypertension, cardiac diseases or seizure disorders that currently are not well controlled by medication or that may interfere with the successful completion of this protocol.. * Subject with a history of substance abuse or drug abuse within 12 months preceding study start. Urine drug test must be negative at study start.. * Subject with greater than 10 pack year history of cigarette smoking or use of any tobacco products within 6 months of study start.. * Subject with a documented history of bronchopulmonary aspergillosis or any form of allergic alveolitis.. * Subject who has suffered from a clinically significant upper or lower respiratory tract infection in the 3 weeks prior to study start.. * Subjects with unstable asthma; or who have had a change in asthma therapy; or a visit to the Emergency Department or hospital for worsening asthma within 4 weeks.. * Subject who is a staff member or relative of a staff member.", "labeled_rules": [{"type": "INCLUSION", "field": "age", "operator": "<=", "value": 60, "unit": "years", "evidence_text": "Female subjects 12-60 years of age must have a negative serum pregnancy test"}, {"type": "INCLUSION", "field": "age", "operator": ">=", "value": 12, "unit": "years", "evidence_text": "Female subjects 12-60 years of age must have a negative serum pregnancy test"}, {"type": "INCLUSION", "field": "history", "operator": "IN", "value": "* Subject, male or female, must be at least 12 years of age at the time of consent.. * Female subjects 12-60 years of a", "unit": null, "evidence_text": "Female subjects 12-60 years of age must have a negative serum pregnancy test"}, {"type": "INCLUSION", "field": "lab", "operator": "IN", "value": "negative pregnancy test", "unit": null, "evidence_text": "Female subjects 12-60 years of age must have a negative serum pregnancy test"}, {"type": "INCLUSION", "field": "other", "operator": "IN", "value": "* Subject, male or female, must be at least 12 years of age at the time of consent.. * Female subjects 12-60 years of a", "unit": null, "evidence_text": "Female subjects 12-60 years of age must have a negative serum pregnancy test"}, {"type": "INCLUSION", "field": "condition", "operator": "NOT_IN", "value": "hospitalization for asthma within 4 weeks prior to study start, or who is scheduled for in patient hospitalization, including elective surgery during the course of the trial", "unit": null, "evidence_text": "Subject must have a documented diagnosis of asthma for a minimum of 6 months prior to study start"}, {"type": "INCLUSION", "field": "history", "operator": "WITHIN_LAST", "value": 6, "unit": "months", "evidence_text": "Subject must have a documented diagnosis of asthma for a minimum of 6 months prior to study start"}, {"type": "INCLUSION", "field": "history", "operator": "WITHIN_LAST", "value": 12, "unit": "months", "evidence_text": "Subject must have a chest X-ray for the study or within 12 months prior to randomization"}, {"type": "INCLUSION", "field": "medication", "operator": "WITHIN_LAST", "value": 12, "unit": "months", "evidence_text": "Subject must have a chest X-ray for the study or within 12 months prior to randomization"}, {"type": "INCLUSION", "field": "procedure", "operator": "WITHIN_LAST", "value": 12, "unit": "months", "evidence_text": "Subject must have a chest X-ray for the study or within 12 months prior to randomization"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "these activities", "unit": null, "evidence_text": "Subject must be able to complete the diary cards and medical event calendars reliably on a daily basis and understand dosing instructions. Any minor subject who is not able to do this must have a parent/legal guardian who can assist them during the study with these activities.. Exclusion Criteria:"}, {"type": "EXCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "Female subject who is pregnant or lactating"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "measurements or compliance or both", "unit": null, "evidence_text": "Subject who has travel commitments during the study that would interfere with trial measurements or compliance or both"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "trial measurements or compliance or both", "unit": null, "evidence_text": "Subject who has travel commitments during the study that would interfere with trial measurements or compliance or both"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "a known sensitivity to levalbuterol or racemic", "unit": null, "evidence_text": "Subject with a known sensitivity to levalbuterol or racemic albuterol, or any of the excipients contained in any of these formulations"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "which albuterol sulfate administration is contraindicated", "unit": null, "evidence_text": "Subject using any prescription drug with which albuterol sulfate administration is contraindicated"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "asthma episodes requiring intubation, associated with hypercapnia, respiratory arrest, or hypoxic seizures within 12 months prior to study start", "unit": null, "evidence_text": "Subject with currently diagnosed life-threatening asthma defined as a history of asthma episodes requiring intubation, associated with hypercapnia, respiratory arrest, or hypoxic seizures within 12 months prior to study start"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "hypercapnia", "unit": null, "evidence_text": "Subject with currently diagnosed life-threatening asthma defined as a history of asthma episodes requiring intubation, associated with hypercapnia, respiratory arrest, or hypoxic seizures within 12 months prior to study start"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "hypercapnia, respiratory arrest, or hypoxic seizures within", "unit": null, "evidence_text": "Subject with currently diagnosed life-threatening asthma defined as a history of asthma episodes requiring intubation, associated with hypercapnia, respiratory arrest, or hypoxic seizures within 12 months prior to study start"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "cancer (exception: basal cell carcinoma in remission)", "unit": null, "evidence_text": "Subject with a history of cancer (exception: basal cell carcinoma in remission)"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "hyperthyroidism", "unit": null, "evidence_text": "Subject with hyperthyroidism, diabetes, hypertension, cardiac diseases or seizure disorders that currently are not well controlled by medication or that may interfere with the successful completion of this protocol"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "the successful completion of this protocol", "unit": null, "evidence_text": "Subject with hyperthyroidism, diabetes, hypertension, cardiac diseases or seizure disorders that currently are not well controlled by medication or that may interfere with the successful completion of this protocol"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "a history of substance abuse or drug", "unit": null, "evidence_text": "Subject with a history of substance abuse or drug abuse within 12 months preceding study start. Urine drug test must be negative at study start"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "substance abuse or drug abuse within 12 months preceding study start", "unit": null, "evidence_text": "Subject with a history of substance abuse or drug abuse within 12 months preceding study start. Urine drug test must be negative at study start"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "cigarette smoking or use of any tobacco", "unit": null, "evidence_text": "Subject with greater than 10 pack year history of cigarette smoking or use of any tobacco products within 6 months of study start"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "cigarette smoking or use of any tobacco products within 6 months of study start", "unit": null, "evidence_text": "Subject with greater than 10 pack year history of cigarette smoking or use of any tobacco products within 6 months of study start"}, {"type": "EXCLUSION", "field": "lab", "operator": ">=", "value": 10, "unit": "pack", "evidence_text": "Subject with greater than 10 pack year history of cigarette smoking or use of any tobacco products within 6 months of study start"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "a documented history of bronchopulmonary aspergillosis or", "unit": null, "evidence_text": "Subject with a documented history of bronchopulmonary aspergillosis or any form of allergic alveolitis"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "bronchopulmonary aspergillosis or any form of allergic alveolitis", "unit": null, "evidence_text": "Subject with a documented history of bronchopulmonary aspergillosis or any form of allergic alveolitis"}, {"type": "EXCLUSION", "field": "sex", "operator": "=", "value": "all", "unit": null, "evidence_text": "Subject with a documented history of bronchopulmonary aspergillosis or any form of allergic alveolitis"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "unstable asthma", "unit": null, "evidence_text": "Subjects with unstable asthma; or who have had a change in asthma therapy; or a visit to the Emergency Department or hospital for worsening asthma within 4 weeks"}, {"type": "EXCLUSION", "field": "history", "operator": "WITHIN_LAST", "value": 4, "unit": "weeks", "evidence_text": "Subjects with unstable asthma; or who have had a change in asthma therapy; or a visit to the Emergency Department or hospital for worsening asthma within 4 weeks"}, {"type": "EXCLUSION", "field": "medication", "operator": "IN", "value": "or who have had a change in asthma therapy", "unit": null, "evidence_text": "Subjects with unstable asthma; or who have had a change in asthma therapy; or a visit to the Emergency Department or hospital for worsening asthma within 4 weeks"}, {"type": "EXCLUSION", "field": "procedure", "operator": "WITHIN_LAST", "value": 4, "unit": "weeks", "evidence_text": "Subjects with unstable asthma; or who have had a change in asthma therapy; or a visit to the Emergency Department or hospital for worsening asthma within 4 weeks"}], "annotator_id": "annotator_c", "guideline_version": "m5-v1", "adjudicated": true, "adjudication_source": "parsing_relabel_round1"}
{"nct_id": "NCT00687440", "eligibility_text": "Inclusion Criteria:. Patients must fulfill all the following criteria:. * Females aged 18 to 70 years-old.. * Willingness to participate in the study and comply with its procedures.. * Documented diagnosis of metastatic breast carcinoma (stage IV) Human Epidermal Growth Factor Receptor 2 (HER2) overexpressing (Immunohistochemistry (IHC) 3+ or Fluorescence In Situ Hybridization(FISH) +).. * No prior chemotherapy for metastatic breast cancer.. * Adjuvant or neo-adjuvant chemotherapy is allowed according to the following rules:. * patients treated with anthracyclines if all the following conditions are met:. * Doxorubicin total dose \\<= 300 mg/m\\^2. * Epirubicin total dose \\<= 480 mg/m\\^2. * Chemotherapy-free interval of \\> 12 months. * no taxane-based adjuvant or neo-adjuvant chemotherapy is allowed;. * patients treated with non-anthracycline/taxane adjuvant or neo-adjuvant chemotherapy regimens are freely eligible (i.e. cyclophosphamide/methotrexate/fluorouracil (CMF) or similar regimens).. * At least one measurable lesion according to RECIST criteria.. * Complete hematologic and biologic baseline evaluation within 2 weeks prior to start of treatment.. * Complete Tumor baseline evaluation including a total body computed tomography (CT) scan within 4 weeks prior to start of treatment.. * Left ventricular ejection fraction (LVEF) \\>= 50% as determined by echocardiogram or Multi Gated Acquisition (MUGA) scan.. * World Health Organization (WHO) performance status 0,1.. * Life expectancy \\> 3 months.. * Laboratory requirements :. * Hematology :. * Neutrophils \\> 1.5 x 10\\^9/L. * Platelets \\> 100 x 10\\^9/L. * Hemoglobin \\> 10 g/dL. * Hepatic function:. * Total bilirubin \\<= 1.25 x the upper-normal limits (UNL);. * ASAT (Aspartate Aminotransferase or SGOT), ALAT (Alanine aminotransferase or SGPT) \\<= 2.5 x the upper-normal limits;. * For patients with liver metastases:. * Total bilirubin \\< 1.5 x the UNL (Upper limit of normal) ;. * ASAT and/or ALAT \\< 3 x the UNL;. * Renal function :. * Serum Creatinine \\< 1.5 x the UNL.. * Women of child bearing potential must have a negative serum pregnancy test and be using adequate contraception.. * Patients must be accessible for treatment and follow-up.. Exclusion Criteria:. Patients will not be enrolled if any of the following criteria apply:. * Prior chemotherapy for metastatic disease.. * History of prior malignancy in the last 10 years (other than non melanoma skin cancer or excised cervical carcinoma in situ).. * Radiation to disease areas within 3 weeks of study initiation.. * Symptomatic peripheral neuropathy \\> grade 2 according to the National Cancer Institute (NCI) Common Toxicity Criteria.. * Other serious illness or medical condition.. * LVEF \\< 50% as determined by echocardiogram or MUGA scan.. * Congestive hearth failure or angina pectoris even if it is medically controlled. Previous history of myocardial infarction within 1 year from study entry, uncontrolled high risk hypertension or arrhythmia.. * History of significant neurologic or psychiatric disorders including dementia or seizures.. * Active infection.. * Active peptic ulcer, unstable diabetes mellitus or other contraindications for the use of dexamethasone.. * Concurrent treatment with other experimental drugs. Participation in another clinical trial with any investigational drug within 30 days prior to study screening.. * Concurrent treatment with corticosteroids used for reasons other than for premedication. However patients receiving chronic treatment with corticosteroids (\\> 6 months) at low dose (\\< 20 mg of methylprednisolone or equivalent dose of other corticosteroids) for whichever reason are eligible.. * Taxane-based adjuvant or neo-adjuvant chemotherapy \\< 12 months.. * Other concurrent chemotherapy, immunotherapy, radiotherapy or any other investigational medication, for the treatment of the tumor.. * Pregnant or breast-feeding women.", "labeled_rules": [{"type": "INCLUSION", "field": "age", "operator": "<=", "value": 70, "unit": "years", "evidence_text": "Females aged 18 to 70 years-old"}, {"type": "INCLUSION", "field": "age", "operator": ">=", "value": 18, "unit": "years", "evidence_text": "Females aged 18 to 70 years-old"}, {"type": "INCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "Females aged 18 to 70 years-old"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "its procedures", "unit": null, "evidence_text": "Willingness to participate in the study and comply with its procedures"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "documented", "unit": null, "evidence_text": "Documented diagnosis of metastatic breast carcinoma (stage IV) Human Epidermal Growth Factor Receptor 2 (HER2) overexpressing (Immunohistochemistry (IHC) 3+ or Fluorescence In Situ Hybridization(FISH) +)"}, {"type": "INCLUSION", "field": "medication", "operator": "IN", "value": "Patients must fulfill all the following criteria:. * Females aged 18 to 70 years-old.. * Willingness to participate in", "unit": null, "evidence_text": "patients treated with anthracyclines if all the following conditions are met:"}, {"type": "INCLUSION", "field": "other", "operator": "IN", "value": "Patients must fulfill all the following criteria:. * Females aged 18 to 70 years-old.. * Willingness to participate in", "unit": null, "evidence_text": "patients treated with anthracyclines if all the following conditions are met:"}, {"type": "INCLUSION", "field": "procedure", "operator": "IN", "value": "Patients must fulfill all the following criteria:. * Females aged 18 to 70 years-old.. * Willingness to participate in", "unit": null, "evidence_text": "patients treated with anthracyclines if all the following conditions are met:"}, {"type": "INCLUSION", "field": "lab", "operator": "<=", "value": 300, "unit": "mg/m", "evidence_text": "Doxorubicin total dose \\<= 300 mg/m\\^2"}, {"type": "INCLUSION", "field": "lab", "operator": "<=", "value": 480, "unit": "mg/m", "evidence_text": "Epirubicin total dose \\<= 480 mg/m\\^2"}, {"type": "INCLUSION", "field": "lab", "operator": "<=", "value": 12, "unit": "months", "evidence_text": "Chemotherapy-free interval of \\> 12 months"}, {"type": "INCLUSION", "field": "lab", "operator": ">=", "value": 12, "unit": "months", "evidence_text": "Chemotherapy-free interval of \\> 12 months"}, {"type": "INCLUSION", "field": "medication", "operator": "WITHIN_LAST", "value": 2, "unit": "weeks", "evidence_text": "Complete hematologic and biologic baseline evaluation within 2 weeks prior to start of treatment"}, {"type": "INCLUSION", "field": "procedure", "operator": "WITHIN_LAST", "value": 2, "unit": "weeks", "evidence_text": "Complete hematologic and biologic baseline evaluation within 2 weeks prior to start of treatment"}, {"type": "INCLUSION", "field": "lab", "operator": ">=", "value": 3, "unit": "months", "evidence_text": "Life expectancy \\> 3 months"}, {"type": "INCLUSION", "field": "lab", "operator": "<=", "value": 1.5, "unit": "x", "evidence_text": "Neutrophils \\> 1.5 x 10\\^9/L"}, {"type": "INCLUSION", "field": "lab", "operator": ">=", "value": 1.5, "unit": "x", "evidence_text": "Neutrophils \\> 1.5 x 10\\^9/L"}, {"type": "INCLUSION", "field": "lab", "operator": ">=", "value": 100, "unit": "x", "evidence_text": "Platelets \\> 100 x 10\\^9/L"}, {"type": "INCLUSION", "field": "lab", "operator": ">=", "value": 10, "unit": "g/dl", "evidence_text": "Hemoglobin \\> 10 g/dL"}, {"type": "INCLUSION", "field": "lab", "operator": "<=", "value": 1.25, "unit": "x", "evidence_text": "Total bilirubin \\<= 1.25 x the upper-normal limits (UNL)"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "* For patients with liver metastases:. * Total bilirubin \\< 1.5 x the UNL (Upper limit of normal)", "unit": null, "evidence_text": "For patients with liver metastases:"}, {"type": "INCLUSION", "field": "history", "operator": "IN", "value": "* Renal function :. * Serum Creatinine \\< 1.5 x the UNL.. * Women of child bearing potential must have a negative serum pregnancy test and", "unit": null, "evidence_text": "Serum Creatinine \\< 1.5 x the UNL"}, {"type": "INCLUSION", "field": "other", "operator": "IN", "value": "* Renal function :. * Serum Creatinine \\< 1.5 x the UNL.. * Women of child bearing potential must have a negative serum pregnancy test and", "unit": null, "evidence_text": "Serum Creatinine \\< 1.5 x the UNL"}, {"type": "INCLUSION", "field": "lab", "operator": "IN", "value": "negative pregnancy test", "unit": null, "evidence_text": "Women of child bearing potential must have a negative serum pregnancy test and be using adequate contraception"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "prior malignancy in the last 10 years (other than non melanoma skin cancer or excised cervical carcinoma in situ)", "unit": null, "evidence_text": "History of prior malignancy in the last 10 years (other than non melanoma skin cancer or excised cervical carcinoma in situ)"}, {"type": "EXCLUSION", "field": "history", "operator": "WITHIN_LAST", "value": 1, "unit": "years", "evidence_text": "History of prior malignancy in the last 10 years (other than non melanoma skin cancer or excised cervical carcinoma in situ)"}, {"type": "EXCLUSION", "field": "history", "operator": "WITHIN_LAST", "value": 10, "unit": "years", "evidence_text": "History of prior malignancy in the last 10 years (other than non melanoma skin cancer or excised cervical carcinoma in situ)"}, {"type": "EXCLUSION", "field": "medication", "operator": "WITHIN_LAST", "value": 10, "unit": "years", "evidence_text": "History of prior malignancy in the last 10 years (other than non melanoma skin cancer or excised cervical carcinoma in situ)"}, {"type": "EXCLUSION", "field": "procedure", "operator": "WITHIN_LAST", "value": 10, "unit": "years", "evidence_text": "History of prior malignancy in the last 10 years (other than non melanoma skin cancer or excised cervical carcinoma in situ)"}, {"type": "EXCLUSION", "field": "lab", "operator": "<=", "value": 50, "unit": "%", "evidence_text": "LVEF \\< 50% as determined by echocardiogram or MUGA scan"}, {"type": "EXCLUSION", "field": "lab", "operator": ">=", "value": 50, "unit": "%", "evidence_text": "LVEF \\< 50% as determined by echocardiogram or MUGA scan"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "myocardial infarction within 1 year from study entry, uncontrolled high risk hypertension or arrhythmia", "unit": null, "evidence_text": "Congestive hearth failure or angina pectoris even if it is medically controlled. Previous history of myocardial infarction within 1 year from study entry, uncontrolled high risk hypertension or arrhythmia"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "significant neurologic or psychiatric disorders including dementia", "unit": null, "evidence_text": "History of significant neurologic or psychiatric disorders including dementia or seizures"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "significant neurologic or psychiatric disorders including dementia or seizures", "unit": null, "evidence_text": "History of significant neurologic or psychiatric disorders including dementia or seizures"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "active infection", "unit": null, "evidence_text": "Active infection"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "any investigational drug within 30 days prior", "unit": null, "evidence_text": "Concurrent treatment with other experimental drugs. Participation in another clinical trial with any investigational drug within 30 days prior to study screening"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "other experimental drugs", "unit": null, "evidence_text": "Concurrent treatment with other experimental drugs. Participation in another clinical trial with any investigational drug within 30 days prior to study screening"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "corticosteroids used for reasons other than for", "unit": null, "evidence_text": "Concurrent treatment with corticosteroids used for reasons other than for premedication. However patients receiving chronic treatment with corticosteroids (\\> 6 months) at low dose (\\< 20 mg of methylprednisolone or equivalent dose of other corticosteroids) for whichever reason are eligible"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "however", "unit": null, "evidence_text": "Concurrent treatment with corticosteroids used for reasons other than for premedication. However patients receiving chronic treatment with corticosteroids (\\> 6 months) at low dose (\\< 20 mg of methylprednisolone or equivalent dose of other corticosteroids) for whichever reason are eligible"}, {"type": "EXCLUSION", "field": "lab", "operator": "<=", "value": 20, "unit": "mg", "evidence_text": "Concurrent treatment with corticosteroids used for reasons other than for premedication. However patients receiving chronic treatment with corticosteroids (\\> 6 months) at low dose (\\< 20 mg of methylprednisolone or equivalent dose of other corticosteroids) for whichever reason are eligible"}, {"type": "EXCLUSION", "field": "lab", "operator": ">=", "value": 6, "unit": "months", "evidence_text": "Concurrent treatment with corticosteroids used for reasons other than for premedication. However patients receiving chronic treatment with corticosteroids (\\> 6 months) at low dose (\\< 20 mg of methylprednisolone or equivalent dose of other corticosteroids) for whichever reason are eligible"}], "annotator_id": "annotator_c", "guideline_version": "m5-v1", "adjudicated": true, "adjudication_source": "parsing_relabel_round1"}
{"nct_id": "NCT00697580", "eligibility_text": "Inclusion Criteria:. * Overweight (age- \\& sex-specific body mass index  85th percentile based on CDC BMI growth charts \\[US Department of Health and Human Services, 2000\\], calculated by Epi Info Software, version 3.3). * Latino (both sets of grandparents must be of Latino heritage as defined by self-report; limited to Latinos to maintain a homogeneous sample and because Latinos are at increased risk of insulin resistance and type 2 diabetes.) If the participant or the parent is unsure of the country of origin of all 4 grandparents they will be excluded from the study. The participants and their families are not asked whether or not their grandparents are undocumented immigrants.. Exclusion Criteria:. * Presently taking medication(s) or diagnosed with any syndrome or disease that could influence dietary intake, exercise ability, body composition and fat distribution, or insulin action and secretion.. * Previously diagnosed with any major illness since birth (e.g. severe intrauterine growth retardation, chronic birth asphyxia, cancer).. * Children will not be eligible for participation if they have any diagnostic criteria for diabetes including polyuria, polydipsia with or without unexplained weight loss, fasting plasma glucose \\> 126 mg/dl, or a 2-hour plasma glucose \\>200 mg/dL during an oral glucose tolerance test. Children will also be excluded if they test positive for diabetes-related auto-antibodies, including ICA512 and GAD. Children testing positive for type 2 diabetes will be referred for treatment. Children with impaired glucose tolerance (fasting glucose \\>110 mg/dL or 2-hour glucose \\>140 mg/dl during an OGTT) and/or conditions associated with insulin resistance (e.g. acanthosis nigricans, hypertension, dyslipidemia, PCOS) will be eligible, as long as they are not receiving treatment and meet other eligibility criteria.. * Participants who are involved in any weight training, exercise, nutrition, or weight loss program or have been in the past 6 months.. * Participants that do not follow the rules and guidelines of appropriate conduct during participation, i.e., disruptive behavior, derogatory or racist comments, or any acts of physical violence towards study staff or other participants, and use of illegal substances. The principal investigator Dr. Michael Goran will decide if this conduct warrants exclusion or removal from the study.. * Pregnancy test comes out positive.. * Children who live further than 20 miles away from the General Clinic Research Center (GCRC).. * We can terminate participation if the child fails to follow the rules and guidelines of appropriate behavior and conduct during participation.", "labeled_rules": []}
{"nct_id": "NCT00702325", "eligibility_text": "Inclusion Criteria:. * African American (self-reported). * Documented clinical diagnosis of asthma as defined by the American Thoracic Society (ATS) for at least 6 months prior to Visit 2 and be in stable condition.. * FEV1, measured 6 hours after the last dose of short-acting 2-agonist and at least 48 hours after LABA, of 45%-85%, inclusive, of predicted normal.. Exclusion Criteria:. * Has been hospitalized at least once for an asthma related condition during the 6 months prior to Visit 2, or has required emergency treatment due to an asthma related condition more than once in the 3 months prior to Visit 2.. * Has required treatment with systemic corticosteroids (eg, oral, parenteral, ocular, or rectal) for any reason within the 30 days prior to Visit 2.. * Has a respiratory infection or other viral/bacterial illness, or is recovering from such an illness at the time of Visit 3 that, in the Investigator's opinion, will interfere with the subject's lung function and/or ability to perform spirometry", "labeled_rules": []}
{"nct_id": "NCT00702611", "eligibility_text": "Inclusion Criteria:. * 18 - 75 years old. * Active ulcerative colitis with documented clinical symptoms and endoscopic findings. * Active disease defined as DAI (Mayo score)  4 and 10 with at least 1 point in flexible sigmoidoscopy. * Steroid dependency as defined by:. A. Inability to withdraw corticosteroids within three months of starting treatment, without recurrent active disease. B. appearance of relapse within 3 months after withdrawal of corticosteroids. * Colonic involvement with ulcerative colitis beyond 15cm of the anal verge. * Stable doses:A. Aminosalicylates for the last 4 weeks B. Prednisolone or equivalent dose  20 mg/day for the last 2 weeks C. Azathioprine or 6-mercaptopurine at stable dose for the last 12 weeks. * Signed informed consent form. * Agree to participate in the required follow-up visits. * Able to complete the diary. Exclusion Criteria:. * Febrile (\\> 38C). * Evidence of toxic megacolon. * Anticipated need for surgery within 24 weeks. * Known obstructive diseases of the gastrointestinal system. * Proctocolectomy, total colectomy, ileostomy, stoma or ileal pouch-anal anastomosis. * A history of allergic reaction to heparin or heparin-induced thrombocytopenia. * A history of hypersensitivity reaction associated with an apheresis procedure or intolerance of apheresis procedures. * Requires a central venous access catheter for the apheresis treatments. * Known infection with enteric pathogens, pathogenic ova or parasites, C. difficile toxin or CMV. * Hypotension (systolic blood pressure \\<80 mmHg and/or diastolic blood pressure \\<50 mmHg) at screening visit only. * Uncontrolled hypertension (systolic blood pressure \\>180 mmHg or diastolic blood pressure \\>120 mmHg) despite medical therapy. * A history of myocardial infarction or unstable angina within the past 6 months. * A history of coronary artery bypass grafting surgery or angioplasty within the past 6 months. * Prosthetic heart valve, pacemaker or other permanent implant. * Severe cardiovascular or peripheral vascular disease, severe renal disease. * Liver disease defined as levels of SGOT \\[AST\\], SGPT \\[ALT\\] or alkaline phosphatase \\>2.5x the upper limit of the normal range for the laboratory performing test. * History of cirrhosis. * Known bleeding disorder (PT or PTT\\>1.5x the upper limit of the normal range for the laboratory performing the test), or concomitant anticoagulant therapy for purposes other than apheresis treatment. * Prior history suggestive of a hypercoagulable disorder, including 1 or more episodes of pulmonary embolism or deep vein thrombosis. * Known infection with Hepatitis B or C, or HIV. * Abnormal hematology parameters defined as severe anemia with hemoglobin \\<8.5g/dL, white blood cell count of \\<3,500/l and a granulocyte count \\< 2,000/l. * Fibrinogen level \\>700mg/dL. * Major surgery within the past 6 months. * Infection:Active infections less than 4 weeks from successful completion of antibiotic treatment for routine bacterial infectionFebrile viral infection within 4 weeks of entry into the clinical investigationLess than 12 weeks from conclusion of therapy for systemic fungal infections. * Malignancy within the past 2 years other than surgically cured skin carcinoma or cervical dysplasia (CIN I-II). * History of dysplasia or carcinoma of the colon or lack of a complete colonoscopy in the last 12 months in patients with longstanding UC (\\> 10 aos). * Current drug or alcohol abuse. * Pregnant, lactating or planning to become pregnant during the course of the clinical investigation. * Used within the last 30 days an investigational drug, biologic or device or 5 half-lifes, if known, for any investigational drug or biologic. * Received cyclosporine or tacrolimus within the last 8 weeks. * Received infliximab within the last 8 weeks. * Fulminant ulcerative colitis", "labeled_rules": [{"type": "INCLUSION", "field": "age", "operator": "<=", "value": 75, "unit": "years", "evidence_text": "18 - 75 years old"}, {"type": "INCLUSION", "field": "age", "operator": ">=", "value": 18, "unit": "years", "evidence_text": "18 - 75 years old"}, {"type": "INCLUSION", "field": "lab", "operator": "<=", "value": 2000, "unit": "/l", "evidence_text": "18 - 75 years old"}, {"type": "INCLUSION", "field": "lab", "operator": "<=", "value": 3500, "unit": "/l", "evidence_text": "18 - 75 years old"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "active ulcerative colitis with documented clinical", "unit": null, "evidence_text": "Active ulcerative colitis with documented clinical symptoms and endoscopic findings"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "documented clinical symptoms and endoscopic findings", "unit": null, "evidence_text": "Active ulcerative colitis with documented clinical symptoms and endoscopic findings"}, {"type": "INCLUSION", "field": "history", "operator": "IN", "value": "* 18 - 75 years old. * Active ulcerative colitis with documented clinical symptoms and endoscopic findings. * Active di", "unit": null, "evidence_text": "Active ulcerative colitis with documented clinical symptoms and endoscopic findings"}, {"type": "INCLUSION", "field": "other", "operator": "IN", "value": "* 18 - 75 years old. * Active ulcerative colitis with documented clinical symptoms and endoscopic findings. * Active di", "unit": null, "evidence_text": "Active ulcerative colitis with documented clinical symptoms and endoscopic findings"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "at least 1 point in flexible sigmoidoscopy", "unit": null, "evidence_text": "Active disease defined as DAI (Mayo score)  4 and 10 with at least 1 point in flexible sigmoidoscopy"}, {"type": "INCLUSION", "field": "lab", "operator": ">=", "value": 10, "unit": "a", "evidence_text": "Active disease defined as DAI (Mayo score)  4 and 10 with at least 1 point in flexible sigmoidoscopy"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "ulcerative colitis beyond 15cm of the anal", "unit": null, "evidence_text": "Colonic involvement with ulcerative colitis beyond 15cm of the anal verge"}, {"type": "EXCLUSION", "field": "lab", "operator": ">=", "value": 38, "unit": null, "evidence_text": "Febrile (\\> 38C)"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "allergic reaction to heparin or heparin-induced thrombocytopenia", "unit": null, "evidence_text": "A history of allergic reaction to heparin or heparin-induced thrombocytopenia"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "an apheresis procedure or intolerance of apheresis", "unit": null, "evidence_text": "A history of hypersensitivity reaction associated with an apheresis procedure or intolerance of apheresis procedures"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "hypersensitivity reaction associated with an apheresis procedure or intolerance of apheresis procedures", "unit": null, "evidence_text": "A history of hypersensitivity reaction associated with an apheresis procedure or intolerance of apheresis procedures"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "enteric pathogens", "unit": null, "evidence_text": "Known infection with enteric pathogens, pathogenic ova or parasites, C. difficile toxin or CMV"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "enteric pathogens, pathogenic ova or parasites, c", "unit": null, "evidence_text": "Known infection with enteric pathogens, pathogenic ova or parasites, C. difficile toxin or CMV"}, {"type": "EXCLUSION", "field": "lab", "operator": "<=", "value": 50, "unit": "mmhg", "evidence_text": "Hypotension (systolic blood pressure \\<80 mmHg and/or diastolic blood pressure \\<50 mmHg) at screening visit only"}, {"type": "EXCLUSION", "field": "lab", "operator": "<=", "value": 80, "unit": "mmhg", "evidence_text": "Hypotension (systolic blood pressure \\<80 mmHg and/or diastolic blood pressure \\<50 mmHg) at screening visit only"}, {"type": "EXCLUSION", "field": "lab", "operator": ">=", "value": 120, "unit": "mmhg", "evidence_text": "Uncontrolled hypertension (systolic blood pressure \\>180 mmHg or diastolic blood pressure \\>120 mmHg) despite medical therapy"}, {"type": "EXCLUSION", "field": "lab", "operator": ">=", "value": 180, "unit": "mmhg", "evidence_text": "Uncontrolled hypertension (systolic blood pressure \\>180 mmHg or diastolic blood pressure \\>120 mmHg) despite medical therapy"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "myocardial infarction or unstable angina within the", "unit": null, "evidence_text": "A history of myocardial infarction or unstable angina within the past 6 months"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "myocardial infarction or unstable angina within the past 6 months", "unit": null, "evidence_text": "A history of myocardial infarction or unstable angina within the past 6 months"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "coronary artery bypass grafting surgery or angioplasty", "unit": null, "evidence_text": "A history of coronary artery bypass grafting surgery or angioplasty within the past 6 months"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "coronary artery bypass grafting surgery or angioplasty within the past 6 months", "unit": null, "evidence_text": "A history of coronary artery bypass grafting surgery or angioplasty within the past 6 months"}, {"type": "EXCLUSION", "field": "lab", "operator": ">=", "value": 2.5, "unit": "x", "evidence_text": "Liver disease defined as levels of SGOT \\[AST\\], SGPT \\[ALT\\] or alkaline phosphatase \\>2.5x the upper limit of the normal range for the laboratory performing test"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "cirrhosis", "unit": null, "evidence_text": "History of cirrhosis"}, {"type": "EXCLUSION", "field": "lab", "operator": ">=", "value": 1.5, "unit": "x", "evidence_text": "Known bleeding disorder (PT or PTT\\>1.5x the upper limit of the normal range for the laboratory performing the test), or concomitant anticoagulant therapy for purposes other than apheresis treatment"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "hepatitis b or c", "unit": null, "evidence_text": "Known infection with Hepatitis B or C, or HIV"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "hepatitis b or c, or hiv", "unit": null, "evidence_text": "Known infection with Hepatitis B or C, or HIV"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "hiv positive", "unit": null, "evidence_text": "Known infection with Hepatitis B or C, or HIV"}, {"type": "EXCLUSION", "field": "lab", "operator": "<=", "value": 8.5, "unit": "g/dl", "evidence_text": "Abnormal hematology parameters defined as severe anemia with hemoglobin \\<8.5g/dL, white blood cell count of \\<3,500/l and a granulocyte count \\< 2,000/l"}, {"type": "EXCLUSION", "field": "lab", "operator": ">=", "value": 700, "unit": "mg/dl", "evidence_text": "Fibrinogen level \\>700mg/dL"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "active infection", "unit": null, "evidence_text": "Infection:Active infections less than 4 weeks from successful completion of antibiotic treatment for routine bacterial infectionFebrile viral infection within 4 weeks of entry into the clinical investigationLess than 12 weeks from conclusion of therapy for systemic fungal infections"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "dysplasia or carcinoma of the colon or lack of a complete colonoscopy in the last 12 months in patients with longstanding uc (\\> 10 aos)", "unit": null, "evidence_text": "History of dysplasia or carcinoma of the colon or lack of a complete colonoscopy in the last 12 months in patients with longstanding UC (\\> 10 aos)"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "or carcinoma of the colon or lack", "unit": null, "evidence_text": "History of dysplasia or carcinoma of the colon or lack of a complete colonoscopy in the last 12 months in patients with longstanding UC (\\> 10 aos)"}, {"type": "EXCLUSION", "field": "history", "operator": "WITHIN_LAST", "value": 12, "unit": "months", "evidence_text": "History of dysplasia or carcinoma of the colon or lack of a complete colonoscopy in the last 12 months in patients with longstanding UC (\\> 10 aos)"}, {"type": "EXCLUSION", "field": "medication", "operator": "WITHIN_LAST", "value": 3, "unit": "months", "evidence_text": "Used within the last 30 days an investigational drug, biologic or device or 5 half-lifes, if known, for any investigational drug or biologic"}, {"type": "EXCLUSION", "field": "procedure", "operator": "WITHIN_LAST", "value": 3, "unit": "months", "evidence_text": "Used within the last 30 days an investigational drug, biologic or device or 5 half-lifes, if known, for any investigational drug or biologic"}], "annotator_id": "annotator_c", "guideline_version": "m5-v1", "adjudicated": true, "adjudication_source": "parsing_relabel_round1"}
{"nct_id": "NCT00710255", "eligibility_text": "Inclusion Criteria:. * Physician diagnosed asthma. * Age 12-75 yrs. * FEV1 \\> 70% predicted. * HIB response \\> 10 %. * No smoking last 6 mo and \\< 10 pack yrs. * No URI last 4 weeks. * No asthma exacerbation last 4 weks. * Able to withhold SABA \\> 8 hrs and LABA \\> 24 hrs. Exclusion Criteria:. * Other lung disease. * Cardiac disease or other condition that would preclude safe participation, on theophylline or leukotriene modifiers", "labeled_rules": [{"type": "INCLUSION", "field": "age", "operator": ">=", "value": 12, "unit": "years", "evidence_text": "* Age 12-75 yrs"}, {"type": "INCLUSION", "field": "age", "operator": "<=", "value": 75, "unit": "years", "evidence_text": "* Age 12-75 yrs"}]}
{"nct_id": "NCT00719134", "eligibility_text": "Inclusion Criteria:. * Patients will be considered for this study if they suffer from classical or common migraine for at least 3 years.. * Candidates will recruited from the clinical case load of Dr. Zahid Bajwa and the headache and pain management center at BIDMC.. * Only patients older than 18 years of age,. * Able to communicate clearly in English,. * Able to give an informed consent will be considered as candidates.. * No limitation of gender or race is justified and thus, it is open to all patients fulfilling criteria for migraine type headache.. * Patients will be able to withdraw from the study at any time.. * They will be included in the study if they meet the criteria for migraine with or without aura (Headache-classification-committee-of-the-International-Headache-Society 1988), if they had \\>4 migraine attacks each month for the previous year.. Exclusion Criteria:. * Exclusion criteria will include cardiovascular or cerebrovascular disorders,. * Cardiac risk factors and liver disease,. * Uncontrolled hypertension,. * Peripheral and central nervous system disorders that affect sensory functions (such as sensory neuropathies and chronic pain),. * The use of opiates or other analgesic drugs for any reason, and the use of other prophylactic anti-migraine drugs.. * Any patient with active hepatitis or elevated liver enzymes (based on their BIDMC medical record) will be excluded as well.. * Employees who are under the direct supervision of the investigators will not participate in the study.", "labeled_rules": [{"type": "INCLUSION", "field": "age", "operator": ">=", "value": 18, "unit": "years", "evidence_text": "* Only patients older than 18 years of age,"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "only", "unit": null, "evidence_text": "* Only patients older than 18 years of age,"}]}
{"nct_id": "NCT00721318", "eligibility_text": "2000 RA patients from the East Tallinn Central Hospital's and the North Estonian Regional Hospital's in- and outpatients who live in Tallinn or Harju County. The control sample will be found from the Population Register through matching by gender, age (the same year) and place of residence (living in the city or in the countryside) with the subjects from RA sample according to the official procedure. If required, the research subjects from the control sample will be contacted by a rheumatologist participating in the study.. \\-", "labeled_rules": [{"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "the from ra sample according to the", "unit": null, "evidence_text": "The control sample will be found from the Population Register through matching by gender, age (the same year) and place of residence (living in the city or in the countryside) with the subjects from RA sample according to the official procedure"}]}
{"nct_id": "NCT00724841", "eligibility_text": "Inclusion Criteria:. * Histologically or cytologically confirmed metastatic melanoma. * Up to 1 prior chemotherapy regimen allowed; prior immunotherapy allowed. * Normal organ and marrow function. * Willing to submit to blood sampling for planned PK/PD analyses. * Ability of understand and willingness to sign a written informed consent. Exclusion Criteria:. * No other investigational or commercial agents or therapies. * Prior exposure to GMX1777, GMX1778 or CHS828. * Patients with uncontrolled, intercurrent illness. * Pregnant or breastfeeding women", "labeled_rules": [{"type": "INCLUSION", "field": "medication", "operator": "IN", "value": "* Histologically or cytologically confirmed metastatic melanoma. * Up to 1 prior chemotherapy regimen allowed", "unit": null, "evidence_text": "Histologically or cytologically confirmed metastatic melanoma"}, {"type": "INCLUSION", "field": "medication", "operator": "IN", "value": "prior immunotherapy allowed. * Normal organ and marrow function. * Willing to submit to blood sampling for planned PK/PD analyses. * Ability", "unit": null, "evidence_text": "Normal organ and marrow function"}, {"type": "INCLUSION", "field": "other", "operator": "IN", "value": "prior immunotherapy allowed. * Normal organ and marrow function. * Willing to submit to blood sampling for planned PK/PD analyses. * Ability", "unit": null, "evidence_text": "Normal organ and marrow function"}, {"type": "INCLUSION", "field": "procedure", "operator": "IN", "value": "prior immunotherapy allowed. * Normal organ and marrow function. * Willing to submit to blood sampling for planned PK/PD analyses. * Ability", "unit": null, "evidence_text": "Normal organ and marrow function"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "uncontrolled", "unit": null, "evidence_text": "Patients with uncontrolled, intercurrent illness"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "uncontrolled, intercurrent illness", "unit": null, "evidence_text": "Patients with uncontrolled, intercurrent illness"}, {"type": "EXCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "Pregnant or breastfeeding women"}, {"type": "INCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "Pregnant or breastfeeding women"}], "annotator_id": "annotator_c", "guideline_version": "m5-v1", "adjudicated": true, "adjudication_source": "parsing_relabel_round1"}
{"nct_id": "NCT01316497", "eligibility_text": "Inclusion Criteria:. * Children admitted for surgery for congenital heart disease. Exclusion Criteria:. * heart surgeries of low complexity such as closure of septal defects, aortico-pulmonary windows, establishment of glenn shunts, subaortic membrane resection, redirection of anomalous pulmonary veins, valvotomies, repair of pulmonary artery stenosis and surgeries without the use of extracorporeal circulation", "labeled_rules": [{"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "study-specific condition", "unit": null, "evidence_text": "Inclusion Criteria:"}]}
{"nct_id": "NCT90000001", "eligibility_text": "Inclusion: Participants must be 18 years or older. HbA1c <= 8.5%. Exclusion: Active infection or major surgery within the last 3 months.", "labeled_rules": [{"type": "INCLUSION", "field": "age", "operator": "<=", "value": 8, "unit": "years", "evidence_text": "Inclusion: Participants must be 18 years or older. HbA1c <= 8.5%. Exclusion: Active infection or major surgery within the last 3 months"}, {"type": "INCLUSION", "field": "age", "operator": ">=", "value": 18, "unit": "years", "evidence_text": "Inclusion: Participants must be 18 years or older. HbA1c <= 8.5%. Exclusion: Active infection or major surgery within the last 3 months"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "active infection", "unit": null, "evidence_text": "Inclusion: Participants must be 18 years or older. HbA1c <= 8.5%. Exclusion: Active infection or major surgery within the last 3 months"}, {"type": "INCLUSION", "field": "lab", "operator": "<=", "value": 8.5, "unit": "%", "evidence_text": "Inclusion: Participants must be 18 years or older. HbA1c <= 8.5%. Exclusion: Active infection or major surgery within the last 3 months"}, {"type": "INCLUSION", "field": "lab", "operator": "<=", "value": 1, "unit": null, "evidence_text": "Inclusion: Participants must be 18 years or older. HbA1c <= 8.5%. Exclusion: Active infection or major surgery within the last 3 months"}, {"type": "EXCLUSION", "field": "procedure", "operator": "WITHIN_LAST", "value": 3, "unit": "months", "evidence_text": "Inclusion: Participants must be 18 years or older. HbA1c <= 8.5%. Exclusion: Active infection or major surgery within the last 3 months"}, {"type": "INCLUSION", "field": "procedure", "operator": "WITHIN_LAST", "value": 3, "unit": "months", "evidence_text": "Inclusion: Participants must be 18 years or older. HbA1c <= 8.5%. Exclusion: Active infection or major surgery within the last 3 months"}], "annotator_id": "annotator_c", "guideline_version": "m5-v1", "adjudicated": true, "adjudication_source": "parsing_relabel_round1"}
{"nct_id": "NCT90000002", "eligibility_text": "Inclusion Criteria: Female participants, 18 to 75 years. Exclusion Criteria: Pregnancy or breastfeeding.", "labeled_rules": [{"type": "INCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "Inclusion Criteria: Female participants, 18 to 75 years"}]}
{"nct_id": "NCT90000003", "eligibility_text": "Inclusion: Adults with heart failure, NYHA II-III. Exclusion: Prior treatment within the last 30 days.", "labeled_rules": [{"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "heart failure, nyha ii-iii", "unit": null, "evidence_text": "Inclusion: Adults with heart failure, NYHA II-III"}]}
{"nct_id": "NCT90000004", "eligibility_text": "Inclusion: Age 6 to 17 years, asthma diagnosis. Exclusion: Active infection.", "labeled_rules": [{"type": "INCLUSION", "field": "age", "operator": ">=", "value": 6, "unit": "years", "evidence_text": "Inclusion: Age 6 to 17 years, asthma diagnosis"}, {"type": "INCLUSION", "field": "age", "operator": "<=", "value": 17, "unit": "years", "evidence_text": "Inclusion: Age 6 to 17 years, asthma diagnosis"}, {"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "active infection", "unit": null, "evidence_text": "Exclusion: Active infection"}]}
{"nct_id": "NCT90000005", "eligibility_text": "Inclusion Criteria: Participants with rheumatoid arthritis. Exclusion Criteria: major surgery in the last 6 months.", "labeled_rules": [{"type": "EXCLUSION", "field": "condition", "operator": "IN", "value": "rheumatoid arthritis", "unit": null, "evidence_text": "Inclusion Criteria: Participants with rheumatoid arthritis. Exclusion Criteria: major surgery in the last 6 months"}, {"type": "EXCLUSION", "field": "procedure", "operator": "WITHIN_LAST", "value": 6, "unit": "months", "evidence_text": "Inclusion Criteria: Participants with rheumatoid arthritis. Exclusion Criteria: major surgery in the last 6 months"}], "annotator_id": "annotator_c", "guideline_version": "m5-v1", "adjudicated": true, "adjudication_source": "parsing_relabel_round1"}
{"nct_id": "NCT90000006", "eligibility_text": "Inclusion: Male or female participants, age >= 18. Exclusion: previous treatment in the last 4 weeks.", "labeled_rules": [{"type": "INCLUSION", "field": "age", "operator": ">=", "value": 18, "unit": "years", "evidence_text": "Inclusion: Male or female participants, age >= 18"}, {"type": "INCLUSION", "field": "sex", "operator": "=", "value": "female", "unit": null, "evidence_text": "Inclusion: Male or female participants, age >= 18"}]}
{"nct_id": "NCT90000007", "eligibility_text": "Inclusion Criteria: long covid symptoms for at least 3 months. Exclusion Criteria: uncontrolled psychiatric disorder.", "labeled_rules": []}
{"nct_id": "NCT90000008", "eligibility_text": "Inclusion: Adults with migraine. Exclusion: pregnancy, breastfeeding, or active infection.", "labeled_rules": [{"type": "EXCLUSION", "field": "condition", "operator": "NOT_IN", "value": "active infection", "unit": null, "evidence_text": "Exclusion: pregnancy, breastfeeding, or active infection"}, {"type": "INCLUSION", "field": "condition", "operator": "IN", "value": "migraine", "unit": null, "evidence_text": "Inclusion: Adults with migraine"}]}
